

WO0021985

Publication Title:

GENES ENCODING OLFACTORY RECEPTORS AND BIALLELIC MARKERS THEREOF

Abstract:

Abstract of WO0021985

The invention concerns the genomic sequence and coding regions of a new olfactory receptor gene cluster. The invention also concerns polypeptides encoded by the olfactory receptor genes as well as to methods and kits for detecting these polynucleotides and screening substances interacting with these polypeptides. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the olfactory receptor gene useful in genetic analysis. Data supplied from the esp@cenet database - Worldwide

Courtesy of <http://v3.espacenet.com>



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07K 14/00	A2	(11) International Publication Number: WO 00/21985 (43) International Publication Date: 20 April 2000 (20.04.00)
(21) International Application Number: PCT/IB99/01729 (22) International Filing Date: 13 October 1999 (13.10.99) (30) Priority Data: 60/104,299 14 October 1998 (14.10.98) US (71) Applicant (for all designated States except US): GENSET [FR/FR]; 24, rue Royale, F-75008 Paris (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): BOUGUELERET, Lydie [FR/FR]; 108, avenue Victor Hugo, F-92170 Vanves (FR). MALEKZADEH, Kattayoun [IR/FR]; 41, rue des Laitieres, F-94300 Vincennes (FR). (74) Common Representative: GENSET; 24, rue Royale, F-75008 Paris (FR).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: GENES ENCODING OLFACTORY RECEPTORS AND BIALLELIC MARKERS THEREOF		
(57) Abstract <p>The invention concerns the genomic sequence and coding regions of a new olfactory receptor gene cluster. The invention also concerns polypeptides encoded by the olfactory receptor genes as well as to methods and kits for detecting these polynucleotides and screening substances interacting with these polypeptides. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the olfactory receptor gene useful in genetic analysis.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

GENES ENCODING OLFACTORY RECEPTORS AND BIALLELIC MARKERS THEREOF

FIELD OF THE INVENTION

The present invention pertains to a purified or isolated nucleic acid comprising ten open
5 reading Frames (ORFs) encoding ten different olfactory receptor-like proteins, non-coding regions
flanking the ORFs as well as fragments thereof. The invention also provides recombinant expression
vectors and recombinant cell hosts containing a nucleic acid encoding said olfactory receptor
proteins. The invention also concerns the olfactory receptor proteins encoded by these ORFs as well
as polypeptides that are homologous to said olfactory receptor proteins and the peptide fragments of
10 both the olfactory receptor proteins and their homologous polypeptide counterparts. The invention
also deals with antibodies directed specifically against such polypeptides that are useful as
diagnostic reagents. The invention further encompasses biallelic markers of the olfactory receptor
gene useful in genetic analysis. The invention also deals with methods and kits for the detection of
the olfactory receptor proteins and with methods and kits for screening ligand molecules binding to
15 these proteins.

BACKGROUND OF THE INVENTION

Throughout this application, various bibliographic publications are cited. Full bibliographic
references for these publications may be found at the end of this application, preceding the sequence
listing and the claims.

20 OLFACTORY SYSTEM

The olfactory receptor cells, the first cells in the pathway that give rise to the sense of smell,
lie in a small patch of membrane, the olfactory epithelium, in the upper part of the nasal cavity.
These cells are specialized afferent neurons that have an enlarged extension analogous to a dendrite.
Several long hairlike processes extend out from this extension along the surface of the olfactory
25 epithelium where they are bathed in mucus. The hairlike processes contain the receptor proteins for
olfactory stimuli. The axons of these neurons form the olfactory nerve.

For the detection of an odorous substance which is called an odorant, molecules of the
substance must first diffuse into the air and pass into the nose to the region of the olfactory
epithelium. Once there, they dissolve in the mucus that covers the epithelium and then bind to
30 specific receptor proteins on the cilia.

Although there are many thousands of olfactory neurons, each contains one, or at most a
few, of the 1,000 or so different receptor types, each of which responds only to a specific chemically
related group of odorant molecules. Each odorant has characteristic chemical groups that distinguish
it from other odorants, and each of these groups activates a different receptor type. Thus the identity

of a particular odorant is determined by the activation of a precise combination of receptors, each of which is contained in a distinct group of olfactory neurons.

The axons of the olfactory neurons synapse in the brain structures known as olfactory bulbs, which lie on the undersurface of the frontal lobes. Axons from olfactory neurons sharing a common
5 receptor specificity synapse together on certain olfactory-bulb neurons, thereby maintaining the specificity of the original stimuli.

OLFACTORY RECEPTORS

In contrast with the immunoglobulin system, the diversity of olfactory receptors is encoded by a large germ-line repertoire of olfactory receptor genes. The size of the olfactory receptor gene
10 family in the human genome is unknown but it has been estimated to encompass 200 to 1,000 genes.

The locations of only a few human genes have been determined to date. The picture that has emerged so far is that several large clusters of olfactory genes and pseudogenes span hundreds of kilobases on several chromosomes. Using FISH analyses, more than 25 distinct locations of olfactory receptors gene have been identified in the human genome.

15 In mammals, the olfactory epithelium appears to be organized into distinct topographic regions or zones in which expression of a particular receptor gene appears to be restricted to one of the four zones in the epithelium. Within the zone, the distribution of neurons expressing a given receptor is random. Chromosomal mapping studies have revealed clusters of odorant receptor genes at a single locus, and numerous such loci have been mapped to different chromosomes. However,
20 receptors expressed in the same zone map to different loci, and a single locus can contain genes expressed in different zones. A putative odorant receptor promoter, consisting of the 6.7 kb DNA fragment upstream of the receptor coding region, has been shown to be sufficient to direct olfactory receptor expression in a tissue-specific, zonal-specific manner.

Olfactory receptors share a seven-transmembrane domain structure (TM1 to TM7) with
25 many neurotransmitter and hormone receptors. They show a high degree of sequence similarity in some conserved domains (TM2 and TM7) as well as regions of diversity (TM3, TM4, TM5, and TM6). They are responsible for the recognition and G protein-mediated transduction of odorant signals. The genes encoding these receptors are devoid of introns within their coding regions.

Olfactory receptors display all hallmarks of the G-protein coupled receptor superfamily but
30 have also some unique motifs. Most notably they appear to be minimal in structure with very short cytoplasmic and extracellular loops. In addition, they display a striking structural diversity in the third, fourth and fifth transmembrane domains which are supposed to form the hydrophobic core of these proteins, and may form the ligand binding site of the receptors.

An understanding of the genetic basis of olfaction and a knowledge of olfactory receptors
35 are important to enable the design of fragrance, the identification of compounds which control appetite, or the detection of compounds which can be harmful or dangerous.

SUMMARY OF THE INVENTION

This invention provides a nucleic acid molecule encoding ten different olfactory receptor-like proteins (OLF).

The invention also deals with a nucleic acid molecule comprising a nucleotide sequence
5 encoding an olfactory receptor-like protein, which nucleotide sequence is selected from the group consisting of SEQ ID Nos 2-11, as well as with the corresponding polypeptide encoded by this nucleotide sequence and with antibodies directed against the corresponding polypeptide.

Oligonucleotide probes or primers hybridizing specifically with an olfactory receptor genomic sequence are also part of the present invention, as well as DNA amplification and detection
10 methods using said primers and probes.

The invention also concerns a purified and/or isolated biallelic marker located in the sequence of the olfactory receptor gene cluster of the invention, wherein said biallelic marker is useful as a diagnostic tool in order to detect an allele associated with a specific phenotype as regards to the olfaction system, including an alteration of the olfactory perception of substances or
15 molecules.

A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described above, and in particular of recombinant vectors comprising a sequence encoding an olfactory receptor protein, as well as of cell hosts and transgenic non human animals comprising said nucleic acid sequences or recombinant vectors.

20 A further object of the invention consists of methods for screening substances or molecules interacting with an olfactory receptor encoded by any of the nucleic acid molecule described above.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 : Alignment of the amino acid sequences of the olfactory polypeptides encoded by
25 the Open Reading Frames of the olfactory receptor gene cluster of the invention. The lower line represents the consensus sequence. The locations of the seven transmembrane domains TM1 to TM7 are boxed.

BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING

30 SEQ ID No 1 contains the olfactory receptor genomic sequence.

SEQ ID Nos 2-11 contains the nucleotide sequences of the open reading frame sequences of SEQ ID No 1 encoding the OLF1 to OLF10 polypeptides.

SEQ ID No 12-21 contain the amino acid sequence of OLF1 to OLF10 polypeptides encoded by the open reading frames of SEQ ID Nos 2-11.

SEQ ID Nos 22-25 contain the amplification primers used for FISH experiments described in Example 1.

SEQ ID No 26 contains a primer containing the additional PU 5' sequence described further in Example 3.

5 SEQ ID No 27 contains a primer containing the additional RP 5' sequence described further in Example 3.

In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code "r" in the sequences
 10 indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine. The code "y" in the sequences indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code "m" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an cytosine. The code "k" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine.
 15 The code "s" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code "w" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an thymine.

The nucleotide code of the original allele for each biallelic marker is the following:

	Biallelic marker	Original allele
20	99-13670-305	G
	99-13669-471	G
	99-13666-275	A
	99-13664-221	T
25	99-13663-218	G
	99-13660-277	C
	99-13652-407	G
	99-13652-357	A
	99-13652-308	A
30	99-13671-396	A
	99-13649-286	C
	99-13648-259	G
	99-13647-278	G

DETAILED DESCRIPTION OF THE INVENTION

35 The aim of the present invention is to provide polynucleotides and polypeptides related to novel olfactory receptors, notably useful in order to design suitable means for detecting specific odorant molecules in a material sample, particularly in a material sample suspected to contain an odorant molecule that consists of one of the specific ligands for the olfactory receptors of the invention.

DEFINITIONS

Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

General definitions

5 The terms "olfactory receptor gene" or "OLF1 to OLF10" genes, when used herein, encompasses genomic, mRNA and cDNA sequences encoding the OLF1 to OLF10 olfactory receptor proteins.

 The term "heterologous protein", when used herein, is intended to designate any protein or polypeptide other than the OLF1 to OLF10 proteins.

10 The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide
15 could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

 The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly
20 contemplated. As an example, purification from 0.1 % concentration to 10 % concentration is two orders of magnitude. The term "purified polynucleotide" is used herein to describe a polynucleotide or polynucleotide vector of the invention which has been separated from other compounds including, but not limited to other nucleic acids, carbohydrates, lipids and proteins (such as the enzymes used in the synthesis of the polynucleotide), or the separation of covalently closed polynucleotides from
25 linear polynucleotides. A polynucleotide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polynucleotide sequence and conformation (linear versus covalently close). A substantially pure polynucleotide typically comprises about 50%, preferably 60 to 90% weight/weight of a nucleic acid sample, more usually about 95%, and preferably is over about 99% pure. Polynucleotide purity or homogeneity is indicated by a number of means well
30 known in the art, such as agarose or polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polynucleotide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

 The term "polypeptide" refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of
35 polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term

polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term “recombinant polypeptide” is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

10 The term “purified polypeptide” is used herein to describe a polypeptide of the invention which has been separated from other compounds including, but not limited to nucleic acids, lipids, carbohydrates and other proteins. A polypeptide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure polypeptide typically comprises about 50%, preferably 60 to 90% weight/weight of a protein sample, 15 more usually about 95%, and preferably is over about 99% pure. Polypeptide purity or homogeneity is indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

As used herein, the term “non-human animal” refers to any non-human vertebrate, birds and 20 more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term “animal” is used to refer to any vertebrate, preferable a mammal. Both the terms “animal” and “mammal” expressly embrace human subjects unless preceded with the term “non-human”.

As used herein, the term “antibody” refers to a polypeptide or group of polypeptides which 25 are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as wells as fragments, including Fab, 30 Fab', F(ab)₂, and F(ab')₂ fragments.

As used herein, an “antigenic determinant” is the portion of an antigen molecule, in this case a OLF1 to OLF10 polypeptide, that determines the specificity of the antigen-antibody reaction. An “epitope” refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope 35 comprises at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional

nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by Geysen et al. 1984; PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506.

Throughout the present specification, the expression “nucleotide sequence” may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression “nucleotide sequence” encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

As used interchangeably herein, the terms “nucleic acids”, “oligonucleotides”, and “polynucleotides” include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form. The term “nucleotide” as used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. The term “nucleotide” is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. The term “nucleotide” is also used herein to encompass “modified nucleotides” which comprise at least one modifications (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No. WO 95/04064. The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, *ex vivo* generation, or a combination thereof, as well as utilizing any purification methods known in the art.

A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell required to initiate the specific transcription of a gene.

A sequence which is “operably linked” to a regulatory sequence such as a promoter means that said regulatory element is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the nucleic acid of interest. As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. More precisely, two DNA molecules (such as a polynucleotide containing a promoter region and a polynucleotide encoding a desired polypeptide or polynucleotide) are said to be “operably linked” if the nature of the linkage between the two polynucleotides does not (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding polynucleotide.

The term “vector” is used herein to designate either a circular or a linear DNA or RNA molecule, which is either double-stranded or single-stranded, and which comprise at least one

polynucleotide of interest that is sought to be transferred in a cell host or in a unicellular or multicellular host organism.

The term “primer” denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves
5 as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

The term “probe” denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined hereinbelow) which can be used to identify a specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence
10 complementary of the specific polynucleotide sequence to be identified.

The terms “trait” and “phenotype” are used interchangeably herein and refer to any visible, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example.

The term “allele” is used herein to refer to variants of a nucleotide sequence. A biallelic
15 polymorphism has two forms. Diploid organisms may be homozygous or heterozygous for an allelic form.

The term “genotype” as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention, a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term “genotyping” a sample
20 or an individual for a biallelic marker involves determining the specific allele or the specific nucleotide carried by an individual at a biallelic marker.

The term “mutation” as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

The term “polymorphism” as used herein refers to the occurrence of two or more alternative
25 genomic sequences or alleles between or among different genomes or individuals. “Polymorphic” refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A “polymorphic site” is the locus at which the variation occurs. A single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide also gives rise to single nucleotide
30 polymorphisms. In the context of the present invention, “single nucleotide polymorphism” preferably refers to a single nucleotide substitution. Typically, between different individuals, the polymorphic site may be occupied by two different nucleotides.

The term “biallelic polymorphism” and “biallelic marker” are used interchangeably herein to refer to a single nucleotide polymorphism having two alleles at a fairly high frequency in the
35 population. A “biallelic marker allele” refers to the nucleotide variants present at a biallelic marker site.

The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be "at the center" of the polynucleotide, and any nucleotide immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1 nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would be considered to be "within 2 nucleotides of the center", and so on.

Biallelic markers can be defined as genome-derived polynucleotides having between 2 and 100, preferably between 20, 30, or 40 and 60, and more preferably about 47 nucleotides in length, which exhibit biallelic polymorphism at one single base position. Each biallelic marker therefore corresponds to two forms of a polynucleotide sequence included in a gene which, when compared with one another, present a nucleotide modification at one position.

The term "upstream" is used herein to refer to a location which is toward the 5' end of the polynucleotide from a specific reference point.

The terms "base paired" and "Watson & Crick base paired" are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another by virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., *Biochemistry*, 4th edition, 1995).

The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. For the purpose of the present invention, a first polynucleotide is deemed to be complementary to a second polynucleotide when each base in the first polynucleotide is paired with its complementary base. Complementary bases are, generally, A and T (or A and U), or C and G. "Complement" is used herein as a synonym from "complementary polynucleotide", "complementary nucleic acid" and "complementary nucleotide sequence". These terms are applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two polynucleotides would actually bind.

Variants and fragments

1- Polynucleotides

The invention also relates to variants and fragments of the polynucleotides described herein, particularly of an olfactory receptor gene containing one or more biallelic markers according to the
5 invention.

Variants of polynucleotides, as the term is used herein, are polynucleotides that differ from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the polynucleotide may be made by mutagenesis techniques,
10 including those applied to polynucleotides, cells or organisms. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical.

Variants of polynucleotides according to the invention include, without being limited to, nucleotide sequences at least 95% identical to a nucleic acid selected from the group consisting of
15 SEQ ID Nos 1-11, or to any polynucleotide fragment of at least 12 consecutive nucleotides from a nucleic acid selected from the group consisting of SEQ ID Nos 1-11, and preferably at least 99% identical, more particularly at least 99.5% identical, and most preferably at least 99.8% identical to a nucleic acid selected from the group consisting of SEQ ID Nos 1-11, or to any polynucleotide fragment of at least 12 consecutive nucleotides from a nucleic acid selected from the group
20 consisting of SEQ ID Nos 1-11.

Changes in the nucleotide of a variant may be silent, which means that they do not alter the amino acids encoded by the polynucleotide. However, nucleotide changes may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides.
25 The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

In the context of the present invention, particularly preferred embodiments are those in which the polynucleotides encode polypeptides which retain substantially the same biological
30 function or activity as the mature olfactory receptor protein, or those in which the polynucleotides encode polypeptides which maintain or increase a particular biological activity, while reducing a second biological activity.

A polynucleotide fragment is a polynucleotide which sequence is fully comprised within part of a given nucleotide sequence, preferably the nucleotide sequence of an olfactory receptor gene
35 of the invention, and variants thereof. The fragment can be a portion of a coding or non-coding region of the olfactory receptor gene cluster. Preferably, such fragments comprise at least one of the biallelic markers A1 to A13 or the complements thereto or a biallelic marker in linkage

disequilibrium with one or more of the biallelic markers A1 to A13, for which the respective locations in the sequence listing are provided in Table 2.

Such fragments may be "free-standing", i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region.

5 However, several fragments may be comprised within a single larger polynucleotide.

As representative examples of polynucleotide fragments of the invention, there may be mentioned those which have from about 4, 6, 8, 15, 20, 25, 40, 10 to 30, 30 to 55, 50 to 100, 75 to 100 or 100 to 200 nucleotides in length. Preferred are those fragments having about 47 nucleotides in length, such as those comprising at least one of the biallelic markers A1 to A13 of the olfactory
10 receptor gene. Optionally, such fragments may consist of, or consist essentially of a contiguous span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 70, 80, 100, 250, 500 or 1000 nucleotides in length. A set of preferred fragments contain at least one of the biallelic markers A1 to A13 of the olfactory receptor gene which are described herein or the complements thereto.

2- Polypeptides

15 The invention also relates to variants, fragments, analogs and derivatives of the polypeptides described herein, including mutated olfactory receptor proteins.

The variant may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid
20 residues includes a substituent group, or 3) one in which the mutated olfactory receptor is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mutated olfactory receptor, such as a leader or secretory sequence or a sequence which is employed for purification of the mutated olfactory receptor or a preprotein sequence. Such variants are deemed to
25 be within the scope of those skilled in the art.

In the case of an amino acid substitution in the amino acid sequence of a polypeptide according to the invention, one or several amino acids can be replaced by "equivalent" amino acids. The expression "equivalent" amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids having similar properties, such that one skilled in the art of
30 peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Generally, the following groups of amino acids represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

More particularly, a variant olfactory receptor polypeptide comprises amino acid changes
35 ranging from 1, 2, 3, 4, 5, 10 to 20 substitutions, additions or deletions of one amino acid, preferably from 1 to 10, more preferably from 1 to 5 and most preferably from 1 to 3 substitutions, additions or deletions of one amino acid. The preferred amino acid changes are those which have little or no

influence on the biological activity or the capacity of the variant olfactory receptor polypeptide to bind to antibodies raised against a native olfactory receptor protein.

A specific, but not restrictive, embodiment of a modified peptide molecule of interest according to the present invention, which consists in a peptide molecule which is resistant to
5 proteolysis, is a peptide in which the -CONH- peptide bond is modified and replaced by a (CH₂NH) reduced bond, a (NHCO) retro inverso bond, a (CH₂-O) methylene-oxy bond, a (CH₂-S) thiomethylene bond, a (CH₂CH₂) carba bond, a (CO-CH₂) cetomethylene bond, a (CHOH-CH₂) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or also a -CH=CH- bond.

The polypeptide according to the invention could have post-translational modifications. For
10 example, it can present the following modifications: acylation, disulfide bond formation, prenylation, carboxymethylation and phosphorylation.

A polypeptide fragment is a polypeptide which sequence is fully comprised within part of a given polypeptide sequence, preferably a polypeptide encoded by an olfactory receptor gene and variants thereof.

15 Such fragments may be "free-standing", i.e. not part of or fused to other polypeptides, or they may be comprised within a single larger polypeptide of which they form a part or region. However, several fragments may be comprised within a single larger polypeptide.

As representative examples of polypeptide fragments of the invention, there may be mentioned those which have from about 5, 6, 7, 8, 9 or 10 to 15, 10 to 20, 15 to 40, or 30 to 55
20 amino acids long. Preferred polypeptide fragments according to the invention comprise a contiguous span of at least 6 amino acids, preferably at least 8 or amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of one amino acid sequence. Preferred are those fragments containing at least one amino acid mutation in the olfactory receptor protein under consideration.

Identity between nucleic acids or polypeptides

25 The terms "percentage of sequence identity" and "percentage homology" are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise
30 additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using either any of the
35 variety of sequence comparison algorithms and programs known in the art, or by eye inspection. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988; Altschul et al., 1990; Thompson

et al., 1994; Higgins et al., 1996; Altschul et al., 1990; Altschul et al., 1993). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well known in the art (see, e.g., Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997). In particular, five specific BLAST programs are

5 used to perform the following task:

(1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

(2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

10 (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

(4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

(5) TBLASTX compares the six-frame translations of a nucleotide query sequence against
15 the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring
20 matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992; Henikoff and Henikoff, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-
25 specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990). The BLAST programs may be used with the default parameters or with modified parameters provided by the user.

Stringent Hybridization Conditions

30 By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured
35 salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2

x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1 X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals.

Following the wash steps, the hybridized probes are detectable by autoradiography. Other
5 conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989; and Ausubel et al., 1989. These hybridization conditions are suitable for a nucleic acid molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for
10 example be adapted according to the teachings disclosed in the book of Hames and Higgins (1985) or in Sambrook et al.(1989).

HOMOLOGIES OF THE NOVEL OLFACTORY RECEPTOR GENE WITH KNOWN OLFACTORY RECEPTORS

A comparison analysis of various olfactory receptor amino acid sequences, including the
15 novel sequences of the invention, has been performed with the alignment program Pileup and the translation program MAP (Winsconsin Package version 8, GCG). The protein sequences were sorted into different families and subfamilies, taking into account their Amino acid Sequence Identity (ASI). It was observed the Open Reading Frames of the OLF1 to OLF10 genes are genetically clearly distinguished from the already known olfactory receptor sequences. For example, the
20 olfactory receptor OLF2 presents respectively 39.9 %, 43.1 % and 44.2 % of identity with prior art olfactory receptors referred in Genbank as L35475, U58675_1 and Y10530. In addition, the nucleotide sequences of Orf-2 to Orf-10 according to the invention are all grouped together, whereas the nucleotide Orf-1 of the invention forms a new family by itself. These amino acid sequence comparison data clearly indicate that the novel olfactory receptor sequences of the invention share
25 common genetic characteristics (Orf-2 to Orf-10) or have specific characteristics (Orf-1) that are not found in the prior art olfactory receptor sequences.

A. OLF1 TO OLF10 GENE POLYNUCLEOTIDES.

The cluster of ten olfactory receptor genes has been found by the inventors to be located on the human chromosome 11, more precisely within the 11q12-q13 locus of said chromosome as
30 described in Example 1.

1. Genomic sequences of the olfactory receptor gene

The present invention concerns the genomic sequence of an olfactory receptor cluster. The present invention encompasses the olfactory receptor gene, or olfactory receptor genomic sequences consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 1, a sequence

complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of SEQ ID No 1 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to the nucleotide sequence of SEQ ID No 1 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 1 are predominantly located outside the coding sequences contained in the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the olfactory receptor gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the olfactory receptor sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with the nucleotide sequence of SEQ ID No 1 or a complementary sequence thereto, under stringent hybridization conditions as defined above.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-113643, 114064-127488, 127855-144460. Additional preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-10000, 10001-20000, 20001-30000, 30001-40000, 40001-50000, 50001-60000, 60001-70000, 70001-80000, 80001-90000, 90001-100000, 100001-110000, 110001-120000, 120001-130000, 130001-140000, and 140001-144460. Further preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-5000, 5001-10000, 10001-15000, 15001-20000, 20001-25000, 25001-30000, 30001-35000, 35001-40000, 40001-45000, 45001-50000, 50001-55000, 55001-60000, 60001-65000, 65001-70000, 70001-75000, 75001-80000, 80001-85000, 85001-90000, 90001-95000, 95001-100000, 100001-105000, 105001-110000, 110001-115000, 115001-120000, 120001-125000, 125001-130000, 130001-135000, 135001-140000, and 140001-144460.

The olfactory receptor genomic nucleic acid comprises 10 open reading frames, each carried by a single exon and encoding a polypeptide designated OLF1 to OLF10. The open reading frames positions of OLF1 to OLF10 in SEQ ID No 1 are given as features in the sequence listing and are also detailed below in Table A.

- 5 Two truncated ubiquitin polypeptides Ubi1 and Ubi2, unrelated to olfactory receptor coding sequences, are encoded on the complementary strand of the olfactory receptor gene. The complementary sequence of the Ubi1 ORF is located between the nucleotide in position 114063 and the nucleotide in position 113644 of the nucleotide sequence of SEQ ID No 1. The complementary sequence of the Ubi2 ORF is located between the nucleotide in position 127854 and the nucleotide
- 10 in position 127489 of the nucleotide sequence of SEQ ID No 1.

Table A

Coding regions			Non-coding regions		
Name	Position in SEQ ID No 1		Name	Position in SEQ ID No 1	
	Beginning	End		Beginning	End
OLF1	2406	2600	NC1	1	2405
OLF2	9711	10658	NC2	2601	9710
OLF3	24851	25369	NC3	10659	24850
OLF4	45714	46661	NC4	25370	45713
OLF5	80198	81115	NC5	46662	80197
OLF6	96291	96902	NC6	81116	96290
OLF7	110758	111564	NC7	96903	110757
OLF8	122525	122887	NC8	111565	122524
OLF9	132454	133389	NC9	122888	132453
OLF10	143398	143577	NC10	133390	143397
			NC11	143578	144460

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 10 open reading frames of the

15 olfactory receptor gene, or a sequence complementary thereto.

The nucleic acid of SEQ ID No 1 also comprises non coding portions flanking each of the ten olfactory receptor open reading frames of the sense DNA strand.

The invention also embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the non-coding regions contained in the

20 olfactory receptor gene cluster of SEQ ID No 1, or a sequence complementary thereto as well as their fragments or variants. The term "non-coding" sequence refers to any nucleotide sequence which does not encode an amino acid. The non-coding sequences encompass upstream and downstream regions of the olfactory receptor ORFs of the invention, as well as regions located

between two successive olfactory receptor ORFs, as indicated in Table A which lists the 11 non-coding regions named from NC1 to NC11.

The nucleic acids defining the non-coding sequences of the polynucleotide of SEQ ID No 1 described above, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of one of the olfactory receptor genes of the invention in a test sample, or alternatively in order to amplify a target nucleotide sequence within the cluster of olfactory receptor encoding sequences according to the invention.

While this section is entitled "Genomic Sequences of the olfactory receptor gene," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of olfactory receptor on either side or between two or more such genomic sequences.

2. Coding regions of the olfactory receptor gene

The 10 olfactory receptor open reading frames are presented individually as SEQ ID Nos 2-11 in the appended sequence listing.

Thus, another object of the invention is a purified, isolated, or recombinant nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 2-11, complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant olfactory receptor cDNAs consisting of, consisting essentially of, or comprising a sequence selected from the group consisting of SEQ ID Nos 2-11.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2-11, advantageously 99 % nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of SEQ ID Nos 2-11, or a sequence complementary thereto or a biologically active fragment thereof.

Another object of the invention relates to purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of SEQ ID Nos 2-11, or a sequence complementary thereto or a biologically active fragment thereof.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the complements thereof. Additional preferred embodiments of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the

complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of said selected sequence : 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 601-650, 651-700, 701-750, 751-800, 801-850, 851-900, 901- the terminal nucleotide of the olfactory receptor coding regions, to the extent that such nucleotide positions are consistent with the lengths of the particular olfactory receptor coding region being referred to. Further preferred embodiments of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2, 4, 7, 9 and 11, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of said selected sequence: 1-25, 26-50, 51-75, 76-100, 101-125, 126-150, 151-175, 176-200, 201-225, 226-250, 251-275, 276-300, 301-325, 326-350, 351-375, 376-400, 401-425, 426-450, 451-475, 476-500, 501-525, 526-550, 551-575, 576-the terminal nucleotide of the olfactory receptor coding regions, to the extent that such nucleotide positions are consistent with the lengths of the particular olfactory receptor coding region being referred to.

The present invention also embodies isolated, purified, and recombinant polynucleotides encoding olfactory receptor polypeptides, wherein olfactory receptor polypeptides comprise an amino acid sequence selected from the group consisting of SEQ ID Nos 12-21, a nucleotide sequence complementary thereto, a fragment or a variant thereof. The present invention also embodies isolated, purified, and recombinant polynucleotides which encode polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12-21. In a preferred embodiment, the present invention embodies isolated, purified, and recombinant polynucleotides which encode polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12-21 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions in said selected sequence: 1-20, 21-40, 41-60, 61-80, 81-100, 101-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-the terminal amino acid of the olfactory receptor proteins, to the extent that such amino acid positions are consistent with the lengths of the particular olfactory receptor protein being referred to. In another preferred embodiment, the present invention embodies isolated, purified, and recombinant polynucleotides which encode polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12, 14, 17, 19 or 21 wherein said contiguous span includes at least 1, 2, 3, 5 or 7 of the following amino acid positions in said selected sequence: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, 101-

110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180, 181-190, 191-the terminal amino acid of the olfactory receptor proteins, to the extent that such amino acid positions are consistent with the lengths of the particular olfactory receptor protein being referred to.

In further preferred embodiments, the present invention embodies isolated, purified, and
 5 recombinant polynucleotides which encode olfactory receptor polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID No 12-21, wherein said contiguous span includes at least one amino acid at the following positions of said selected sequence:

- 10 i) 1-3, 10, 16, 21, 28, 33, 34, 36, 42-44, 46, 49, 53, 54, 57, 59, 63, and 64 for SEQ ID No 12;
- ii) 2, 4, 6, 8, 18, 25, 34, 37, 44, 52, 56, 80, 83, 89, 98, 101, 102, 113, 114, 117, 120, 139, 148, 158, 186, 195, 212, 219, 247, 266, 270, 280, 295, 298, 299, 301, 311, and 313-315 for SEQ ID No 13;
- 15 iii) 2-4, 6, 18, 21, 25, 34, 37, 98, 99, 102, 113, 114, 133, 143, 148, 158-163, 166, 167, 169, and 170 for SEQ ID No 14;
- iv) 2, 4, 6, 8, 18, 25, 34, 37, 44, 52, 54, 56, 80, 83, 89, 98, 101, 102, 113, 114, 117, 120, 139, 148, 158, 186, 195, 212, 219, 247, 266, 270, 280, 298, 299, 311, and 313-315 for SEQ ID No 15;
- 20 v) 3, 18, 20, 25, 34, 47, 49, 67, 97, 100, 107, 108, 112, 113, 126, 135, 142, 146, 147, 157, 159-160, 194, 196, 228, 245, 264, 265, 269, 279, 298, and 302 for SEQ ID No 16;
- vi) 2, 6, 18, 20, 33, 34, 37, 65, 68, 69, 72, 86, 88, 101, 107, 113, 114, 148, 158, 161, 164, 195, and 198 for SEQ ID No 17;
- 25 vii) 2, 6, 7, 52, 56, 67, 88, 94, 97, 110, 113, 116, 119, 120, 127, 135, 150, 153, 164, 174, 175, 180, 184, 217, 221, 259, 261, and 268 for SEQ ID No 18;
- viii) 17, 18, 20, 28, 33, 35, 49-52, 105, 111, and 112 for SEQ ID No 19;
- ix) 17, 20, 33, 35, 49-53, 56, 111, 112, 132, 138, 141, 147, 154, 157, 160, 163, 164, 194, 197, 204, 211, 214, 218, 219, 252, 265, 286, 295, 301, 303, 305, 306 and 309 for SEQ ID No 20; and
- 30 x) 9, 18, 26-28, 34, 47 and 50 for SEQ ID No 21, to the extent that such amino acid lengths are consistent with the lengths of the particular olfactory receptor protein being referred to.

Additional preferred fragments of the nucleotide sequences of SEQ ID Nos 2-11 are those
 35 encoding olfactory receptor polypeptide fragments located outside the transmembrane domains of the corresponding protein as located in boxes in Figure 1.

The above disclosed polynucleotides that contain only coding sequences derived from the olfactory receptor ORFs may be expressed in a desired host cell or a desired host organism, when said polynucleotides are placed under the control of suitable expression signals. Such a polynucleotide, when placed under suitable expression signals, may be inserted in a vector for its
5 expression.

While this section is entitled “Coding regions of the olfactory receptor gene,” it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of olfactory receptor on either side or between two or more such genomic sequences.

10 3. Polynucleotide Constructs

The terms “polynucleotide construct” and “recombinant polynucleotide” are used interchangeably herein to refer to linear or circular, purified or isolated polynucleotides that have been artificially designed and which comprise at least two nucleotide sequences that are not found as contiguous nucleotide sequences in their initial natural environment.

15 DNA Construct That Enables Directing Temporal And Spatial olfactory receptor Gene Expression In Recombinant Cell Hosts And In Transgenic Animals.

In order to study the physiological and phenotypic consequences of a lack of synthesis of the olfactory receptor protein, both at the cell level and at the multi cellular organism level, the invention also encompasses DNA constructs and recombinant vectors enabling a conditional
20 expression of a specific allele of the olfactory receptor genomic sequence or cDNA and also of a copy of this genomic sequence or cDNA harboring substitutions, deletions, or additions of one or more bases as regards to the olfactory receptor nucleotide sequence of SEQ ID Nos 1-11, or a fragment thereof, these base substitutions, deletions or additions being located in the coding regions of the olfactory receptor genomic sequence or within the olfactory receptor open reading frames of
25 SEQ ID Nos 2-11. In a preferred embodiment, the olfactory receptor sequence comprises a biallelic marker of the present invention. In a preferred embodiment, the olfactory receptor sequence comprises a biallelic marker of the present invention, preferably one of the biallelic markers A1 to A13.

The present invention embodies recombinant vectors comprising any one of the
30 polynucleotides described in the present invention. More particularly, the polynucleotide constructs according to the present invention can comprise any of the polynucleotides described in the “Genomic sequences of the olfactory receptor gene” section, the “Coding regions of the olfactory receptor Gene” section, and the “Oligonucleotide probes and primers” section.

DNA Constructs Allowing Homologous Recombination: Replacement Vectors

A first preferred DNA construct will comprise, from 5'-end to 3'-end: (a) a first nucleotide sequence that is comprised in the olfactory receptor genomic sequence; (b) a nucleotide sequence comprising a positive selection marker, such as the marker for neomycine resistance (*neo*); and (c) a second nucleotide sequence that is comprised in the olfactory receptor genomic sequence, and is located on the genome downstream the first olfactory receptor nucleotide sequence (a).

In a preferred embodiment, this DNA construct also comprises a negative selection marker located upstream the nucleotide sequence (a) or downstream the nucleotide sequence (c). Preferably, the negative selection marker comprises the thymidine kinase (*tk*) gene (Thomas et al., 1986), the hygromycine beta gene (Te Riele et al., 1990), the *hprt* gene (Van der Lugt et al., 1991; Reid et al., 1990) or the Diphtheria toxin A fragment (*Dt-A*) gene (Nada et al., 1993; Yagi et al. 1990). Preferably, the positive selection marker is located within an olfactory receptor open reading frame sequence so as to interrupt the sequence encoding an olfactory receptor protein. These replacement vectors are described, for example, by Thomas et al. (1986; 1987), Mansour et al. (1988) and Koller et al. (1992).

The first and second nucleotide sequences (a) and (c) may be indifferently located within an olfactory receptor regulatory sequence, an intronic sequence, an exon sequence or a sequence containing both regulatory and/or intronic and/or exon sequences. The size of the nucleotide sequences (a) and (c) ranges from 1 to 50 kb, preferably from 1 to 10 kb, more preferably from 2 to 6 kb and most preferably from 2 to 4 kb.

DNA Constructs Allowing Homologous Recombination: Cre-LoxP System.

These new DNA constructs make use of the site specific recombination system of the P1 phage. The P1 phage possesses a recombinase called Cre which interacts specifically with a 34 base pairs *loxP* site. The *loxP* site is composed of two palindromic sequences of 13 bp separated by a 8 bp conserved sequence (Hoess et al., 1986). The recombination by the Cre enzyme between two *loxP* sites having an identical orientation leads to the deletion of the DNA fragment.

The Cre-*loxP* system used in combination with a homologous recombination technique has been first described by Gu et al. (1993, 1994). Briefly, a nucleotide sequence of interest to be inserted in a targeted location of the genome harbors at least two *loxP* sites in the same orientation and located at the respective ends of a nucleotide sequence to be excised from the recombinant genome. The excision event requires the presence of the recombinase (Cre) enzyme within the nucleus of the recombinant cell host. The recombinase enzyme may be brought at the desired time either by (a) incubating the recombinant cell hosts in a culture medium containing this enzyme, by injecting the Cre enzyme directly into the desired cell, such as described by Araki et al. (1995), or by lipofection of the enzyme into the cells, such as described by Baubonis et al. (1993); (b) transfecting the cell host with a vector comprising the *Cre* coding sequence operably linked to a promoter functional in the recombinant cell host, which promoter being optionally inducible, said vector being

introduced in the recombinant cell host, such as described by Gu et al.(1993) and Sauer et al.(1988);
(c) introducing in the genome of the cell host a polynucleotide comprising the *Cre* coding sequence
operably linked to a promoter functional in the recombinant cell host, which promoter is optionally
inducible, and said polynucleotide being inserted in the genome of the cell host either by a random
5 insertion event or an homologous recombination event, such as described by Gu et al.(1994).

In a specific embodiment, the vector containing the sequence to be inserted in the olfactory
receptor gene by homologous recombination is constructed in such a way that selectable markers are
flanked by *loxP* sites of the same orientation, it is possible, by treatment by the Cre enzyme, to
eliminate the selectable markers while leaving the olfactory receptor sequences of interest that have
10 been inserted by an homologous recombination event. Again, two selectable markers are needed: a
positive selection marker to select for the recombination event and a negative selection marker to
select for the homologous recombination event. Vectors and methods using the Cre-*loxP* system are
described by Zou et al.(1994).

Thus, a second preferred DNA construct of the invention comprises, from 5'-end to 3'-end:
15 (a) a first nucleotide sequence that is comprised in the olfactory receptor genomic sequence; (b) a
nucleotide sequence comprising a polynucleotide encoding a positive selection marker, said
nucleotide sequence comprising additionally two sequences defining a site recognized by a
recombinase, such as a *loxP* site, the two sites being placed in the same orientation; and (c) a second
nucleotide sequence that is comprised in the olfactory receptor genomic sequence, and is located on
20 the genome downstream of the first olfactory receptor nucleotide sequence (a).

The sequences defining a site recognized by a recombinase, such as a *loxP* site, are
preferably located within the nucleotide sequence (b) at suitable locations bordering the nucleotide
sequence for which the conditional excision is sought. In one specific embodiment, two *loxP* sites
are located at each side of the positive selection marker sequence, in order to allow its excision at a
25 desired time after the occurrence of the homologous recombination event.

In a preferred embodiment of a method using the third DNA construct described above, the
excision of the polynucleotide fragment bordered by the two sites recognized by a recombinase,
preferably two *loxP* sites, is performed at a desired time, due to the presence within the genome of
the recombinant host cell of a sequence encoding the Cre enzyme operably linked to a promoter
30 sequence, preferably an inducible promoter, more preferably a tissue-specific promoter sequence and
most preferably a promoter sequence which is both inducible and tissue-specific, such as described
by Gu et al.(1994).

The presence of the Cre enzyme within the genome of the recombinant cell host may result
from the breeding of two transgenic animals, the first transgenic animal bearing the olfactory
35 receptor-derived sequence of interest containing the *loxP* sites as described above and the second
transgenic animal bearing the *Cre* coding sequence operably linked to a suitable promoter sequence,
such as described by Gu et al.(1994).

Spatio-temporal control of the Cre enzyme expression may also be achieved with an adenovirus based vector that contains the Cre gene thus allowing infection of cells, or *in vivo* infection of organs, for delivery of the Cre enzyme, such as described by Anton and Graham (1995) and Kanegae et al.(1995).

5 The DNA constructs described above may be used to introduce a desired nucleotide sequence of the invention, preferably an olfactory receptor genomic sequence or an olfactory receptor coding region sequences, and most preferably an altered copy of an olfactory receptor genomic or coding region sequences, within a predetermined location of the targeted genome, leading either to the generation of an altered copy of a targeted gene (knock-out homologous
10 recombination) or to the replacement of a copy of the targeted gene by another copy sufficiently homologous to allow an homologous recombination event to occur (knock-in homologous recombination). In a specific embodiment, the DNA constructs described above may be used to introduce an olfactory receptor genomic sequence or an olfactory receptor coding region sequence comprising at least one biallelic marker of the present invention, preferably at least one biallelic
15 marker selected from the group consisting of A1 to A13.

Nuclear Antisense DNA Constructs

Other compositions containing a vector of the invention comprising an oligonucleotide fragment of the nucleic sequence SEQ ID Nos 2-11, preferably a fragment including the start codon of the olfactory receptor gene, as an antisense tool that inhibits the expression of the corresponding
20 olfactory receptor gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995) or those described in PCT Application No WO 95/24223.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the mRNAs of olfactory receptor that contains the translation initiation codon ATG.

25 Preferably, the antisense polynucleotides of the invention have a 3' polyadenylation signal that has been replaced with a self-cleaving ribozyme sequence, such that RNA polymerase II transcripts are produced without poly(A) at their 3' ends, these antisense polynucleotides being incapable of export from the nucleus, such as described by Liu et al.(1994). In a preferred embodiment, these olfactory receptor antisense polynucleotides also comprise, within the ribozyme
30 cassette, a histone stem-loop structure to stabilize cleaved transcripts against 3'-5' exonucleolytic degradation, such as the structure described by Eckner et al.(1991).

4. Oligonucleotide probes and primers

Polynucleotides derived from the olfactory receptor gene are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID Nos 1-11, or a fragment,
35 complement, or variant thereof in a test sample, preferably a human olfactory epithelium tissue or isolated human olfactory epithelium cells.

Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-113643, 114064-127488, 127855-144460. Additional preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-10000, 10001-20000, 20001-30000, 30001-40000, 40001-50000, 50001-60000, 60001-70000, 70001-80000, 80001-90000, 90001-100000, 100001-110000, 110001-120000, 120001-130000, 130001-140000, and 140001-144460. Further preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-5000, 5001-10000, 10001-15000, 15001-20000, 20001-25000, 25001-30000, 30001-35000, 35001-40000, 40001-45000, 45001-50000, 50001-55000, 55001-60000, 60001-65000, 65001-70000, 70001-75000, 75001-80000, 80001-85000, 85001-90000, 90001-95000, 95001-100000, 100001-105000, 105001-110000, 110001-115000, 115001-120000, 120001-125000, 125001-130000, 130001-135000, 135001-140000, and 140001-144460.

Other particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 45 or 50 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of said selected sequence : 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 601-650, 651-700, 701-750, 751-800, 801-850, 851-900, 901- the terminal nucleotide of the olfactory receptor coding regions, to the extent that such nucleotide positions are consistent with the lengths of the particular olfactory receptor coding region being referred to. Further preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 22 or 25 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2, 4, 7, 9 and 11, or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of said selected sequence: 1-25, 26-50, 51-75, 76-100, 101-125, 126-150, 151-175, 176-200, 201-225, 226-250, 251-275, 276-300, 301-325, 326-350, 351-375, 376-400, 401-425, 426-450, 451-475, 476-500, 501-525, 526-550, 551-575, 576-the terminal nucleotide of the olfactory receptor coding regions, to the extent that such nucleotide

positions are consistent with the lengths of the particular olfactory receptor coding region being referred to.

Thus, the invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected
5 from the group consisting of SEQ ID Nos 1-11, a variant thereof and a sequence complementary thereto.

In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 and the complement thereof, wherein said span includes an olfactory receptor-related
10 biallelic marker in said sequence; optionally, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof; optionally, wherein said contiguous span is 18 to 47 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is
15 at the center of said polynucleotide; optionally, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide; and optionally, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide. In a preferred embodiment, said probes comprises, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P13 and the complementary
20 sequences thereto, for which the respective locations in the sequence listing are provided in Table 3.

In another embodiment the invention encompasses isolated, purified and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1, or the complements thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is
25 located within 20 nucleotides upstream of an olfactory receptor-related biallelic marker in said sequence; optionally, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof; optionally, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said olfactory receptor-related biallelic marker in said sequence; and optionally, wherein said polynucleotide consists essentially of a sequence
30 selected from the following sequences: D1 to D13 and E1 to E13, for which the respective locations in the sequence listing are provided in Table 4.

In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B11 and C1 to C11, for which the respective locations in the sequence
35 listing are provided in Table 1.

In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assays, sequencing assays, and enzyme-based mismatch detection assays for

determining the identity of the nucleotide at an olfactory receptor-related biallelic marker in SEQ ID No 1, or the complements thereof, as well as polynucleotides for use in amplifying segments of nucleotides comprising an olfactory receptor-related biallelic marker in SEQ ID No 1, or the complements thereof; optionally, wherein said olfactory receptor-related biallelic marker is selected
5 from the group consisting of A1 to A13, and the complements thereof.

A probe or a primer according to the invention has between 8 and 1000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 nucleotides in length. More particularly, the length of these probes and primers can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30
10 nucleotides. Shorter probes and primers tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes and primers are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art. A preferred probe or
15 primer consists of a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P13 and the complementary sequence thereto, B1 to B11, C1 to C11, D1 to D13, and E1 to E13.

Primers and other oligonucleotides according to the invention are synthesized to be “substantially” complementary to a strand of the olfactory receptor gene of the invention to be
20 amplified. The primer sequence does not need to reflect the exact sequence of the DNA template. Minor mismatches can be accommodated by reducing the stringency of the hybridization conditions. Among the various methods available to design useful primers, the OSP computer software can be used by the skilled person (see Hillier & Green, 1991). All primers contained a common upstream oligonucleotide tail enabling the easy systematic sequencing of the resulting amplification
25 fragments.

The formation of stable hybrids depends on the melting temperature (T_m) of the DNA. The T_m depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in
30 the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979),
35 the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in that additional
5 dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or
10 modified, U.S. Patent Application Serial No. 07/049,061 filed April 19, 1993 describes modifications, which can be used to render a probe non-extendable.

Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating any label known in the art to be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive
15 substances (including, ^{32}P , ^{35}S , ^3H , ^{125}I), fluorescent dyes (including, 5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3' and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In addition, the probes according to the present invention may have structural characteristics such that
20 they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture
25 label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For
30 example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer
35 itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA or Northern hybridization to mRNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the OLF1 to OLF10 genes or mRNA using other techniques. Generally, the probes
5 are complementary to the OLF1 to OLF10 gene coding sequences, although probes complementary to non-coding sequences are also contemplated. The probes of the present invention can also be useful for genotyping the biallelic markers of the cluster of olfactory receptor genes of the present invention.

Any of the polynucleotides, primers and probes of the present invention can be conveniently
10 immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of
15 microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent.

20 Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to
25 immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other
30 configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

35 Consequently, the invention also comprises a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-11, a

fragment or a variant thereof and a complementary sequence thereto in a sample, said method comprising the following steps of:

a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-11, a fragment or a variant thereof and a complementary sequence thereto and the sample to be assayed; and

b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

The invention further concerns a kit for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-11, a fragment or a variant thereof and a complementary sequence thereto in a sample, said kit comprising:

a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-11, a fragment or a variant thereof and a complementary sequence thereto; and

b) optionally, the reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P13 and the complementary sequence thereto, B1 to B11, C1 to C11, D1 to D13, E1 to E13 or a biallelic marker selected from the group consisting of A1 to A13 and the complements thereto.

Oligonucleotide arrays

A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in the olfactory receptor gene and may also be used for detecting mutations in the coding or in the non-coding sequences of the olfactory receptor gene.

Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the

polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPST™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPST™ technologies are provided in US Patents 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in the olfactory receptor gene. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations, it is meant, mutations on the olfactory receptor gene that have been identified according to, for example, the technique used by Huang et al.(1996) or Samson et al.(1996).

Another technique that is used to detect mutations in the olfactory receptor gene is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of the olfactory receptor genomic DNA or cDNA. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence with the wild gene sequence, measure its amount, and detect differences between the target sequence and the reference wild gene sequence of the olfactory receptor gene. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a

“footprint” for the probes flanking a mutation position. This technique was described by Chee et al. in 1996.

Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

A further object of the invention consists of an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P13, B1 to B11, C1 to C11, D1 to D13, E1 to E13, the sequences complementary thereto, a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, and at least one sequence comprising a biallelic marker selected from the group consisting of A1 to A13 and the complements thereto.

The invention also pertains to an array of nucleic acid sequences comprising either at least two of the sequences selected from the group consisting of P1 to P13, B1 to B11, C1 to C11, D1 to D13, E1 to E13, the sequences complementary thereto, a fragment thereof of at least 8 consecutive nucleotides thereof, and at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A13 and the complements thereof.

B. OLF1 TO OLF10 PROTEINS AND POLYPEPTIDE FRAGMENTS

The proteins encoded by the Open Reading Frames of the OLF1 to OLF10 genes are listed individually in the sequence listing as SEQ ID Nos 12-21.

The term “olfactory receptor polypeptides” is used herein to embrace all of the proteins and polypeptides of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies olfactory receptor proteins from humans, including isolated or purified olfactory receptor proteins consisting of, consisting essentially of, or comprising the sequences of SEQ ID Nos 12-21 or naturally-occurring variants or fragments thereof.

The present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 12-21. In a preferred embodiment, the present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 12-21 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions in SEQ ID Nos 12-21: 1-20, 21-40, 41-60, 61-80, 81-100, 101-120, 121-140, 141-160, 161-180, 181-200, 201-220, 221-240, 241-260, 261-280, 281-300, 301-the terminal amino acid of the olfactory receptor proteins, to the extent that such amino acid positions are consistent with the lengths of the particular olfactory receptor protein being referred to. In another preferred embodiment, the present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6

amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12, 14, 17, 19 and 21 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions of said selected sequence: 1-10, 11-20, 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, 91-100, 101-110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180, 181-190, 191-200, 201-210, 211-220, 221-230, 231-240, 241-250, 251-260, 261-270, 271-280, 281-290, 291-300, 301-310, 311-320, 321-330, 331-340, 341-350, 351-360, 361-370, 371-380, 381-390, 391-400, 401-410, 411-420, 421-430, 431-440, 441-450, 451-460, 461-470, 471-480, 481-490, 491-500, 501-510, 511-520, 521-530, 531-540, 541-550, 551-560, 561-570, 571-580, 581-590, 591-600, 601-610, 611-620, 621-630, 631-640, 641-650, 651-660, 661-670, 671-680, 681-690, 691-700, 701-710, 711-720, 721-730, 731-740, 741-750, 751-760, 761-770, 771-780, 781-790, 791-800, 801-810, 811-820, 821-830, 831-840, 841-850, 851-860, 861-870, 871-880, 881-890, 891-900, 901-910, 911-920, 921-930, 931-940, 941-950, 951-960, 961-970, 971-980, 981-990, 991-1000, 1001-1010, 1011-1020, 1021-1030, 1031-1040, 1041-1050, 1051-1060, 1061-1070, 1071-1080, 1081-1090, 1091-1100, 1101-1110, 1111-1120, 1121-1130, 1131-1140, 1141-1150, 1151-1160, 1161-1170, 1171-1180, 1181-1190, 1191-1200, 1201-1210, 1211-1220, 1221-1230, 1231-1240, 1241-1250, 1251-1260, 1261-1270, 1271-1280, 1281-1290, 1291-1300, 1301-1310, 1311-1320, 1321-1330, 1331-1340, 1341-1350, 1351-1360, 1361-1370, 1371-1380, 1381-1390, 1391-1400, 1401-1410, 1411-1420, 1421-1430, 1431-1440, 1441-1450, 1451-1460, 1461-1470, 1471-1480, 1481-1490, 1491-1500, 1501-1510, 1511-1520, 1521-1530, 1531-1540, 1541-1550, 1551-1560, 1561-1570, 1571-1580, 1581-1590, 1591-1600, 1601-1610, 1611-1620, 1621-1630, 1631-1640, 1641-1650, 1651-1660, 1661-1670, 1671-1680, 1681-1690, 1691-1700, 1701-1710, 1711-1720, 1721-1730, 1731-1740, 1741-1750, 1751-1760, 1761-1770, 1771-1780, 1781-1790, 1791-1800, 1801-1810, 1811-1820, 1821-1830, 1831-1840, 1841-1850, 1851-1860, 1861-1870, 1871-1880, 1881-1890, 1891-1900, 1901-1910, 1911-1920, 1921-1930, 1931-1940, 1941-1950, 1951-1960, 1961-1970, 1971-1980, 1981-1990, 1991-2000, 2001-2010, 2011-2020, 2021-2030, 2031-2040, 2041-2050, 2051-2060, 2061-2070, 2071-2080, 2081-2090, 2091-2100, 2101-2110, 2111-2120, 2121-2130, 2131-2140, 2141-2150, 2151-2160, 2161-2170, 2171-2180, 2181-2190, 2191-2200, 2201-2210, 2211-2220, 2221-2230, 2231-2240, 2241-2250, 2251-2260, 2261-2270, 2271-2280, 2281-2290, 2291-2300, 2301-2310, 2311-2320, 2321-2330, 2331-2340, 2341-2350, 2351-2360, 2361-2370, 2371-2380, 2381-2390, 2391-2400, 2401-2410, 2411-2420, 2421-2430, 2431-2440, 2441-2450, 2451-2460, 2461-2470, 2471-2480, 2481-2490, 2491-2500, 2501-2510, 2511-2520, 2521-2530, 2531-2540, 2541-2550, 2551-2560, 2561-2570, 2571-2580, 2581-2590, 2591-2600, 2601-2610, 2611-2620, 2621-2630, 2631-2640, 2641-2650, 2651-2660, 2661-2670, 2671-2680, 2681-2690, 2691-2700, 2701-2710, 2711-2720, 2721-2730, 2731-2740, 2741-2750, 2751-2760, 2761-2770, 2771-2780, 2781-2790, 2791-2800, 2801-2810, 2811-2820, 2821-2830, 2831-2840, 2841-2850, 2851-2860, 2861-2870, 2871-2880, 2881-2890, 2891-2900, 2901-2910, 2911-2920, 2921-2930, 2931-2940, 2941-2950, 2951-2960, 2961-2970, 2971-2980, 2981-2990, 2991-3000, 3001-3010, 3011-3020, 3021-3030, 3031-3040, 3041-3050, 3051-3060, 3061-3070, 3071-3080, 3081-3090, 3091-3100, 3101-3110, 3111-3120, 3121-3130, 3131-3140, 3141-3150, 3151-3160, 3161-3170, 3171-3180, 3181-3190, 3191-3200, 3201-3210, 3211-3220, 3221-3230, 3231-3240, 3241-3250, 3251-3260, 3261-3270, 3271-3280, 3281-3290, 3291-3300, 3301-3310, 3311-3320, 3321-3330, 3331-3340, 3341-3350, 3351-3360, 3361-3370, 3371-3380, 3381-3390, 3391-3400, 3401-3410, 3411-3420, 3421-3430, 3431-3440, 3441-3450, 3451-3460, 3461-3470, 3471-3480, 3481-3490, 3491-3500, 3501-3510, 3511-3520, 3521-3530, 3531-3540, 3541-3550, 3551-3560, 3561-3570, 3571-3580, 3581-3590, 3591-3600, 3601-3610, 3611-3620, 3621-3630, 3631-3640, 3641-3650, 3651-3660, 3661-3670, 3671-3680, 3681-3690, 3691-3700, 3701-3710, 3711-3720, 3721-3730, 3731-3740, 3741-3750, 3751-3760, 3761-3770, 3771-3780, 3781-3790, 3791-3800, 3801-3810, 3811-3820, 3821-3830, 3831-3840, 3841-3850, 3851-3860, 3861-3870, 3871-3880, 3881-3890, 3891-3900, 3901-3910, 3911-3920, 3921-3930, 3931-3940, 3941-3950, 3951-3960, 3961-3970, 3971-3980, 3981-3990, 3991-4000, 4001-4010, 4011-4020, 4021-4030, 4031-4040, 4041-4050, 4051-4060, 4061-4070, 4071-4080, 4081-4090, 4091-4100, 4101-4110, 4111-4120, 4121-4130, 4131-4140, 4141-4150, 4151-4160, 4161-4170, 4171-4180, 4181-4190, 4191-4200, 4201-4210, 4211-4220, 4221-4230, 4231-4240, 4241-4250, 4251-4260, 4261-4270, 4271-4280, 4281-4290, 4291-4300, 4301-4310, 4311-4320, 4321-4330, 4331-4340, 4341-4350, 4351-4360, 4361-4370, 4371-4380, 4381-4390, 4391-4400, 4401-4410, 4411-4420, 4421-4430, 4431-4440, 4441-4450, 4451-4460, 4461-4470, 4471-4480, 4481-4490, 4491-4500, 4501-4510, 4511-4520, 4521-4530, 4531-4540, 4541-4550, 4551-4560, 4561-4570, 4571-4580, 4581-4590, 4591-4600, 4601-4610, 4611-4620, 4621-4630, 4631-4640, 4641-4650, 4651-4660, 4661-4670, 4671-4680, 4681-4690, 4691-4700, 4701-4710, 4711-4720, 4721-4730, 4731-4740, 4741-4750, 4751-4760, 4761-4770, 4771-4780, 4781-4790, 4791-4800, 4801-4810, 4811-4820, 4821-4830, 4831-4840, 4841-4850, 4851-4860, 4861-4870, 4871-4880, 4881-4890, 4891-4900, 4901-4910, 4911-4920, 4921-4930, 4931-4940, 4941-4950, 4951-4960, 4961-4970, 4971-4980, 4981-4990, 4991-5000, 5001-5010, 5011-5020, 5021-5030, 5031-5040, 5041-5050, 5051-5060, 5061-5070, 5071-5080, 5081-5090, 5091-5100, 5101-5110, 5111-5120, 5121-5130, 5131-5140, 5141-5150, 5151-5160, 5161-5170, 5171-5180, 5181-5190, 5191-5200, 5201-5210, 5211-5220, 5221-5230, 5231-5240, 5241-5250, 5251-5260, 5261-5270, 5271-5280, 5281-5290, 5291-5300, 5301-5310, 5311-5320, 5321-5330, 5331-5340, 5341-5350, 5351-5360, 5361-5370, 5371-5380, 5381-5390, 5391-5400, 5401-5410, 5411-5420, 5421-5430, 5431-5440, 5441-5450, 5451-5460, 5461-5470, 5471-5480, 5481-5490, 5491-5500, 5501-5510, 5511-5520, 5521-5530, 5531-5540, 5541-5550, 5551-5560, 5561-5570, 5571-5580, 5581-5590, 5591-5600, 5601-5610, 5611-5620, 5621-5630, 5631-5640, 5641-5650, 5651-5660, 5661-5670, 5671-5680, 5681-5690, 5691-5700, 5701-5710, 5711-5720, 5721-5730, 5731-5740, 5741-5750, 5751-5760, 5761-5770, 5771-5780, 5781-5790, 5791-5800, 5801-5810, 5811-5820, 5821-5830, 5831-5840, 5841-5850, 5851-5860, 5861-5870, 5871-5880, 5881-5890, 5891-5900, 5901-5910, 5911-5920, 5921-5930, 5931-5940, 5941-5950, 5951-5960, 5961-5970, 5971-5980, 5981-5990, 5991-6000, 6001-6010, 6011-6020, 6021-6030, 6031-6040, 6041-6050, 6051-6060, 6061-6070, 6071-6080, 6081-6090, 6091-6100, 6101-6110, 6111-6120, 6121-6130, 6131-6140, 6141-6150, 6151-6160, 6161-6170, 6171-6180, 6181-6190, 6191-6200, 6201-6210, 6211-6220, 6221-6230, 6231-6240, 6241-6250, 6251-6260, 6261-6270, 6271-6280, 6281-6290, 6291-6300, 6301-6310, 6311-6320, 6321-6330, 6331-6340, 6341-6350, 6351-6360, 6361-6370, 6371-6380, 6381-6390, 6391-6400, 6401-6410, 6411-6420, 6421-6430, 6431-6440, 6441-6450, 6451-6460, 6461-6470, 6471-6480, 6481-6490, 6491-6500, 6501-6510, 6511-6520, 6521-6530, 6531-6540, 6541-6550, 6551-6560, 6561-6570, 6571-6580, 6581-6590, 6591-6600, 6601-6610, 6611-6620, 6621-6630, 6631-6640, 6641-6650, 6651-6660, 6661-6670, 6671-6680, 6681-6690, 6691-6700, 6701-6710, 6711-6720, 6721-6730, 6731-6740, 6741-6750, 6751-6760, 6761-6770, 6771-6780, 6781-6790, 6791-6800, 6801-6810, 6811-6820, 6821-6830, 6831-6840, 6841-6850, 6851-6860, 6861-6870, 6871-6880, 6881-6890, 6891-6900, 6901-6910, 6911-6920, 6921-6930, 6931-6940, 6941-6950, 6951-6960, 6961-6970, 6971-6980, 6981-6990, 6991-7000, 7001-7010, 7011-7020, 7021-7030, 7031-7040, 7041-7050, 7051-7060, 7061-7070, 7071-7080, 7081-7090, 7091-7100, 7101-7110, 7111-7120, 7121-7130, 7131-7140, 7141-7150, 7151-7160, 7161-7170, 7171-7180, 7181-7190, 7191-7200, 7201-7210, 7211-7220, 7221-7230, 7231-7240, 7241-7250, 7251-7260, 7261-7270, 7271-7280, 7281-7290, 7291-7300, 7301-7310, 7311-7320, 7321-7330, 7331-7340, 7341-7350, 7351-7360, 7361-7370, 7371-7380, 7381-7390, 7391-7400, 7401-7410, 7411-7420, 7421-7430, 7431-7440, 7441-7450, 7451-7460, 7461-7470, 7471-7480, 7481-7490, 7491-7500, 7501-7510, 7511-7520, 7521-7530, 7531-7540, 7541-7550, 7551-7560, 7561-7570, 7571-7580, 7581-7590, 7591-7600, 7601-7610, 7611-7620, 7621-7630, 7631-7640, 7641-7650, 7651-7660, 7661-7670, 7671-7680, 7681-7690, 7691-7700, 7701-7710, 7711-7720, 7721-7730, 7731-7740, 7741-7750, 7751-7760, 7761-7770, 7771-7780, 7781-7790, 7791-7800, 7801-7810, 7811-7820, 7821-7830, 7831-7840, 7841-7850, 7851-7860, 7861-7870, 7871-7880, 7881-7890, 7891-7900, 7901-7910, 7911-7920, 7921-7930, 7931-7940, 7941-7950, 7951-7960, 7961-7970, 7971-7980, 7981-7990, 7991-8000, 8001-8010, 8011-8020, 8021-8030, 8031-8040, 8041-8050, 8051-8060, 8061-8070, 8071-8080, 8081-8090, 8091-8100, 8101-8110, 8111-8120, 8121-8130, 8131-8140, 8141-8150, 8151-8160, 8161-8170, 8171-8180, 8181-8190, 8191-8200, 8201-8210, 8211-8220, 8221-8230, 8231-8240, 8241-8250, 8251-8260, 8261-8270, 8271-8280, 8281-8290, 8291-8300, 8301-8310, 8311-8320, 8321-8330, 8331-8340, 8341-8350, 8351-8360, 8361-8370, 8371-8380, 8381-8390, 8391-8400, 8401-8410, 8411-8420, 8421-8430, 8431-8440, 8441-8450, 8451-8460, 8461-8470, 8471-8480, 8481-8490, 8491-8500, 8501-8510, 8511-8520, 8521-8530, 8531-8540, 8541-8550, 8551-8560, 8561-8570, 8571-8580, 8581-8590, 8591-8600, 8601-8610, 8611-8620, 8621-8630, 8631-8640, 8641-8650, 8651-8660, 8661-8670, 8671-8680, 8681-8690, 8691-8700, 8701-8710, 8711-8720, 8721-8730, 8731-8740, 8741-8750, 8751-8760, 8761-8770, 8771-8780, 8781-8790, 8791-8800, 8801-8810, 8811-8820, 8821-8830, 8831-8840, 8841-8850, 8851-8860, 8861-8870, 8871-8880, 8881-8890, 8891-8900, 8901-8910, 8911-8920, 8921-8930, 8931-8940, 8941-8950, 8951-8960, 8961-8970, 8971-8980, 8981-8990, 8991-9000, 9001-9010, 9011-9020, 9021-9030, 9031-9040, 9041-9050, 9051-9060, 9061-9070, 9071-9080, 9081-9090, 9091-9100, 9101-9110, 9111-9120, 9121-9130, 9131-9140, 9141-9150, 9151-9160, 9161-9170, 9171-9180, 9181-9190, 9191-9200, 9201-9210, 9211-9220, 9221-9230, 9231-9240, 9241-9250, 9251-9260, 9261-9270, 9271-9280, 9281-9290, 9291-9300, 9301-9310, 9311-9320, 9321-9330, 9331-9340, 9341-9350, 9351-9360, 9361-9370, 9371-9380, 9381-9390, 9391-9400, 9401-9410, 9411-9420, 9421-9430, 9431-9440, 9441-9450, 9451-9460, 9461-9470, 9471-9480, 9481-9490, 9491-9500, 9501-9510, 9511-9520, 9521-9530, 9531-9540, 9541-9550, 9551-9560, 9561-9570, 9571-9580, 9581-9590, 9591-9600, 9601-9610, 9611-9620, 9621-9630, 9631-9640, 9641-9650, 9651-9660, 9661-9670, 9671-9680, 9681-9690, 9691-9700, 9701-9710, 9711-9720, 9721-9730, 9731-9740, 9741-9750, 9751-9760, 9761-9770, 9771-9780, 9781-9790, 9791-9800, 9801-9810, 9811-9820, 9821-9830, 9831-9840, 9841-9850, 9851-9860, 9861-9870, 9871-9880, 9881-9890, 9891-9900, 9901-9910, 9911-9920, 9921-9930, 9931-9940, 9941-9950, 9951-9960, 9961-9970, 9971-9980, 9981-9990, 9991-10000, 10001-10010, 10011-10020, 10021-10030, 10031-10040, 10041-10050, 10051-10060, 10061-10070, 10071-10080, 10081-10090, 10091-10100, 10101-10110, 10111-10120, 10121-10130, 10131-10140, 10141-10150, 10151-10160, 10161-10170, 10171-10180, 10181-10190, 10191-10200, 10201-10210, 10211-10220, 10221-10230, 10231-10240, 10241-10250, 10251-10260, 10261-10270, 10271-10280, 10281-10290, 10291-10300, 10301-10310, 10311-10320, 10321-10330, 10331-10340, 10341-10350, 10351-10360, 10361-10370, 10371-10380, 10381-10390, 10391-10400, 10401-10410, 10411-10420, 10421-10430, 10431-10440, 10441-10450, 10451-10460, 10461-10470, 10471-10480, 10481-10490, 10491-10500, 10501-10510, 10511-10520, 10521-10530, 10531-10540, 10541-10550, 10551-10560, 10561-10570, 10571-10580, 10581-10590, 10591-10600, 10601-10610, 10611-10620, 10621-10630, 10631-10640, 10641-10650, 10651-10660, 10661-10670, 10671-10680, 10681-10690, 10691-10700, 10701-10710, 10711-10720, 10721-10730, 10731-10740, 10741-10750, 10751-10760, 10761-10770, 10771-10780, 10781-10790, 10791-10800, 10801-10810, 10811-10820, 10821-10830, 10831-10840, 10841-10850, 10851-10860, 10861-10870, 10871-10880, 10881-10890, 10891-10900, 10901-10910, 10911-10920, 10921-10930, 10931-10940, 10941-10950, 10951-10960, 10961-10970, 10971-10980, 10981-10990, 10991-11000, 11001-11010, 11011-11020, 11021-11030, 11

Other preferred OLF1 to OLF10 polypeptide fragments are those located outside the transmembrane domains, most preferably peptide fragments naturally exposed on the cell membrane, particularly those that are available for binding to ligand molecules, either odorant substances or molecules or antibodies directed to the olfactory receptor polypeptides of the invention. Such transmembrane domains TM1 to TM7 are boxed in Figure 1. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the olfactory receptor protein sequence.

The invention also encompasses a purified, isolated, or recombinant polypeptides comprising an amino acid sequence having at least 70, 75, 80, 85, 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID Nos 12-21 or a fragment thereof.

The invention also encompasses an olfactory receptor polypeptide or a fragment or a variant thereof in which at least one peptide bound has been modified as defined in the "Definitions" section.

A further object of the invention concerns a purified or isolated polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 1-11 or fragment or variants thereof.

Such mutated olfactory receptor proteins may be the target of diagnostic tools, such as specific monoclonal or polyclonal antibodies, useful for the detecting the mutated olfactory receptor proteins in a sample.

Olfactory receptor proteins are preferably isolated from human or mammalian tissue samples or expressed from human or mammalian genes.

The olfactory receptor polypeptides of the invention is extracted from cells or tissues of humans or non-human animals. Methods for purifying proteins are known in the art, and include the use of detergents or chaotropic agents to disrupt particles followed by differential extraction and separation of the polypeptides by ion exchange chromatography, affinity chromatography, sedimentation according to density, and gel electrophoresis.

In addition, shorter protein fragments may also be prepared by the conventional methods of chemical synthesis, either in a homogenous solution or in solid phase. As an illustrative embodiment of such chemical polypeptide synthesis techniques, it may be cited the homogenous solution technique described by Houbenweyl in 1974. For solid phase synthesis the technique described by Merrifield (1965) may be used in particular.

Alternatively, the proteins of the invention can be made using routine expression methods known in the art as described below and in the section "Expression of a OLF1 to OLF10 coding polynucleotide". Briefly, the polynucleotide encoding the desired polypeptide, is ligated into an expression vector suitable for any convenient host. Both eukaryotic and prokaryotic host systems is used in forming recombinant polypeptides. The polypeptide is then isolated from lysed cells or from

the culture medium and purified to the extent needed for its intended use. Purification is by any technique known in the art, for example, differential extraction, salt fractionation, chromatography, centrifugation, and the like. See, for example, Methods in Enzymology for a variety of methods for purifying proteins.

- 5 Any olfactory receptor cDNA, including SEQ ID Nos 12-21, may be used to express olfactory receptor proteins and polypeptides. The nucleic acid encoding the olfactory receptor protein or polypeptide to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The olfactory receptor insert in the expression vector may comprise the full coding sequence for the olfactory receptor protein or a portion thereof. For example, the olfactory receptor
10 derived insert may encode a polypeptide comprising at least 10 consecutive amino acids of the olfactory receptor protein of SEQ ID Nos 12-21, including any of the polypeptide fragment defined in this section.

The expression vector is any of the mammalian, yeast, insect or bacterial expression systems known in the art. Commercially available vectors and expression systems are available from a variety
15 of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon context and codon pairing of the sequence is optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767.

- 20 In one embodiment, the entire coding sequence of the olfactory receptor cDNA through the poly A signal of the cDNA are operably linked to a promoter in the expression vector. Alternatively, if the nucleic acid encoding a portion of the olfactory receptor protein lacks a methionine to serve as the initiation site, an initiating methionine can be introduced next to the first codon of the nucleic acid using conventional techniques. Similarly, if the insert from the olfactory receptor cDNA lacks a poly A
25 signal, this sequence can be added to the construct by, for example, splicing out the Poly A signal from pSG5 (Stratagene) using BglI and SalI restriction endonuclease enzymes and incorporating it into the mammalian expression vector pXT1 (Stratagene).

- The ligated product is transfected into mouse NIH 3T3 cells using Lipofectin (Life Technologies, Inc., Grand Island, New York) under conditions outlined in the product specification.
30 Positive transfectants are selected after growing the transfected cells in 600ug/ml G418 (Sigma, St. Louis, Missouri).

The above procedures may also be used to express a mutant olfactory receptor protein responsible for a detectable phenotype or a portion thereof.

- Purification of the recombinant protein or peptide according to the present invention may be
35 realized by passage onto a Nickel or Copper affinity chromatography column. The Nickel chromatography column may contain the Ni-NTA resin (Porath et al., 1975). The polypeptides or peptides thus obtained may be purified, for example by high performance liquid chromatography,

such as reverse phase and/or cationic exchange HPLC, as described by Rougeot et al. (1994). The reason to prefer this kind of peptide or protein purification is the lack of side products found in the elution samples which renders the resultant purified protein or peptide more suitable for a therapeutic use.

5 The expressed protein may also be purified using other conventional purification techniques such as ammonium sulfate precipitation or chromatographic separation based on size or charge. The protein encoded by the nucleic acid insert may also be purified using standard immunochromatography techniques. In such procedures, polyclonal or monoclonal antibodies capable of specifically binding to the expressed olfactory receptor protein of SEQ ID Nos 12-21, or a fragment or a variant thereof, have
10 been previously immobilized onto a chromatography matrix. Such antibodies are described in the section "Antibodies that bind olfactory receptor polypeptides" below. Then, a solution containing the expressed olfactory receptor protein or portion thereof, such as a cell extract, is applied to the chromatography column in conditions allowing the expressed protein to bind to the antibodies in the immunochromatography column. Thereafter, the column is washed to remove non-specifically bound
15 proteins. The specifically bound expressed protein is then released from the column and recovered using standard techniques.

If antibody production is not possible, the nucleic acids encoding the olfactory receptor protein or a portion thereof is incorporated into expression vectors designed for use in purification schemes employing chimeric polypeptides. In such strategies the nucleic acid encoding the olfactory receptor
20 protein or a portion thereof is inserted in frame with the gene encoding the other half of the chimera. The other half of the chimera is β -globin or a nickel binding polypeptide encoding sequence. A chromatography matrix having antibody to β -globin or nickel attached thereto is then used to purify the chimeric protein. Protease cleavage sites are engineered between the β -globin gene or the nickel binding polypeptide and the olfactory receptor protein or portion thereof. Thus, the two polypeptides of the
25 chimera are separated from one another by protease digestion.

One useful expression vector for generating β -globin chimeric proteins is pSG5 (Stratagene), which encodes rabbit β -globin. Intron II of the rabbit β -globin gene facilitates splicing of the expressed transcript, and the polyadenylation signal incorporated into the construct increases the level of expression. These techniques are well known to those skilled in the art of molecular biology. Standard
30 methods are published in methods texts such as Davis et al., (1986) and many of the methods are available from Stratagene, Life Technologies, Inc., or Promega. Polypeptide may additionally be produced from the construct using in vitro translation systems such as the In vitro ExpressTM Translation Kit (Stratagene).

To confirm expression of the olfactory receptor protein or a portion thereof, the proteins
35 expressed from host cells containing an expression vector containing an insert encoding the olfactory receptor protein or a portion thereof can be compared to the proteins expressed in host cells containing the expression vector without an insert. The presence of a band in samples from cells containing the

expression vector with an insert which is absent in samples from cells containing the expression vector without an insert indicates that the olfactory receptor protein or a portion thereof is being expressed. Generally, the band will have the mobility expected for the olfactory receptor protein or portion thereof. However, the band may have a mobility different than that expected as a result of modifications such as glycosylation, ubiquitination, or enzymatic cleavage.

Other suitable techniques for producing and purifying the olfactory receptor proteins of the invention or their fragments or variants are also described under the heading "Methods for screening substances or molecules interacting with an olfactory receptor protein".

Thus, the present invention also concerns a method for the producing a polypeptide of the invention, and especially a polypeptide selected from the group of SEQ ID Nos 12-21 or a fragment or a variant thereof, wherein said methods comprises the steps of :

- a) culturing, in an appropriate culture medium, a cell host previously transformed or transfected with the recombinant vector comprising a nucleic acid encoding an olfactory receptor polypeptide of the invention, or a fragment or a variant thereof;
- b) harvesting the culture medium thus conditioned or lyse the cell host, for example by sonication or by an osmotic shock;
- c) separating or purifying, from the said culture medium, or from the pellet of the resultant host cell lysate the thus produced polypeptide of interest.
- d) optionally characterizing the produced polypeptide of interest.

In a specific embodiment of the above method, step a) is preceded by a step wherein the nucleic acid coding for an olfactory receptor polypeptide, or a fragment or a variant thereof, is inserted in an appropriate vector, optionally after an appropriate cleavage of this amplified nucleic acid with one or several restriction endonucleases. The nucleic acid coding for an olfactory receptor polypeptide or a fragment or a variant thereof may be the resulting product of an amplification reaction using a pair of primers according to the invention (by PCR, SDA, TAS, 3SR NASBA, TMA etc.).

C. ANTIBODIES THAT BIND OLFACTORY RECEPTOR POLYPEPTIDES

Any olfactory receptor polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed olfactory receptor protein or fragments thereof as described.

One antibody composition of the invention is capable of specifically binding or specifically bind to the variant of the olfactory receptor protein of SEQ ID Nos 12-21. For an antibody composition to specifically bind to a first variant of olfactory receptor protein, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for a first variant of the olfactory receptor protein than for a second variant of the olfactory receptor protein in an ELISA, RIA, or other antibody-based binding assay.

In a preferred embodiment, the invention concerns antibody compositions, either polyclonal or monoclonal, capable of selectively binding, or that selectively bind to an epitope-containing a polypeptide comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments". Preferred peptide fragments are portions of OLF1 to OLF10 polypeptides that are located outside the transmembrane domains, most preferably peptide fragments naturally exposed on the cell membrane, particularly those that are available for binding to ligand molecules, either odorant substances or molecules or antibodies directed to the olfactory receptor polypeptides of the invention.

The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated olfactory receptor protein or to a fragment or variant thereof comprising an epitope of the mutated olfactory receptor protein. In another preferred embodiment, the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of an olfactory receptor protein.

In a preferred embodiment, the invention concerns the use in the manufacture of antibodies of a polypeptide comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments". Preferred peptide fragments are portions of OLF1 to OLF10 polypeptides that are located outside the transmembrane domains, most preferably peptide fragments naturally exposed on the cell membrane, particularly those that are available for recognition of ligand molecules, either odorant substances or molecules or antibodies directed to the olfactory receptor polypeptides of the invention.

The olfactory receptor expressed from a DNA comprising at least one of the nucleic sequences of SEQ ID Nos 1-11 or a fragment or a variant thereof may also be used to generate antibodies capable of specifically binding to the expressed olfactory receptor or fragments or variants thereof. In a preferred embodiment, any of the polynucleotide fragment encoding a polypeptide described in the section "Coding regions of the olfactory receptor gene" may be used to generate such antibodies.

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the olfactory receptor protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibodies to the protein can then be prepared as follows:

1. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes in the olfactory receptor of the present invention or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler and Milstein, (1975) or derivative methods thereof. Briefly, a mouse is repetitively inoculated with a few micrograms of the considered olfactory receptor or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are

fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of
5 antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al.

2. Polyclonal Antibody Production by Immunization

10 Polyclonal antiserum containing antibodies to heterogeneous epitopes in the olfactory receptor of the present invention or a portion thereof can be prepared by immunizing suitable animals with the considered olfactory receptor or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal, preferably a non-human mammal, is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been
15 enriched for olfactory receptor concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin
20 (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen
25 and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. (1971).

30 Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum. Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for
35 example, by Fisher, (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances

in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

Non-human animals or mammals, whether wild-type or transgenic, which express a different species of olfactory receptor than the one to which antibody binding is desired, and animals which do not express olfactory receptor (i.e. an olfactory receptor knock out animal as described herein) are particularly useful for preparing antibodies. Olfactory receptor knock out animals will recognize all or most of the exposed regions of an olfactory receptor protein as foreign antigens, and therefore produce antibodies with a wider array of olfactory receptor epitopes. Moreover, smaller polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to any one of the olfactory receptor proteins. In addition, the humoral immune system of animals which produce a species of olfactory receptor that resembles the antigenic sequence will preferentially recognize the differences between the animal's native olfactory receptor species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique will be particularly useful in obtaining antibodies that specifically bind to any one of the olfactory receptor proteins.

The present invention also includes, chimeric single chain Fv antibody fragments (Martineau et al., 1998), antibody fragments obtained through phage display libraries (Ridder et al., 1995; Vaughan et al., 1995) and humanized antibodies (Reinmann et al., 1997; Leger et al., 1997).

The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

Consequently, the invention is also directed to a method for detecting specifically the presence of a polypeptide according to the invention in a biological sample, said method comprising the following steps :

a) bringing into contact the biological sample with an antibody according to the invention;

b) detecting the antigen-antibody complex formed.

Is also part of the invention a diagnostic kit for in vitro detecting the presence of a polypeptide according to the present invention in a biological sample, wherein said kit comprises:

a) a polyclonal or monoclonal antibody as described above, optionally labeled;

b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent carrying optionally a label, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

D. OLFACTORY RECEPTOR-RELATED BIALLELIC MARKERS

The invention also concerns olfactory receptor-related biallelic markers. As used herein the term "olfactory receptor-related biallelic marker" relates to a set of biallelic markers in linkage

disequilibrium with the olfactory receptor gene. The term olfactory receptor-related biallelic marker includes the biallelic markers designated A1 to A13.

The biallelic markers of the present invention, namely A1 to A13, are disclosed in Table 2 of Example 4. The 13 olfactory receptor-related biallelic markers, A1 to A13, are all located in the genomic non coding regions of the olfactory gene cluster of the invention. Their precise location on the olfactory receptor genomic sequence and their single base polymorphism are indicated in Table 2 and also as features in the sequence listing for SEQ ID No 1. Appropriate pairs of primers allowing the amplification of a nucleic acid containing the polymorphic base of the disclosed olfactory receptor biallelic marker are also listed in Table 1 of Example 3 and in features of SEQ ID No 1.

In the present invention, the biallelic markers can be defined by nucleotide sequences corresponding to oligonucleotides of 47 bases in length comprising at the middle one of the polymorphic base. More particularly, the biallelic markers can be defined by the polynucleotides P1 to P13.

The biallelic markers contained in the olfactory gene cluster of the present invention, or a subset of such biallelic markers, are useful tools to perform association studies, preferably to perform association studies between the statistically significant occurrence of an allele of said biallelic marker in the genome of an individual and a specific phenotype, including a phenotype consisting of an alteration of the olfactory perception of odorant substances or molecules by said individual. The biallelic markers of the invention can also be used, for example, in linkage analysis in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, such as an alteration of olfactory perception. In addition, the biallelic markers of the invention may be included in the generation of any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

1. Identification of biallelic markers

Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms such as differential hybridization with oligonucleotide probes, detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

In a first embodiment, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained thereby usually shows a sufficient degree of informativeness to be useful in conducting association studies.

In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele may be less than about 10%. Such a biallelic marker will, however, be sufficiently informative to conduct association studies and it will further be appreciated that including less informative biallelic markers in the genetic analysis studies of the present invention, may allow in some cases the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations.

The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.

Genomic DNA Samples

The genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, preferably from about 50 to about 200 individuals. It is usually preferred to collect DNA samples from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as many markers as possible and to generate statistically significant results.

As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor. Techniques to prepare genomic DNA from biological samples are well known to the skilled technician. Details of a preferred embodiment are provided in Example 2. The person skilled in the art can choose to amplify pooled or unpooled DNA samples.

DNA Amplification

The identification of biallelic markers in a sample of genomic DNA may be facilitated through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art.

Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A- 320 308, WO 9320227 and EP-A-439 182, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli J.C., et al.(1990) and in Compton J.(1991), Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in Walker et al.(1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3'hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes, which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall et al.(1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see White (1997) and the publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are

extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including US Patents 4,683,195; 4,683,202; and 4,965,188.

5 The PCR technology is the preferred amplification technique used to identify new biallelic markers. A typical example of a PCR reaction suitable for the purposes of the present invention is provided in Example 3.

One of the aspects of the present invention is a method for the amplification of the human olfactory receptor gene, particularly of a fragment of the genomic sequence of SEQ ID No 1 or of
10 the coding region sequences of SEQ ID Nos 2-11, or a fragment or a variant thereof in a test sample, preferably using the PCR technology. This method comprises the steps of:

- a) contacting a test sample with amplification reaction reagents comprising a pair of amplification primers as described above and located on either side of the polynucleotide region to be amplified, and
- 15 b) optionally, detecting the amplification products.

The invention also concerns a kit for the amplification of an olfactory receptor gene sequence, particularly of a portion of the genomic sequence of SEQ ID No 1 or of the coding region sequences of SEQ ID Nos 2-11, or a variant thereof in a test sample, wherein said kit comprises:

- a) a pair of oligonucleotide primers located on either side of the olfactory receptor region to
20 be amplified;
- b) optionally, the reagents necessary for performing the amplification reaction.

In one embodiment of the above amplification method and kit, the amplification product is detected by hybridization with a labeled probe having a sequence which is complementary to the amplified region. In another embodiment of the above amplification method and kit, primers
25 comprise a sequence which is selected from the group consisting of the nucleotide sequences of B1 to B11, C1 to C11, D1 to D13, and E1 to E13.

In a first embodiment of the present invention, biallelic markers are identified using genomic sequence information generated by the inventors. Sequenced genomic DNA fragments are used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified
30 from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms

35 The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to

those of ordinary skill in the art. Such methods are for example disclosed in Sambrook et al.(1989). Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee et al.(1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Following gel image analysis and DNA sequence extraction, sequence data are automatically processed with adequate software to assess sequence quality.

A polymorphism analysis software is used that detects the presence of biallelic sites among individual or pooled amplified fragment sequences. Polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern. These peaks which present distinct colors correspond to two different nucleotides at the same position on the sequence. The polymorphism has to be detected on both strands for validation.

Validation Of The Biallelic Markers Of The Present Invention

The polymorphisms are evaluated for their usefulness as genetic markers by validating that both alleles are present in a population. Validation of the biallelic markers is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. Microsequencing is a preferred method of genotyping alleles. The validation by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group can be as small as one individual if that individual is heterozygous for the allele in question. Preferably the group contains at least three individuals, more preferably the group contains five or six individuals, so that a single validation test will be more likely to result in the validation of more of the biallelic markers that are being tested. It should be noted, however, that when the validation test is performed on a small group it may result in a false negative result if as a result of sampling error none of the individuals tested carries one of the two alleles. Thus, the validation process is less useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that there is a *bona fide* biallelic marker at a particular position in a sequence. All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with validated biallelic markers.

2. Genotyping of biallelic markers

The polymorphisms identified above can be further confirmed and their respective frequencies can be determined through various methods using the previously described primers and probes. These methods can also be useful for genotyping either new populations in association studies or individuals in the context of detection of alleles of biallelic markers which are known to be associated with a given trait. Those skilled in the art should note that the methods described below can be equally performed on individual or pooled DNA samples.

Once a given polymorphic site has been found and characterized as a biallelic marker as described above, several methods can be used in order to determine the specific allele carried by an individual at the given polymorphic base.

The identification of biallelic markers described previously allows the design of appropriate
5 primers to amplify a region of the olfactory receptor gene cluster containing the polymorphic site of interest and for the detection of such polymorphisms.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic
10 fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and genetic analysis applications.

In one embodiment the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at an olfactory receptor-related biallelic marker or the
15 complement thereof in a biological sample; optionally, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof; optionally, wherein said biological sample is derived from a single subject; optionally, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, wherein said biological sample is derived
20 from multiple subjects; Optionally, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; Optionally, said method is performed *in vitro*; optionally, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; Optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant
25 vector comprising an origin of replication and said fragment in a host cell; optionally, wherein said determining is performed by a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.

Source of Nucleic Acids for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting
30 nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described above. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

Amplification Of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention. Amplification of DNA may be achieved by any method known in the art. Amplification techniques are described above in the section entitled, "DNA amplification."

Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described below.

The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention. Amplification can be performed using the primers initially used to discover new biallelic markers which are described herein or any set of primers allowing the amplification of a DNA fragment comprising a biallelic marker of the present invention.

In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. Preferred amplification primers are listed in Example 3. It will be appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention are also of use.

The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention, amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in "Oligonucleotide probes and primers".

Methods of Genotyping DNA samples for Biallelic Markers

Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the

DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot
5 analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al.(1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al.(1991), White et al.(1992), Grompe et al.(1989 and 1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant
10 nucleotide derivative as described in US patent 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term "sequencing" is generally used herein to refer to polymerase
15 extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

1) Sequencing Assays

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as
20 described above. DNA sequencing methods are described in "Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms".

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

25 2) Microsequencing Assays

In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one
30 single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883.
35 Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in Example 5.

Different approaches can be used for the labeling and detection of ddNTPs. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al.(1997). In this method, amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein-labeled primer in the presence of
5 allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time.

10 Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff and Smirnov, 1997).

Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase
15 microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is conducted as a heterogeneous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase
20 extension. The 5' ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator reagent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if
25 more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner,
30 oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of anti fluorescein antibody conjugated with alkaline phosphatase, followed by
35 incubation with a chromogenic substrate (such as *p*-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated

streptavidin with *o*-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al.(1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

5 Pastinen et al.(1997) describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described below.

In one aspect the present invention provides polynucleotides and methods to genotype one or
10 more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include the nucleotide sequences D1 to Dn and E1 to En. It will be appreciated that the microsequencing primers listed in Example 5 are merely exemplary and that, any primer having a 3' end immediately adjacent to the polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic
15 marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Example 5, or fragments comprising at least 8, 12, 15, 20, 25, 30, 40, or 50 consecutive nucleotides thereof, to the extent that such lengths are consistent with the primer described, and having a 3' terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a
20 nucleotide at a biallelic marker site.

3) Mismatch detection assays based on polymerases and ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of
25 polymerases and ligases. Polymerization reactions places particularly stringent requirements on correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3' end. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described above in "Amplification
30 Of DNA Fragments Comprising Biallelic Markers".

Allele Specific Amplification Primers

Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. For allele specific amplification, at least one member of the pair of
35 primers is sufficiently complementary with a region of an olfactory receptor gene comprising the polymorphic base of a biallelic marker of the present invention to hybridize therewith and to initiate

the amplification. Such primers are able to discriminate between the two alleles of a biallelic marker.

This is accomplished by placing the polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3' end of the primer, a mismatch at or
5 near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Determining the precise location of the mismatch and the corresponding assay conditions are well within the ordinary skill in the art.

Ligation/Amplification Based Methods

10 The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable
15 of detecting single nucleotide polymorphisms and may be advantageously combined with PCR as described by Nickerson et al.(1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other amplification methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are
20 described above in "DNA Amplification". LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a
25 biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when
30 they hybridize to the target molecule, a "gap" is created as described in WO 90/01069. This gap is then "filled" with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

35 Ligase/Polymerase-mediated Genetic Bit AnalysisTM is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide

present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

4) Hybridization Assay Methods

5 A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., 1989).

10 Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are
15 often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions,
20 under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Although such hybridization can be performed in solution, it is preferred to employ a solid-
25 phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to
30 either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

35 Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the

accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., 1995). In an alternative homogeneous hybridization based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

The polynucleotides provided herein can be used to produce probes which can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes are characterized in that they preferably comprise between 8 and 50 nucleotides, and in that they are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence for only one nucleotide variation. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred probes, the biallelic marker is at the center of said polynucleotide. Preferred probes comprise a nucleotide sequence selected from the group consisting of amplicons listed in Table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. Preferred probes comprise a nucleotide sequence selected from the group consisting of P1 to P13 and the sequences complementary thereto. In preferred embodiments the polymorphic base(s) are within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide.

Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in "Oligonucleotide Probes and Primers". The probes can be non-extendable as described in "Oligonucleotide Probes and Primers".

By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample. High-Throughput parallel hybridization in array format is specifically encompassed within "hybridization assays" and are described below.

5) Hybridization To Addressable Arrays Of Oligonucleotides

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (e.g., the chip) at selected

positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP 785280 describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be “tilled” for a large number of specific polymorphisms. By “tiling” is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular, the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and US patent No. 5,424,186.

Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of amplicons listed

in table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. In preferred embodiments the polymorphic base is within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in "Oligonucleotide Probes And Primers".

6) Integrated Systems

Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in US patent 5,589,136 which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts.

For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

E. EXPRESSION OF AN OLF1 TO OLF10 CODING POLYNUCLEOTIDE

Any of the coding polynucleotides of the invention may be inserted into recombinant vectors for expression in a recombinant host cell or a recombinant host organism.

Thus, the present invention also encompasses a family of recombinant vectors that contains a coding polynucleotide from the group of coding polynucleotides OLF1 to OLF10 genes. Consequently, the present invention further deals with a recombinant vector comprising a polynucleotide comprising any of the coding sequence of SEQ ID No 1, preferably those selected from the group consisting of SEQ ID Nos 2-11.

In a first preferred embodiment, the present invention relates to expression vectors which include nucleic acids encoding an olfactory receptor protein described herein under the control of an exogenous regulatory sequence.

In a second preferred embodiment, a recombinant vector of the invention is used to amplify the inserted polynucleotide derived from an olfactory receptor genomic sequence selected from the group consisting of the nucleic acids of SEQ ID No 1 and of olfactory receptor cDNAs, for example

the open reading frames of SEQ ID Nos 2-11, in a suitable cell host, this polynucleotide being amplified at every time that the recombinant vector replicates.

More particularly, the present invention relates to expression vectors which include nucleic acids encoding an olfactory receptor protein, preferably the olfactory receptor proteins of the amino acid sequence of SEQ ID Nos 12-21 or variants or fragments thereof, under the control of an
5 exogenous regulatory sequence.

Generally, a recombinant vector of the invention may comprise any of the polynucleotides described herein, including regulatory sequences, and coding sequences, as well as any olfactory receptor primer or probe as defined above. More particularly, the recombinant vectors of the present
10 invention can comprise any of the polynucleotides described in the "Coding Regions of the olfactory receptor gene" section, "Genomic sequence of the olfactory receptor gene" section, the "Oligonucleotide Probes And Primers" section and the "Polynucleotide constructs" section.

Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

15 Vectors

A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may consist of a chromosomal, non-chromosomal and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit
20 comprising an assembly of

(1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp that act on the promoter to increase the transcription.

(2) a structural or coding sequence which is transcribed into mRNA and eventually
25 translated into a polypeptide, and

(3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where recombinant protein is expressed without a leader or transport sequence, it may include an N-
30 terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural
35 sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium.

The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicine or ampicillin resistance in *E. coli*, or levan saccharase for mycobacteria.

For facilitating the purification of the expressed protein and increasing its stability, the
5 coding sequence of an olfactory receptor according to the invention can be fused in its N- or C-terminus with protein such as MBP (maltose binding protein) and GST (Glutathione S transferase) or with tag such as poly-histidine tag, Strep tag, Bio tag, and flag peptide epitope tag, those being detailed below. Thioredoxin can be eventually inserted between the olfactory receptor and the tag.

Useful expression vectors for bacterial use are constructed by inserting a structural DNA
10 sequence encoding a desired polypeptide with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within the host.

As a representative but non-limiting example, useful expression vectors for bacterial use can
15 comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, WI, USA).

Large numbers of suitable vectors and promoters are known to those of skill in the art, and
20 commercially available, such as bacterial vectors : pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); or eukaryotic vectors : pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); baculovirus transfer vector pVL1392/1393 (Pharming); pQE-30 (QIAexpress).

25 A suitable vector for the expression of the olfactory receptor above-defined or their peptide fragments is baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharming) that is used to transfect the SF9 cell line (ATCC N°CRL 1711) which is derived from *Spodoptera frugiperda*.

30 Other suitable vectors for the expression of an olfactory receptor or their peptide fragments or variants in a baculovirus expression system include those described by Chai et al. (1993), Vlasak et al. (1983) and Lenhard et al. (1996).

Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and
35 acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter,

enhancer, splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

Promoters

The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account of the cell host in which the heterologous gene has to be expressed.

A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

Thus, the promoter is selected among the group comprising :

- an internal or an endogenous promoter, such as the natural promoter associated with the structural gene coding for the desired olfactory receptor polypeptide or the fragment or variant thereof; such a promoter may be completed by a regulatory element derived from the vertebrate host, in particular an activator element;
- a promoter derived from a cytoskeletal protein gene such as the desmin promoter (Bolmont et al., 1990; Zhenlin et al., 1989) or a promoter derived from a gene specifically expressed in epithelial cells and most preferably in olfactory epithelial cells.

Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983.; O'Reilly et al., 1992), the lambda P_R promoter or also the trc promoter.

Promoter regions can be selected from any desired gene using, for example, CAT (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors. Particularly preferred bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, PL and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

The choice of a determined promoter, among the above-described promoters is well in the ability of one skill in the art, guided by his knowledge in the genetic engineering technical field, and by being also guided by the book of Sambrook et al. in 1989 or also by the procedures described by Fuller et al. in 1996 (Fuller S.A. et al., 1996).

A preferred constitutive promoter that is used is one of the internal promoters that are active in the resting fibroblasts such the promoter of the phosphoglycerate kinase gene (PGK-1). The PGK-1 promoter is either the mouse promoter or the human promoter such as described by Adra et al. (

1987). Other constitutive promoters may also be used such that the beta-actin promoter (Kort et al., 1983) or the vimentin promoter (Rettiez and Basenga, 1987).

The vector containing the appropriate DNA sequence as described above, more preferably a OLF1 to OLF10 coding polynucleotide, can be utilized to transform an appropriate host to allow the
5 expression of the desired polypeptide or polynucleotide.

Other types of vectors

The *in vivo* expression of an olfactory receptor polypeptide encompassed by the invention or a fragment or a variant thereof may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of biologically active olfactory
10 receptor proteins.

Consequently, the present invention also deals with recombinant expression vectors mainly designed for the *in vivo* production of a therapeutic peptide fragment by the introduction of the genetic information in the organism of the patient to be treated. This genetic information may be introduced *in vitro* in a cell that has been previously extracted from the organism, the modified cell
15 being subsequently reintroduced in the said organism, directly *in vivo* into the appropriate tissue, and preferably in the olfactory epithelium.

One specific embodiment for a method for delivering the corresponding protein or peptide to the interior of a cell of a vertebrate *in vivo* comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for
20 the polypeptide into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect.

In a specific embodiment, the invention provides a composition for the *in vivo* production of an olfactory receptor polypeptide described therein containing a naked polynucleotide operatively coding for an olfactory receptor selected from the group of OLF1 to OLF10 or a fragment or a
25 variant thereof, in solution in a physiologically acceptable carrier and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or polypeptide.

Advantageously, the composition described above is administered locally, near the site in which the expression of the olfactory receptor polypeptide under consideration or a fragment or a variant thereof is sought.

30 The polynucleotide operatively coding for an olfactory receptor polypeptide or a fragment or variant thereof may be a vector comprising the genomic DNA or the complementary DNA (cDNA) coding for the corresponding protein and a promoter sequence allowing the expression of the genomic DNA or the complementary DNA in the desired eukaryotic cells, such as vertebrate cells, specifically mammalian cells.

35 This vector may also contain one origin of replication that allows it to replicate in the eukaryotic host cell such as an origin of replication from a bovine papillomavirus. Alternatively, the vector can contain several, for example two, origins of replication of different origins in order to

allow said vector to replicate in different host cells, typically both in a prokaryotic cell such as *E. coli* and in an eukaryotic cell such as a mammalian epithelial cell, preferably a mammalian olfactory epithelial cell.

Compositions comprising a polynucleotide are described in the PCT application N° WO 90/11092 (Vical Inc.) and also in the PCT application N° WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tacson et al. (1996) and of Huygen et al. (1996).

In another embodiment, the DNA to be introduced is complexed with DEAE-dextran (Pagano et al., 1967) or with nuclear proteins (Kaneda et al., 1989), with lipids (Felgner et al., 1987) or encapsulated within liposomes (Fraley et al., 1980).

10 In another embodiment, the polynucleotide encoding an olfactory receptor polypeptide of the invention or a fragment or a variant thereof may be included in a transfection system comprising polypeptides that promote its penetration within the host cells as it is described in the PCT application WO 95/10534 (Seikagaku Corporation). They can also be encapsulated in polymer microparticles as it is described in the PCT Application No WO 94/27238.

15 The vector according to the present invention may advantageously be administered in the form of a gel that facilitates their transfection into the cells. Such a gel composition may be a complex of poly-L-lysine and lactose, as described by Midoux (1993) or also poloxamer 407 as described by Pastore (1994). Said vector may also be suspended in a buffer solution or be associated with liposomes.

20 The amount of the vector to be injected to the desired host organism vary according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 µg of the vector in an animal body, preferably a mammal body, for example a mouse body.

In another embodiment of the vector according to the invention, said vector may be introduced in vitro in a host cell, preferably in a host cell previously harvested from the animal to be
25 treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired olfactory receptor polypeptide or the desired fragment or variant thereof is implanted back into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

Suitable vectors for the *in vivo* expression of an olfactory receptor polypeptide of the
30 invention or a fragment or a variant thereof are described hereunder.

In one specific embodiment, the vector is derived from an adenovirus. Preferred adenoviruses vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al. (1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the adenovirus described by Ohwada et al. (1996) or the human
35 adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N° FR-93.05954).

Among the adenoviruses of animal origin it can be cited the adenoviruses of canine (CAV2, strain Manhattan or A26/61[ATCC VR-800]), bovine, murine (Mav1, Beard et al., 1980) or simian (SAV).

Preferably, the inventors are using recombinant defective adenoviruses that may be prepared following a technique well-known by one skill in the art, for example as described by Levrero et al. (1991) or by Graham (1984) or in the European patent application N° EP-185.573. Another defective recombinant adenovirus that may be used according to the present invention, as well as a composition of matter containing such a defective recombinant adenovirus, is described in the PCT application N° WO 95/14785.

10 Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous polynucleotides *in vivo*, particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host.

The use of recombinant retrovirus vectors containing a nucleic acid according to the invention is also encompassed within the scope of the invention. A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication defective retroviruses has increased the utility of retroviruses for *in vivo* gene delivery, and defective retroviruses are well characterized for use in gene transfer. Thus, recombinant retroviruses can be constructed in which a part of the retroviral coding sequence (*gag*, *pol*, *env*) has been replaced by nucleic acid encoding an olfactory receptor rendering the retrovirus defective. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* and *in vivo* with such viruses can be found in "Current Protocols in Molecular Biology" (1989).

25 Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging proteins on the surface of the viral particle, as described for example in the PCT Application No WO 93/25234 or in the PCT Application No WO 94/ 06920. For instance, strategies for the modification of the infection spectrum of retroviral vectors include : coupling antibodies specific for cell surface antigens to the viral *env* protein (Julan et al., 1992) or coupling cell surface receptor ligands to the viral *env* protein (Neda et al., 1991). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well by generating fusion proteins (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, can also be used to convert an ecotropic vector into an amphotropic vector.

Particularly preferred retroviruses for the preparation or construction of retroviral *in vitro* or *in vitro* gene delivery vehicles of the present invention include retroviruses selected from the group

consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include 4070A and 1504A (Hartley et al., 1976), Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; 5 PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high titer (ATCC Nos VR-334, VR-657, VR-726, VR-659 and VR-728). Another preferred retroviral vector is that described by Roth et al. (Roth J.A. et al., 1996).

Yet another viral vector system that is contemplated by the invention consists in the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires 10 another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

15 Cell hosts

Another object of the invention consists in host cell that have been transformed or transfected with one of the polynucleotides described therein, and more precisely a polynucleotide comprising the coding sequence of any of the olfactory receptor polypeptide having the amino acid sequence of SEQ ID Nos 12-21 or fragments or variants thereof. Are included host cells that are 20 transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.

A recombinant host cell of the invention comprises any one of the polynucleotides or the recombinant vectors described therein. More particularly, the cell hosts of the present invention can comprise any of the polynucleotides described in the "Coding regions of the olfactory receptor gene" 25 section, "Genomic sequence of olfactory receptor gene" section, the "Oligonucleotide Probes And Primers" section, the "Polynucleotide constructs" section, and the "Expression of an OLF1 to OLF10 coding polypeptide" section.

Suitable prokaryotic hosts for transformation include *E. coli*, *Bacillus subtilis*, as well as various species within the genera of *Streptomyces* or *Mycobacterium*. Suitable eukaryotic hosts 30 comprise yeast, insect cells, such as *Drosophila* and Sf9. Various mammalian cell hosts can also be employed to express recombinant protein. Examples of mammalian cell hosts include the COS-7 lines of monkey kidney fibroblasts (Guzman, 1981), and other cell lines capable of expressing a compatible vector, for example the C127, 3T3, CHO, HeLa and BHK cell lines. The selection of an host is within the scope of the one skilled in the art.

35 Preferred cell hosts used as recipients for the expression vectors of the invention are the followings :

a) Prokaryotic host cells : *Escherichia coli* strains (I.E. DH5- α strain) or *Bacillus subtilis*.

b) Eukaryotic host cells : HeLa cells (ATCC N^oCCL2; N^oCCL2.1; N^oCCL2.2), Cv 1 cells (ATCC N^oCCL70), COS cells (ATCC N^oCRL1650; N^oCRL1651), Sf-9 cells (ATCC N^oCRL1711).

The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

- 5 Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

- 10 Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

Transgenic animals

- 15 The terms “transgenic animals” or “host animals” are used herein designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from *Mus* (e.g. mice), *Rattus* (e.g. rats) and *Oryctogalus* (e.g. rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention.

- 20 The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising an olfactory receptor coding sequence selected from the group OLF1 to OLF10 an olfactory receptor regulatory polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

- 25 More particularly, transgenic animals according to the invention contain in their somatic cells and/or in their germ line cells any of the polynucleotides described in the “Coding regions of the olfactory receptor gene” section, “Genomic sequence of olfactory receptor gene” section, the “Oligonucleotide Probes And Primers” section, the “Polynucleotide constructs” section and the “Expression of an OLF1 to OLF10 coding polypeptide” section.

- 30 The replacement of the native genomic olfactory receptor sequence by a defective copy of said sequence may be preformed by techniques of gene targeting. Such techniques are notably described by Burright et al. (1997), Bates et al. (1997), Mangiarini et al. (1997), Davies et al. (1997).

- Second preferred transgenic animals of the invention have the murine olfactory receptor gene replaced either by a defective copy of the murine olfactory receptor gene or by an interrupted
35 copy of the human olfactory receptor gene. A “defective copy” of a murine or a human olfactory receptor gene, is intended to designate a modified copy of these genes that is not or poorly transcribed in the resulting recombinant host animal or a modified copy of these genes leading to the

absence of synthesis of the corresponding translation product or alternatively leading to a modified and/or truncated translation product lacking the biological activity of the wild type olfactory receptor protein. The altered translation product thus contains amino acid modifications, deletions and substitutions. Modifications and deletions may render the naturally occurring gene nonfunctional, thus leading to a "knockout animal". These transgenic animals are critical for the creation of animal models of human diseases, and for eventual treatment of disorders related to alteration of the olfactory perception of odorant substances or molecules. Examples of such knockout mice are described in the PCT Applications Nos WO 97/34641, WO 96/12792 and WO 98/02354.

The endogenous murine olfactory receptor gene can be interrupted by the insertion, between two contiguous nucleotide of said gene, of a part of all of a marker gene placed under the control of the appropriate promoter, for example the endogenous promoter of the endogenous murine olfactory receptor gene. The marker gene may be the neomycin resistance gene (*neo*) that may be operably linked to the phosphoglycerate kinase-1 (PGK-1) promoter, as described in the PCT Application No WO 98/02534.

Thus, the invention is also directed to a transgenic animal contain in their somatic cells and/or in their germ line cells a polynucleotide selected from the following group of polynucleotides:

- a) a defective copy of the human olfactory receptor gene;
- b) a defective copy of the endogenous olfactory receptor gene, wherein the expression "endogenous olfactory receptor gene" designates an olfactory receptor gene that is naturally present within the genome of the animal host to be genetically modified.

The invention also concerns a method for obtaining transgenic animals, wherein said methods comprise the steps of :

- a) replacing the endogenous copy of the animal olfactory receptor gene by a nucleic acid selected from the group consisting of a defective copy of the human olfactory receptor gene and a defective copy of the endogenous olfactory receptor gene in animal cells, preferably embryonic stem cells (ES);
- b) introducing the recombinant animal cells obtained at step a) in embryos, notably blastocysts of the animal;
- c) selecting the resulting transgenic animals, for example by detecting the defective copy of an olfactory receptor gene with one or several primers or probes according to the invention.

Optionally, the transgenic animals may be bred together in order to obtain homozygous transgenic animals for the defective copy of the olfactory receptor gene introduced.

The transgenic animals of the invention thus contain specific sequences of exogenous genetic material such as the nucleotide sequences described above in detail.

In a preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to disorders associated to alteration of the olfactory

perception of odorant substances or molecules, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native olfactory receptor protein, or alternatively a mutant olfactory receptor protein.

Third preferred transgenic animals according to the invention contains in their somatic cells
5 and/or in their germ line cells a polynucleotide selected from the following group of polynucleotides
:

a) purified or isolated nucleic acid encoding an olfactory receptor polypeptide selected from OLF1 to OLF10, or a polypeptide fragment or variant thereof.

b) a purified or isolated nucleic comprising at least 8 consecutive nucleotides of the
10 nucleotide sequence SEQ ID No 1, a nucleotide sequence complementary thereto or a fragment or a variant thereof;

c) a purified or isolated nucleic acid comprising a nucleotide sequence selected from the group of SEQ ID 2-11, a sequence complementary thereto or a fragment or a variant thereof.

The transgenic animals of the invention thus contain specific sequences of exogenous
15 genetic material such as the nucleotide sequences described above in detail.

In a first preferred embodiment, these transgenic animals may be good experimental models in order to screen the candidate substance of interest interacting with the olfactory receptor under consideration.

Since it is possible to produce transgenic animals of the invention using a variety of different
20 sequences, a general description will be given of the production of transgenic animals by referring generally to exogenous genetic material. This general description can be adapted by those skilled in the art in order to incorporate the DNA sequences into animals. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to Sandou et al. (1994) and also to US Patents Nos 4,873,191, issued Oct.10, 1989, 5,968,766, issued Dec. 16,
25 1997 and 5,387,742, issued Feb. 28, 1995.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that incorporates exogenous genetic material which is integrated into the genome. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a coding sequence, a non-coding polynucleotide or a DNA sequence
30 encoding an antisense polynucleotide of an olfactory receptor selected from the group OLF1 to OLF10 such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is made using electroporation. The cells subjected to electroporation are screened (e.g. Southern blot analysis) to find positive cells which have integrated the exogenous recombinant
35 polynucleotide into their genome. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al. (1988). Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice. The blastocysts are then

inserted into a female host animal and allowed to grow to term. The offsprings of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a
5 recombinant expression vector or a recombinant host cell according to the invention.

Recombinant Cell Lines Derived From The Transgenic Animals Of The Invention.

A further object of the invention comprises recombinant host cells obtained from a transgenic animal described herein. In one embodiment the invention encompasses cells derived from non-human host mammals and animals comprising a recombinant vector of the invention or an
10 olfactory receptor gene disrupted by homologous recombination with a knock out vector.

Recombinant cell lines may be established *in vitro* from cells obtained from any tissue of a transgenic animal according to the invention, for example by transfection of primary cell cultures with vectors expressing *onc*-genes such as SV40 large T antigen, as described by Chou (1989) and Shay et al.(1991).

15 F. METHODS FOR SCREENING SUBSTANCES OR MOLECULES INTERACTING WITH AN OLFACTORY RECEPTOR PROTEIN

The present invention pertains to methods for screening substances of interest, in particular odorant substances or molecules that interact with an olfactory receptor protein selected from the group consisting of OLF1 to OLF10, or one peptide fragment or variant thereof. In one embodiment,
20 the candidate substance is devoid of odorant propriety but it is able to bind the olfactory receptor and to trigger the transduction of signals.

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the olfactory receptor protein or one of its fragments or variants or to modulate the expression of the
25 polynucleotide coding for olfactory receptor or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the olfactory receptor protein is brought into contact with the corresponding purified olfactory receptor protein, for example the corresponding purified recombinant olfactory receptor protein produced by a recombinant cell host as described
30 herein, in order to form a complex between this protein and the putative ligand molecule to be tested.

As an illustrative example, to study the interaction of the olfactory receptor protein, or a fragment comprising comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments" with drugs or small molecules, such as molecules generated through combinatorial chemistry approaches, the microdialysis coupled to HPLC method described
35 by Wang et al. (1997) or the affinity capillary electrophoresis method described by Bush et al. (1997) can be used.

In further methods, peptides, drugs, fatty acids, lipoproteins, or small molecules which interact with the olfactory receptor protein, or a fragment comprising any of the fragments described in the section "OLF1 to OLF10 proteins and polypeptide fragments" may be identified using assays such as the following. The molecule to be tested for binding is labeled with a detectable label, such as a fluorescent, radioactive, or enzymatic tag and placed in contact with immobilized olfactory receptor protein, or a fragment thereof under conditions which permit specific binding to occur, such as affinity columns. In some embodiments, chimeric proteins containing the olfactory receptor protein fused to proteins facilitating purification, such as glutathion S transferase (GST) are used. After removal of non-specifically bound molecules, bound molecules are detected using appropriate means.

In one embodiment, proteins, peptides, carbohydrates, lipids, or small molecules generated by combinatorial chemistry interacting with the olfactory receptor protein, or a fragment or a variant thereof can also be screened by using an Optical Biosensor as described in Edwards and Leatherbarrow (1997) and also in Szabo et al. (1995). The main advantage of the method is that it allows the determination of the association rate between the olfactory receptor protein and molecules interacting with the olfactory receptor protein. It is thus possible to select specifically ligand molecules interacting with the olfactory receptor protein, or a fragment thereof, through strong or conversely weak association constants.

Another object of the present invention comprises methods and kits for the screening of candidate substances that interact with olfactory receptor polypeptide.

The present invention pertains to methods for screening substances of interest that interact with an olfactory receptor protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to an olfactory receptor protein or to a fragment or variant thereof, these substances or molecules may be advantageously used both *in vitro* and *in vivo*. *In vitro*, said interacting molecules may be used as detection means in order to identify the presence of an olfactory receptor protein in a sample, preferably a biological sample.

A first method for the screening of a candidate substance interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, or fragments or variants thereof, comprises the following steps :

- a) providing a polypeptide selected from the group consisting of the polypeptides comprising, consisting essentially of, or consisting of the amino acid sequences of SEQ ID Nos 12-21, or a peptide fragment or a variant thereof;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance; and
- d) detecting the complexes formed between said polypeptide and said candidate substance.

Various candidate substances or molecules can be assayed for interaction with an olfactory receptor polypeptide. These substances or molecules include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides. When the candidate substance or molecule comprises a polypeptide, this polypeptide may be the resulting
5 expression product of either a phage clone belonging to a phage-based random peptide library, or of a cDNA library cloned in a vector suitable for performing a two-hybrid screening assay.

In one embodiment of the screening method defined above, the complexes formed between the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a monoclonal antibody that specifically binds to the olfactory receptor protein of the invention under
10 consideration or to said peptide fragment or variant thereof.

In another embodiment of the present screening method, increasing concentrations of a substance competing for binding to the olfactory receptor with the considered candidate substance is added, simultaneously or prior to the addition of the candidate substance or molecule, when performing step c) of said method. By this technique, the detection and optionally the quantification
15 of the complexes formed between the olfactory receptor protein or the peptide fragment or variant thereof and the candidate substance or molecule to be screened allows the one skilled in the art to determine the affinity value of said substance or molecule for said olfactory receptor protein or the peptide fragment or variant thereof.

The olfactory receptor selected from the group consisting of OLF1 to OLF10, or a peptide
20 fragment or a variant thereof, can be overexpressed and purified in a bacterial system such as E coli as described in Kiefer et al. (1996) and Tucker et al. (1996). The olfactory receptor coding sequence can be fused to its N-terminus with GST (Glutathione S transferase) or MBP (Maltose Binding Protein) and to its C-terminus with poly-histidine tag, Bio tag or Strep tag for facilitating the purification of the expressed protein. The Bio tag is 13 amino acid residues long, is biotinylated *in*
25 *vivo* in E. coli, and will therefore bind to both avidin and streptavidin. The Strep tag is 9 amino acid residues long and binds specifically to streptavidin, but not to avidin. Therewith, a purification step by affinity can be carried out based on the interaction of a poly-histidine tail with immobilized metal ions, of the biotinylated Bio tag with monomeric avidin, of the Strep tag with streptavidin, of the GST segment with the glutathione, or of the MBP segment with the maltose. Thioredoxin can be
30 eventually inserted between the receptor C-terminus and the tag and could increase the expression level. The fusion protein is solubilized in 1% N-laurroyl sarcosine, and 0.2 % digitonin is added. It is purified by affinity chromatography. The MBP, GST or tag segment can be then removed. After the olfactory receptor protein purification, sarcosyl can be replaced with digitonin which is a detergent widely used to stabilize the G protein-coupled receptors. The purified receptor is reconstituted into
35 lipid vesicles preferably composed of phosphatidylcholine: phosphatidylglycerol (4:1) by adding the lipid dissolved in dodecyl maltoside and removing the detergent.

The olfactory receptor selected from the group consisting of OLF1 to OLF10, or a peptide fragment or a variant thereof, can also be overexpressed and purified in a baculovirus/Sf9 system as described in Nekrasova et al. (1996). The olfactory receptor gene, or a fragment thereof, is preferably expressed with a "flag" peptide epitope tag and/or a poly-histidine tag to either its N- or C-terminus for facilitating the purification of the expressed protein. Therefore, the olfactory receptor gene, or a fragment or a variant thereof, is preferably subcloned into the baculovirus transfer vector pAcSGHisNT to create constructs that encoded olfactory receptor with amino-terminal poly-histidine tag. The resulting transfer vector is transfected preferably with BaculoGold DNA into Sf9 cells. The expressed olfactory receptors are then solubilized either in 1 % N-lauryl sarcosine or 1.5 % lysophosphatidylcholine, but preferably in lysophosphatidylcholine. After solubilization, the olfactory receptors are purified by affinity chromatography on nickel nitrilotriacetic acid resin and by cation-exchange chromatography with carboxymethyl sepharose cation-exchange column. The tag segment can be then removed. The purified receptor is reconstituted into lipid vesicles preferably composed of dimyritoylglycerophosphocholine, cholesterol, dialmitoylglycerophosphoserine and dipalmitoylglycerophosphoethanolamine (in molecular ratio 54:35:10:1)

Once the olfactory receptor protein or one of its peptide fragments or variants has been obtained as described above, candidate substances or molecules can then be assayed for their capacity to bind thereto.

The candidate substance or molecule to be assayed for interacting with an olfactory receptor of the invention may be of diverse nature, including, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as peptide. It can comprise aromatic or aliphatic compounds with various functional groups such as alcohol, aldehyde, ester, ether, ketone, carboxylic, amine. An example of a substance panel which can be used is provided by Zhao et al. (1998).

The screening of substances or molecules interacting with an olfactory receptor, or a fragment thereof, is carried out by photoaffinity labeling experiments described in Kiefer et al. (1996). The odorant is labeled, preferably radiolabeled, and incubated with lipid vesicles including the purified olfactory receptor. The odorants bound to the olfactory receptors are crosslinked by exposure to ultraviolet light. Then, the samples are subjected to SDS polyacrylamide gel electrophoresis. Proteins are visualized by Coomassie-blue staining and the odorants are revealed, preferably by autoradiography. In another embodiment, the proteins can be visualized by Western Blot with a polyclonal or monoclonal antibody that specifically binds to the olfactory receptor under consideration. Once a substance binding to the considered olfactory receptor is identified, the binding specificity of this substance is confirmed with competition experiments demonstrating that increasing concentrations of unlabeled ligand accomplish a dose-dependent displacement of the radioactive ligand.

The identification of a first substance specific to one of the olfactory receptors of the present invention facilitates the screening of other substances. Indeed, the binding capacity of the screened substances to this olfactory receptor can be carried out through a competition experiments against the first identified substance which is labeled.

5 The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21 or a peptide fragment or a variant thereof, and optionally means useful to detect the complex formed between the considered olfactory receptor polypeptide or its peptide fragment or variant and the candidate substance. In a
10 preferred embodiment, the kit can comprise an already identified substance specific of the olfactory receptor under consideration which is labeled, preferably radiolabeled, and a monoclonal or polyclonal antibody directed against the considered olfactory receptor.

A second screening method embodiment consists of a method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of
15 SEQ ID Nos 12-21, wherein said method comprises :

- a) providing a recombinant eukaryotic host cell containing a nucleic acid encoding a polypeptide selected from the group comprising, consisting essentially of, or consisting the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, or variants or fragments thereof;
- 20 b) preparing membrane extracts of said recombinant eukaryotic host cell;
- c) bringing into contact the membrane extracts prepared at step b) with a selected ligand molecule; and
- d) detecting the production level of second messengers metabolites.

The baculovirus-Sf9 cell system enables a foreign DNA encoding an olfactory receptor
25 selected from the group consisting of OLF1 to OLF10, or a peptide fragment or a variant thereof, to be expressed with high efficiency. Moreover, it can be used to couple a heterologous expressed olfactory receptor to the second messenger cascades. Therefore, the binding specificity of an olfactory receptor can be assessed through an assay of odorant-induced generation of cAMP or inositol triphosphate (InsP3) described in Raming et al. (1993).

30 Briefly, a cell line derived from Sf9 is infected by baculovirus, such as baculovirus transfer vector pVL1393, harboring DNA encoding the olfactory receptor or a fragment thereof downstream from a strong promoter, preferably the polyhedrin promoter. Recombinant virus are purified and used to infect 1.5×10^8 Sf9 cells in 100 ml spinner cultures at high multiplicity of infection. Cells are collected after a postinfection delay, preferably 48 h, and membrane fractions are isolated as follow.

35 Cells are pelleted (at 250g for 10 min at 4°C), washed with Ringer solution (120 mM NaCl, 5 mM KCl, 1.6 mM K_2HPO_4 , 1.2 mM $MgSO_4$, 25 mM $NaHCO_3$, 5 mM glucose, pH7.4) and disrupted using a glass homogenizer in homogenization buffer (10 mM Tris-HCl, pH 8.0, 2 mM

EGTA, 3 mM MgCl₂) containing antiproteases. The homogenate is centrifuged and the pellet is washed. Supernatants are centrifuged at 33,000g for 20 min. The final pellet is resuspended in homogenization buffer and the protein concentration is determined.

Assay of odorant substance-induced generation of second messengers cAMP and InsP₃ is performed as follow. Suspensions of Sf9 cell membrane preparations (300 µg protein) are rapidly mixed with a stimulation buffer (200 mM NaCl, 10 mM EGTA, 50 mM MOPS, 2.5 mM MgCl₂, 1 mM DTT, 0.05 % Na-cholate, 1 mM ATP, 1 µM GTP, and 0.02 µM free Ca²⁺) containing the candidate substances at the appropriate concentrations. The reaction is stopped after a short time, preferably 1 sec, by injecting 10 % Perchloric acid. Quenched samples are assayed for second messenger concentrations. The quenched and cooled samples are vortexed and centrifuged for 5 min at 2500g at 4°C. 400 µl of the supernatants are transferred to a separate tube containing 100 µl of 10 mM EDTA (pH 7). The sample are neutralized by adding 500 µl of a 1:1 (v/v) mixture of 1,1,2 trichlorofluoroethane, followed by thorough mixing. After centrifugation for 2 min at 500g, three phases are obtained. The upper phase, which contains all water soluble components, is used for carrying out the concentration measurements. cAMP and InsP₃ concentrations are determined according the procedure of Steiner et al. (1972) and Palmer et al. (1989), respectively.

The invention also concerns a kit for the screening of odorant ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, wherein said kit comprises :

- a) a recombinant eukaryotic host cell containing a nucleic acid encoding a polypeptide selected from the group comprising, consisting essentially of, or consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21 or variants or fragments thereof; and
- b) optionally, reagents necessary for the measurement of second messenger metabolites in a sample.

The screening of substances or molecules interacting with an olfactory receptor, or a fragment thereof, can also be carried out through the measurement of the increase of the response to odorants in an olfactory epithelium overexpressing an olfactory receptor selected from the group consisting of OLF1 to OLF10, or a peptide fragment or a variant thereof, as described in Zhao et al. (1998). The response is assessed by electro-olfactogram which measures a transepithelial potential resulting from the summed activity of many olfactory neurons. In order to overexpress the olfactory receptor, or a fragment thereof, in an olfactory epithelium, an adenovirus containing the olfactory receptor gene is generated. To aid in electro-olfactogram electrode placements, the olfactory receptor coding sequence is preferably combined in the adenovirus with the physiological marker green fluorescent protein (GFP) in such manner that the two proteins are simultaneously expressed. The olfactory epithelium of an animal, preferably of a rat, is infected by the adenovirus. Animals are killed 3 to 8 days after infection and the nasal cavity is opened, exposing the medial surface of the

nasal turbinates. Under fluorescent illumination, the GFP clearly marked the pattern of viral infection and olfactory receptor expression. Odorant substance are applied to the olfactory epithelium in the vapor phase by injecting a pressurized pulse of odorant vapor into a continuous stream of humidified clean air. Electro-olfactogram recordings are obtained with a glass capillary electrode placed on the surface of the epithelium and connected to a differential amplifier. The olfactory receptor specificity is assessed from the increase of response in infected animals compared to uninfected animals. To account for the variability between animals, a standard odorant to which all other odorant responses are normalized is used.

A third screening method embodiment consists of a method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, wherein said method comprises :

- a) providing an adenovirus containing a nucleic acid encoding a polypeptide selected from the group comprising, consisting essentially of, or consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21, or variants or fragments thereof;
 - b) infecting an olfactory epithelium with said adenovirus;
 - c) bringing into contact the olfactory epithelium b) with a selected ligand molecule;
- and
- d) detecting the increase of the response to said ligand molecule.

20 G. METHODS FOR INHIBITING THE EXPRESSION OF AN OLFACTORY RECEPTOR GENE

Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of olfactory receptor as an antisense tool or a triple helix tool that inhibits the expression of the corresponding olfactory receptor gene. A preferred fragment of the nucleic sequence of olfactory receptor comprises an allele of at least one of the biallelic markers A1 to A13.

Antisense Approach

Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al.(1995).

Preferred antisense polynucleotides are described in the section entitled "Nuclear Antisense DNA Constructs".

The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the olfactory receptor mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984).

In some strategies, antisense molecules are obtained by reversing the orientation of the olfactory receptor coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of olfactory receptor antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al.(1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European Patent Application No. EP 0 572 287 A2

An alternative to the antisense technology that is used according to the present invention comprises using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely "hammerhead ribozymes"). Briefly, the simplified cycle of a hammerhead ribozyme comprises (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al.(1995), the specific preparation procedures being referred to in said article.

Triple Helix Approach

The olfactory receptor genomic DNA may also be used to inhibit the expression of the olfactory receptor gene based on intracellular triple helix formation.

Triple helix oligonucleotides are used to inhibit transcription from a genome. They are particularly useful for studying alterations in cell activity when it is associated with a particular gene.

Similarly, a portion of the olfactory receptor genomic DNA can be used to study the effect of inhibiting olfactory receptor transcription within a cell. Traditionally, homopurine sequences were considered the most useful for triple helix strategies. However, homopyrimidine sequences can also inhibit gene expression. Such homopyrimidine oligonucleotides bind to the major groove at homopurine:homopyrimidine sequences. Thus, both types of sequences from the olfactory receptor genomic DNA are contemplated within the scope of this invention.

To carry out gene therapy strategies using the triple helix approach, the sequences of the olfactory receptor genomic DNA are first scanned to identify 10-mer to 20-mer homopyrimidine or homopurine stretches which could be used in triple-helix based strategies for inhibiting olfactory

receptor expression. Following identification of candidate homopyrimidine or homopurine stretches, their efficiency in inhibiting olfactory receptor expression is assessed by introducing varying amounts of oligonucleotides containing the candidate sequences into tissue culture cells which express the olfactory receptor gene.

- 5 The oligonucleotides can be introduced into the cells using a variety of methods known to those skilled in the art, including but not limited to calcium phosphate precipitation, DEAE-Dextran, electroporation, liposome-mediated transfection or native uptake.

- Treated cells are monitored for altered cell function or reduced olfactory receptor expression using techniques such as Northern blotting, RNase protection assays, or PCR based strategies to
10 monitor the transcription levels of the olfactory receptor gene in cells which have been treated with the oligonucleotide.

The oligonucleotides which are effective in inhibiting gene expression in tissue culture cells may then be introduced in vivo using the techniques described above in the antisense approach at a dosage calculated based on the in vitro results, as described in antisense approach.

- 15 In some embodiments, the natural (beta) anomers of the oligonucleotide units can be replaced with alpha anomers to render the oligonucleotide more resistant to nucleases. Further, an intercalating agent such as ethidium bromide, or the like, can be attached to the 3' end of the alpha oligonucleotide to stabilize the triple helix. For information on the generation of oligonucleotides suitable for triple helix formation see Griffin et al.(1989).

20 **H. COMPUTER-RELATED EMBODIMENTS**

- As used herein the term "nucleic acid codes of the invention" encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any of the polynucleotides described in the "Coding Regions of the olfactory receptor gene" section, "Genomic sequence of the olfactory receptor gene" section and the "Oligonucleotide Probes And Primers" section, or variants
25 thereof, or complementary sequences thereto. Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be determined using any method described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also may include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention.

- 30 As used herein the term "polypeptide codes of the invention" encompass the polypeptide sequences comprising any of the polypeptides described in the "OLF1 to OFL10 proteins and polypeptide fragments".

- It will be appreciated that the nucleic acid and polypeptide codes of the invention can be represented in the traditional single character format or three letter format respectively (See the inside
35 back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any

other format or code which records the identity of the nucleotides or the amino acid respectively in a sequence.

It will be appreciated by those skilled in the art that the nucleic acid codes of the invention and polypeptide codes of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid codes of the invention, or one or more of the polypeptide codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 nucleic acid codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of the invention.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disc, a floppy disc, a magnetic tape, CD-ROM, DVD, RAM, or ROM as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which contain the sequence information described herein. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to store and/or analyze the nucleotide sequences of the nucleic acid codes of the invention, the amino acid sequences of the polypeptide codes of the invention, or other sequences. The computer system preferably includes the computer readable media described above, and a processor for accessing and manipulating the sequence data.

In some embodiments, the computer system may further comprise a sequence comparer for comparing the nucleic acid codes or polypeptide codes of the invention stored on a computer readable medium to reference nucleotide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which are implemented on the computer system to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals the sequences or structures of which are stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of the invention or a

polypeptide code of the invention, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of the invention or polypeptide code of the invention and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences
5 compared or identify structural motifs in the nucleic acid code of the invention and polypeptide codes of the invention or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or polypeptide codes of the invention.

10 Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of the invention and a reference nucleotide sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code and the reference nucleotide sequence with the computer program. The computer program
15 may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic acid codes of the invention through the use of the computer program and determining homology
20 between the nucleic acid codes and reference nucleotide sequences.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference nucleotide sequences in order to determine whether the nucleic acid code of the invention differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and
25 identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of the invention. In one embodiment, the computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of the invention contain one or more single nucleotide polymorphisms (SNP) with respect to a reference nucleotide sequence. These single nucleotide polymorphisms may each comprise a single
30 base substitution, insertion, or deletion.

Another aspect of the present invention is a method for determining the level of homology between a polypeptide code of the invention and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of the invention and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the
35 polypeptide code and the reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of the invention differs at one or more nucleotides from a reference nucleotide

sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms. The method may be implemented by the computer systems described above. The method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

10 An "identifier" refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention.

In one embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of the invention. In some 15 embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Patent No. 5,436,850 issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling 20 technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of the invention. (See e.g., Srinivasan, et al., U.S. Patent No. 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the 25 protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

The recent development of threading methods now enables the identification of likely 30 folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as 35 QUANTA. According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural

equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these

5 low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszódi et al., (1997)).

he results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of the invention.

Accordingly, another aspect of the present invention is a method of identifying a feature

10 within the nucleic acid codes of the invention or the polypeptide codes of the invention comprising reading the nucleic acid code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or polypeptide code(s) with the computer program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer

15 program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or the polypeptide codes of the invention through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

20 The nucleic acid codes of the invention or the polypeptide codes of the invention may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, they may be stored as text in a word processing file, such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence

25 comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of the invention or the polypeptide codes of the invention. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of the invention or the polypeptide codes of the invention. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase

30 (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, 1990), FASTA (Pearson and Lipman, 1988), FASTDB (Brutlag et al., 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight

35 II, (Molecular Simulations Inc.), Discover (Molecular Simulations Inc.), CHARMM (Molecular Simulations Inc.), Felix (Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler

(Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent specification referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.

EXAMPLES

EXAMPLE 1: LOCALIZATION OF THE OLFACTORY RECEPTOR GENE OLF3 AND OLF5 ON THE HUMAN CHROMOSOMES.

Metaphase chromosome preparation

Metaphase chromosomes were prepared from phytohemagglutinin (PHA)-stimulated blood cell donors. PHA stimulated lymphocytes from healthy males were cultured for 72 h in RPMI-1640 medium. For synchronization, methotrexate (10 μ M) was added for 17 h, followed by addition of 5-bromodeoxyuridine (5-BrdU, 0.1 mM) for 6 h. Colcemid (1 mg/ml) was added for the last 15 min before harvesting the cells. Cells were collected, washed in RPMI, incubated with a hypotonic solution of KCl (75 mM) at 37°C for 15 min and fixed in three changes of methanol:acid acetic (3:1). The cell suspension was dropped onto a glass slide, air-dried and kept in darkness at -20°C until use.

Probes:

- The BAC H0526H04 containing Olf3 and Olf5 genes was used to generate probe by Alu-PCR. PCR amplification of BAC recombinant DNA (50 ng) was carried out as described by Romana et al. (1993).

- Two DNA fragments carrying respectively Olf3 and Olf5 sequences were generated by long range PCR with specific primers (SEQ ID 96-99) and used as probes to confirm the localization of each genes. Olf3 and Olf5 amplicons are respectively 2.8 kb and 3.2 kb fragments.

Probes were labeled by nick translation with bio-16-dUTP (Boehringer Mannheim), and
5 purified over a Sephadex G50 column.

Fluorescence In Situ Hybridization

To determine the chromosomal localization of both genes, the BAC probe was initially hybridized to human metaphase cells. When biotinylated PCR products of BAC DNA were used in hybridization experiment, 75 ng of probe was precipitated with 75 µg of competitor DNA (human
10 Cot1 DNA, GIBCO-BRL) and resuspended in 10 µl of hybridization buffer (50% formamide, 2 X SSC, 10% dextran sulfate, 1 mg/ml sonicated herring DNA, pH 7). When long range PCR products of Olf3 or Olf5 genes were used as probe, 5 ng of biotinylated probe were mixed with 5 µg of human Cot1 DNA. Prior to hybridization, the probe was denatured at 70°C for 10 min and preannealed at 37°C for 2 h.

15 Slides were treated for 1 h at 37°C with Rnase A (100 µg/ml), rinsed three times in 2 X SSC and dehydrated in an ethanol serie. Chromosome preparations were denatured in 70% formamide, 2 X SSC (pH 7), for 2 min at 70°C, then dehydrated at 4°C. The slides were treated with proteinase K (10 µg/ml in 20 mM Tris-HCl, 2 mM CaCl₂) at 37°C for 8-10 min and dehydrated. After
preannealing, the hybridization mixture containing the probe was placed on the slide, covered with a
20 coverslip, sealed with rubber cement and incubated overnight in a humid chamber at 37°C. After hybridization and post hybridization washes, the biotinylated probe was detected by avidin-FITC (5 µg/ml, Vector Laboratories) and amplified once with additional layers of biotinylated goat anti-avidin (5 µg/ml, Vector Laboratories) and avidin-FITC. For chromosomal localization, fluorescent R-Bands were obtained as described by Cherif et al. (1990). The slides were observed under a
25 LEICA fluorescent microscope (DMRXA). Chromosomes were counterstained with propidium iodide and the fluorescent signal of the probe appeared as two symmetrical yellow-green spots on both chromatids of the fluorescent R-band chromosome.

Localization

A specific signal (a double yellow-green spot) was observed on band 11q12-q13 on at least
30 on chromosome 11 in >80% of the metaphases with all the probes.

EXAMPLE 2 : IDENTIFICATION OF BIALLELIC MARKERS: DNA EXTRACTION

Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a French heterogeneous population. The DNA from 100 individuals was extracted and tested for the
35 detection of the biallelic markers.

30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume : 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red
 5 cells present in the supernatant, after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M
- 200 µl SDS 10%
- 10 - 500 µl K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was
 15 rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 µg/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used
 20 in the subsequent examples described below.

The pool was constituted by mixing equivalent quantities of DNA from each individual.

EXAMPLE 3 : IDENTIFICATION OF BIALLELIC MARKERS: AMPLIFICATION OF GENOMIC DNA BY PCR

The amplification of specific genomic sequences of the DNA samples of example 2 was
 25 carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

PCR assays were performed using the following protocol:

	Final volume	25 µl
	DNA	2 ng/µl
30	MgCl ₂	2 mM
	dNTP (each)	200 µM
	primer (each)	2.9 ng/µl
	Ampli Taq Gold DNA polymerase	0.05 unit/µl
	PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl	1x

35 Each pair of first primers was designed using the sequence information of the olfactory receptor gene cluster disclosed herein and the OSP software (Hillier & Green, 1991). This first pair

of primers was about 20 nucleotides in length and had the sequences disclosed in Table 1 in the columns labeled PU and RP.

Table 1

Amplicon	Position range of the amplicon in SEQ ID 1		Primer name RP	Position range of amplification primer in SEQ ID No 1		Primer name PU	Complementary position range of amplification primer in SEQ ID No 1	
99-13670	7362	7824	B1	7362	7380	C1	7805	7824
99-13669	8120	8662	B2	8120	8140	C2	8643	8662
99-13666	14308	14757	B3	14308	14328	C3	14740	14757
99-13664	19346	19845	B4	19346	19366	C4	19826	19845
99-13663	20298	20800	B5	20298	20318	C5	20781	20800
99-13660	76752	77223	B6	76752	76772	C6	77205	77223
99-13652	90967	91494	B7	90967	90987	C7	91474	91494
99-13671	133925	134393	B8	133925	133945	C8	134375	134393
99-13649	139807	140351	B9	139807	139826	C9	140331	140351
99-13648	140912	141434	B10	140912	140932	C10	141416	141434
99-13647	143828	144309	B11	143828	143847	C11	144292	144309

5 Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

Primers PU contain the following additional PU 5' sequence :

TGTAAAACGACGGCCAGT; primers RP contain the following RP 5' sequence :

CAGGAAACAGCTATGACC. The primer containing the additional PU 5' sequence is listed in

10 SEQ ID No 26. The primer containing the additional RP 5' sequence is listed in SEQ ID No 27.

The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at
15 72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the amplification products obtained were determined on 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

EXAMPLE 4 : IDENTIFICATION OF BIALLELIC MARKERS: SEQUENCING OF AMPLIFIED GENOMIC DNA AND IDENTIFICATION OF POLYMORPHISMS.

20 The sequencing of the amplified DNA obtained in example 3 was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version)).

The sequence data were further evaluated using the above mentioned polymorphism analysis software designed to detect the presence of biallelic markers among the pooled amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

- 5 11 fragments of amplification were analyzed. In these segments, 13 biallelic markers referred to as A1 to A13 in the BM column were detected. The localization of these biallelic markers is as shown in Table 2.

Table 2

Amplicon	BM	Marker Name	Localization in <i>OLF</i> gene cluster	Polymorphism	BM position in SEQ ID No 1
99-13670	A1	99-13670-305	Between Orf1 and Orf2	A/C	7521
99-13669	A2	99-13669-471	Between Orf1 and Orf2	A/C	8192
99-13666	A3	99-13666-275	Between Orf2 and Orf3	A/T	14483
99-13664	A4	99-13664-221	Between Orf2 and Orf3	A/G	19625
99-13663	A5	99-13663-218	Between Orf2 and Orf3	C/T	20583
99-13660	A6	99-13660-277	Between Orf4 and Orf5	G/T	76947
99-13652	A7	99-13652-407	Between Orf5 and Orf6	G/C	91088
99-13652	A8	99-13652-357	Between Orf5 and Orf6	C/T	91138
99-13652	A9	99-13652-308	Between Orf5 and Orf6	C/T	91187
99-13671	A10	99-13671-396	Between Orf9 and Orf10	C/T	133998
99-13649	A11	99-13649-286	Between Orf9 and Orf10	A/G	140066
99-13648	A12	99-13648-259	Between Orf9 and Orf10	C/T	141176
99-13647	A13	99-13647-278	After Orf10	C/T	144033

10

Table 3

BM	Marker Name	Position range of probes in SEQ ID No 1		Probes
A1	99-13670-305	7498	7544	P1
A2	99-13669-471	8169	8215	P2
A3	99-13666-275	14460	14506	P3
A4	99-13664-221	19602	19648	P4
A5	99-13663-218	20560	20606	P5
A6	99-13660-277	76924	76970	P6
A7	99-13652-407	91065	91111	P7
A8	99-13652-357	91115	91161	P8
A9	99-13652-308	91164	91210	P9
A10	99-13671-396	133975	134021	P10
A11	99-13649-286	140043	140089	P11
A12	99-13648-259	141153	141199	P12
A13	99-13647-278	144010	144056	P13

EXAMPLE 5 : VALIDATION OF THE POLYMORPHISMS THROUGH MICROSEQUENCING

The biallelic markers identified in example 4 were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example 2.

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 1).

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the primers used in microsequencing are detailed in Table 4.

Table 4

Marker Name	BM	Mis. 1	Position range of microsequencing primer mis 1 in SEQ ID No 1		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No 1	
99-13670-305	A1	D1	7502	7520	E1	7522	7540
99-13669-471	A2	D2	8173	8191	E2	8193	8211
99-13666-275	A3	D3	14464	14482	E3	14484	14502
99-13664-221	A4	D4	19606	19624	E4	19626	19644
99-13663-218	A5	D5	20564	20582	E5	20584	20602
99-13660-277	A6	D6	76928	76946	E6	76948	76966
99-13652-407	A7	D7	91069	91087	E7	91089	91107
99-13652-357	A8	D8	91119	91137	E8	91139	91157
99-13652-308	A9	D9	91168	91186	E9	91188	91206
99-13671-396	A10	D10	133979	133997	E10	133999	134017
99-13649-286	A11	D11	140047	140065	E11	140067	140085
99-13648-259	A12	D12	141157	141175	E12	141177	141195
99-13647-278	A13	D13	144014	144032	E13	144034	144052

Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the non-coding strand of the olfactory receptor gene or with the coding strand of the olfactory receptor gene.

The microsequencing reaction was performed as follows :

After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20µl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 µl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95°C before

being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

5 The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is
10 categorized classification as homozygous or heterozygous type based on the height ratio.

While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein by the one skilled in the art without departing from the spirit and scope of the invention.

15 **REFERENCES :**

- Adra et al.,1987, Gene, **60**:65-74
- Beard et al., 1980, Virology, Vol. 75:81
- Beaucage et al., *Tetrahedron Lett* 1981, **22**: 1859-1862
- Bolmont et al., J. of Submicroscopic cytology and pathology, 1990, **22**:117-122
- 20 Brown EL, Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* 1979;**68**:109-151
- Chai H. et al., 1993, Biotechnol. Appl. Biochem., **18**:259-273
- Cherif D, Julier C, Delattre O, Derré J, Lathrop GM and Berger R, *P.N.A.S. USA* (1990) **87**: 6639-6643
- Compton J. *Nature*. 1991 Mar 7; **350**(6313): 91-92.
- 25 Current Protocols in Molecular Biology, 1989, Ausubel FM et al. (eds), Greene Publishing Associates, Sections 9.10-9.14.
- Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2
- Engvall E, 1980, Methods Enzymol, **70**(A):419-439
- Feldman and Steg, 1996, Medecine/Sciences, synthese, **12**:47-55
- 30 Felgner et al., 1987, Proc. Natl. Acad. Sci., **84**:7413
- Fisher, D., Chap. 42 in: Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980).
- Flotte et al., 1992, Am. J. Respir. Cell Mol. Biol., **7** : 349-356.
- Fraley et al., 1980, J. Biol. Chem., **255**:10431).
- 35 Fuller S.A. et al., 1996, Immunology in Current Protocols in Molecular Biology, Ausubel et al. Eds, John Wiley & Sons, Inc., USA

- Graham, 1984, EMBO J., 3:2917
- Guatelli JC et al., 1990, Proc. Natl. Acad. Sci. USA, 87 : 1874-1878.
- Guzman, 1981, Cell, 23 : 175
- Hames BD and Higgins SJ, 1985, "Nucleic acid hybridization : a practical approach", Hames and
5 Higgins Ed., IRL Press, Oxford.
- Harju L, et al., *Clin Chem* 1993;39(11Pt 1):2282-2287
- Hartley JW, Rowe WP, *J Virol* 1976;19(1):19-25
- Hillier L. and Green P. *Methods Appl.*, 1991, 1: 124-8.
- Houbenweyl, 1974, in *Meuthode der Organischen Chemie*, E. Wunsch Ed., Volume 15-I et 15-II,
10 Thieme, Stuttgart
- Huygen et al., 1996, *Nature Medicine*, 2(8):893-898
- Julan et al., 1992, *J. Gen. Virol.*, 73 : 3251 – 3255.
- Kaneda et al., 1989, *Science*, 243:375
- Kiefer H et al., 1996, *Biochemistry*, 35(50):16077-16084.
- 15 Koch Y., 1977, *Biochem. Biophys. Res. Commun.*, 74:488-491
- Kohler G. and Milstein C., 1975, *Nature*, 256 : 495.
- Kort et al., 1983, *Nucleic Acids Research*, 11:8287-8301
- Lenhard T. et al., 1996, *Gene*, 169:187-190
- Levrero et al., 1991, *Gene*, 101:195
- 20 Lin Z, Floros J, 1998, *Biotechniques*, 24(6):937-940
- Livak KJ, and Hainer JW., 1994, *Hum Mutat.*, 3(4): 379-385.
- Mackey K, Steinkamp A, Chomczynski P, 1998, *Mol Biotechnol*, 9(1):1-5
- Mansour SL, Thomas KR, Capecchi MR, *Nature* 1988;336(6197):348-52
- McLaughlin et al., 1989, *J. Virol.*, 62 : 1963 – 1973.
- 25 Merrifield RB 1965 *Nature*. 207: 522-523.
- Merrifield RB 1965 *Science*. 150: 178-185.
- Midoux, 1993, *Nucleic Acids Research*, 21:871-878
- Muzyczka et al., 1992, *Curr. Topics in Micro. and Immunol.*, 158 : 97-129.
- Narang SA, Hsiung HM, Brousseau R, *Methods Enzymol* 1979;68:90-98
- 30 Neda et al., 1991, *J. Biol. Chem.*, 266 : 14143 – 14146.
- Nekrasova E, Sosinskaya A, Natochin M, Lancet D, Gat U, *Eur J Biochem* 1996;238(1):28-37
- O'Reilly et al., 1992, *Baculovirus expression vectors : a Laboratory Manual*. W.H. Freeman and Co.,
New York Adra et al., 1987, *Gene*, 60:65-74
- Ohno et al., 1994, *Sciences*, 265:781-784
- 35 Ohwada A, Hirschowitz EA, Crystal RG, *Hum Gene Ther* 1996;7:1567-76
- Ouchterlony, O. et al., Chap. 19 in: *Handbook of Experimental Immunology* D. Wier (ed) Blackwell
(1973)

- Pagano et al., 1967, *J. Virol.*, **1**:891
- Palmer S et al., 1989, *Biochim Biophys Acta*, **1014**(3):239-246.
- Pastore, 1994, *Circulation*, **90**:I-517
- PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press
- 5 Pearson WR, Lipman DJ, *Proc Natl Acad Sci U S A* 1988;**85**(8):2444-8
- Porath J et al., 1975, *Nature*, **258**(5536) : 598-599.
- Raming K et al., 1993, *Nature*, **361**(6410):353-356
- Rettiez and Basenga, 1987, *Mol. Cell. Biol.*, **7**:1676-1685
- Romana SP, Tachdjian G, Druart L, Cohen D, Berger R, Cherif D *Eur J Hum Genet* (1993) **1**: 245-
- 10 251.
- Roth J.A. et al., 1996, *Nature Medicine*, **2**(9):985-991
- Rougeot, C. et al., *Eur. J. Biochem.* **219** (3): 765-773, 1994
- Sambrook, J. Fritsch, E. F., and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*. 2ed. Cold Spring Harbor Laboratory, Cold spring Harbor, New York
- 15 Samulski et al., 1989, *J. Virol.*, **63** : 3822-3828.
- Sanchez-Pescador R., 1988, *J. Clin. Microbiol.*, **26**(10):1934-1938
- Sczakiel G. et al., 1995, *Trends Microbiol.*, 1995, **3**(6):213-217
- Smith et al., 1983, *Mol. Cell. Biol.*, **3**:2156-2165.
- Steiner AL et al., 1972, *J Biol Chem*, **247**(4):1106-1113
- 20 Syvanen AC, et al., 1994, *Hum Mutat.*, **3**(3): 172-179.
- Tacson et al., 1996, *Nature Medicine*, **2**(8):888-892
- Tucker J, Grishammer R, *Biochem J* 1996;**317**(Pt 3):891-899
- Urdea M.S., 1988, *Nucleic Acids Research*, **11**: 4937-4957
- Urdea MS et al., 1991, *Nucleic Acids Symp Ser.*, **24**: 197-200.
- 25 Vaitukaitis J. et al., 1971, *J. Clin. Endocrinol. Metab.*, **33** : 988-991
- Vlasak R. et al., 1983, *Eur. J. Biochem.*, **135**:123-126
- White, B.A. *Molecular Cloning to Genetic Engineering* Ed. in *Methods in Molecular Biology* **67**: Humana Press, Totowa 1997
- Zhao H et al., 1998, *Science*, **279**(5348):237-242
- 30 Zhenlin et al., *Gene*, 1989, **78**:243-254.

SEQUENCE LISTING FREE TEXT

The following free text appears in the accompanying Sequence Listing :

open reading frame

ubiquitin 1 pseudogene complement

5 ubiquitin 2 pseudogene complement

polymorphic base

or

complement

probe

10 sequencing oligonucleotide PrimerPU

sequencing oligonucleotide PrimerRP

What is claimed:

1. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1 of the following nucleotide positions of SEQ ID No 1: 1-113643, 114064-
5 127488, 127855-144460.

2. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of a sequence selected from the group consisting of SEQ ID Nos 2-11 or the complements thereof.

10

3. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 or the complement thereof, wherein said span includes an olfactory receptor-related biallelic marker in said sequence.

15 4. A polynucleotide according to claim 3, wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13, and the complements thereof.

5. A polynucleotide according to claims 3 or 4, wherein said contiguous span is 18 to 47 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said
20 polynucleotide.

6. A polynucleotide according to claim 5, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: P1 to P13, and the complementary sequences thereto.

25

7. A polynucleotide according to any one of claims 1, 2 or 3, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide.

8. A polynucleotide according to claims 3 or 4, wherein the 3' end of said contiguous span is
30 located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

9. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID No 1 or the complement thereof, wherein the 3' end of said
35 contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said

polynucleotide is located within 20 nucleotides upstream of an olfactory receptor-related biallelic marker in said sequence.

10. A polynucleotide according to claim 9, wherein the 3' end of said polynucleotide is
5 located 1 nucleotide upstream of said olfactory receptor-related biallelic marker in said sequence.

11. A polynucleotide according to claim 10, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D13, and E1 to E13.

10 12. A polynucleotide according to claim 7 consisting essentially of a sequence selected from the following sequences: B1 to B11 and C1 to C11.

13. An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of a sequence selected from the group
15 consisting of SEQ ID Nos 12-21.

14. A polynucleotide for use in a genotyping assay for determining the identity of the nucleotide at an olfactory receptor-related biallelic marker or the complement thereof.

20 15. A polynucleotide according to claim 14, wherein the polynucleotide is used in an assay selected from the group consisting of: a hybridization assay, a sequencing assay, an enzyme-based mismatch detection assay, and an amplification of a segment of nucleotides comprising said biallelic marker.

25 16. A polynucleotide according to any one of claims 1-15 attached to a solid support.

17. An array of polynucleotides comprising at least one polynucleotide according to claim
16.

30 18. An array according to claim 17, wherein said array is addressable.

19. A polynucleotide according to any one of claims 1-15, further comprising a label.

20. A recombinant vector comprising a polynucleotide according to any one of claims 1-15.

35

21. A host cell comprising a recombinant vector according to claim 20.

22. A non-human host animal or mammal comprising a recombinant vector according to claim 20.

23. A mammalian host cell comprising an olfactory receptor gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1-15.

24. A non-human host mammal comprising an olfactory receptor gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1-15.

25. An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of a sequence selected from the group consisting of SEQ ID Nos 12-21.

26. An isolated or purified antibody composition are capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 25.

27. A method of genotyping comprising determining the identity of a nucleotide at an olfactory receptor-related biallelic marker or the complement thereof in a biological sample.

28. A method according to claim 27, wherein said biological sample is derived from a single subject.

29. A method according to claim 28, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome.

30. A method according to claim 27, wherein said biological sample is derived from multiple subjects.

31. A method according to claim 27, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step.

32. A method according to claim 31, wherein said amplifying step is performed by PCR.

33. A method according to claim 27, wherein said determining is performed by an assay selected from the group consisting of: a hybridization assay, a sequencing assay, a microsequencing assay, and an enzyme-based mismatch detection assay.

34. A method according to claim 27 wherein said olfactory receptor-related biallelic marker is selected from the group consisting of A1 to A13 and the complements thereof.

5 35. A method for the screening of a candidate substance interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, or fragments or variants thereof, comprises the following steps :

a) providing a polypeptide selected from the group consisting of the sequences of SEQ ID Nos 12-21 , or a peptide fragment or a variant thereof;

10 b) obtaining a candidate substance;

c) bringing into contact said polypeptide with said candidate substance; and

d) detecting the complexes formed between said polypeptide and said candidate substance.

36. A method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, wherein said method comprises :

a) providing a recombinant eukaryotic host cell containing a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21;

20 b) preparing membrane extracts of said recombinant eukaryotic host cell;

c) bringing into contact the membrane extracts prepared at step b) with a selected ligand molecule; and

d) detecting the production level of second messengers metabolites.

25 37. A method for the screening of ligand molecules interacting with an olfactory receptor polypeptide selected from the group consisting of SEQ ID Nos 12-21, wherein said method comprises :

a) providing an adenovirus containing a nucleic acid encoding a polypeptide selected from the group consisting of the polypeptides comprising the amino acid sequences SEQ ID Nos 12-21;

30 b) infecting an olfactory epithelium with said adenovirus;

c) bringing into contact the olfactory epithelium b) with a selected ligand molecule; and

d) detecting the increase of the response to said ligand molecule.

1/2

FIGURE 1

		TM1				
		1				50
list1.msf{orf-8}	~MRRNFTLV	EFILLGLTNH	QELQILLFML	FLAIYMTVA	GNLSMIALI	Q
list1.msf{orf-9}	~MRRNCTLV	EFILLGLTSR	RELQILLFTL	FLAIYMTVA	GNLGMIVLI	Q
list1.msf{orf-7}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~LPSSR	
list1.msf{orf-2}	MFSPNHTIV	EFILLGLTDD	PVLEKILFGV	FLAIYELITL	GNLCMILLIR	
list1.msf{orf-4}	MLSPNHTIV	EFILLGLTDD	PVLEKILFGV	FLAIYELITL	GNLCMILLIR	
list1.msf{orf-5}	MSNTNGSAIT	EFILLGLTDC	PELQSLLFVL	FLVVYLVTL	GNLGMIMLMR	
list1.msf{orf-6}	MVRGNSTLV	EFILLGLKDL	PELQPILFVL	FLLIYELITV	GNLGMIVLIR	
list1.msf{orf-10}	MSRRNYTELT	EFVLLGLTSR	PELRVAFAL	FLFVYIATV	GNLGMILIK	
list1.msf{orf-3}	MLKKNHTAV	EFVLLGLTDR	AELQSLLFV	FLVIYELITV	GNVSMILLIR	
list1.msf{orf-1}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~MSFLIR	
Consensus	M-R-N-T-VT	EFILLGLTD	PELQ-LLF-L	FLAIYELITVA	GNLGMILIR	
		TM2				
		51				100
list1.msf{orf-8}	ANARLHTPMY	FFLSHLSFLD	LCFSSNVTPK	MLEIFLSEKK	SISYPACLVQ	
list1.msf{orf-9}	ANAWLHMPMY	FFLSHLSFVD	LCFSSNVTPK	MLEIFLSEKK	SISYPACLVQ	
list1.msf{orf-7}	PTPRLHTPMY	FFLSNLSFVD	LCFSSNVTPR	MLEIFLSEKK	SISYPARLVQ	
list1.msf{orf-2}	TNSHLQTPMY	FFLGHLSFVD	ICYSSNVTPN	MLHNFLSEQK	TISYAGCFTQ	
list1.msf{orf-4}	TNSQLQTPMY	FFLGHLSFLD	ICYSSNVTPN	MLHNFLSEQK	TISYAGCFTQ	
list1.msf{orf-5}	LDSRLHTPMY	FFLTNLAFVD	LCYTSNATPQ	MSTNIVSE.K	TISFAGCFTQ	
list1.msf{orf-6}	IDSRLHTPMY	FFLASLSCLD	LYYSTNVTPK	MLVNFFSDKK	AISYAACLVQ	
list1.msf{orf-10}	VDSRLHTPM~	~~~~~	~~~~~	~~~~~	~~~~~	
list1.msf{orf-3}	SDSTLHTPMY	FFLSHLSFVD	LCYTTNVTPQ	MLVNFLSKRK	TISFIGCFIQ	
list1.msf{orf-1}	SDSTLHTPMC	LFLSHLSFVD	LYYATNATP	MLVNFFFPRE	KPFPLLVALS	
Consensus	-DSRLHTPMY	FFLSHLSFVD	LCYSSNVTP	ML-NFLSEKK	TISYA-C-VQ	
		TM3				
		101				150
list1.msf{orf-8}	CYLYIILVHV	EIYILAVMAF	D-~~~~~	~~~~~	~~~~~	
list1.msf{orf-9}	CYLFIALVHV	EIYILAVMAF	DRYMAICNPL	LYGSRMSKSV	CSFLITVPYV	
list1.msf{orf-7}	CYLFITLVHV	ELYILAVMAF	DRYMAICNPL	LYGSRMSKSV	CSFLITVLVY	
list1.msf{orf-2}	CLLFIALVIT	EFYFLASMAL	DRYVAICSP	HYSSRMSKNI	CISLVTVPYM	
list1.msf{orf-4}	CLLFIALVIT	EFYFLASMAL	DRYVAICSPX	HYSSRMSKNI	CISLVTVPYM	
list1.msf{orf-5}	CYIFIALLLT	EFYMLAAMAY	DRYVAIYDPL	RYSVKTSRRV	CICLATFPYV	
list1.msf{orf-6}	CYFFIAVVIT	EYMLAVMAY	DRYVAICNPL	LYSSKMSKGL	CIRLIAGPYV	
list1.msf{orf-10}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
list1.msf{orf-3}	FHFFIALVIT	DYYMLTVMAY	DRYMAICKPL	LYGSKMTROV	CLCLAAAPYI	
list1.msf{orf-1}	NFTFSLHW~	~~~~~	~~~~~	~~~~~	~~~~~	
Consensus	CYLFIALVIT	E-Y-LAVMA-	DRYVAIC-PL	LYSSRMSK-V	CI-L-TVPYV	
		TM4				
		151				200
list1.msf{orf-8}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
list1.msf{orf-9}	YGALTGLMET	MWTYNLAFCG	PNEINHFYCA	DPPLIKLACS	DTYNKELSMF	
list1.msf{orf-7}	YGALTGLMET	MWTYNLAFCG	PSEINHFYCV	DPPLIKLACS	DTYNKEVSMF	
list1.msf{orf-2}	YGFLNGLSQT	LLTFHLSFCG	SLEINHFYCA	DPPLIMLACS	DTRVKKMAMF	
list1.msf{orf-4}	YGXLNGLSQT	LLTFHLSFCG	SLEINHFYCA	DPPLIMLACS	DTRVKKMAMF	
list1.msf{orf-5}	YGFSDDLFGA	ILTFRLTFCR	SNVINHFYCA	DPPLIKLSCS	DTYVKEHAMF	
list1.msf{orf-6}	YGFLSGLMET	MWTYHLTFCG	SNIINHFYCA	DPPLIRLSCS	DTFIKETSMF	
list1.msf{orf-10}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
list1.msf{orf-3}	YGFANGLSTD	HPDASSVLLW	TQ-~~~~~	~~~~~	~~~~~	
list1.msf{orf-1}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	
Consensus	YGFL-GL--T	--T--L-FCG	S-EINHFYCA	DPPLI-LACS	DT--KE--MF	

FIGURE 1 (continued)

	TM5				TM6			
	201				250			
list1.msf{orf-8}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-9}	IVAGWNLSFS	LFIICISYLY	IFPAILKIRS	TEGRQKAFST	CGSHLTAVTI	~~~~~	~~~~~	~~~~~
list1.msf{orf-7}	VVAGFNFTYP	LLIILISYLY	IFPATLRICS	TEGRHKAFST	CGSHLTAVTI	~~~~~	~~~~~	~~~~~
list1.msf{orf-2}	VVAGFTLSSS	LFIILLSYLF	IFAAIFRIRS	AEGRHKAFST	CASHLTIVTL	~~~~~	~~~~~	~~~~~
list1.msf{orf-4}	VVAGFTLSSS	LFIILLSYLF	IFAAIFRIRS	AEGRHKAFST	CASHLTIVTL	~~~~~	~~~~~	~~~~~
list1.msf{orf-5}	ISAGFNLSSS	LTIVLVSYAF	ILAAILRIKS	AEGRHKAFST	CGSHMMAVTL	~~~~~	~~~~~	~~~~~
list1.msf{orf-6}	VVA~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-10}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-3}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-1}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
Consensus	VVAGF-LS-S	L-IIL-SYL	IF-AI-RI-S	-EGRHKAFST	C-SHLT-VT-	~~~~~	~~~~~	~~~~~

	TM6				TM7			
	251				300			
list1.msf{orf-8}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-9}	FYATLFFMYL	RPPSKESVEQ	GKMVAVFYTT	VIPMLNLIY	SLRNKNVKEA	~~~~~	~~~~~	~~~~~
list1.msf{orf-7}	FYSALFFMYL	RRPSEESMEQ	GKMVAVFYTT	VIPMLNPMIY	SLRNKDVKEA	~~~~~	~~~~~	~~~~~
list1.msf{orf-2}	FYGTLFCEMYV	RPPSEKSVVEE	SKITAVFYTF	LTPLNPLIY	SLRNTDVILA	~~~~~	~~~~~	~~~~~
list1.msf{orf-4}	FYGTLFCEMYV	RPPSEKSVVEE	SKIIAVFYTF	LSPMLNPLIY	SLRNRDVILA	~~~~~	~~~~~	~~~~~
list1.msf{orf-5}	FYGTLFCEMYI	RPPTDKTVEE	SKIIAVFYTF	VSPVLNPLIY	SLRNKDVQQA	~~~~~	~~~~~	~~~~~
list1.msf{orf-6}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-10}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-3}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
list1.msf{orf-1}	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~	~~~~~
Consensus	FY-TLF-MY-	RPPS--SVE-	-K--AVFYT-	--PMLNP-IY	SLRN-DV--A	~~~~~	~~~~~	~~~~~

	301	315
list1.msf{orf-8}	~~~~~	~~~~~
list1.msf{orf-9}	LIKELSMKIY	FS~~~
list1.msf{orf-7}	LCKELFKRKL	FSK~~
list1.msf{orf-2}	MQQMIRGKSF	HKIAV
list1.msf{orf-4}	IQQMIRGKSF	CKIAV
list1.msf{orf-5}	LKNVLR~~~~	~~~~~
list1.msf{orf-6}	~~~~~	~~~~~
list1.msf{orf-10}	~~~~~	~~~~~
list1.msf{orf-3}	~~~~~	~~~~~
list1.msf{orf-1}	~~~~~	~~~~~
Consensus	~~~~~	~~~~~

<110> Genset SA

<120> Genes encoding olfactory receptors and biallelic markers thereof.

<150> US 60/104,299

<151> 1999-10-13

<160> 27

<170> Patent.pm

<210> 1

<211> 144460

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> 2406..2600

<223> open reading frame 1

<220>

<221> CDS

<222> 9711..10658

<223> open reading frame 2

<220>

<221> CDS

<222> 24851..25369

<223> open reading frame 3

<220>

<221> CDS

<222> 45714..46661

<223> open reading frame 4

<220>

<221> CDS

<222> 80198..81115

<223> open reading frame 5

<220>

<221> CDS

<222> 96291..96902

<223> open reading frame 6

<220>

<221> CDS

<222> 110758..111564

<223> open reading frame 7

<220>

<221> CDS

<222> 122525..122887

<223> open reading frame 8

<220>

<221> CDS

<222> 132454..133389

<223> open reading frame 9

<220>

<221> CDS
<222> 143398..143577
<223> open reading frame 10

<220>
<221> misc_feature
<222> 113644..114063
<223> ubiquitin 1 pseudogene complement

<220>
<221> misc_feature
<222> 127489..127854
<223> ubiquitin 2 pseudogene complement

<220>
<221> allele
<222> 7521
<223> 99-13670-305 : polymorphic base G or T

<220>
<221> allele
<222> 8192
<223> 99-13669-471 : polymorphic base G or T

<220>
<221> allele
<222> 14483
<223> 99-13666-275 : polymorphic base A or T

<220>
<221> allele
<222> 19625
<223> 99-13664-221 : polymorphic base C or T

<220>
<221> allele
<222> 20583
<223> 99-13663-218 : polymorphic base A or G

<220>
<221> allele
<222> 76947
<223> 99-13660-277 : polymorphic base A or C

<220>
<221> allele
<222> 91088
<223> 99-13652-407 : polymorphic base G or C

<220>
<221> allele
<222> 91138
<223> 99-13652-357 : polymorphic base A or G

<220>
<221> allele
<222> 91187
<223> 99-13652-308 : polymorphic base A or G

<220>
<221> allele
<222> 133998
<223> 99-13671-396 : polymorphic base A or G

<220>
<221> allele
<222> 140066
<223> 99-13649-286 : polymorphic base C or T

<220>
<221> allele
<222> 141176
<223> 99-13648-259 : polymorphic base A or G

<220>
<221> allele
<222> 144033
<223> 99-13647-278 : polymorphic base A or G

<220>
<221> primer_bind
<222> 7362..7380
<223> 99-13670.rp

<220>
<221> primer_bind
<222> 7805..7824
<223> 99-13670.pu complement

<220>
<221> primer_bind
<222> 8120..8140
<223> 99-13669.rp

<220>
<221> primer_bind
<222> 8643..8662
<223> 99-13669.pu complement

<220>
<221> primer_bind
<222> 14308..14328
<223> 99-13666.rp

<220>
<221> primer_bind
<222> 14740..14757
<223> 99-13666.pu complement

<220>
<221> primer_bind
<222> 19346..19366
<223> 99-13664.rp

<220>
<221> primer_bind
<222> 19826..19845
<223> 99-13664.pu complement

<220>
<221> primer_bind
<222> 20298..20318
<223> 99-13663.rp

<220>
<221> primer_bind

<222> 20781..20800
<223> 99-13663.pu complement

<220>
<221> primer_bind
<222> 76752..76772
<223> 99-13660.rp

<220>
<221> primer_bind
<222> 77205..77223
<223> 99-13660.pu complement

<220>
<221> primer_bind
<222> 90967..90987
<223> 99-13652.rp

<220>
<221> primer_bind
<222> 91474..91494
<223> 99-13652.pu complement

<220>
<221> primer_bind
<222> 133925..133945
<223> 99-13671.rp

<220>
<221> primer_bind
<222> 134375..134393
<223> 99-13671.pu complement

<220>
<221> primer_bind
<222> 139807..139826
<223> 99-13649.rp

<220>
<221> primer_bind
<222> 140331..140351
<223> 99-13649.pu complement

<220>
<221> primer_bind
<222> 140912..140932
<223> 99-13648.rp

<220>
<221> primer_bind
<222> 141416..141434
<223> 99-13648.pu complement

<220>
<221> primer_bind
<222> 143828..143847
<223> 99-13647.rp

<220>
<221> primer_bind
<222> 144292..144309
<223> 99-13647.pu complement

<220>
<221> misc_binding
<222> 7498..7544
<223> 99-13670-305.probe

<220>
<221> misc_binding
<222> 8169..8215
<223> 99-13669-471.probe

<220>
<221> misc_binding
<222> 14460..14506
<223> 99-13666-275.probe

<220>
<221> misc_binding
<222> 19602..19648
<223> 99-13664-221.probe

<220>
<221> misc_binding
<222> 20560..20606
<223> 99-13663-218.probe

<220>
<221> misc_binding
<222> 76924..76970
<223> 99-13660-277.probe

<220>
<221> misc_binding
<222> 91065..91111
<223> 99-13652-407.probe

<220>
<221> misc_binding
<222> 91115..91161
<223> 99-13652-357.probe

<220>
<221> misc_binding
<222> 91164..91210
<223> 99-13652-308.probe

<220>
<221> misc_binding
<222> 133975..134021
<223> 99-13671-396.probe

<220>
<221> misc_binding
<222> 140043..140089
<223> 99-13649-286.probe

<220>
<221> misc_binding
<222> 141153..141199
<223> 99-13648-259.probe

<220>
<221> misc_binding
<222> 144010..144056

<223> 99-13647-278.probe

<220>
<221> primer_bind
<222> 7502..7520
<223> 99-13670-305.mis

<220>
<221> primer_bind
<222> 7522..7540
<223> 99-13670-305.mis complement

<220>
<221> primer_bind
<222> 8173..8191
<223> 99-13669-471.mis

<220>
<221> primer_bind
<222> 8193..8211
<223> 99-13669-471.mis complement

<220>
<221> primer_bind
<222> 14464..14482
<223> 99-13666-275.mis

<220>
<221> primer_bind
<222> 14484..14502
<223> 99-13666-275.mis complement

<220>
<221> primer_bind
<222> 19606..19624
<223> 99-13664-221.mis

<220>
<221> primer_bind
<222> 19626..19644
<223> 99-13664-221.mis complement

<220>
<221> primer_bind
<222> 20564..20582
<223> 99-13663-218.mis

<220>
<221> primer_bind
<222> 20584..20602
<223> 99-13663-218.mis complement

<220>
<221> primer_bind
<222> 76928..76946
<223> 99-13660-277.mis

<220>
<221> primer_bind
<222> 76948..76966
<223> 99-13660-277.mis complement

<220>

<221> primer_bind
<222> 91069..91087
<223> 99-13652-407.mis

<220>
<221> primer_bind
<222> 91089..91107
<223> 99-13652-407.mis complement

<220>
<221> primer_bind
<222> 91119..91137
<223> 99-13652-357.mis

<220>
<221> primer_bind
<222> 91139..91157
<223> 99-13652-357.mis complement

<220>
<221> primer_bind
<222> 91168..91186
<223> 99-13652-308.mis

<220>
<221> primer_bind
<222> 91188..91206
<223> 99-13652-308.mis complement

<220>
<221> primer_bind
<222> 133979..133997
<223> 99-13671-396.mis

<220>
<221> primer_bind
<222> 133999..134017
<223> 99-13671-396.mis complement

<220>
<221> primer_bind
<222> 140047..140065
<223> 99-13649-286.mis

<220>
<221> primer_bind
<222> 140067..140085
<223> 99-13649-286.mis complement

<220>
<221> primer_bind
<222> 141157..141175
<223> 99-13648-259.mis

<220>
<221> primer_bind
<222> 141177..141195
<223> 99-13648-259.mis complement

<220>
<221> primer_bind
<222> 144014..144032
<223> 99-13647-278.mis

<220>
 <221> primer_bind
 <222> 144034..144052
 <223> 99-13647-278.mis complement

<400> 1
 caattaaagt tttgttcact ataagtcctt tttggaaaag agagagaaac attcaaatta 60
 ttacatatacc agtttccatt agcatgtgaa gaacaaacag aaacactttt caggggtgaac 120
 aaaattcctg ctacagttat aaaatcctgc atatactctt tactttgtga ttctgaaaaa 180
 caccgttcta cctggtttat tgaaatgtgt gaaagctcta atgcaatgtt attttttaca 240
 ttttgtaaca cttaagtcac aaagccaagc tattctcaaa ccttgatgaa acatgttgga 300
 agaaattatg ttttagtggt tgggtgaaaac attatgtttc gtcacttaag gtgataaatt 360
 gtactcatta aagaactttg aaagttcaca catagccaat ggtttaaaat gcactaattt 420
 agattcccaa ttctcacaaa ggccagttac tctggaccat tcaatcgcca aagaggaaaa 480
 ctgggggcat tcccattccc ggatatggga agtccccgag cttccagcct ggtccttgtg 540
 gccgaaaaat ggcattgttt gcttttgctt ttggatcctg ttctgtccgc caaaaatggt 600
 ctgtgtgggg aaagtgcgag gggagagaaa agacacggac atgatacgtt taagggtaaa 660
 caacgtttat cccatgtaag tggccatgca gatatagtaa gcaaatgata taataataag 720
 caaatgatat aataagcaga ttgatataat aagtagattg caatggaacg gggaaaaggg 780
 aaaatacatc tacattcacc agactatgga ggattcaaca acagactggg acgcaacagc 840
 ctgggctcca gagtcagata ggtaggcaaa gagatcctag ttctatacag atacgtacca 900
 tggagcagtt ccactttcct aagcacattc agttgtgata aaaatagatg agtttcaagg 960
 gctgatacat tacatgccac actcaaagtt gtgttggttaa acaatttcaa ttgttggttac 1020
 aatttcaaat aaaagcaatg ttacaacca tgggttcaag agaagtctaa gtgaacacat 1080
 ataataaaga cttgcaaaat aataaaagat aaggctcttt aactatcaaa agacttgcag 1140
 aaaagaacca cagaaaacca ttttaaatat aactgccttc gtatgtaaga aattctacat 1200
 tatttttgat gttaaaacat caatctcatg cttactaggc tatttcttaa tgacacatgt 1260
 atttacaat ttgagagaag aggaagaaat atcagggtgac accactgggt taatgcataa 1320
 atgacaaacc taaatgcatt ttaatttctt tttctttaa tctgagctgag cttcagcccc 1380
 ttctttttgt ggtgttctta gtcattctacc ttatcacagt aatcacatg taagcatgat 1440
 cttctttttt ttttttaagt gcacaatatt ttttaactgt aacaatatac ctattgttac 1500
 ctatgggac aatgatatac agcatatctc tagaatttat tcttgcaaaa ctataacttt 1560
 atacctgctg aacagcaaca cccattttct ccctttcctc cagccgctgc aaccaccttc 1620
 tattctctgt ttctatgagt ttgactattt tggattcctc atataaattt aatcatgcag 1680
 tatttgcct tccgtgcctg gcttatttca cttaacataa tgtcctccag gttcatcata 1740
 tgacaggatt tcttcttttt cttaatgatg aataatattc cattacatgt gtgtactaca 1800
 ttttcttcat ctttcaatgg acatttaggt tgtttctata tctggactat tgtaaataat 1860
 ggtgcaatga acataagagt acctatgtct cttcaagagc ttgattttaa ttcttttgga 1920
 tatatgccc gaagtgcaat tgctgggtta tatgataatt cgatttttaa ttatttgaag 1980
 actcatcata ctgtttttta tagtggctgc acaattttat attcccacca atgttgtaca 2040
 agggttccaa tttcttcata tgtcaccat atttgttgtc ttttggattt ttttaaaata 2100
 aagtaacagc catcataaca aatgtgatat catgcttttg tttcatatgc attttcttga 2160
 tgattagtgt gttgagcacc ttttcatttt tatttattta ttatttata ctctaagttc 2220
 tgggatacat ctgcagaaca cgcagggttg ttacataggt atacatgtgc catgggtgtt 2280
 tgcctgcgcc attaacctgt catctacatt aggtattttc gctaatacta tccctcccc 2340
 agccccgac cccctgacag gtccgtgtgt gtgatgtttc ccttctgtg tccatgtgtg 2400
 tgagcatgag cttcttaata agaagtgatt caacactaca cactccaatg tgcttgttcc 2460
 tcagtcatt ctcccttgta gatctctatt atgccaccaa tgccactcct ccgatgctgg 2520
 ttaacttttt ttttccaaga gaaaaaccgt ttccctttatt ggttgcttta tccaatttca 2580
 ccttttcatt gcactggtga tcacagatta tcatatgtct acagtgatgg tgtatgacca 2640
 ctacatggcc atctgcaagc ctttgttata tgggaagcaaa atgtccaggt gtgtctgcct 2700
 ctgtctcact gctgtccct atatttatgg ctctgcaaat ggtctggtac aggtcatcct 2760
 gatgctttgt ctgttcttct gtgaacccaa ttgatctaac cacttttttt ttttttggag 2820
 aaaatgcatt atatgccat ttaattccac tataaatttt tgaatggacg gttggagagg 2880
 aaggagaaaa tacatattaa cggagagaat accaccaga aagtatatac aatgggagaa 2940
 aggaacctgt tgatccaagt ttccatattc ttattatggc atataaggct atgattattt 3000
 tctcagtatg aagcatctcc cagggctgac tctgatgtaa aattggagat caaccacttt 3060
 tattatgcag aaccaccct cttagtctc gcctgcttgg atacttatgt caaagaaact 3120
 gccatgttca tgggtgctgg ttccaacctc atctgccctc tcaactatcat ctttatttcc 3180
 tacactttca tcttcacaga cattctgcat atctgcactg ctgaggggag gtacaatgcc 3240
 ttctccacct gcgggtccct tgtgactgcc gtcactgtct ttcaagggaac gctgtttcac 3300
 atgtgcctga ggcccccttc tgaggcatct gtagaacagg ggaaaattgt agctgctttt 3360

tatatctttg	tgagtcctac	gttaaaccaca	ttgatctacc	gtctgaggaa	taaaaatggt	3420
aaaagaacaa	taaggggaagt	tatccaaaag	aaactgtttg	ctaagtaagg	tagatatttt	3480
agttgcaggt	tatgtaatac	attattttta	tcttaccat	taacgagcat	tataaattaa	3540
caaatcactt	tctgtcattg	agtgtttttt	gtcttttgta	acttgcatat	gggaattgaa	3600
agtgtatacc	aaattattag	ctagagttag	cagtgtcatc	tcagtgaatt	taagaagaaa	3660
tcatagaaat	ttaaataagaa	gacttatggc	atgtaaaagt	caataaagaa	cagtgattcc	3720
ttcttttagta	ctcatattgg	tagcaaacga	taaaagacag	aatgcaatgg	aaattacagt	3780
tcattacatt	tttatagtac	ttaataactt	ccaaactatt	ttctagacac	ctttcaaaca	3840
tagtatatga	agttttctcc	tttcttttat	acagataatg	caacaataaa	gatcactgat	3900
gtagggaaaa	gagagatcag	actgttactg	tgtctatgta	gaaaagggaag	gcataagaaa	3960
cttcattttg	acttgtaccc	tgaacaattg	ttttgtcctg	agatgctgtt	aatctgtaac	4020
tttgccccaa	ccttgagctt	ataaaaaacat	gtgttgatg	gaatcaaggt	ttaagggatc	4080
tagggctgtg	caggatgtgc	cttgtagca	gaatgtatac	aggcagtatg	cttggtaaaa	4140
gtcatcgcca	ttctccagtc	tccataaacc	aggggcacaa	tgcactgtgg	aaagtccacag	4200
ggacctctgc	cctggaaagc	cgggtattgc	caagggtttct	ccccatgtga	tagtctgaaa	4260
tatggcctcg	tgggatggga	aagacctgac	cggccccccag	cctgacaccc	gtgaaggggtc	4320
tgtgctcggg	aggattagta	aaagaggatg	gcctcttata	gctgagataa	gaggaaggcc	4380
tctgtctcct	gacctgccc	gggaactgaa	tgtctcggta	taaaacctga	ttgcaccttt	4440
cttctattct	gagataggag	aaaaaccgcc	ctgtggcggg	aggcgagaca	tgttggcagc	4500
aatgctgctt	tgttattctt	tactccactg	agatgtttgg	gtggagagaa	ggaaaaatct	4560
ggcttacgtg	cacatccagg	catagtacct	ccccctgaac	ttatttgtga	cacagattcc	4620
tttgctcaca	tgttttcttg	ctgaccttct	ccctattatc	accctgttct	cctaccacat	4680
tcctcttgct	gagatagtga	aaatagtaat	caataaaaaac	tgagggatct	cagagaccgg	4740
tgccgatgca	ggtcttccat	atgctgagcg	ccagtcacct	ggggccactg	ttctttctct	4800
atactttgtc	tctgtgtctt	atctcttttc	tcagtctctc	atcccacctg	acgagatata	4860
cccacagggt	cagaggggca	ggccacccct	tcaattgaag	tatatctcag	aatactactt	4920
tgagatacag	tcttagaatt	atatttttag	ccaatgaaat	cttctttctt	gaagcttttg	4980
aagcaatgcc	aaatttccgt	tagtaggctt	tataaatatc	attgtttgca	ttaccaggag	5040
gcattcacat	caatatgtga	cctcacttct	ccactctttc	attgccattg	aagcagatac	5100
tttcaagtat	gtcttaatat	attgattttt	atcttctcat	tgggggaaca	tgggaagtgt	5160
cacatgtggg	actacaccgt	aatttgggta	tttgtagtct	taagggtttc	atgaagcttc	5220
gtgtgggcct	ccatttctct	agaacgattt	gatgtgttcg	ttttttatcc	ttcacagcaa	5280
cacatgctta	ggcagatgaa	tactgcagc	agcatttaga	cacatttgtg	attcagggat	5340
agatagctct	tcagtaggat	ggtgtgaatt	ttgggataat	ggcacatact	taaaacagaa	5400
ctaccttttg	acccagcaat	cccattactg	ggatatatac	ccaaggaata	taaatcattc	5460
caccataaag	acacatgcac	gtgtatgttc	atcacacag	tattcacaat	agcaaagaca	5520
tggaatcaac	ctaaatggcc	ttcaacagta	gattggatag	aaaaaaatgt	ggtatatata	5580
catcatggaa	tgctatgcag	ccgtaaaaaa	aaagaatgag	attatgtctt	ttgtagcaac	5640
acggatgaag	ctggaggaca	atatccaaag	caaaccaatg	caggaacagg	aaaccaaagt	5700
ctgcaagttc	tcacttacat	gtggaagcta	aacattgaat	acacatggac	acaaaaaagg	5760
gaacaacagg	caccaggacc	tacttgaggg	tgaagtgtgg	gaggagggtg	aggattgaaa	5820
ctctgcctat	caggcactgt	gcttatcaac	tgggtgatga	aataacctgt	acacaaaaac	5880
cctgtgacat	ggaattttacc	tttataacaa	agctgcacat	ggacccctga	acctaaaata	5940
aaagttaaaa	aaagaaatct	gtcccaagga	gactgttttc	tcttaatgtg	ctgcatcctg	6000
cttaatgaac	tatggatttc	atgcattctt	tttcaagatt	atattgccta	cttgattgta	6060
gacgttttga	tgcatttttac	atagtatcag	ttaaacatta	aacataatta	agagcatttg	6120
gcttcaaaat	aatagtaaat	gggtagaatt	tattatgggt	atagtactac	tcatacaaat	6180
aataatacaa	catcagtgat	gtagtgtcta	gtgagcatga	cactattata	gaacacttct	6240
taggctggat	tttgataata	atagcatgct	ataacttttg	aataaaaaata	gtaaattgaa	6300
taatcacaaa	caagtaaaaa	tctaaagggc	cagtagtatg	tattcaacta	gcttaccagt	6360
gtatcatttg	tgtagctaaa	tccattcgct	gtccctctag	cagacacaca	tgctagttat	6420
tgagtgaggaa	gaaaaatgaa	atgaactaag	gaattaatgt	ctttgagtaa	tataaacaga	6480
gccttctgga	ggttttctat	gaaaaataac	ataagtatgt	gtaaaactct	tctttgagta	6540
agtatcatac	acatagctaa	attctgtatt	ttctattcat	tgctgtataa	ataaattaac	6600
attgccttct	ttcgtgtgga	catctgatca	tgtgattcca	tacttaaaat	tacataact	6660
ttgctctttc	taaatgaaaa	tagcccatc	atctataact	ttcatctaac	cattcagtta	6720
ttatagggct	agttttat	ttgtcagaaa	attcactttg	taaatcttat	gtttttattat	6780
gtagccattg	tataccaaca	tataaaagaa	aatacataca	tacatacaca	catacattag	6840
ggaatttttt	cttcaaagtg	aaagcagctc	acttaaaaaat	tatccaaatc	ttcaacattt	6900
ttatgcaaaa	caaggtagct	ctacattaa	ggaggaggaa	atgaggagaa	ccagttttat	6960
aatcttatga	taccttatat	tccatcttaa	tttttttttt	tgagatgaag	tctcgtctctg	7020
tcacccaggc	tgaggtgcag	tggtgtaatt	ttggctcatt	gcaacctctg	cctcctgggt	7080
tcaagcaatt	ctccctgctt	cagcctcctg	agtagctggg	attacaggca	cgcaccacca	7140

aacctggcta	agttttgtat	ttttagtaga	gacaggggtt	cgccatggtg	gccaggctgg	7200
cctcaaactc	ttgacctcag	gtgatctagc	ggccttggcc	tcccaaagtg	ctggggattat	7260
aggcaagagc	caccgtgccc	ggcttccaaa	atattttaagc	aatattattg	catttttacia	7320
tttttagtaat	gcaaggaacc	aaaataaaaac	agaataattg	agatagagaa	gacttttacac	7380
atcaatttga	aataaacata	taggaatgcc	ctatattctc	aaatttcatg	ggatgtaaca	7440
aatctacatt	ttgattttga	tatatagcta	tattttatta	aatgatttct	cagagtataa	7500
cccaccaccc	gcaactctaa	kaaaattagg	gatgattctc	cgtcttggtc	agactgtact	7560
ttgatccatt	tgtgctaacc	tggaaactata	tgtgcactgg	aagatacaga	ctaataaacg	7620
catctctagg	tccttttgtc	ctccaacaaa	tacagtgcta	cacaattttc	aaataattctc	7680
attctatttg	tcaattccctt	tctaaatcaa	caattttatg	catcatcaat	tttataaata	7740
gccctgggtc	tgagaccttt	gatgattagc	atgttaatat	taaccttgat	agtgcagact	7800
agttccaaaa	taaatccata	acgcccgtcc	tccaaaggat	cctggggcct	gaccaatact	7860
tctgctcct	tctactgatt	atgccactct	tctgctctca	cagtctttga	aatctttcat	7920
cttctcaaat	gtctcacctg	ccacaacttc	ctaccctca	ctcattagat	gacctcactg	7980
cagtgtttat	aggcaaaagc	tgaagagttc	tgatgagaat	tccttggttt	catcatacta	8040
aaaaggcaga	agttatctac	ccatgttttc	ctcttccatg	ttattgaaag	ggatggctaa	8100
tttctctggt	tgtactaagg	atctcatgca	cacttgtacc	gaaactctac	ataaatgtaa	8160
aataggaatt	ttatcctcgc	aggagagtct	akctccagga	agcatcaaat	gaaggttatg	8220
ctcttgagga	acaaagcata	ttttaattgg	ctctttagaa	ttagtttaaa	aatactctag	8280
ggaagatacc	taataaatat	attgtaaatc	ttgctacctt	gttttcataa	gatatgggtc	8340
attaacatta	acaggtaggt	cattttctac	atttggtcac	taaaaatata	atttggtgtg	8400
gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtagag	ataagtattc	catcaatggg	8460
gaaaacaaat	attttctcca	atttcactag	acttttctat	ccatatgtta	gtattgcatt	8520
gactctctac	aatcaattat	atgtaagctc	ttttgatgta	tacatgagaa	ctaaataaac	8580
aatggcttta	aggtggaatt	tttgagtag	aaatttttac	aatcttatgt	tactttcaaa	8640
gagaactgag	agggagtggc	ttgagttgga	agctaagacc	ccttttaaaa	attatctgtg	8700
catacctaaa	caatattgtc	atgagtgggt	tagtggcaca	aaaatgggaa	caaaaaaat	8760
ccacactttc	ccaaatag	agaattgcat	atctgctgtt	taaatgctgc	attcctagaa	8820
agatcttctt	tgagtgggtc	tctaaaagca	tctacattc	atgttttctt	cacagaaaag	8880
tggtttgctt	gaaattgtat	gtaacttttt	ctgtgtgttt	aatctctgtt	ccctctatta	8940
taatgtgtgc	tctgtctcct	ctattataat	gtgtgtctcc	tgagctggga	gacttggtta	9000
ctgtagtaac	cgcaggaatt	ggaacagaaa	gaaatgaagc	tatacagtat	acatgagtaa	9060
acaggcagtg	acattacaaa	gtggaaaaaa	acaagtcttc	attttgtacc	ctcttagcca	9120
tatatcgat	agaaattaat	ttctctagtt	taatcgttcc	tgaataaagg	taaggcacac	9180
aactatgggt	cttaattgaa	aatgcttttg	ttttctttct	tcattttgta	tctgaaacaa	9240
tacaatatca	gagctggagg	tataataaag	atcacagctc	ctttatttat	ccatttgaaa	9300
gatgcaaata	acctagggtt	tttgatttta	attttcattc	ctttggattt	tttgtttctt	9360
cacgaagttt	gaataaaaat	accaaatgtg	gagtacacca	agaagacagg	tataaatgta	9420
ggaatgaata	aacttatgta	tgtatacatg	tatggcagag	agaaatagag	aatatgtatg	9480
tttggtgaag	ttatgtgggt	ttgatgtata	gaaagataca	gattaaaaca	gacatatagg	9540
gagacaatgt	tatgtaaaat	ttccgatgtg	attattgaaa	caagagaagt	aattgtcacc	9600
tagataaata	gatgaatgag	cgaatgataa	atggatgaaa	caaatgccaa	atctgaatca	9660
gagagaaatc	ctcacattct	ttgtcacttt	cagtttcaag	agataagaag	atgttctccc	9720
caaaccacac	catagtgaca	gaattcattc	tcttgggact	gacagacgac	ccagtgcctg	9780
agaagatcct	gtttggggta	ttccttgcca	tctacctaat	cacactggca	ggcaacctgt	9840
gcatgatcct	gctgatcagg	accaattccc	acctgcaaac	acctatgtat	ttcttctctg	9900
gccacctctc	ctttgtagac	atttgctatt	cttccaatgt	tactccaaat	atgctgcaca	9960
atttctctct	agaacagaag	accatctcct	acgctggatg	cttcacacag	tgtcttctct	10020
tcacgcctct	agtgatcact	gagttttact	tccttgcttc	aatggcattg	gatcgctatg	10080
tagccatttg	cagcccttta	cattacagtt	ccaggatgtc	caagaacatt	tgcattctct	10140
tggtcactgt	gccttacatg	tatggcttcc	ttaatgggct	ctctcagaca	ctgctgacct	10200
ttcacttatc	cttctgtggc	tccttgaaa	tcaatcattt	ctactgcgct	gatectctct	10260
ttatcatgct	ggcctgctct	gacacccgtg	tcaaaaagat	ggcaatgttt	gtagttgcag	10320
gctttactct	ctcaagctct	ctcttcatca	ttcttctgtc	ctatcttttc	atttttgacg	10380
cgatccttcg	gactcgttct	gctgaaggca	ggcacaaaagc	cttttctacg	tgtgcttccc	10440
acctgacaat	agtcactttg	ttttatggaa	ccctcttctg	catgtacgta	aggcctccat	10500
cagagaagtc	tgtagaggag	tccaaaataa	ctgcagtctt	ttatactttt	ttgaccccaa	10560
tgtgaaccc	attgatctat	agcctacgga	acacagatgt	aatccttgcc	atgcaacaaa	10620
tgattagggg	aaaatccttt	cataaaattg	cagtttaggc	ttgtgtttat	ttgcagtcac	10680
gaattgcttg	tggagtaaca	aactggcttt	tgaatgggaa	aaacctagtg	tagtcgtgat	10740
ttattttaaca	tcattggactg	tcagtaacca	ctttactttc	ttatccaaat	gaaaaccttg	10800
aagattgatt	tcttagaaat	aaaagcctta	atgttgagaa	attttaaagt	ttttatttgt	10860
cagaaattct	atgaaaataa	attttttagt	atctaataat	tctatatgaa	aatactatgt	10920

ttacttactt	gggggggtggg	taaatttttta	actaacttag	cctgagagaa	attctgaaaa	10980
ttcatctcct	ttgaatatga	tgggtccacag	agccataatg	aggttcaaga	taggggtggat	11040
aatttttacac	tttttaaaaa	atgaaattat	ttctacttca	atatggtgtc	ttgaacaata	11100
gctcagctac	ctttgtgctt	attgtaatca	atgtgcaaaa	aatataaata	tatgggtcac	11160
tgatacgtta	aatttgctgt	aagtgttccc	caaaccctac	ttgtaaatat	cttgagaagc	11220
ttcttttttg	ttcatgtgat	aatactgggt	atcgctcctg	attctgaaaa	tcaactctca	11280
acaccttttt	atgagtttcc	aagtgtatgg	atccaattct	atcatcaaac	tacttttaact	11340
gcattccagt	tatgttttcc	agtgccttac	ctctgactta	ggactaattc	agtaggagtc	11400
aataggggtc	attaactgcc	ctgtgcatac	ccataaatgt	cttgaaacag	tatacaaata	11460
aataggggtg	tatatatgtt	tctggaggaa	atactcagtg	tttatttttg	ttcatgaagc	11520
ttctgtgtgg	ccattatttt	taaaataagg	gtgttctagt	agttcttgaa	gctgctatag	11580
agaaaaatca	tctcagagag	gctacctaag	gagacacatt	aatccatgca	ttatttagtca	11640
accagatgac	tgcataattga	tacatatgta	tttagcccta	ataaattgcc	tcatatgttt	11700
ggcattttta	tattttgcat	tctgatatta	actaacacca	tacagaatat	gctacagaaa	11760
atgtctgtat	gatatcaact	actatatcta	ctataaagtg	ttcaaattgg	tttccagaat	11820
attaagcaga	tgacttgcat	tttttgtaaa	atgggggcat	attcttgagt	ctcattttgat	11880
taagtctggg	tctagccaaa	tcttctttca	gaaacagtat	ctgaaaaaga	aggaaggcaa	11940
atttcgggtga	caagaattta	acaattacat	tttagcactg	tttggttttg	tatttgcttg	12000
gtttttggcaa	tgatgggtgg	acaacagagg	aaggctcatc	gcagagacaa	caatgaagca	12060
gaaaagctgg	gaattgagtg	acacagagtc	ctcacttcct	ttttgagggc	cagcatcatt	12120
tcatcggtgg	gggtatttctt	tattttatga	gaaatttcca	tctatttaggc	aaagcattgt	12180
attccatttc	tggcaagcag	aatgggtctca	tatccagatt	tgaaccctca	tttgaaaatt	12240
ggatttttaga	atgagtgcga	aaaatactct	atattttggc	taaataactg	tacgattcca	12300
tttattttct	agttatgaga	attgctctgg	cttgacagca	ccatttttaa	actttgacat	12360
ccttttagtc	aaaatgactg	acctgtttct	aattgatttt	taataaaaata	ttttatttat	12420
ttctattttg	gatttaattt	tttcttctg	catgtctttg	ggtaaaagtc	acctcagaaa	12480
ttctttggag	ataggtatga	acataaatcg	acatgaataa	aagtaattat	aagagttgca	12540
gtcacagtgt	agtgtctgatt	ttaggaacac	tttattttta	tcttcataaa	tgaataatg	12600
agagaattat	tactctcatt	tacaactatg	gagcctgagg	cacggagaga	ttaaatttct	12660
tgcccaaagt	cattttggcca	ctcagtagga	caaaagcagg	tttcttggtt	tcaaatcttc	12720
tctcttttcta	attcatactg	tagttgttat	taaagaaatt	ctcaaaacac	tgcaaatgct	12780
tgggtggaatg	ttggagatta	tgaattgatg	agattattgc	tatagatgaa	atagtggtta	12840
ttatgtgata	gttatatgta	tctaagaat	agctaattgag	aatttccctt	gaaaattccg	12900
gttaacataa	tttataggca	ttataattaa	aattgtctta	acgtccatgt	gaaggggagaa	12960
aatttttgata	tacagaagac	atatatgcta	tttaggctgc	attttattta	tatatatttcc	13020
cagtcgcaaa	ggcatacata	ttcatattaa	ttaattacca	ggtacagaca	aatatgaggg	13080
agtaaaattt	atgagggatc	tgtcctgtga	caaaggatac	attttcttta	tattttgtta	13140
catttcttct	caataagttt	atatgcgtac	atgttactaa	aatgcatcaa	gcaaatgtga	13200
aatcacttat	catatacaaa	tttgaacact	gatttttact	tgatataatg	tatgcacctt	13260
tatatagatt	aaatatttct	gatgaacatc	atgttgaatg	tcatataata	gttagatcat	13320
atgaccttaa	tacaataata	atacatatca	attgtagaaa	actgactgaa	ccatattgac	13380
atacataaga	catagaagca	acatttactt	ataatcacct	acctgaagag	agctgaactc	13440
agcattcact	tgtgttttat	tccatttgat	tatcttgcaa	accatgattc	catcatatca	13500
atgtatctta	gtgtttttat	gactgatgta	tctgtgcac	tctaattgtt	ccttttgtgt	13560
atgttcccag	aagtggaaat	gctgaattaa	atgttttcaa	tgcttttgaa	actcctgcta	13620
aatttttcta	tgggttaaatt	tttctccaga	aagcttctag	caacttaaac	ctgtcataga	13680
aataatttgag	aataatccatt	tcaactataac	tctatcagta	gtaggagctc	ttgtttatgg	13740
ttatttgcct	ctttgatgtc	tcaaggggaag	tcttagaaaa	taattctgtt	ctaataagca	13800
cagaataaaa	attgaagcat	atattgaaca	aatgaaggct	acacataagg	ttgataattt	13860
ctcttcatgc	tattgctgat	aatttcttgc	atgaataatg	tttgattttc	tatttggaaa	13920
aatgtgacct	tttgcttatt	gctgttatgt	aagttttcct	catcctaaaa	ttgaaaaaac	13980
aagcacttat	attcattgca	atatttgata	gtgatatcag	gaattatttt	agatataata	14040
cattttttgta	ctgtgttgta	atattaaaaa	ttatcttttc	cctcttattt	ttaaccaatt	14100
tcctcccact	atttattaag	caatgctttg	tttttcaact	gatttgtgat	gtcaccttta	14160
ttataccata	agtgaatcta	tttctgccta	tttctctttt	atgtttggcc	acaatatata	14220
tataattttta	actaaattcg	tatgattagt	gtacacttaa	aatatgtttt	aatttctgat	14280
ggaaaaatgt	tatcttccact	tttctcttag	gagactgcaa	atcatctgat	gatttgctttt	14340
agatatccag	tatttttaac	ccataaatta	tgcatactat	tgttcaattt	agaaactata	14400
tgcatacttt	atatatgcaa	atatatattt	caatgtggct	atacatgaaa	tacttaaaca	14460
ctgtaaatta	tttgaaaaac	aawgaaaaact	attttcctct	ctatgggggc	cataggaaaa	14520
ctgcttattg	ttaagtttgt	tttccagaaa	ggcaggaaaa	cgttgggtgg	ctgtgagtaa	14580
ggagaaaaaca	cttaaccttg	gtatattaat	tctatcgatt	cattaacaac	tttatacaaa	14640
catttatttt	tataccatac	cggcgttcat	aataaaacac	tttttttcaa	caaatatctc	14700

taaatacaga	ttctttttctc	taactatgct	gacttttttgc	caacaactcc	acccaaaaga	14760
gttgacatgc	ccacatatat	tcttctgcta	ggaatcattt	caaacactga	aaaaacccta	14820
ttaattagaa	ttaaaaataa	tattaaacat	ttaaataatc	agagaaaaat	tactctgtgc	14880
ttcctaagaa	tgggaatact	tcacagtaat	actgttgctt	taatttgaca	ataaaactat	14940
ttaaaaataa	gacccaccct	acagtctggc	aatgtatttg	tcacaaataa	gacaaagtgg	15000
cacaattact	gaaatatggt	atgttaatat	aaatcatttg	aagcactaaa	acatgaccat	15060
ataaataaat	gttgaatact	atacgtagaa	aattgattaa	aatacaaaaat	gctaaaatta	15120
acgcagaaaa	tagtggcagc	taaaaacatg	aagtacaata	ctgtttatgt	gtctatatatt	15180
aagacagctg	aaaaagtcta	gcacgttcat	acattgggtg	attaatggta	taaaattttt	15240
ctagaaataa	atacaatatt	attaatat	taaggagtc	aatgtttcta	taatttttatt	15300
cagctattcc	aaatttaaga	atctactgaa	ggcataatta	gaaacttggt	tgaagagttt	15360
catgggtgtc	attttataat	caagaaaaag	caaacaaatg	atgttcgaaa	tacaagtagc	15420
tcccacttag	caccgtacca	tgtaacagaa	acctttctat	atggcaaacg	tgtcttgttt	15480
tgcatgggtc	ttacttagat	attacaaaat	ctcaaagtga	ggactgcctg	ctttggataa	15540
ctggtaaagc	acaggcatct	accagatggg	gtagaagggt	tttctaaata	actagaatgt	15600
catcagcctt	gatcatgaag	gaaagtgtaa	agtacagttt	aatttttttt	tcttagaatg	15660
ttatacagct	attaaagtga	ggatgttcct	agttaagaaa	aaggtaaata	attttgtgta	15720
atatattatg	tgcaaagaca	tatccaatgc	tacatatgga	tatcttgtaa	aatatcaggg	15780
ataaagagaa	acaaaactta	ttaatagcta	tgtccaaatt	ttccatgata	agcaattggt	15840
gctattacat	tgagaaaata	agctaacaaa	aaactttgtat	gccagttta	attcagatct	15900
caggatata	aattacagga	tgcttattta	taatagtaga	atttaaaaaat	aaaagtagga	15960
aaaagcaagg	agttaaaaac	ttgttgtaga	gcgtgatggc	agaagaggag	gtgctcagtt	16020
ctggtttcca	gaacagaatg	accagttagc	aaacttctac	agataagaat	gcctaggtaa	16080
aaattccata	acccaagggt	gaggtggggc	acactcttgg	agcacagaaa	ctgggaaaag	16140
tcatattaga	agtgtaaagg	gagcagtttc	actttgactg	tgttgcttct	ttcccagacca	16200
aacagtgtca	cactgaaagg	gatttcttgg	gcctgcgttc	tctagtggag	aaaagagagc	16260
ccacggcaga	catccaactt	ccctgtgttc	cagggcactt	cccaaggggc	ctagttctgt	16320
ctaactttgt	ggggaataat	ggaggaattg	gcagggcttg	accccttatg	gtcagttcat	16380
aactacctcc	tctacaacc	cattctgtat	tccctttacc	ttcagcaagc	accttagcag	16440
gacacggttt	tttacctggg	ggagtgcac	aaatcttcat	tcctgatggg	tctgggccat	16500
ttgtagtttt	gcctggattg	ggttggtgta	gtttctcact	gaccttaatc	acaggacatg	16560
gtaatactgt	gacgtcctat	gggatctcct	gtattccaca	aatactcttc	cttaacctcc	16620
attgtggagt	agtagtttga	tttcatcttg	atagtctggg	tcagtcaccc	cagccaacac	16680
tgtacctccc	ttcttagcct	gttgacttag	aggcaggaag	agctcaaagt	ggccaggtgg	16740
caaacttatc	ttccagtttg	atggaatcat	ctttctgtct	tctgggtggc	aagtccctcc	16800
ctccggaacg	aagacctcta	ggcccacaga	acataatgtc	acagaaacag	gaaggaaaat	16860
tttgctagt	ggtcagtaga	ggtgatggta	agtggcacca	cttccacttc	cacctcttga	16920
ttcctgcatt	cttggatcct	ggctatggaa	gaaacagtac	cacatattgg	atgcctactc	16980
agagcataca	aagacttctg	gagaaatttg	ccccaggcct	gcattttttt	tttttttttt	17040
tgtaaaatga	agtctgtctg	tgtcttccag	aggcctatag	tgcaagtgtc	cgatcttggg	17100
tcactgcaac	ctctgcctcc	caggttcatg	cgattctctt	gtctcagcct	cccgaatagc	17160
tgggattaca	ggcatgtgcc	accacggctg	gctaaacttt	gtatttttag	tatggatgag	17220
ggttcacat	gttggtctag	ctgggtctga	actcctgacc	tcaagtgatc	caccgccttc	17280
agcctcccaa	agtgtctgga	ttacaggcat	gagccaccgt	gcccagcccc	tgtaataaag	17340
tatcacctag	ttgttgtaac	tgttacttca	aaaggctttt	ccacctttct	atcacctcat	17400
ctgcttttag	ataatgggaa	acatggtaag	acaagtatat	cccatgagca	tgaagccact	17460
gtcttattct	ttagctgtaa	aatgagtgcc	ttggtcagag	gcaatgggtc	gtggaatacc	17520
atgacagtgg	ataaggcatt	ctgggagtc	acgaatggta	atcttggcag	aagcattgca	17580
tgagagatag	gtaaacctat	atccagagga	agtgtcta	gtgactaatc	cactctagaa	17640
ttctaatac	ccaaagcttt	tggattcctc	cctctacatt	aaaccaggga	agatctggca	17700
tttcaaggtc	gctcacagta	ggccatcctt	tgatccatat	ttcagcta	aaactattag	17760
aacatttttt	aactccctga	tttgtaacat	tgagtgcaga	atctctgctt	agtgggcccc	17820
tatcaatata	ttcagcctga	tccaacttta	tattcctccc	accattatcc	cacaccctta	17880
atatccattc	ctacacctgt	tctccagaat	tctgcttata	taaactagaa	aactcaagca	17940
gctcttttag	ggtgtagcac	acctccttgg	agacttttgg	cttacaccaa	ctagccacag	18000
atcttggaag	gagaaaagg	attaaagtct	gaatgtattt	cctaaagaag	aagaccaacc	18060
aaaataggtt	atttaaatat	ttggctatct	taagtccaaa	gctactcttt	aaaaggaagc	18120
catatttaac	cactccatgt	aatatgta	tatgtcttga	catacagaac	taggtaatgc	18180
aataattaaa	ggtattttgg	caccataatt	tttttctaaa	aacggagaaa	tgtgcaaatt	18240
atttacctac	cagtttacac	aaacaggcaa	agcaaaaaca	aaagcacttg	tcaaggtgga	18300
caaaaatgct	gctacagtta	aaaatctgca	tatactcttt	actttgtcat	tcttaaaaaat	18360
gtgtttctgg	gtagtgtggt	tactgaaata	ggtgaaagct	gtactgta	gtcatttttta	18420
aattttgtaa	cactttttgt	aacattttgt	aacattttgt	gaagaaatta	tgtttcttca	18480

cttaaggaga	taaatttgtgt	tcattataga	actttgaaag	tgaacgacca	aaccaaatgt	18540
gcaaaaaattg	actgaatatg	aattacttta	cacttatgtg	tgaaaataat	cttcaacatt	18600
atgtattcca	tacacatggt	tttggtgttt	taaattatct	ccgggctttc	ctaaattcaa	18660
gttggagaag	cagaattagt	tagatttata	gcacactcac	tatagaaaac	atattttgaa	18720
aacttgtttt	accacatctc	tgttcagctg	gatggggctc	ctgtgaaaga	acaaagcaat	18780
tacatagaat	tttacacaga	attgtaaaac	ctgcaaattt	tttttaacat	tttctttacc	18840
ttatctgata	gcacagcaca	tacgttgcaa	ctcttactct	gaaaactact	atcacttctg	18900
aatgtttatt	aaataacagc	cataggtgtg	cgaaggattt	acaaatggat	agccacattt	18960
actgccaatg	aaaaacaaag	tttattttaa	atgtgcagta	tctttgtgat	atatatatta	19020
ctccttattt	ggtacagatg	aaaacgctga	agctcagaag	aatgaaataa	tgttttcocag	19080
gaacacagca	agagctaggt	ttcaattaaa	atattattct	cgtagctact	tctgggttga	19140
ctctagaaac	acccaagcc	acatgggttt	gttaagatgt	ttaactgggt	aattattttt	19200
atgggtaatt	atgtttcaga	cagttttaca	attttacaga	tataaaaaata	tatatgaaaa	19260
agatatatat	atgttgtaat	gcataatat	atattcatat	ttcatatgaa	gaaggcacia	19320
gaggaacact	cagtgcctag	gtaaaaagaa	tggagttgga	tagtaggtta	atagtgggtg	19380
atgagataag	aagtagtcat	ggatcatgact	tactttcctg	gtgtcatgca	atctctattg	19440
acagcatttc	ttcaaagttg	taatttttat	tgagaataaa	ttaataaaaac	tctgtaagat	19500
tttaagataa	aagatctccc	aatattttta	aagcatcatt	acaaccttct	ttaaagtttc	19560
tagcaattgt	atcaatttct	ttattcttat	tttcattgta	gaaaaaaatt	gatttttgag	19620
gtatyttaaa	agtcataagag	aaaatatttg	cccatggaaa	gggtccaaaa	tgggaggagg	19680
aaattaaaaa	ggactgagat	ttctgaaaca	catacattgt	tccaaggagg	taccaagcat	19740
gctacaaagg	aggcagagga	ttgaatgact	gaagaaaaga	ttttgaagga	cactttgagg	19800
tgttcttctc	acaccttcca	tcattcctatc	tcaggagggt	gaatggattg	gagagattat	19860
aaaaagagtt	atttgtgatg	ccttgatggt	agtccaaaac	atccttttct	agtctatgtg	19920
attgataagg	atgctgaagc	tgttcatggc	tgtggaaagg	gaaggggaga	ggagagttat	19980
cccattgctg	tactgtatct	gagtgacttc	acctcagagg	aaaggaacag	agaagcatct	20040
ctaaaccaca	ttctcaaate	caaattcacc	agcaataatg	ctagtaattt	tcatatctga	20100
ctccattgtg	tagactctaa	ttgagtcagg	atccaaaagg	agggcaattc	aatggctcct	20160
tttaagttcta	acatgatgaa	tgtagaagta	ttccaaattt	ttagctaaaa	taatatattat	20220
cataatagtt	attattactg	ctactaaactc	actgcaagac	ttatggaata	actactatat	20280
gatgctctgg	ccaggatctg	agatgtccac	aattctactc	atatgtttta	gctaaagaga	20340
atttaatgaa	aagacagaga	ataaaaagggt	aaagttaaag	gaatcagcca	aaggggttaa	20400
aaaagtcaag	gctaactgta	gaaaaccatt	tccatcttta	ggtctgaagg	accaaggaca	20460
gtggcttctg	tcacagagct	cagtgagagc	tgaagccagg	aagaaatccc	ttgccaacat	20520
cttcccaaga	cacacatccc	aagacattct	ccaggagggg	atgcagccaa	tttagcacac	20580
ttttaatgaa	gcaggaaggg	aatgagaaa	aaattgaggt	aattccctat	ctttccctact	20640
tctgacatcc	tagagagtct	tctcaaaagc	caaggctcagc	tggaaaccag	acaccatagg	20700
tgccctgttg	accaggtcca	taggagccca	actccagggtg	aacaatgcaa	ggcacagaag	20760
agaagacaat	agatgtgaat	gggagtaggg	tggaaaagga	gaatcaccag	cacacctata	20820
ttatctataa	atccaaaatg	ttccacactt	acacattact	atccctatta	aaaagataaa	20880
tgtacaaaac	tcaaaattga	tatatcacta	gttcaagttc	aacaaaagtt	agtttatctt	20940
ccaatggtgt	tccagactct	gaaaccttct	cccgatacca	tccactatac	ttgctgtaag	21000
caggaactta	atattttcca	aagtctaaca	tattaaatta	tttgggagta	aagtaaaata	21060
aataatgaat	cccattccta	catcactctt	gggggatgcg	attccctgaa	gacagtgtgg	21120
agttggcaaa	actcatgtgc	tccgtgagct	taggattttc	agaagaatcg	aaatatttgtg	21180
gttggtcata	atttgaatga	ctttttgcta	gaaataattg	acctgcaggg	atttggctctc	21240
cacacagttaa	ttgcattata	aactctacag	gttctcaata	cccatctctgt	aatcatgaaa	21300
tcattgcttct	ttctcaggta	ggattagata	tatttttttaa	aaagtttaaa	atccggcagt	21360
aaatattttta	attgatagaa	ataaatggag	ctgaaacata	ttctgatgaa	ttagaaaatg	21420
tttatatttaa	agtgttgcta	ttcttttcag	agtactgggtg	tttacagagt	gtttgcataa	21480
tgaaaagaaa	ataggccaaa	agaatttttta	tttcatcaat	aattattgac	tgccctccaat	21540
tcaggaggca	caaactctagg	tgctgctgag	tctataacta	gatcagataa	aaatccttga	21600
ccctaaagga	gctcatgctt	tgatgttgag	tttcgttcta	gactagacct	ggatcattca	21660
ccaaataata	ctagtagcct	caattttgta	agcatgtagt	acatgacaga	tatattttaa	21720
aaactttttac	tgaatttaact	ttctcatcaa	gagagaattg	ctattaatca	aaattttatgg	21780
ataagaaaac	tgaggcacac	agaaattaat	aacttgcccc	aggccacaca	ggtaggaact	21840
agaggcactg	ggttttttcac	ccagggaagtg	tgactgcaaa	ctcccagtaa	ctgtcccact	21900
ctgctggctt	tcaatagtaa	actatgctta	ctgtttatatac	ttgattttaga	acaatcaaga	21960
tctgggtatta	aatcatcctt	ctgattcatt	ttgtgttaac	aatgccactc	tttactatta	22020
taagagctgt	atcatgtaat	attttatagc	cctttcataa	agaatgggct	acttttaggt	22080
ttatagccta	tattacttaa	aaataataaaa	aatatgtttt	gtgaagctgc	cttctctaga	22140
tttcttttttc	cactccaaat	tgaaccatga	ccactttcca	aggagacacc	actcttggtta	22200
aagacaaaaga	ccaaccttct	agactctttg	taggacagaa	tagaagaagc	aagcattcac	22260

atgggaatgt	ctcagtgtag	ggtgcatgtc	aggagagcac	aggctcagat	gcctccaaag	22320
ccatttctgt	ccaattgcag	aagcttctcc	ctgagatttc	cttgctcaaa	gcagtaggat	22380
attgtgttct	tgttttttca	gaagaaagac	tatttccaca	aaattctcag	ttaaattatt	22440
tggactattt	attgcttgca	ttacttcaac	ttccaataga	aaaaaaaaaa	gactcataaa	22500
aaaacagatg	aattgagaag	ttattttgaa	gggtgattaa	tatttcaata	aaaaagccca	22560
ttaaaaatgt	aattaggcgg	ggcacggtgg	ctcccgcctg	ttatcccagt	actttgggag	22620
gctgaagcgg	gtggattgcc	tgaggacagg	agttcaagac	cagcttggcc	aacatagtga	22680
aaccccgttt	ctactaaaaa	tacaaaaaaa	ttagctgaac	gtggtggtgg	gcacctgtaa	22740
tcccagctac	tcgggaggtt	gaggcagcag	tattgcttga	acctgggaga	cagaggttgc	22800
agtgaagcga	gattgcacca	ttgcactcca	gcctgggcga	caagagtga	actccgccac	22860
acacacacac	acaaatgaaa	tccagcacca	aaacagttat	tgcctatttg	gcaattaaat	22920
gtaccatcaa	acagagggat	agagaatgtg	gtatatata	tatatatcat	acattataat	22980
gtgatataat	atataatata	ccacagtttc	tttatccact	tgttggttga	tggatatata	23040
catatatatt	atatgtaata	tatatataaa	atgtatatga	tggaaacta	ctcagccata	23100
aaaagggatg	aagtaatggc	attcacagca	acttggatgg	gattggagac	taatattcta	23160
agtgaagtaa	ttcagaaata	aaataccaaa	tatagtgtgt	tctcactcat	aagtggaaac	23220
taagctgtca	ggatgcaaag	gcataagaat	gacacaaagg	acttcgggga	cttgggggaa	23280
acggtggagg	agggtgagga	taaaaggcta	cacattgggt	tcattgtata	ctggtttgat	23340
gatgggtgca	ccaaaatctc	acaaatcacc	actaaagaac	ttactcatgt	aaccaaatac	23400
caccttttcc	ccaaaaacct	atggaaataa	aaaataaaaa	taaaaaccaa	aagaaattca	23460
attggacctt	gtgagcttta	acaaggtaat	tatgattcta	ttgatttagg	tgaacttatct	23520
tctaacttat	taccctaggg	agaagcccaa	tgtccttttg	tgtagaatga	gataatacgg	23580
tggacaagtt	ttgaacattg	aatttacaga	gtgctttatt	tatgaagtga	cctggttcca	23640
gtgttggcat	ggtagtattt	aaaaaaaaag	tagtataaca	ttgtcaagtc	tggatatgtg	23700
tcatagaaga	aacacgtcga	ttgttccatc	atgatcttca	tggtcacttt	tatcttgccc	23760
aatgtttgag	agattcaggt	caggatatatt	taagtatggt	ctcagtcatg	ttgttaatat	23820
gattatgatt	tcactttgat	ctgttacatg	ttttaacaaa	ttcatattga	acttgtgttc	23880
caatgttttt	tcttagtttt	tcaagtgtta	gaatgaggtg	gagttaaaac	aacagcattt	23940
tagtttgagg	ataagtttct	tcatcatttt	atccttattg	ccccctccc	caggagccct	24000
ttgatacact	attgttttct	ttatatccct	atcaacattt	aataccatca	atacagggtgc	24060
acttgtgtat	ctatatacca	tgcaaagtga	tatggtttat	gtattatgtg	catatgtatt	24120
ataaatacaa	atatgtaata	tctactttca	ttccccaaga	accaattttt	gcccccttgg	24180
acaaaaatat	acaaaatgaa	gaaatgtagc	ttggtcttta	aagttaaaaa	agatttggtg	24240
ataagagggc	cagctgaggt	agaataaagt	gaagaaaatg	ggcacacatt	agaggggtgag	24300
ggaagatctg	gaaaatgatc	tccagttcac	aggggcaggc	aaagcgattc	ttgttctaca	24360
gggatgtata	ccaggcatca	gtcccacttt	cctaagcacg	ttcagttgtg	ataaaccttg	24420
agggtttcaa	aggctgatac	tttagatccc	acattcaaag	gtgtgttgtt	aaacaaagaa	24480
ttacagtttc	aaagaaaagc	aatgtttaca	accatgggtt	caagaaaagt	ctaagtgaac	24540
acataataca	aagacttgca	aaaagataaa	agataaggct	ctttaactat	caaaagactt	24600
gcagaaaaga	accacagaaa	accattttta	atattattgc	ctttgtatat	taaaaaactc	24660
tatattagtt	tagatgttta	aagcatcaat	cacatgctca	ctaggctatt	tcttaatgtc	24720
acatgtattt	acattttgag	agaagaggaa	gaaatagcag	atgacaccac	tggggtaatg	24780
cataaatgac	aaacctaaat	gcattttaat	ttccttttat	ttagatgtca	tttgaagcca	24840
agcaaacaca	atgttaaaga	aaaaccatac	agccgtgact	gagtttggtc	tcttgggact	24900
gacagatcgg	gctgagctgc	agtcccttct	ttttgtggta	tttctagtca	tctaccttat	24960
cacagtaatc	ggcaatgtga	gcatgatctt	gttaatcaga	agtgaactga	cactcacac	25020
tccaatgtac	ttcttcctca	gtcacctctc	ctttgtagat	ctctgttata	ccaccaatgt	25080
tactcctcag	atgctgggta	actttttatc	caagagaaaa	accatttcct	tcatcggtcg	25140
ctttatccaa	tttcaacttt	tcattgcact	ggtgattaca	gattattata	tgctcacagt	25200
gatggcttat	gaccgtaca	tggccatctg	caagcccttg	ttatatggaa	gcaaaatgac	25260
cagggtgtgc	tgcctctgtc	tggctgctgc	tccctatatt	tatggctttg	caaatgggtc	25320
aagcacagac	caccctgatg	cttcgtctgt	ccttctgtgg	acccaatgac	atcaaccact	25380
tttactgtgc	ggacccaccc	ctcttagtcc	tgcctgctc	agatacttat	gtcaaagaga	25440
ccgccatggt	ggtgggtggc	ggttccaacc	tcatttgctc	tctcaccgtc	atcctcattt	25500
cctacacttt	catcttctac	gccattctgc	gtatccacac	tgctgagggg	aggcgcaagg	25560
ccttctccac	ctgcgggtct	catgtgaccc	ctgtcactgt	cttctatggg	acactgttct	25620
gcatgtacct	gaggccccct	tctgagacat	ctatacaaca	ggggaaaatt	gtagctgttt	25680
tttatatctt	tgtgagtcgg	atgttaaacc	cattgatcta	cagcctgagg	aataaagacg	25740
ttaaaaagaag	tataaggaaa	gttattcaaa	agaaactggt	tgctaagtaa	ggtagatatt	25800
ttggtcatag	gcgttggaat	ctgttcttat	tatctgacca	attaatgaac	attttaaatt	25860
aacaaatcaa	tctgtcattg	agtgtttttt	gtcctttgta	atttgcata	gggacttaaa	25920
agtgtatgtc	aaattattag	ctagagctta	cactgccacc	tcagtaaatt	gaaaatgaaa	25980
gcatagaat	tcaaatataa	gactagaaga	cattgttcta	gctctgtaa	aagtaatgaa	26040

gtacagatga	ttccattatt	agtactcata	gtactaatat	atcatagtag	tatatcatag	26100
tactaatata	tcatagtact	atatcatagt	actaatatat	catagtacta	tatcatagta	26160
ctaatatatc	atagtactat	atcatagtag	taatatatca	tagtactata	tcatagtact	26220
aatatatcat	agtactatat	catagtacta	atatatcata	gtactatatc	atagtactaa	26280
tatatcatag	tactatatca	tagtactgta	tcatagtact	aatatatcat	agtactgtat	26340
catagtacta	atatatcata	gtactgtatc	atagtactaa	tatatcatag	tactgtatca	26400
tagtactata	tatcatagta	ctatatatca	tagtactata	tatcatagta	ctatatatca	26460
tagtactata	tatcatacta	aaatatcata	aaagacagaa	ttatcaattg	ctgagaaaat	26520
gacagctcat	tacatttttt	taaatgtttt	tgtttgtccc	tttgaatgaa	tggaggatat	26580
ctacctaact	tctatgtatt	cagaatctca	catgaggcag	cacatttagc	acacttgttt	26640
agtgtgaatc	ttctatgctt	atcttcgtga	gtctgtttga	aaagttggat	aaatggcaat	26700
gagtgtactac	atthtgcata	tacattttat	aatacttaat	aagcctccaa	gctattttcc	26760
agaaacttgc	caaccatagt	agatgaggtt	tctgtttttc	ttttatacat	attatataga	26820
aatgaagatc	cttttaggtg	actttggatt	attactttta	gttatatcct	tagaatgata	26880
tcatagatcc	aatgaaaccc	tatttcataa	ggcttttcat	ggaaatgcca	aatttccttt	26940
agaaagaggt	tttaattgtt	tgtatgttgt	accagtaagg	attcccatca	acatgtgaac	27000
tcaattcttc	actcttttat	taccattgcc	tgtttctctt	gaataaataa	attgaattga	27060
atgtttttat	cacgaatgca	tgtggatatt	tgtgtgtttt	atgtgtgtat	gtagggtgtg	27120
gtgtgtatth	tgattacaat	ataacatttt	ctttttttta	attgcttatt	caaatthttt	27180
tggtgagaat	caaggctgta	tgcttttttt	tttttttttt	ttttttttga	cagagtattg	27240
ctctgttgct	caggctggag	tacagtggcg	cgatctcggc	tactgaaaag	ctccgcctcc	27300
cgggttcacg	ccattctcct	gcctcagcct	cccgagtagc	tgggactaca	ggcgcccgcc	27360
accacgcccc	gctaattttt	tgtattttta	gtagagacgg	ggtttcaccg	tgttagccag	27420
gatggtcttg	atctcctgac	ctcgtgatcc	gcccgcctcg	gcctcccaaa	gtactgggat	27480
tacaggcatg	agccaccgcg	cccagctgct	tcacctgttt	ttaaattgtg	gtgtttatat	27540
gttttcttat	ttatttccaga	tatttctcaa	tgatataaac	atgtttttgt	tatatatata	27600
ggtgtagcaa	ttgtatatat	atacacatga	atttccattt	atctcttcta	ttgtgtcttt	27660
tccaaagtta	atattttatc	attttaaatt	ttctcaatat	ttttttattt	cactttattg	27720
tgtctttttt	tacttttagg	aagttaaagt	tatgccacct	atgatcatgt	ggatttttac	27780
atatattatt	aaattatttt	catggtttcg	cttggttaatt	ttttcttatg	aactattttt	27840
aatatacatc	taaaatagaa	aataatataa	agactccttt	gtaagcacia	ctaatacata	27900
ttaaatcttc	acagaatgcc	ccatttgttt	cagttatttc	agaaatttaa	aacttacaaa	27960
gatacatctc	tcttgactga	ttctgtctct	tgtcccatth	cttgctgtaa	actctattac	28020
aaatttaatt	tttcttatcc	ttctgtagag	ttacatcatt	ggataggtgt	ttatatattc	28080
atagaaatat	gtagtactga	tttgctacat	ttaaaacttg	aaataaatgc	atccactcta	28140
tgtatctttc	tgcaattttat	ttatcttgca	ctaaatatgt	ttggatgtat	ctgtgggtgaa	28200
tcatgcagca	gcaattttta	gtggtatagt	ctatgccaat	atataaatat	gcctcaatat	28260
gtgtattttat	tctacgatttt	tttttttttt	ttgagacaga	gtctcactct	tgttgcccag	28320
gctgggggtgc	aatggcacga	tctcggtcca	ccgcaaaact	cgccccccag	ggtcaagcga	28380
ttctcctgtc	tagcctccta	gtagctggga	ttacaggtgc	ccaccaccat	gccaggctaa	28440
ttttgtatth	ttaatagaga	cgggatttca	ccatgttagc	caggatgggtc	ttgatcacct	28500
gaccttgtga	tcttcccggc	tcagcctccc	aaattgtatt	ttatttctac	tgttgggtgaa	28560
gagttacatt	ttccagtttc	ttgataatat	gaaaatccat	taataaatgt	tttgtgtgta	28620
attatgaatg	tgtaccacgt	aaggagtthc	tctcaggtag	gttggttaatt	tcttgggtcat	28680
aagatataag	tatcttttaa	tttactatat	attgccaatt	gttttactga	tttatatttc	28740
tatcaacagt	ttgtgagtgt	tacttttaca	tcactttatt	cttgccaaaa	ctagggtgtg	28800
tcagacttta	aatgtttttc	aatctgatgg	gtaaaccaat	aattctcatt	tgtgttttaa	28860
ggttgaattg	ttattacaag	tgaaactaag	tattttttaag	tatatgtatg	ctaatactcat	28920
atttctcttt	cacttatatg	tccatatact	ttgttaactt	ttcaggtagg	gtgatttgtc	28980
tttatttcat	acattttata	tagttcctta	tgtaccaaatt	gctacataca	aatcttttgg	29040
tgttatatgc	catttaacct	taaaaacct	gggtataaat	gccaggcag	gtggctcaca	29100
catgtaatcc	cagtactttg	ggaggctgag	gcaggaggat	tgcttgagcc	caggagttht	29160
aggccaaact	acacaagata	gagactctgt	ctttacaaaa	aaataaaaaa	aaatttagcca	29220
gttgtgggtg	gatgcccttg	tgggtcccagc	tacatgggaa	gctgaggcag	gaggatcact	29280
tgagcctggg	aggtagaggc	ttcagtgaac	catgttgtca	ccacgacact	ccagtctgga	29340
tgacagagga	tggatgcacg	agcctggatg	actccagcct	ggatgaccct	gtctcaataa	29400
aacaaaacaa	accccaaaaa	acctagggtg	agatgaacag	atgaacgtta	tttcttgaat	29460
gcctcagcaa	atagccatag	gtatctatth	ttctggtagc	tgcaatttga	ttgggacaag	29520
tttggaattt	cagctcattt	gacaagtatt	ttcataatag	atattttccc	agtaggattg	29580
gatttttttt	ttccacatag	tgaatgctta	tatgtgagca	taaaatgttt	cccacagatt	29640
gggattggat	aaattatatg	aagtgtgatc	ctagtatatt	gctttgccat	tgaataactg	29700
gttattaccc	aaatagaaaa	ttaacattta	aaagagccaa	caggctgggc	aaagtggctt	29760
aggcctgtaa	tcccagcctt	ttgggaggcc	aaggcccaca	gatcacttga	gttcaggagt	29820

tcgagactaa	cctgggcaac	atgaggaaac	cctgtctcta	aaaaaaccac	aaaaattagt	29880
taggtctggt	ggcaagtgtc	tgtagtccaa	gctactcagg	aggctgatgt	gggaggatgg	29940
cttcagcctg	ggaggcaaaag	gttgacgtga	gctgagatca	tgccagtgc	ctccagcctg	30000
ggtaacagag	taagatcctg	tcttaaaaaa	ataataaaat	aggccagggtg	cagtagttca	30060
tgctgtaat	cccagcactt	tgggaggccg	aggcagggtga	atcacaaggt	caggagtctg	30120
agaccagcct	ggccaagatg	gcgaaacccc	gtctctacta	aaaatacaaaa	aattagccgg	30180
gtgcagtgg	gggtgcctgt	aattccagct	acttgggagg	ctgaggcagg	agaatcgctt	30240
gaacccgggg	ggcagaggtt	gccatgagcc	aagatcgtgc	caactgtactc	tagccttggt	30300
gacagagcca	gactccaact	caaaaaataaa	taaataaata	aataaaaataa	taaaatataa	30360
tataactaaga	atgccaacag	aataattctg	atttcagcta	cagtttatgc	ttttttatga	30420
gaaattcaac	tccaatcttt	taatttttatt	ctccttttatt	ctgtttgttca	gacattgcat	30480
attaaaaagg	cattttttttt	cttaaccaat	agtttttatcc	ttattgctgt	ccttattctg	30540
gagagaactt	catattttcaa	ggcacagccc	aaatatcaac	tcccttgctcc	tttcatgagc	30600
aaacagttgc	acatacccat	tctgtgtgatt	gtgtagatat	tgcaactcta	tttgtctgtt	30660
agtcacacag	aaaattcata	ataatacaat	gccatgtttc	ctaataatatt	ctgagagttc	30720
tgtgagaaat	gaaacctatt	gtatcggtta	agtactgaag	atggccgaat	aggaacagct	30780
ccagtctaca	gctcccagcg	tgagcgacgc	agaagatggg	tgattttctgc	atttccatct	30840
gaggtaccgg	gttcatctca	ctagggagtg	gcagacagtg	ggccgagggtc	agtgggtgctg	30900
cgcacctgc	gcgagccgaa	gcagggtgag	gcattgcctc	actctggaag	cacaagggtg	30960
cagggagtgc	ccttttctag	tcaaaagaaag	gggtgacaga	tgccacctgg	aaaatcggtt	31020
cactcccacc	ccaatactgt	gctttttccaa	cgggcttaaaa	aaatggcaca	ccaggagatt	31080
atatcccgcg	cctgggtcag	agagtcctat	gcccacggag	tctcactgat	tgctagcaca	31140
gcagtctgag	atcaaaactgc	aaggcggcag	cgagggtggg	ggaggggtgc	ccaccattgc	31200
ccaggcatgc	ttaggtaaac	aaagcagcca	ggaagctcga	actgggtgga	gcccaccaca	31260
gctcaaggag	gcctgcctgc	ctctgtaggc	tccacctctg	ggggcaggac	acagacaaac	31320
aaaagacagc	agtaacctct	gcggacttaa	atgtccctga	cagctttgaa	gagagcagtg	31380
gttctcccag	cacgcagctg	gagatctgag	aaagggcaga	cttccctctc	aagtgggtcc	31440
ctgacccctg	agccccgagc	agcataactg	ggaggcaccc	cccagcatgg	gcagctgac	31500
acctcacacg	gccgggtact	ccaacagacc	tgacgctaag	ggtcctgtct	gttagaagga	31560
aaactaacia	acagaaagga	catccacacc	gaaaacccat	ctgtacatca	ccatcatcaa	31620
agacccaaaag	cagataaaac	cacaaagata	gggaaaaaac	agagcagaaa	aactggaaac	31680
tctaaaaagc	agagcacctc	tctcctcca	aaggaaagca	gttccctacc	agcaacggaa	31740
caaagctgga	tggagaacga	ctttgacgag	atgagagaag	aaggcttcag	atgatcaaat	31800
tactccaagc	tacgggaggt	cattcaaacc	aaaggcaag	aagttgaaaa	ctttgaaaaa	31860
aatttagaag	aatgtataac	tagaataaca	aatagagaga	agtgtttaa	ggagctgatg	31920
gagctgaaaa	ccaaggctcg	agaactacgt	gaagaatgaa	gaagcctcag	gagccgatgc	31980
gatcaactgg	aagaaagggt	atcagcaatg	gaagatgaat	tgaatgaaat	gaagcaagaa	32040
gggaagttaa	gagaaaaaag	aataaaaaaga	aatgagcaaa	gcctccaaga	aatatgggac	32100
tatgtgaaaa	gaccaaactc	atgtctgatt	ggtgtacctg	aaagtgcacg	ggagaatgga	32160
accaagttag	aaaacactct	gcaggatatt	atccaagaga	acttcccca	tctagcaagg	32220
caggccaaca	tccagattca	ggaaatacag	agcacaccac	aaagatactc	ctcgagaaga	32280
gcaactccaa	gacacataat	tgtcagatac	accaaagatg	aatgaagga	aaaaatgtta	32340
agggcagcca	gagagaaagg	tcgggttacc	ttcaaaggga	agcccatcag	actaacagcg	32400
gatctctcag	cagaaactct	acaagccaga	agagagtggg	ggccaatatt	caacattatt	32460
aaagaaaaga	attttcaacc	cagaatttca	tatccagcca	aactaagctt	cataagtga	32520
ggagaaaata	aatactttac	agacaaccaa	atgctgagag	attttgtaac	caccaggcct	32580
accctaaaag	agctcctgaa	ggaagcacta	aacatggaaa	ggaacaaccg	gtaccagccg	32640
ctgcaaaatc	atgccaaaat	gtaaagacca	tcaagactag	gaagaaactg	catcaactaa	32700
cgagcaaaat	aaccagttaa	catcataatt	acaggatgaa	attcacacat	aacaatatta	32760
actttaaaca	caaattggact	aaatgctcca	attaaaagac	atagactggc	aaattggata	32820
aagagtcaag	acccatcagt	gtactgtatt	caggaaaccc	atctcacatg	cagagacaca	32880
cataggctca	aaataaaagg	atggagggaag	atctaccaag	caaattggaaa	acaaaaaaag	32940
gaaggggttg	caatcctagt	ctctgataaa	acagacttta	aaacaacaaa	gatcaaaaaga	33000
gcaaaaagaag	gccattacat	aatggtaaag	ggatcaattc	aacaagaaga	gctaactatc	33060
ctaaatacat	atgcacccaa	tacaggagca	cccagattca	taaagcaagt	cctgagtgc	33120
ctacaaagag	acttagactc	ccacacatta	ataatgggag	actttaacac	cccagtgtca	33180
acattagaca	gatcaacgag	acagaaaagtc	aacaaggata	cccaggaatt	gaactcagct	33240
ctgcaccaag	catacctaatt	agacatctac	agaactctcc	accccaaatc	aacagaatat	33300
acattttttt	cagcaccaca	ccacacctgc	tccaaaattg	accacatact	tggaagttaa	33360
gctcttctca	gcaaattgtaa	aagaacagaa	attataacaa	actatctctc	agaccacagt	33420
gcaatcaaac	tagaactcag	gattaagaat	ctcactcaaa	accactcaac	tacatggaaa	33480
ctgaacaacc	tactcctgaa	tgactactgg	gtacataacg	aaatgaaggc	agaaataaag	33540
atgttctttg	aaaccaacga	gaacaaagac	acaacatacc	agaatctctg	ggacacattc	33600

aaagcagtgt	gtagagggaa	atttatagca	ctgaatgccc	acaagagaaa	gcaggaaaga	33660
tccaaaattg	acaccctaac	atcacaaatta	aaagaactag	aaaagcaaga	gcaaacacat	33720
tcaaaagcta	gcagaaggca	agaaataact	gaaatcagag	cagaactgaa	ggaaatggag	33780
acacaaaaaa	cccttcaaaa	aattaatgaa	tccaggagct	ggttttttga	aaggatcaac	33840
aaaattgata	aaccgctagc	aagactaata	aagaaaaaaa	gagagaagaa	tcaaatagag	33900
gcaataaaaa	atgataaagg	ggatatcacc	accgatccca	cagaaatata	aactaccatc	33960
agaggatact	acaaacacct	ctatgcaaat	agactagaaa	atctagaaga	aatggataaa	34020
ttcctcaaca	catacactct	cccaaactaa	accaggaaga	agttgaatct	ctgaataggc	34080
caataacagg	atctgaaatt	gtggcaataa	tcaatagctt	accaacgaaa	aagagttcag	34140
gaccagatgg	attcacagcc	gaattccacc	agaggtaaaa	ggaggaaactg	gtaccattcc	34200
ttctgaaact	attccaatca	atagaaaaag	agggaaatcct	ccctatctca	ttttatgagg	34260
ccagcatcat	cccgatacca	aagcctggca	gagacacaac	caaaaaagag	aatttttagac	34320
caatatcctt	gatgaacatt	gatgcaaaaa	tcctcagtaa	aatactggca	aaccgaatcc	34380
agcagcatat	caaaaagctt	atccaccatg	atcaagtggg	cttcatccct	gggatgcaag	34440
gctgggtcaa	tatatgcaaa	tcaataaatg	taatccagca	tataaacaga	accaaagaca	34500
aaaaccacat	gattatctca	atagatgcag	aaaaggcctt	tgacaaaatt	caacaacact	34560
tcattgctaaa	aactctcaat	aaattaggta	ttgatgggac	gtattttcaa	ataataagag	34620
ctatctatga	caaacccaca	gccaatatca	tactgaatgg	gcaaaaactg	gaagcattcc	34680
ctttgaaaac	tggcacaagg	cagggatgcc	ctctctcacc	actcctattc	aatatagtgt	34740
tgggaagtct	ggccagggca	attaggcagg	agaaggaaat	aaagggtatt	caattaggaa	34800
aagaggaagt	caaattgtcc	ctgtttgcag	atgacatgat	tgtatatcta	gaaaacccca	34860
tcattctcagc	cccaaactct	cttaagctga	taagcaactt	cagcaaagtc	tcagaatata	34920
aaatcaatgt	gcaaaaatca	caagcattct	tatacaccaa	caacagacaa	acagagagcc	34980
aaatcatgag	tgaaatccca	ttcacagttg	cttcaaagag	aataaaaatac	ctaggaatcc	35040
aacttacaag	ggatgtgaag	gacctcttca	aggagaacta	caaaccactg	ctcaaggaaa	35100
taaaagagga	tacaaacaaa	tggagaagaa	ttccatgctc	atgggttagga	agaattaata	35160
tcttgaaaat	gtccatactg	cccaaggtaa	tttacagatt	caatgccatc	cccataagc	35220
taccaagggc	tttcttcaca	gaattggaaa	aaactacttt	aaagttcata	tggaaaccgaa	35280
aaagagcccg	catcgccaag	tcaatcctaa	gccaaaagaa	caaagctgga	ggcatcacac	35340
tacctgactt	caaactatac	tacaaggcta	cagtaaccaa	aacagcatgg	tactggtagc	35400
aaaacagaga	tatagatgaa	tggaaacagaa	cagagccctt	agaaataacg	ccgcataatct	35460
acaactatct	gatctttgac	aaacctgagg	aaaacaagca	atgggggaaag	gattccctat	35520
ttaataaatg	gtgcagggaa	aactggctag	ccatatgtag	aaagctgaaa	ctggatccct	35580
tccttacacc	ttatacaaaa	atcaattcaa	gatggattaa	agacttaaat	gttagaccta	35640
aaaccataaa	aaccttagaa	gaaaacctag	gcattaccat	tcaggacata	ggcatgggca	35700
aggactttat	gtctaaaaca	ccaaaagcaa	tggcaacaaa	agccaaaatt	tacaaatggg	35760
atctaattaa	actaaagagc	ttctgcacag	caaaagaaac	taccatcaga	gtgaacaggc	35820
aacctacaaa	atggggagaaa	attttcacaa	cctactcatc	tgacaaaggg	ctaataatcca	35880
gaatctacaa	tgaactcaaa	caaattttaca	agaaaaacaa	acaaccctgt	caaaaagtgg	35940
gtgaaggaca	tgaacagaca	cttctcaaaa	gaagacattt	atgcagccaa	aagacacatg	36000
aaaaaatgct	catcatcact	ggccatcaga	gaaatgcaaa	tcaaaagcac	aatgagatac	36060
catctcacac	cagctagaat	ggcaatcatt	aaaaagtcag	gaaactacag	gtgctggaga	36120
ggatgtggag	aaataggaac	actttttacac	tgttggtggg	actgtaaact	agttcaacca	36180
ttgtggaagt	cagtgtggcg	attcctcagg	gatctagaac	tagaaaaacc	atttgaccca	36240
gccatcccat	tactgggtat	atacccaaag	gactataaat	catgctgcta	taaagacaca	36300
tgcacacgta	tgtttattgc	ggcattattc	acaatagcaa	agacttgga	ccaacggaaa	36360
tgtccaacaa	tgatagactg	gattaagaaa	atgtggcaca	tatacaccat	ggaataactat	36420
gcagccataa	aaaatgatga	gttcatgtcc	tttgtaggga	tatggatgaa	attggaaatc	36480
atcattctca	gtaaactatc	gcaagaacaa	aaaaccaaac	actgcataatc	ctcactcata	36540
gatgggaatt	gaacaatgag	aacacatgga	cacaggaagg	ggaacatcac	actctggggg	36600
cggttggtgg	gtgggggggag	gggggagggg	ttgcattggg	agatatacct	aatgctagat	36660
gacgagttag	tgggtgcagg	gcaccagcaa	ggcacatgta	tacatatgta	actaacctgc	36720
acattgtaca	catgtaccct	aaaacttaaa	gtataataat	agtaataata	ataaatttaa	36780
aaacagaaac	attatatcta	tctccttggt	ttcatagcaa	gtcatcaata	catgtttcta	36840
aattgagaaa	gaataattac	aattgaaggc	acatagtgat	gaaagaaaaa	ttgttgattc	36900
tgacatttgg	agctgaaaat	atttaatagc	tacaatcttt	aaaagtcagt	atttgaaatg	36960
aaaagttctt	ttatatatgg	ttgggtgatc	tgttggtata	tgtttttattc	ttcttaaagc	37020
aaggtgtcct	tgttcttttg	acatattttc	agtgttgtga	gttgtctttc	cttgtctctg	37080
tctctttctc	tctgttgccc	tctctgtatc	actgcctttc	tctcaattcc	tatttcataa	37140
tttggttttag	cttatattgt	gtcttacaga	ctcttcacat	gttggcctca	gccttacata	37200
ctttcaggac	aatctcagta	cagacaaggc	tgctgcttgt	ttttggaaat	gactcctctt	37260
gcctgaaatg	gctcaagtgc	acagcaggtg	tatgtgtgtt	tgttggtgtg	tatgtattgt	37320
gtatgttcat	gtatggtgct	ggtggaggtg	caatcataca	acgagaataa	tttttgctct	37380

acaatagcta	ctaccatttta	ttttactttt	tgcagtaaaa	tttttttctt	accactgct	37440
ctgttcatta	acaaacttct	agttaggtaa	gaagggtgta	ttaactaaga	gtttgttaat	37500
gatagtttat	cctgttcaga	tgtgagaaag	aatgttaaaa	ctagtgtcta	ctctattagg	37560
agatacatta	gatgatctca	catgcacaat	tcctatgtcc	attttgcaaa	catatttact	37620
gcactgccta	ttataatgca	tagaattctg	ttggtggaaa	aatacaagtg	tgtccagaca	37680
ttttcgcact	ggtttgctat	gctaataattg	ttatatgttg	aaagtgcagt	atttgagatt	37740
gactgatgca	ttgtcatttt	ccccataact	tgccatatta	gatcactaca	ttaattttatt	37800
ttgcttgctg	actgtctatt	tgttctaaca	ttatttttta	aaacaatcag	aaactttcta	37860
gtagtatatg	atactgcac	ataattgttt	ggactaaaatt	agcagtttga	ccatccttat	37920
gaggatcaga	acaaaatcag	atcataagac	atgacagaac	acatatagct	ttgagactaa	37980
aaccttaaaa	atgtgactgt	tttcctttct	ttttttgagg	cttcttagag	ttgaaagctt	38040
catgtgtttt	ctcttttctg	tttctgttat	actgcctgac	agaaacatca	ctttacttac	38100
catgcttatt	cagtgtacct	gcttttcaag	gaaaatgtaa	tttgtgtgtt	ggaaaggaat	38160
ttgaaaagtc	actggtcaca	tcagcccaca	tggatactct	ggattcttat	ctccatagag	38220
aaggccaata	accatttgcc	ttgaccacac	ccaattccta	cttaaaactc	tttatctaac	38280
atctaagttt	ctcttcttct	tctctccttc	ttcttatttt	tttttttctt	tttaaccagg	38340
cttccatgat	actggggaca	aaaaaagaga	agataagaga	tgaactagt	gctttctgga	38400
ctctcaactt	gaattatttg	ttttaaaaaa	gtatagggga	aaatgggttt	gaggaacacc	38460
ttagctttcg	atgcttaagc	ttttgacttg	ttgtaactct	gggtatggaa	agaactctga	38520
taactttgtg	gctctgtttt	ctatttggtt	ttgtttttaa	tgattctctg	gatgttaaac	38580
atctagcaag	taatttgatt	tgtttaattc	tgaggaaaga	aaaaatttcc	tttgagttaa	38640
atttatgggg	taaattcact	tacattaaat	gtaggaactt	taagtgtgca	gttcagtaaa	38700
gtttgacaaa	tgtgtacagc	catgttatca	caattccaat	tttcaaggct	actgtgcagc	38760
tgggaagtgt	gagaataggg	caagtaaaga	tgccacaaaag	ttcactgtcc	ttaccaagat	38820
tcaggaattt	tttcttgaat	aaatactcac	ggaattgttg	caagcttttg	attactttct	38880
agtatccaga	aacagttgac	ttttgacttt	tttttagtgt	tctcatgggt	ttcatggagg	38940
gacagttttg	ggaaggtcat	tactatgtca	atcagaaagt	tgattcttag	atagatagat	39000
agatagatag	atgatagatt	catcaagatt	gtatgaacag	tttgttcatt	tttattgctg	39060
agagtagtaa	cccattatag	ggatatacta	taattgggtc	atctatgcat	ctgctgatac	39120
atgtttgaga	ctctgtatgg	atatgtcttc	ttttgccttg	gataaatact	gaagagcaaa	39180
atttctgtgt	catagtttta	tgatgaacta	taaaatttata	taaaatttta	taaagggcca	39240
ccagtttttc	acagcccatt	gaattatttt	cattattata	tcttgttatg	tgttataaga	39300
gtttcagttg	cttcacatta	tcattgttaa	tctttgtatt	gtcaatattt	tttattcctc	39360
ccattgaagt	gagtgtgaag	tgttacaaaag	ataaacaag	ccagctacca	gttaaagtag	39420
taaggacaga	ttttatttcag	taatatata	ttgcaatgga	caggtaggtt	cactgtaaac	39480
tgaactctaa	ttttgttttc	acagagataa	ctgtgtattc	taaaggtaga	atgaggaaat	39540
aggaagaggc	atgagcaggg	ctcaagagag	tcagagaagt	aaaaaaatta	caaaaagtgt	39600
gaaaggagt	ttgatccatg	tgaacccac	ccagttttgc	caactggctc	ctaccctccc	39660
ttgggagcta	gtagacaaga	gctctttctc	cacataattg	ctgaaacaga	cagtatcttt	39720
tgttggcagc	cttgagtttt	ctcaggcagg	ttcttccagg	agtactacag	tcattcccagg	39780
gatatggcct	tgagctgtta	gccactgtgt	ttgtgttttg	ttcaagtctt	tttaggcca	39840
ggttgaggcc	tagtcaagaa	agtgtcaga	ggattctttc	tagagtttg	tccaggagga	39900
aatctttggt	atgcggtgtt	tcataatggg	cataatttac	attttcttga	caaatgcaga	39960
tgttgaattt	cttttcattg	gatcgtttgc	tgttcattga	tcttctttta	tgaagtgtct	40020
gctcacaact	tagactttct	ttttttttt	aattgaaactg	tttatatttg	gaccagtga	40080
ttgtgggaga	tatttatatg	ttcttaatac	caatcatttg	tcagaattac	ttactatgaa	40140
tagtcttctt	agtctatggt	ttgccttttc	attatcttag	cattattttg	aagaatgcgt	40200
gttttaaaat	ttgatgacac	acacacactt	tatatatata	taattatata	tatatatttt	40260
attcacaatt	agtgtcttta	ttttcttctt	aagaaatctt	tgctttcctc	aagatcataa	40320
agctattctt	ccattttttt	ttttttcctg	gaggacttgt	agatttagca	tttacattta	40380
gaatttttat	ttccaccaat	ttagttttga	gtattggcat	gtggtgtgtt	ataggaagtt	40440
aaatatttta	atgaacatat	ccatattttt	cagtagcagt	ctccattaaa	atacctttgc	40500
acctttgttc	aaaaatccat	tggctacata	tacgagtgga	tctattttgt	atctctttat	40560
tctgtacact	taacctcttc	atcatcctta	gatccacaca	ctgctttgaa	tgctataact	40620
cttagtaact	cttaggtgga	tgatattaac	ttaaagggaca	gtttttcaca	tactttattt	40680
ttttcaagaa	agccttcaga	aaccttctgt	caacttgtgt	ttgaagacat	taaatgttta	40740
gttaacctga	ttttacttca	attacaatga	tcaattgatt	gatgtctgct	agaagtgcac	40800
ctaattaatt	agttatgtaa	atactacaat	ggtcagataa	ttggacacat	ggtactgacc	40860
atggacattt	aagtagtgca	aattatgcaa	caatatttgt	tcactttcca	aaggggtttt	40920
tgtgttttta	tgacagcatt	tatttttagaa	tcagatcatg	aagttttgca	aacatcatcc	40980
tgctgaaatt	tgatagaagt	ggcttttaaaa	ttattgatag	atttaggaag	aattaacaca	41040
ttgactatat	tgaatattct	aatgcacaag	tgagacgtat	gtctttatta	tttaggtctt	41100
ctttaatttc	gctctgcaga	cgtttgtgct	tttcagtgtg	tatcttttgc	acacttttta	41160

tttttgtttc	tgagtagctt	atgattttat	gtgatatttt	taagttttat	attctactgt	41220
gtattgcttt	tatgtaactg	tatgagtgtt	tttgggtttt	tttattttgt	tttgttttgt	41280
ttttttagac	agagtcccg	tctgtcacc	agattggagt	gaagtgggtat	aatcctggct	41340
ctatgcaatg	tctgcctccc	aggttcaacg	gattctcctg	cctctgcctc	ccaagtagct	41400
ggggctacag	gcacgttgcc	atcacaccgg	tttcactatg	ttggctaggc	tagtctcaaa	41460
ctccctacct	caaataatct	gccacacctca	ggctcccaaa	gtgctgggat	tacagttgtg	41520
agccatcgca	cctggcctgt	atgagtgggt	tttgtgtatt	gaatttgtaa	ttgtaatcat	41580
atcatcttcc	aaaatatata	cttaattttcc	catttgtata	ttttaaaata	acttttataa	41640
taaagcatca	tgctactctg	gaataacaca	gatttgtttc	ttttcaattt	gtatactttt	41700
tattttagtag	gtaggacttt	cagtaccata	ttgaaccgac	tacaactttt	aaataaaaaa	41760
tagccaattg	agtaatcaca	aacacacaag	taaaatctta	agggccaata	ggatgtatcc	41820
aactgtctga	acatgggtgc	atttgtatag	ctaaatccat	taggtgttcc	actagcagac	41880
atacatcaat	tggtccttcc	agcagaagca	aagtgcacac	gactaaataa	actaatgtgt	41940
tcagtaatat	agatagataa	tataaaactt	tctgaaggct	ttctatgaaa	cataaaataa	42000
gcatgtgtaa	aactcatctt	tgagttagta	taatatacat	agctaaatct	gtattcccta	42060
accaaactta	taagtaaatt	aatgtcacct	tctaattgtg	ggacatctga	tcatgtgatc	42120
ccatattaaa	atttttgaga	ctttgtctct	cctcatcaaa	aataaccaat	ccattacttt	42180
ttgtctatcc	attcagttat	tattgagcca	gaatcatttg	tagtcagaag	agtcattttg	42240
taactcttat	gttttattga	aatgttattg	catattaaca	tatgtaagaa	aacaaataaa	42300
tgaatatata	tatacatata	cacatactat	agggcatatt	gccttcaaat	tgaaagctgc	42360
catttctgtt	aacaaagagc	caaattgtca	attagtttta	tgcattaagg	gatgaggaaa	42420
tgagagacac	cagtattata	gtcctatatg	acccttcatt	ctatagaaat	atttaagaaa	42480
taccatttta	tttttattta	tttatttatt	tatttatttt	ttattttatt	ttattattat	42540
tattatactt	taagtttttag	ggtacatgtg	cacaatgtgc	aggttttgtta	catatgtata	42600
catgtgccat	gttgggtgtg	tgactcatt	aactcgtcat	ttagcattag	gtatatctcc	42660
taatgctatc	cctccccct	ccccccactc	cacaacagtc	cctggagcgt	gatgttcccc	42720
ttcctatgtc	catgtgttct	cattgttcaa	ttccaacctg	tgagtgagaa	catgtgggtg	42780
ttggttttct	gtccttgcg	tagtttgctg	agaatttgct	gaaaattgag	tttccagttt	42840
catccatgtc	ctacaaaagg	acaagaactc	ttcatttttt	atggctgcat	agtattccat	42900
ggtgtatatg	tgccacattt	tcttaatcca	gtctatcgtt	gttggacatt	taggttgggt	42960
tcaagtcttt	gctattgtga	atagtgtccc	aataaacaca	cgtgtgcatg	tgtctttata	43020
gcagcatgat	ttataatcct	ttgggtatat	actcagtaat	gggatggctg	ggtcaaaaaga	43080
aataccattt	tactttttaa	ttagtgtcaag	gaatcaaaac	catacagata	aaaactgaga	43140
taaggcttta	aactcaattt	gaggaaaaaa	atagctatgc	tcaaattctct	caaatttcat	43200
gggatgtaac	aaatctacat	tttgattttg	atatatagct	atatttgtgt	gactgatttc	43260
tcaaagaata	accaccattt	gtgatctaa	agaattagg	atgcctcttc	tgtcttggtc	43320
agagcccat	ttgattcatt	tgtgctaacc	tggaactatc	agtgcactgg	aaaatacaga	43380
ctaataga	catgtctagc	ttcccttatc	atctaacaaa	tgcagtgtaa	acaagtttta	43440
aatattcttc	cttctatttt	cagccctatt	cctaagtcaa	caattttatg	actcatcaat	43500
tttataaacg	gtcctgggtc	cagacctgtc	tttgattcct	agcttggtta	tgactttcaa	43560
tagggcagac	tagttccagc	ataaatccag	aacgtccgtc	ctccaaagga	cctgggcccct	43620
gaccaatact	tctgcttcc	tctactgatt	atgttgtcac	tctgctgctc	tccacatcct	43680
tacaaatcct	tccttttctc	aagtctttca	gctgccacac	ctttctaccc	ctcaccctca	43740
gtaaaggacc	tcaccccgat	gtctatagac	aaaactggag	agttctgatg	aaaaccttct	43800
tggtttttat	atattaaaat	tacaaaactt	atctatctat	attttctctc	ttccatatta	43860
ttgaaagtga	tggttagttt	ctctgtttgt	gctaaagctc	tgatgaacac	atgtaacaaa	43920
actgtacata	aatgttgtat	agggatttca	tcttcaaagg	agaatctagc	tgttcaaact	43980
atcaaataaa	tgtaagccc	ttgaggaaca	aatgatatta	taattgggtc	tttagaatta	44040
ctttaaaaat	actctaggga	atatagctaa	gaaatatata	tcttgccacc	ttgctttaca	44100
aactatgggtg	agttaacatt	aacaggtagg	tcatttgcta	catttgttca	ctaaaaatac	44160
aactttttct	gtgtgtggag	attagtatcc	aatcaataga	ggaaacccat	attttcatca	44220
atttcactgg	acttttctat	tcatatgtta	acatttcatt	gactctaaaa	tcaattatat	44280
gcaagctcct	ctgatgtata	tgtgagagct	aaataagcaa	tttctttagg	gtgcaaat	44340
ttgagcaata	atttttacag	tcatagctta	ttttcatgaa	gaactcagag	agagtggctt	44400
gagttggcag	caaagactgc	ttttaacaat	gttctgtgat	tctctaacia	tattttaata	44460
agtagtttag	tggcatataa	atggagacaa	aaaaacttca	ctctcttcc	tcagggtgcta	44520
taattgttta	tttactgttc	aaatgttgca	ttctcagaaa	aggctacttt	gaatagtcat	44580
ctaaaagaat	ctcacattca	ttgttcttca	cagaccagc	ttttacttga	aattataata	44640
tgtatctttc	tctgtgggtt	taaccattat	ttctcatatt	ataatgtgag	ctccatgaaa	44700
ctggaaaatt	tgttcaactc	aataacccca	ggaattgtaa	tacacacaaa	aaaatcaagc	44760
tatgcagtca	gtgtacatga	ataaacaggc	aggtaaaatt	tcaaagtga	aaaacagttc	44820
ttggttttgt	atattcttag	ccatatatca	agcactaagt	ttaactaatt	taatgttcac	44880
tgacaatcat	aggtttctgt	ttgtttgttt	gtttgtttgt	ttgagacgga	gtctcgctct	44940

gtcgcgccaga	ctggagtgcc	ctgggtgtgat	ctcggtctcac	tgcaagctcc	gcctcccggg	45000
ttcacgccat	tctcctgcct	cagcctccccg	gtagcttgga	ctacaggcac	ccgccactac	45060
gcctggctac	ttttttgtat	tttgagtggga	gatgggggtt	cacagtgtta	gccaggatgg	45120
tcttgatctc	ctgacctcgt	gatctgccccg	cctcggcctc	ccaaagtgtc	aggattacag	45180
gcgtaagcca	ccgcgcccgg	ccgacagtca	taggttttaa	gtgaaaatgc	taccttaatt	45240
tttttcttct	gtttttgtatc	tgaaataata	agatatcaga	catggaggga	aactgaagat	45300
tggacttcct	acattttattt	attttaaata	tgctaataat	aatatctgat	attcattttct	45360
ttgttttttt	tgttccctca	caaaccttga	aaataattac	caaagttaga	attcaccaag	45420
aagacaagta	tgaatgcatt	aatgtataaa	tttataaatg	tatatatata	agagacagaa	45480
atagagaatg	tgcctgtgtg	tgtgtgggtt	tgagatacaa	aaagagacag	aaaacacaca	45540
catataaaga	gaaaacgttg	tgacagaaatt	ctgatgtgtt	tattgaaaaa	agtaattggg	45600
gcctagatga	atagatgaat	gagtgaatga	taaatggatg	aaacaaatgc	caaactctgga	45660
tcagagagaa	tccctcacatt	ctttgtcact	ttcagttttc	aagaaataag	aagatgttgt	45720
ccccaaacca	caccatagtg	acagaattca	ttctcttagg	actgacagac	gacccagtg	45780
tagagaagat	cctgtttggg	gtgttccttg	cgatctacct	aatcacactg	gcaggcaacc	45840
tgtgcatgat	cctgctgatc	aggaccaatt	cccaactgca	aacacccatg	tatttcttcc	45900
ttggtcacct	ctccttttta	gacattttgt	attcttccaa	tgttactcca	aatatgctgc	45960
acaatttctt	ctcagaacag	aagaccatct	cctacgctgg	atgcttcaca	cagtgctctt	46020
tcttcatcgc	cctagtgatc	actgagtttt	acttccttgc	ttcaatggca	ttggatcgct	46080
atgtagccat	ttgcagccct	ttacattaca	gttccaggat	gtccaagaac	atttgcattct	46140
ctctggtcac	tgtgccttac	atgtatggct	tccttaatgg	gctctctcag	acactgctga	46200
cctttcactt	atccttctgt	ggctcccttg	aaatcaatca	tttctactgc	gctgactctc	46260
ctcttatcat	gctggcctgc	tctgacaccc	gtgtcaaaaa	gatggcaatg	tttgtagttg	46320
caggctttac	tctctcaagc	tctctcttca	tcattcttct	gtcctatctt	ttcatttttg	46380
cagcgatctt	caggatccgt	tctgctgaag	gcaggcacaa	agccttttct	acgtgtgctt	46440
cccacctgac	aatagtcaact	ttgttttatg	gaacctctct	ctgcatgtac	gtaaggcctc	46500
catcagagaa	gtctgtagag	gagtccaaaa	taattgcagt	cttttatact	tttttgagcc	46560
caatgctgaa	cccatgtgac	tatagcctac	ggaacagaga	tgtaatcctt	gccatacaac	46620
aaatgattag	gggaaaatcc	ttttgtaaaa	ttgcagttta	ggcctgtgtt	tatttghtaat	46680
ccctaagtgc	ctgtggggta	acaaactgaa	atggaaaaac	ctagtgtagt	tattatttta	46740
cagtatgggc	tcttagtaac	cacttttagt	tcttctcaaa	attaacactt	tgaagattta	46800
gtttttaaaa	ataaaaagct	taatgttgaa	attaataatg	ttttatttgt	cagagattct	46860
atgaatataa	attgttttgt	ttctaataat	tctgtatgaa	aatactgggc	ttacttactt	46920
gggggtaaac	ttttaactaa	cttagcctga	gagaaactct	gaaaaatcaa	cccctttgaa	46980
tattactatc	catagagcca	tagtgaggct	ccagataggg	tggtcaattt	tacattttta	47040
aaaaaatgat	gcccggcgatg	gtggctcaca	tctgtaatcc	cagcactttg	ggagccagag	47100
ataggtggat	cacctgaggt	caggagtgtg	agaccagctt	ggccaacatg	gtgaaacccc	47160
gtctctccta	aaattacaaa	attagctggg	tgtgggtggc	catgcctgta	atcccagcta	47220
ctcaggaggc	tgaggctgga	gaatagcttg	aacctgggag	gcggagggtg	cagtgaagtca	47280
agatcacgcc	attgtactta	ctccacttgg	gcgacaagag	cgaaactcca	tctccaaaaa	47340
aataaataaa	taataaata	aaaagaaaac	gaaaaaagaa	aaaaatttgt	tctacttcaa	47400
tgtggtgtct	tgaacaatag	ttctgaaacc	tgtgaactta	ttgtaatcac	tgtgcaaaaa	47460
atgtaaatat	atgaatcacc	tataagttta	attttctgta	agtattctca	aaaccacac	47520
tgtaaacatc	gtagaagct	tcttattggg	tcattgtgga	ataccagtta	tggtcctcaa	47580
ttctgaaaa	cactctcaa	cacctttttt	tttttttga	gttttcaagt	gcattggatcc	47640
atttctatca	tcaaaatact	tcaattgcat	tccacgtatg	ttttccagt	aggtacacct	47700
gacttaggaa	taatttagta	ggaatcaata	gggtttatca	attgatattt	gcataatgcat	47760
aaatgacttt	gttagtgga	aaaggggtct	tgatccagat	cccagcagg	ggttcttgga	47820
tctacagagg	aaaaatttca	agataagctg	caaagtgcag	tgagaagaga	tagttcatta	47880
aatgctactc	caaagagatc	atttattaaa	ggctattgca	ttacagagta	aggtgttccc	47940
agaaagcaag	tggagggaatg	cacctctctt	aagttttttt	aatggtcttt	tatctacgta	48000
cagactaaag	taagttgtgg	ctacatgtgg	gtaggctgac	ggcatgacaa	aatttatcat	48060
tgtgttgatt	taaagaaaac	gatccttgat	attttagtgt	gtgcataact	attattatca	48120
tgataaaaag	atatactctt	atgagaattg	ggacacctag	gttctcttgc	tgcattatta	48180
gcgtgttctt	ttaggctgtt	ttcctaaacta	acctcaagac	agagttgatt	ttaaaatggt	48240
gtcatgaccg	gccaggactg	tgcttgttta	tttaacaccc	tgaaacagta	taaaaattaa	48300
gtcaccctgg	atctcctaga	ctcctgcttc	agtgtttatt	ttgcttcaca	caactgtctg	48360
taggggctga	cgtatctttt	tggaggaaat	ctagttctca	aagctactac	agggaaaaatc	48420
tggcacatta	tttttttaca	ttagggtatt	ttaatcaatg	tattatttag	tcaaccagat	48480
aatcacaaag	aggctaaata	aagatacaca	ctatttaaatt	gcctcttatg	tttgacattt	48540
gactgcatat	taatacatat	atatttagcc	ctatacagaa	aatgctacag	aaaatgctta	48600
taatattttg	cactctgctt	ttaactaaca	atgttcaagt	ggttttccag	aatattaaac	48660
tatgatataca	actactgtat	ctactataaa				48720

agatgactaa	cagtttttgt	aaaattgggt	tatatctcta	agtgtcagtt	ggttgaataa	48780
gtctgggtct	atccaaatct	gcttttagaa	acagtaactg	aaaaagaaag	aaggcaattt	48840
tgggcagcaa	caattttaata	tttacctttt	agcactattt	gtgtatttgc	ctggtttttg	48900
caatggcagt	ggcacaacag	aagcaggtga	tctgtagaga	caagagtga	gcagaagagc	48960
tgggaactga	gtgacacagc	gtccttactt	ccttttagag	gcccagcatc	atttcatctg	49020
tgggatattt	ctttatctta	tgacaacatc	atttaatctg	tgggatagct	ctttatatta	49080
ttctttttatc	ttcctctttt	ggttaggcaa	agcatttgtt	tcaatttcta	gcaagtagag	49140
tgggtctgata	ctctatttga	aaactgtatt	ttagaattgg	tacaaacaca	ctctatattt	49200
tgcctaaata	actgtatact	tcctttttatt	ttctagttag	gagaattgct	gtggcttgca	49260
gcaaccaaac	ttaaactttg	acacctttgt	aaccocaaatg	cttgacctgt	ttgtaatctc	49320
tttttttttaa	aatatgtatt	tattttattct	atttgtaatt	taattttttta	attgtgcaag	49380
cccttgggta	aaagtattct	cagaaattct	ttggagatag	aatagaacat	aaatggacat	49440
gaatagaaat	agtgacaatt	gatgtaatca	tagtgtattg	ctaatttttag	gattactgtt	49500
ttttcttttac	ttaaataaaa	atgaagtagt	gagagaatta	ttatcttcat	ttacaatatt	49560
tggagtctta	gacacagaga	gatgaaatga	cttgcctaac	gtcatttggc	cactcagtag	49620
cacaaaagca	gatttcttgg	ttttaaattt	tctctctttc	taattcatac	tgaagtgggt	49680
attaagccat	tcttcaacac	acttcaaattg	ctggggggaa	tattggagac	tatgaattaa	49740
taagagtgtt	actatagatt	aaatagtggg	tattatgtga	tagtgagatg	tatcctaaca	49800
acagctaattg	tgaattttcc	ctgacagtca	ggctaattgtg	atcatttata	tgcatgataa	49860
ttaaaattgt	cttaatatcc	atgtgaaggg	agaaaatttt	gatatatggg	aaacctttat	49920
gcttcttagg	ctgcatttta	ttaatatatt	ttcccaatta	taaaagcaca	catattttata	49980
ttaattaatt	tccaggtaca	gacaaatata	aaaacataaa	atttattaag	gacctgctat	50040
gacaaggaat	aagttttgtt	tatatatttgt	tatatctctt	ctcaataaat	gtatatgact	50100
acatgttact	ataatgcaca	aaacaaatat	aaagttactc	accatataat	aatatgaata	50160
cagattttca	tttgatacta	taatgtatgc	acctttacat	agattaaata	ttttatgaac	50220
attttttaatg	tcataattta	attagcttgt	gtgatcctaa	tacaatatta	atacatgtca	50280
aatgtagaaa	accaataaac	catattggca	tacataagaa	atagaagcaa	tgcttacttg	50340
taatcaacta	cctgaaaaga	gttgctctca	gcattcacat	gtgttttatt	ccatttgatt	50400
atcttgcaaa	tcattgattcc	atcatatcaa	tgtatcttag	tattttgatg	accgacgtat	50460
ctgtacgtct	ctctctaatt	gttccttttg	ttatgttccc	agaagtgtaa	ttgctgaatt	50520
aaatgttttg	aacattttta	aaggtcttgc	taaacatttc	tatggataaa	tttttatcca	50580
gaaagcttgt	aacaaacctg	taccactaat	gtttgaaaac	aatcatttta	ctataactct	50640
atcagcagta	ggagctcttg	tttatggtta	tatgtctact	tgatctctca	aaggaagttt	50700
tagaaacaaa	ttctgtttta	atttgcacag	attagaaaatt	gaagaatata	tttaacaaat	50760
aaaggctaca	tataataatt	ttctttcatg	ttatgatggg	gtcttacatg	aagaatattt	50820
gtatttttat	ggagaaaaat	tatattttgt	tatttgggtg	tttgtaactt	tttcttatgc	50880
cacaattgaa	taaacaagca	cttatatggg	gttattgggt	ttcattgcaa	tattttatgg	50940
gaatatcatg	aattatcctg	gatataattt	tgttgcatgt	tttaatgttg	taaattactt	51000
ttgtgccctc	acatttttta	ccaacttcct	ccaagtgtta	ttaagcactg	ctttccact	51060
gatttgtgat	gtcaccttta	ttatacctta	agtcactcta	tttctgcca	tttccactgt	51120
tttttttgtc	tgaattataa	atatatttta	aactaaattc	ttatcattaa	attgaacata	51180
tatttttaatt	tctgggtgaag	atatttttgt	cttcaatttt	ctcttaggag	attgaaaatc	51240
agatactttt	agctatccaa	attttttaact	cagaaattat	aatattatga	ttcaatttag	51300
aaactgtatg	tatagtgtga	taatttttga	tgtagtgtga	catacaatac	ttatacatta	51360
taaagcaatt	aaaaaataag	gaaaattatt	ttagtgccta	tggtggccat	agggagaact	51420
gcttaaggat	gaaatatttt	gaatgagttg	tttgttttcc	agaaaagtcag	gaagatgctg	51480
gtgtctggta	agtgaggaga	aaacaccta	ccttgggtata	ttaattctat	ggattttatta	51540
acactgttat	acaaataactt	atgtttttcac	cataccagtg	tatggtgaaa	tcattcatgta	51600
acattttttt	tcaacaaata	tctctaaata	cagtctcttt	ttcttacaaa	gaggtttttt	51660
ttccagcaat	taccccaaaa	agaactgaga	gggccacata	tgtttttcca	catgagtgca	51720
cttcaaacac	tgaacaaaaa	aggattaatc	agaaagaaaa	taaatatatta	aatttaaata	51780
atcagagaat	aatatatctg	tgcttcataa	cagtgggaaa	aattttagtg	aaaaagagta	51840
agcaaattgc	tttaatttga	agataaaact	attttaaatt	aagaggcacc	ctacaatttg	51900
gaaatgtatt	tgccacaaac	aagataaatt	ggtaaaatta	ttgaaataca	agaaattaat	51960
aaaaataaatt	tgaagcacta	aagaatcaat	atataaatat	caaagactat	aagtaaaaaa	52020
ttgattaaaa	tacaaaaaatg	ctaaaaattaa	cacacaaaaat	attagcaacc	aaaaatatga	52080
tgtaagatat	tgtttgatat	atctacattt	aaaagagctg	atatagattg	gcactttcat	52140
acattgattg	attaagggtta	taaagttttt	ctgaaaataa	atttaattatt	taatagggtg	52200
gtacaaaagt	aatcttggtt	ttttgccatt	aaaagtaaca	gcacttattt	ttttctttac	52260
caaccttaata	ttattatcat	attaaggaga	caaaattttc	ttatgctttt	attcagctat	52320
ttcaattttta	agaatctact	gaaggcataa	gaaacttggt	tgaagagttt	catgggtgtg	52380
tttttatttt	ataatcaaga	caaagtaaac	acatgatgta	ttaaatacaa	atagttcctg	52440
cttggcatgg	taccatgtaa	cagaaacctt	tccatactgg	aaacgtgtct	tagtttttgt	52500

ggttcttagt	tcctacaaaa	tcacaaagt	agaactgcct	gcatttaata	actggtaaaa	52560
tacaggcatc	caccagatgg	gatagaagct	gtctctaact	aagtagaatg	tcatttagcct	52620
tgatcatgaa	ggaaagtgtg	aagtacaggt	gaaacgtttt	ttgtaataga	aagttataca	52680
gccattaaag	tgaggatgtt	cctagttaag	aaaaaggtaa	ttcattttat	gtaatatatt	52740
atgtgcaaag	atatatccta	tgctgtatac	agtgtgatat	cttgtaaaat	attagggata	52800
aggggaaata	aaacttggtt	ttaatagcta	tgctccatatt	taaatagtca	ttgctattgt	52860
gagaaaaata	ggcaacaaaa	actgtgtatt	ttcagtttag	tccagatctc	aggatgtata	52920
attacaggat	acttattttat	taatattgga	atttaaatat	gaaagtaagg	aaaagcaagg	52980
aaaaagcaag	gtaagaaaaa	gaagaggctc	ccaattcttg	tttccagcac	agaatgacca	53040
atgaacaact	tctcagagaa	aaatgcccat	gtgaaaattc	cgtaacccat	gggtgagggtg	53100
gggcacactc	ttggagcata	aaaactggaa	aaaaccacat	tagaattggt	aagaggagca	53160
gtttcacttg	cttctttccc	agccaaacac	agtgtcacac	tgaaagagat	tccttggggc	53220
tgtggtttcc	ccagtgaaga	aaagagagcc	cacggcagac	atccagcttc	cctatgttcc	53280
agagaacttc	ccaagaggcc	cattctgtct	aacctgtgg	gtaataacgg	aagacttggc	53340
aaagcttggc	caccccagtc	agctcataac	aaagttaagg	gggtgtagctt	acggcaacca	53400
gcacccgatc	ttggtgggtg	catcatgttc	tagctggcag	ctttatgtga	ccagagagcc	53460
cagccactag	cattgctcac	atgtggagct	gagttggcag	gccctttcgg	tcaggaggca	53520
tgttgaacag	ttctgtctgg	ctgtggtacc	agtcagtaag	ctggaccagc	tgacagagcac	53580
agcctagagc	accacccaac	cacaaagcac	aacttgcagc	ccacccact	caggtagaga	53640
tccaagccag	caacccact	caaccgctgg	gcatagcctg	cagtcccatc	tgacgacgga	53700
gtctgggtcaa	ttatctctcc	aaactacaga	gcacatccag	taaaacttcc	caattatgga	53760
tcagcttgca	gccccaaaaa	actgcaggaa	atagccagtg	gccctatctg	gccaaagagat	53820
ctggctcagtg	atctcaccta	aatttgagc	aaaggcagtg	accccatcaa	tctgtggacc	53880
acagccagca	gccccactcg	aatacatacc	acagtgaatg	gtcttacctg	attatggagc	53940
ccagtcagca	gccctgagtg	attttggatc	ctagccagca	tactcaccca	cctcagagca	54000
caggcagcag	tcagagggtca	tgtgactaga	gtcagctttc	aaattcatca	agtcctgggt	54060
ccacctctta	ctccctatga	aatctcagc	aaattattta	acctctactc	ctatgcccc	54120
atltgtttgt	ttgtttgttt	tcacagtacc	tatcatcacc	tgccatata	ttgtttgttg	54180
gtgtatttgt	ctctatctc	ctccagcaaa	aaacattatc	aataaagtag	tttttaattt	54240
tttttgagca	acagctatat	tgagttatat	agtggctata	ctaatttaca	tttttgccaa	54300
taatgtacga	gcattccttt	ttctgtgtat	ccttgcaaac	ctctgttcat	ttttttgtct	54360
ttttaatgac	aatcattaca	aattgggtga	ggttatactt	cattatgggtc	ttgatttgca	54420
tttcatttat	gattagtga	ttaaaccctt	ttttcatata	cctgctgaca	atltgaaat	54480
cttctttttg	aagcttttga	taaaatccaa	catctcttca	taataataat	aataaaaaaa	54540
tactcaacaa	actaggcatt	gaagagacat	acctcaaaat	aataagagcc	atctatggca	54600
aacccacagc	caacatcata	ctaaatggga	aaaagctgaa	agcattccac	ctaataaatg	54660
gaacaagaca	aagatgtcct	ctctcatcat	tcctatttca	catagtactg	caagtcttag	54720
ccagagcaat	aaagccagag	aaagaaatat	aaggcatcca	aataggaaaa	gaagtcaagc	54780
tatctctctt	cactgataat	atgattttat	acctagaaaa	ccctaaagac	tacaccaaaa	54840
agctcctaga	tctgataaac	aactttatta	aagtttcagg	atacaaaatc	aatgtataaa	54900
aatatttagca	tctctatact	cccataacat	tcaagctgag	agctaaatca	agaatgtaat	54960
cccattttaca	atagccacac	gcacaaaaat	aaaacaccta	ggaaaacaac	aaaccaagga	55020
ggtgaaagat	ctctacaagg	agaactacaa	aacactactg	gaagaaatca	tagatgatata	55080
aacaaatgga	aatcatccc	atgtttatga	attagaagaa	tcagaatgct	aaaacagcta	55140
tattgcctaa	agcaatctac	agattcaaca	ctattgccat	caagctaata	acactattta	55200
catagaatatt	gagaaaactt	gcctaaaatt	tatatggagc	caaaaaagag	actgtaagt	55260
caaagcaatc	ctaagcaaaa	agaacaatac	tggcagcatc	aaataaccca	acttcgaact	55320
atactacaag	gctacagtaa	ccaaaaaagc	atgggtactg	tacaaagaaa	gacccataga	55380
caaaatgaaa	cagtgaaccc	agaaataaag	tcagacatct	acaactgtct	gatctttaat	55440
aagttgatag	taataaacia	tagggaaaga	actacctatt	caataaatgg	agccaggata	55500
actatttagc	catgtgcaga	agagtgaaac	tggaccata	cctgtcacca	catataaaaa	55560
ttaactcaag	atggattaaa	gacttaata	taaggcctaa	agctataaaa	atcctggaag	55620
aaaactgagg	aaataccact	cgggacattg	gcctcagcaa	aaaatttatg	aataagtctc	55680
cagaagcaat	tgcaataaaa	ataaaaattg	aaaaattgga	tgtaatataa	ctaaagagct	55740
actgcataga	aaataaatta	acagagtaag	caatctaaag	aatgaaagaa	aatgttcaaa	55800
aatgataaat	ccaacaaaaa	tctaatatcc	agaatatata	agaaacataa	acaattcaac	55860
aggcaagaaa	cctcccccta	aaaccattaa	aacacatgga	cacagggagg	ggaacatcac	55920
acactggggc	cttttgtggg	gtgggaggct	aggtaaggga	taccattagg	agaaatacct	55980
aatgtagata	acggattgat	gggtgcagca	agccaccatg	gcatgtgtat	acctgtgtaa	56040
caaacctgca	cgttctgcac	atgtaccca	gatcttaag	tataataaaa	aataggcaaa	56100
agacataaac	agacacttct	caaaatgaag	catacatgtg	gccccaaaa	atattaaaaa	56160
tacagtatca	ttaatcatca	gagaaatgta	tatcacaact	acaatgagat	aacatctcac	56220
accggtcaga	atggctatta	ttaaaaaagt	aaataaataa	cagacattgg	tgagggttgtg	56280

gagaaaaatgg	aatccttata	cacttttgggt	gggaatgtaa	attagttcat	ccactgtgga	56340
agcagtttgg	aaattttctca	aagaacttaa	aacacaagta	ccatttgacc	cagcaatcct	56400
attactgggt	ataaacccaa	aggaaagtaa	ataattttac	caaaaccaca	tgcacttggtg	56460
caatcattgc	agcactatac	actgtagcaa	agacatggaa	tcaacgtaga	taaccatcaa	56520
tgatgaacgg	gataaagaaa	atatgatata	tacacactat	tgaatactat	gaagccatga	56580
aaatgaaatc	atgtctttttg	cagcaacata	gatgcagctg	aaggccatta	tcctaagtga	56640
attaatgtag	gaacagaaaa	ccaaatgtgc	ccatgttctt	attaaaggta	tgagagaaac	56700
attgaatata	catgaaaaat	aaaggagaa	aagcaacact	gggggttaat	agaaggggaa	56760
gagctgggga	gtgcagactg	aaaaatgatc	agaccaatgg	aacagaatag	agagcccaga	56820
aataagacca	cacatctatg	accatctgat	cttcaacaaa	gctgacaaaa	acaggtcaatg	56880
ggaaaaggac	tccctatttta	ataaatgggtg	ctgggataac	tggctagcca	tatgcggaag	56940
attgaagctg	gaccccccttc	cctataccac	acacaacaat	caactcaaga	tggttagagag	57000
acttaaatgc	aaaaccccaa	actgtgaaaa	ccctaggaga	aaatgtcggc	agtatcatcc	57060
tagaaaaaga	aatgggcaat	gatttcatga	caaagacaca	aaaagcaatt	gcaaaaagaa	57120
aaaagcaaaa	attgacaagt	aggatcta	taaacttaag	agcttcttca	cagcaaaaaca	57180
aactgttaac	agagtaaaaa	gacagcctat	ggaatagaag	aaaatatttc	caaactatgt	57240
atctgacaaa	ggtctaatat	tcagcatggt	taagaaactt	aaattttacaa	gagaaaaagca	57300
aacaacacat	ttaaaagtgg	gctaagatgc	tggcaacagt	ggctcatgcc	agtaatccca	57360
gcactttggg	aggcagaggc	agggtggatta	tctgaggtca	ggagttcaag	accagctcgg	57420
ccaacatggc	aaaaccctgt	ttctactaaa	aatacaaaaa	ataactgggc	atgggtggtgc	57480
gtgcctgttaa	tcccagctac	tctagaggct	gaggctggag	aatcacttga	actcaggagg	57540
tagaggttgc	agtgagccga	gattgcacca	ctgcactcca	gcctgggcca	cagagtgaga	57600
ttctgtctca	taaataaata	aataaataaa	taaataaaat	acataataaa	agtgggcaaa	57660
gaacataaac	acttctcaaa	agaagacata	catgcagcca	acaattatat	gaaaaaagggt	57720
caatatcact	gattattaga	gaaatgcaaa	tcaaaaccac	aatgagatgc	catcttacac	57780
cagtcagaat	gactattatt	aaaaagtaaa	aaaataacag	atgctggtga	ggttgcaaaa	57840
aaaaaggaac	attttttatac	tgtttagtggg	agtgtaaact	cgttcagcca	ctgtggaaag	57900
cagtatggca	attcctcaaa	gagctaaaag	cagaactacc	atgtgatcca	acaatcccag	57960
tactaggtat	ataccacag	aattataaat	cattctacca	taaagataca	ttcatgtgac	58020
tgttcatttt	ggtactattc	acaatagcaa	aggcatggaa	tcaacttaaa	tgcccataca	58080
tgacagtttg	gataaagaaa	atgtggtgca	tacacaccat	gtaatactac	atagccataa	58140
agaagaagaa	gatcgtgtct	tttgcaggaa	catggatgga	tctggaggct	attatcttta	58200
acaaactaat	gctgaagcag	aaaaccaagt	accgtatggt	cttattttata	agtgggagct	58260
aaatgattag	aacttacaaa	cacaaagaag	gaaacaacag	acactgggggt	cttcttgagg	58320
ggggagggtg	ggaggaggga	taggagcaga	aaagataatt	atgggtacaa	ggcttaatac	58380
tctggtgatg	aaataatctg	tgcaacaaac	tcccatacaca	catggtcacc	tatgtaacaa	58440
accttcacat	gtatcccaa	aactaaaata	aaagtttttt	tttttaaagg	aaaactgttg	58500
ggtactatgc	tcactactcg	ggtgatggga	tcatttgtat	accaaataatc	agtgcatttc	58560
aatttaccta	tgtaacaaac	ttgcacatat	acccctgaaa	ctaaaaatag	aaaaaattat	58620
taaaaatacaa	caaaaaagaa	aaaagatgaa	aaagagatat	ctataatcat	ttgcacattt	58680
caatcagatt	tttaaaaatt	tattttatttt	gaaattgagt	tgttcaaatt	tcctatgtaa	58740
cctgaatatt	agtcccttgt	cagatgaatg	atgtgtaaat	attttctccc	attgtgtagg	58800
ttgtcttttc	actctataga	ttacttcttt	tgctgtgcag	agatttcttt	tgtttgatga	58860
aatcctgttt	atctatattt	ggttttgttg	cctgtgcttt	agaggcctta	tccaaaaact	58920
ctttacctag	accaatgtct	aaaagtattt	tcccagagtt	ttcttctagt	agatttatag	58980
tttcagggtca	tacatttgtc	tttaaaacat	tttgattaga	tttttgata	gtagtctatg	59040
atagtctttt	atatgtctga	ggaattgatt	gtaattgtcac	ctttgtcatt	tctgatcgtg	59100
ctgatttggga	tcttctttct	tattttcttt	gttaatctag	ctagcagttc	atccattttg	59160
tgtatccttt	caaataaact	tttggtttta	ttgggtttttg	gatgtatttt	ggggctctcag	59220
tttcattcag	ttttactctg	atttagtatt	ttattttctt	ttactggctt	tggagttagt	59280
ttgttgtttt	atagttcctc	taggtgagat	gttagatcat	taatttgaga	actttctaac	59340
tttttgaggg	aagtgttttag	cgctgtacac	tttcccttta	acactgattt	tgctgcattcc	59400
cagagatttc	ggtaaagtgt	gtctctgttt	ttattttattt	caaataatata	ttttgttaat	59460
ttctggttta	gttgtttgccc	caaaagtcac	tcagtagcaa	attgtttaat	tccataataa	59520
ttttgtgggt	ttgagagatc	ttgggtattga	tttttatttt	tattccaagt	ttctccaaga	59580
gggagtttga	catgatttta	tttcttaatt	gattgacact	ggctttatgg	cctagtatgt	59640
gatcaacctt	ccagtatgtt	ccagggtgcag	aggacaagaa	cgtatattct	gtggttatgg	59700
gtggagtact	ccgcagatgt	ctattagggtc	caattaatca	agtgtcaaat	ttaagtccag	59760
aattttattag	ttttcagacc	ttgatgacct	aaggctgtaa	ttgggggtgtt	gaattccctt	59820
actgctattg	tgtggctttt	taggtctttt	tgtcagttca	gaagtacttg	ttttatgaat	59880
ttgggtgctc	caatgtgggg	tgtgtatatg	tgtaggatag	ttaagtcttc	ttgtttaatt	59940
gaaccctatg	tcattaggca	gtgccctttt	tgtcattttt	tccagttttt	ggtttacagc	60000
ttcttttatc	tgacataaca	atagcaaccc	ctgctgtctt	ttatttttca	tttgtctagt	60060

agattatTTTT	tcatacctTTTT	acttttgagcc	tatgtgagat	agatctcttTg	aaaattgCag	60120
atggatggat	cttattttttt	atctaactTg	ctactctagt	atatgcctgt	ctttataggT	60180
aaatttcttTg	aagacagcac	atacttgagt	attgattttt	gtttgtttgt	ttttcttttTg	60240
ttttactttt	ttttccattg	agcagtcact	cagcgtcttt	taattgtaga	attttTgtcta	60300
ttaacattga	agagtattat	tgtaggtaa	gagtttacta	ctgccatttt	gttatttctt	60360
tgcttggtgt	tttctaaatc	ctttatttct	tgtgttctat	cttactgtat	tactctgtag	60420
ttaaagtaatt	ttcttttagaa	gtatgttttTg	attccatgct	atgtttttgt	gtatctgtca	60480
taggtttttTg	ttttgtgggt	accgtgaggt	ttacaaaaa	aatctatagt	ataacagttc	60540
gttttgaaca	gataatgact	taattttTgat	tgcaataaaa	agcatcaaaa	accaactcta	60600
cacttttaatt	atgccctaca	cacattttga	cttttgggtg	ttcaatgtac	atgtttttat	60660
attgcctact	tctaaactgt	agttattgat	ggtttttaata	gttttTgtatt	ttattcttca	60720
tacttatgat	acaagtgggt	tatttaccac	aattatagta	tgacagtatt	ctgatttttga	60780
atgttctttt	acgaggggaat	tttatacatt	ccaatgtttt	cctgtttacat	gttagtacc	60840
atttcttttca	gactgaagaa	ctctcttttag	catttcttga	aaaacaggTc	tggtgttgat	60900
gaatttctct	agcttttTgt	tttctgcgaa	aaaaaaatct	ttatttccac	ttcatgttctg	60960
agaataaact	ttaatgcaca	taatatctct	ccttgaaaga	ttttttctct	tatcatcttTg	61020
agtatagcat	accatttctct	cttgacctgc	tagcttctgt	gagaaatctg	ctgaaagcca	61080
tattcaagct	ctgtattact	ctgttctcac	attgctaacc	aaaattacct	tagcctgagt	61140
agtttataaaa	gtgaagaggT	ttaatTgaca	cacagttcca	caggctgtac	aggaggcatg	61200
gctgggaggc	ttcaggaaaac	ttacaatcat	gatggaaggT	gaaggggaag	caagcacatc	61260
ttcacatggc	gacagaggag	agagggtaaa	ggggaaagtTg	ctacacactt	ttaaacaaaac	61320
agatctcatg	agaactctat	cataagatag	cactagggga	atggtattaa	accattagaa	61380
aacaccccgga	tgatccattc	acctcccacc	aggccccacc	tccaaaactg	ggggattaca	61440
attcaatata	aggcttaggt	gggaacacag	agtcaaacca	tatcattctg	tcccggctccc	61500
tcccaaattt	catgttcttc	tcacatttca	aaacgcaatc	atgtcttccc	aatagttccc	61560
caaagttttta	actcattcca	gcacaaaactt	aaatgtccaa	ttctctcatgt	ccaaatgtcc	61620
aaatgtccaa	aatctcatct	gagacaaggT	ccacaggtaa	gcctgtaaaa	ctaaaaacaa	61680
gttattttatt	tctaagatac	aaggagttga	caggcagtgg	ataaatgctt	ctgttccaaa	61740
aggaagaaat	tggccaaaat	aaaggagcta	catatgccat	gcaagtccaa	aatccgaag	61800
ggcagtcatt	aaatcttaaa	gctccaaaat	aatctctctt	gactccatgt	ttcacatcca	61860
ggccacacta	atgcaagggt	tgctctctca	aggcctgggg	caactccacc	ctcatggctc	61920
tgcaagggtgc	agccctgttg	gctgctttca	caggctgatt	ttgagtgtt	gtggcttttTc	61980
cagatgcatg	gcacaagctg	tgagtggagc	taccattctg	gtttctgaaa	gatagtgtcc	62040
cttttctttac	agatccatta	cgcaggaccc	agtgggaact	cgggtgtgggg	gctccaaacc	62100
cacatttttcc	ctctgcattg	cactagtaga	ggctctctgt	gaggattctg	cccctgcagc	62160
agactctctgc	ctggatatcc	aggcatttgc	atacaacctc	taaaacttag	gcaaaagtTc	62220
ccaagcctta	attcatgtct	tctgcacacc	cacaggccag	acactatgtg	gaacttgcca	62280
aagcttgggg	cttgcaacct	ctgaagcaat	ggcccaagct	gtaccttggt	acttttttagt	62340
cctgactgga	gttgaggtgg	ctaggacgca	ggTcatcatg	ttctgaggct	acacagagca	62400
ctgcagacct	gggtctggcc	cccagacatca	ttttttctcta	tttgccctct	gagcctgtga	62460
tgggagtggc	tgtaataaag	gtctctgaaa	tttcttggag	gcattttccc	cactgtcttTg	62520
gctattaaca	tgtagctcct	ctttattttat	gcaaacttct	gcagccttga	attcctccct	62580
ataaaatggg	tttttctttt	ctaccacatg	ttcaggctgc	aaatttttca	aactttcatg	62640
ctctgctttc	cttttaata	taaattccaa	tttcagacca	tctctttgaa	aatagagaag	62700
aagccaggct	aattcttgaa	tgctttgtg	cttagaaatt	tcttccacca	gatacctgaa	62760
ttcatctctc	tcaaattcaa	agttccacag	ctctctagag	caggggcaca	atgccaccag	62820
tctctttgtt	aaagcatagc	aagagttacc	tttactccac	ttcctaataa	gttctacatc	62880
tccatctgag	accacctcag	cctggacttc	actctccata	ttactattag	tattttgttc	62940
accaccactc	aacaagtctc	taggaagtTc	caaactttct	cctcttctctg	tcttcttctg	63000
agccctccaa	actgttccaa	cctctgcttTg	ttacccaatt	acaaagtcca	ttccacattt	63060
ttgggtatct	ataggaatgc	cccacttctc	tggtaccaat	tttatgtatt	agtccattct	63120
cacatcactg	taaagaacta	actgagattg	agtaattttat	gaagaaaaga	ggtttaatcg	63180
attcacggtt	ccttaggctg	tataggtagc	atggttgaga	aggcctcaga	aaactaacia	63240
tcatggtgga	agggcaagg	gaaaacaagc	acatggcaag	aggagaaaaa	cagagcgaag	63300
ggggaagtgc	tacacactTt	taaataacag	atattgtgag	aactctaaca	caaggcaaca	63360
ctaggggaat	ggtgctaatac	cattagaaat	cacccccatg	atccaatcac	ttcccaccag	63420
gtcccacctc	cagcagtagg	agacggcaaa	tttagatgaa	atttggggtgg	agacacagag	63480
ccaaaccata	tcagtctcca	ttaaatgtga	tatttttctc	ttgctgattt	gaatattatt	63540
tctttgtctt	tgatttttcc	taatttgatt	acagtgtaac	ctgagatatt	actgtttgta	63600
ttgaatttga	ttggtgagca	atggTctttt	ctacctagat	gctattgtgt	ttctccagaa	63660
ctgagaaatt	ttcagttatt	atttcaataa	gtatagtttTc	taggcctttt	tatctctcat	63720
tccatttTgga	tatttcaatt	atgcaaaagt	taatgtactt	gattgtgtcc	cataattttc	63780
ataggcctgc	tttacttttt	tttttttTcag	ctcctctgag	aagttagttt	caaagtgtct	63840

atcttcaagc	ttactgattc	tttctctctgt	catcaaaact	atggggcacgg	tggctcacgc	63900
ctataatccc	agcacttttg	gagggccgaga	aggggtggatc	atctgagggtc	aggagtttga	63960
gaccagtctg	gccaacatgg	tgaaaccccc	tctctactaa	aaaaatacaa	agaattagct	64020
gtttgtgatg	atgggcacct	gtaatcccag	ctacttgtga	ggctgaggca	ggagaatccc	64080
ttgaacccgg	ggggcagagt	ttgcagttag	ccaagatcgt	gccatcgcag	tctagcctgg	64140
gcaacaagag	cgaaactctg	tctcaaaaaa	agaaaaagga	tagaggaggt	tgggaagagg	64200
gaggcagggg	gtcagcgtca	tagcaatggg	tgagaaagat	gaaagatgtg	tggccattgc	64260
tggcttttga	ggtagaatgc	gggcagcctc	caaaacctgg	aaaaagcaag	aaagtagatt	64320
ttccctgaga	acctccaaaa	agaaagcagt	cctgccgaca	ccttgattct	agcccagtaa	64380
gaagcatttt	gggcttttga	catccagaaa	tgcaagacaa	aatttgtgtt	gttttaaggg	64440
attaaatctg	tgatagttta	ttatggcagc	aacagaaaaa	gaatatacct	gtcaaaaactg	64500
ggttcccatc	ttcaaaggct	tccctctctg	ttgccgtcca	gtccacagct	ccacttgcag	64560
gtgcagtaca	gttggttttc	gagcaggggt	tggattgaaa	attcagcatg	taaggaagaa	64620
gtctaaagtc	cagacgaacc	ttgaacaccc	cttaattgcc	cctcccgtcg	agagcagggg	64680
ccaggatcca	ctgagtgtag	agcagagcaa	cattcctcaa	gggtgtcctca	cccccaggca	64740
ccctcccaca	gggctcaacc	agctaacctc	tttccaccct	ttgaattgtc	tctctctccc	64800
ttcaggcata	taattaaatt	tgcataaatt	caaagagcat	atgctgcaat	cccattgtaa	64860
tttcagattt	gttttttatt	cctgagtttt	ctaaggaaat	aataaaaaac	aaacctcctt	64920
aaaaaaaaaa	aagattttcta	atgagttttt	aagttcagtt	tttgtattct	ttatttctgg	64980
gattaatatt	tttaaacttt	gttttttatt	ctctttccaa	tttcttattt	tcttcttgaa	65040
ttattttcct	tttttttttag	ttttctgttt	tcttataatt	tcttttttta	acatttttct	65100
ttcttttaaa	atttttttta	attccttatt	tcttcagaga	tctttgttct	gacctgtaat	65160
ttcttgaact	tctttaagag	gcttatgctg	aattcattgt	cagacattta	atagatcttt	65220
aattgttcag	gggtccattgt	tgagcctctg	ttgatttctt	ttgggtgggt	catatttccc	65280
ttggttttta	taatcttcgc	atattttatgt	cgatgcctgt	gcatttgaag	agagagacac	65340
ttccagtttt	cgcaggtgtt	ctttgttggg	cttagatctt	tagttcttag	tattcttttt	65400
ttttttttta	agacagagtc	ttgctctgtt	acctatgaat	gcagtgggtg	gatcttgggt	65460
tactgcagcc	tctggctccc	aggttcttcc	agcgattctc	ctgcctcagc	ctcccaagta	65520
gctgggatta	cgggcataca	gcactacgcc	tggctaattt	ttgtattttt	agtagagtag	65580
aggttttacc	atgggtggcca	ggctgggtct	gaactcctgg	cctcaggtga	tccacccgcc	65640
ttggccaccc	aaagtgtctg	gattacaggt	gtgagccact	gtgcctggcc	agtatttact	65700
cttaaatgtt	gacttgttgt	tgcttctgct	ggggtaggct	tatagtgaac	actgcaacta	65760
aattttctct	ctgtcattgt	ttcctagtgt	ggggaagtct	tattttgtgc	actgaagctt	65820
aaatactgtg	ttgggactat	attgctgtgc	tgtcattgtt	tccaattccg	gaaagttatt	65880
aatcccagtc	ttttaattgt	tttggggcca	ggctggggga	ggcttcatga	aagaaccttg	65940
ggtttgttga	aaatccggct	aagaattctt	gctgtactgc	caactgtgct	tctgtatttt	66000
ctatgacact	aatcggctctg	ttaaatgtgg	catctctact	aattacagtg	ctgagtagcc	66060
accaggctcc	atgcactcag	tactgcattc	agtgtcctat	tctttgttct	cagttcacct	66120
cagatgattc	aattctccta	gcactcccaa	aggtttttat	gagagaggac	cagagtggat	66180
tactgatgaa	gattcctaag	ctggagggga	gactgaacat	ccaattccat	ttccccctt	66240
cctccttagc	agacataggt	ctagggaat	tctttgtgag	tggcattata	ctagcttggg	66300
aaagggggta	gtgcaaccgg	aaatgaccgt	ttcttttaca	ctccacaact	ttccttgatt	66360
ctgcacttct	cctctgagtt	ctgttgtatt	tacaatggag	ctcccatott	tgaatagctt	66420
ctagttttat	ttttatgggg	acagtgtatg	taggggattt	tctattccat	catctttctt	66480
ctttctgact	ttaccctcca	aaagtgtaat	cctcaaaatt	tcaagatttt	tttttgtatg	66540
ccttccatgg	agctcataca	acaaacaatg	atacatttga	aattatgaca	atagactga	66600
agcataatta	gttttccta	cccagagtcc	tttaattaaa	cacaagaggg	atgattccag	66660
aagtaacact	catcactgct	attccttagt	ccctctgaga	tttgctttta	gagcaggtct	66720
ccacctctca	catcttgcta	taaatatgac	tgcattttaa	agcttagaga	agcacctaaa	66780
aaccttttta	atcaaataatc	aaggaaatga	gtatatatca	gaaccagaat	taagtcttgg	66840
cattttttatg	ttctttattt	ttgggttaaag	gggaaatata	ttaatgtatt	aactgaatct	66900
cacaaaatgt	ttgcattttt	attattaaaa	atcatttttt	tcttttactt	tgcatatcat	66960
tggggggcat	gaatcagttt	ctcctctgaa	aaattctcag	tgcttctctt	cagaggctgt	67020
gagcaaagaa	gtaggaaagg	aggtagtcta	tgaaaagtgt	taactccatt	tgtaaacaata	67080
ctcattacat	gcttaactata	tgcaaatcat	tttcttaagc	acttttaagt	agtaaacat	67140
attattcctc	ctaaaaactc	catttctcat	tttatagctg	ggaacactaa	cgtaaagacag	67200
tttagataat	ttgacactgt	gggtgtgtgt	cgatttgtta	ctgatgaagc	tagaatcaaa	67260
atcactaatg	gggattagat	tcataaaatt	gttacttttt	gaataactaaa	atattttactc	67320
agacatttcag	tatattagag	tagggccagt	atcatgtaat	ctaattttatt	ttgcaaaaat	67380
tgcaaatgag	cgagatatta	accaagttca	attagaaagt	tagttgggtg	cagagctgag	67440
cataggttcc	agagccaccc	agaacttttg	tttgcttggg	agaatctctg	agcacacttg	67500
gatagcttag	ggaattgctg	cttttgggta	tcactgggtca	tttgcactctg	atcataggta	67560
ctagactgct	gacaagttgg	ccattagtgg	acaggtatat	tgagagttga	tttaagtgtt	67620

gcatctgtca	aggttaaacac	gaaacattct	gttggccctg	agtctcacat	ttcaatctag	67680
aatccatctg	tgtactttac	tttccttgca	aataaatgat	ctagtgaatt	tatatatttt	67740
ttccacttag	ctcctagcac	acatcatttg	tattttcaatc	atttattttt	cttcaccata	67800
ttagaacatt	tccaatacca	ttaaagaaga	aggaaggcaa	tgaaaaggag	acggagatag	67860
cctcatacat	tctcctttcg	ctgaaagtaa	tatcattttg	aaaacagact	acgggtccca	67920
tcttcttcct	ctctagtttc	caacagcata	aagctttgta	tgtctctgag	gacaagatag	67980
aaaactacat	tagcaaatat	tttcctttgc	atctccttat	ttcaagtaaa	tgagggactt	68040
atattttcaa	atatttttaag	tcaccttgaa	ggttgcttct	taaaaataa	ctgtttatta	68100
tgcttctact	cttcattttta	aaaattttgc	ttgtttccac	ctttacaaac	aaaaatggac	68160
aaaaatcgat	tttatctctgc	agtcctctag	gacaaattta	actttggggg	actctgtttc	68220
ctaaaaatgc	atatatgtaa	tcttctattt	ctagtagcag	agtttgaact	caattaattt	68280
ccctaacaac	agactcacta	aaattcgctg	tgatattttt	caaatagtat	tttatggaat	68340
tatcactgat	gaaataaaaa	acaaaacaag	aaagacaggg	gaggagccaa	gatggccgaa	68400
taggaagagc	tcgggtctac	agctcccagc	gtgagcaaca	cagaagacag	gtgattttctg	68460
catttccatc	tgaggtactg	ggttcttctc	actagggagt	gccagacagt	gggcacaggt	68520
cagtgggtgc	gcacaccctg	cgcgagcgga	agcagggcga	ggcattgcct	cactcaggaa	68580
gcgcaagggg	tcagggagtt	cccttttcta	gtcaaagaaa	gggggtgacag	atggcacctg	68640
gaaaatcagg	tcactcccac	cccaatactg	cactttttctg	acgggattaa	aaaacggcgt	68700
gccagattat	atcccacacc	tggtctggag	ggctctacac	ccacggagtc	tcactgattg	68760
ctagcacagc	agtcctgagat	caaactgcaa	ggctggcagcg	aggctagggg	aggggcgccc	68820
gccattgccc	aggcttgctt	aggtaaacaa	agcagccctg	aagctggaac	tggttgaggc	68880
ccaccacagc	tcaaggaggc	ctgcctgcct	ctgtaggctc	cacctctggg	ggcagggcac	68940
agacaaacaa	aaagacagca	gtaacctctg	cagacttaaa	tgctcctgtc	tgacagcttt	69000
gaagagagca	atgggttctcc	cagcacacag	ctggagatct	gcctcctcaa	gtgggtccct	69060
gaccctgac	ccctgagcag	cctaactggg	aggcaacccc	cagcgggggc	agactgacac	69120
ctcacacggc	cgggtactcc	aacagacctg	cagctgaggg	tcctgtctgt	tagaaggaaa	69180
actaacaac	agaaaggaca	tccacaccga	aaacccatct	gtacatcacc	atcatcaaa	69240
accaaagta	gataaaacca	caaagatagg	gaaaaaacag	agcagaaaaa	ctggaacccc	69300
taaaaagcag	agcgcctctc	ctcctccaaa	ggaacgcaat	tcctcaccag	caatggaaca	69360
aagctggacg	gagaatgact	ttgacgagct	gagagaaggc	ttcagacgat	caaaactactc	69420
caagctacgg	gaggacattc	aaaccaaaag	taaagaactt	gaaaactttg	aaaaaaattt	69480
agaagaatgt	ataactagaa	taaccaatag	agagaagtgc	ttaaaggagc	tgatggagct	69540
gaaaaccaag	ctcgagaact	acatgaagaa	tgcagaagcc	tcaggagccg	atgcatcaa	69600
ctggaagaaa	gggtatcagc	aattggaagat	gaattgaatg	aatgaagtg	agaagggaag	69660
tttagagaaa	aaagaataaa	aagaaatgag	caaagcctcc	aagaaatatg	ggactatgtg	69720
aaaagaccaa	atctacgtct	gattgggtga	cctgaaagtg	atggggagaa	tggaaccaag	69780
ttggaataca	ctctgcagga	tattatccaa	gagaacttcc	ccaatctagc	aaggcaggcc	69840
aacatccaga	ctcaggaaat	acagagaacg	ccacaaagac	actcctccag	aagagcaact	69900
ccaagacaca	taattgtcag	attcaccaaa	gttgaaatga	aggaaaaaat	gttaagggca	69960
gccagagaga	aaggctcgggt	taccctcaaa	gggaagccca	tcagactaac	agcggatctc	70020
tcggcagaaa	ctctacaagc	cagaagatag	tgggggccaa	cattcaacat	tcttaaagaa	70080
aagaattttc	aaccacagaat	ttcatatcca	gccaaactaa	gcttcataag	tgaaggagaa	70140
ataaaaatact	ttacagacaa	gcaaattgctg	agagattttg	tcaccaccag	gcctgcctta	70200
aaagagctcc	tgaagggaagc	gctaaacatg	gaaaggaaca	accggtacca	gccactgaaa	70260
aatcatacca	aaatgtaaag	accatcgaga	ctaggaagaa	actgcatcaa	ctgacagca	70320
aaataaccag	ctaactcat	aatgacagga	tcaaattcac	acataacaat	attgaacttta	70380
aaagtaaatg	gactaaacac	tccaattaaa	agacacagac	tggaatttg	gataccaaga	70440
gtcaagacc	atcagtgtgc	tgtattcagg	agacctctct	cacgtgcaga	gacacacata	70500
ggctcaaaat	aaaaggatgg	aggaagatct	accaagcaaa	tggaatacaa	aaaaaggcag	70560
gggttgcaat	cctagtctct	gataaaacag	acttttaaac	aacaaagatc	aaaagagaca	70620
aagaaggcca	ttacataatg	gtaaagggat	caattcaaca	agaagagcta	actatcctaa	70680
atatatatgc	acccaataca	ggagcaccga	gattcataaa	gcaagtccctg	agtgcactac	70740
aaagagactt	agactcccac	acattaataa	tgaggagactt	taacaaacac	cccactgtca	70800
acattagaca	gatcaacgag	acagaaagtc	aacaaggata	cccaggaatt	gaactcagct	70860
ctgcaccaag	cgtacctaata	agacatctac	agaactctcc	accccaaatc	aacagaatat	70920
atattttttt	cagcaccaca	ccacacctac	tccaaaactg	accacatact	tggaagttaa	70980
cctctactca	gcaaatgtaa	aagaacagaa	attataacaa	actatctctc	agaccacagt	71040
gcaatcaaac	tagaactcag	gattaagaat	ctaactcaaa	accactcaac	tatgtagaaa	71100
ctgaacaacc	tgctcctgaa	tgactgctgg	gtacataacg	aaatgaaggc	agaaataaag	71160
atgttctttg	aaaccaacga	gaacaaagac	acaacatacc	agaatctctg	ggacacattc	71220
aaagcagtg	gtagagggaa	atztatagca	ctaaatgcct	acaagagaaa	gcaggaaaga	71280
tccaaaattg	acaccctaac	atcacaaat	aaagaactag	aaaagcaaga	gcaaacacat	71340
tcaaaagcta	gcagaaggca	agaaataact	aaaatcagag	cagaactgaa	ggaaatagag	71400

acacaaaaaa	cccttcaaaa	aattaatgaa	tccaggagct	gtttttttga	aaagatcaac	71460
aaaattgata	aaccagtagc	aagactaata	aagaaaataa	gagagaagaa	tcaaataaggc	71520
gtgataaaaa	atgataaagg	ggatatcacc	accgatccca	cagaaataca	aactaccatc	71580
agagaatact	acaaacacct	ctatgcaaat	agactagaaa	atctagaaga	aatggataaa	71640
ttcctggaca	catacactct	cccaaactaa	accaggaaga	agttgaatct	ctgactagac	71700
caataacagg	atctgaaatt	gtggcaataa	tcaatagctt	accaaccaaa	aagagtccag	71760
gaccagatgg	attcacagcc	gaattctacc	agaggatcaa	ggaggagctg	gtaccattcc	71820
ttctgaaact	attccaacca	atagaaaaag	agggaaatcct	ccctaactca	ttttatgagg	71880
tcagcatcat	cctgatacca	aagccgggca	gagacacaac	caaaaaagga	attttagacc	71940
aatatccctg	atgaacattg	atgcaaaaat	cctcagtaaa	atactggcaa	accgaatcca	72000
gcagcacatc	aaaaagcttg	tccaccatga	tcaagtgggc	ttcatccctg	ggatgcaagg	72060
ctgggtcaat	atatgcaaat	caataaatgt	aatccagcat	ataaacagaa	ccaaagacaa	72120
aaaccacatg	attatctcaa	tagatgcaga	aaaggccttt	gacaaaattc	aacaacactt	72180
catgctaaaa	actctcaata	aattaggtat	tgatgggacg	tattttcaaaa	taataagagc	72240
tatctatgac	aaaccacacg	ccaatatcat	actgaatggg	caaaaactgg	aagcattccc	72300
tttgaaatct	ggcacaagac	agggatgtcc	tctctcacca	ctcctattca	acatagtgtt	72360
ggaagtcttg	gccagggcaa	ttaggcagga	gaaggaaata	aatgggtattc	aattaggaaa	72420
agaggaagtc	aaattgtccc	tgtttgcaga	cgacatgatt	gtatatctag	aaaaccccat	72480
catctcagcc	ccaaatctcc	ttaagctgat	aagcaacttc	agcaaagtct	caggatacaa	72540
aatcaatgta	caaaatcaca	agtattctta	tacaccaaca	acagacaaac	agagagccaa	72600
atcatgagtg	aactcccatt	cacaattgct	tcaaagagaa	taaaatacct	aggaatccaa	72660
cttacaaggg	acgtgaagga	cctcttcaag	gagaactaca	aaccactgct	caatgaaata	72720
aaagaggata	caaaccaatg	gaagaacatt	ccatgctcat	gggtaggaag	aatcaatatc	72780
gtgaaaatgg	ccatactgcc	caaggtaatt	tacagattca	atgccatccc	catcaagcta	72840
ccaatgactt	tcttcacaga	attgcaaaaa	actactttta	agttcatata	gaacccaaaa	72900
agagcccgca	tcgccaagtc	aatcctaagc	caaaaagaaca	aagctggagg	catcatggta	72960
cctgacttca	atctatacta	caaggctaca	gtaacccaaa	cagcatggta	ctggtagcaa	73020
aacagagata	tagatgaatg	gaacagaaca	gagccctcag	aaatatcgcc	gcatactctac	73080
aactatctga	tctttgacaa	acctgaggaa	aacaagcaat	ggggaaagga	ttccctatttt	73140
aataaatggt	gcagggaaaa	ctggctagcc	atatgtagaa	agctgaaact	ggatcccttc	73200
cttacacctt	atacaaaaat	caattcaaga	tggattaaag	acttaaactgt	tagacctaaa	73260
accataaaaa	ctctagaaga	aaacctaggc	tttacctttc	aggacatagg	catgggcaag	73320
gacttttatgt	ctaaaacacc	aaaagcaatg	gcaacaaaaag	ccaaaattga	caaatgggat	73380
ctagttaaac	taaagagctt	ctgcacagca	aaagaaacta	ccatcagagt	gaacaggcaa	73440
cctacaaaaat	gggagaaaaat	tttcacaacc	tactcatctg	acaaagggct	aatatccaga	73500
atctacaatg	aacttaaaaca	aatgtacaag	aaaatcaaac	aaccccatca	aaaagtgggc	73560
gaaggacatg	aacagacact	tctcaaaaaga	agacattttat	gcagccaaaa	aacacatgaa	73620
aaaatgctca	ccatcactgg	ccatcagaga	aatgcaaatc	aaaaccacaa	tgagatacca	73680
tctcacacca	gttagaatgg	caatcattaa	aaagtcagga	aaaaacaggt	gctggagagg	73740
atgtggagaa	ataggaacac	ttttacactg	ttgggtgggac	tgtaaactag	ttcaaccatt	73800
gtggaagtca	gtgtggtgat	tcctcaggga	tctagaacta	gaaataccat	ttgacccagc	73860
catcccatta	ctgggtatat	acccaaagga	ctataaatca	tgctgctata	aagacacatg	73920
cacaagtatg	tttattgtgg	cattattcac	aatagcaaag	acttgggaacc	aacccaaaatg	73980
tccaacaatg	ttagactgga	ttcagaaaaat	gtggcacata	tacaccatgg	aatactatgc	74040
agccataaaa	atgatgagtt	catgtccttt	gtagggacat	ggatgaaatt	ggaaatcatc	74100
attctcagta	aactatcgca	agaacaaaaa	accaaactct	gcataccctc	actcataggt	74160
gggaattgaa	caatgagaac	actggacaca	ggaaggggaa	catcacactc	tggggagtggt	74220
tgtgggggtg	gggagggggg	agggatagca	ttgggagata	aacctaatgc	tagatgacga	74280
gttagtgggt	gcagcacacc	agcatggcac	atgtatacat	atgttacaaa	cctgcattgt	74340
gtgcacatgt	accctaaaac	ttaaagtata	ataataataa	agaaatgggt	cttctctacc	74400
caagaacaca	cacacacaca	cacacaaaaa	aaaaaaaaaa	aaaacaagaa	agacaaacag	74460
tatgctcatc	acacacaaat	gcaaggatcat	ttttaggcat	tagatggggc	ttaattttaat	74520
ctaagttttt	catgtacttt	gtatctttcta	acctgcatac	ctctattttcc	tcttctagcc	74580
ctctacctct	ggtaaccact	gttttatattt	tatcactgta	tattttaattt	tttaaatatt	74640
cccatataaa	gtgagatcat	tcagtattttg	tctttctgtg	tctgggtttat	ttcaacttaga	74700
ataatgtcct	ccaggcttgt	acgtgttgtta	tcaataaaca	cgatcttcct	tttcagggat	74760
gaataatatt	ctattgtaaa	tatataccac	catttcttta	tctattttgtc	cttcatgagg	74820
cacttggggt	gtttcaatac	cttagctgtg	atgaataata	ctgcaaaaac	atggaagtac	74880
agatgcttta	agaggtgggtg	aattcacagg	ataaacaagt	ctagagatct	aatgaacaac	74940
atgaggacta	ggggtaataa	aattataccg	tatttgggat	tcgtgctaaa	tgaatatatc	75000
ttagctgatc	ttgcacacag	acacacaaaa	agggttaacta	tatgttaattg	tttgtgttaa	75060
tttgctttac	tatagtaaga	ttttactcta	tgtatcacat	gacattatgt	tgtgaacctt	75120
aaatagatgc	attaaaaattt	atttttttaa	agggttcatt	aactgcgggt	caggcaatct	75180

ataaaccttt	tacatttttg	aggtgagatt	ttcagtatct	gcatttatct	tggattttca	75240
aggggttcat	ttgaacaagc	aaacaaacga	agaaacaagc	ttaagaatct	ttcttacaat	75300
gaattcttcc	taagtagttt	tcttgactgg	tttcttttct	tttctgaaa	cagtcttttc	75360
ttattcactt	gtgattgaat	agcctacaaa	attgatctag	acaattaggc	tcttgaaatt	75420
gattacggcc	tagtgcattc	tcacctggaa	taaaagcctt	cctttggagc	atcttctatt	75480
ttttaattgt	tgagagttgg	ggactttcct	tctcattctg	tattttcagt	gtcagttttt	75540
atggcttgtg	tgttccaggt	atggttgggt	catggtcag	cagtctattc	acaaggcctt	75600
gtgcttagaa	gaccatccca	agcttgggtt	aatgctttga	tctcatgggc	ctgaaatttt	75660
acataatttt	tttgtacaag	gattcttgca	gttttatttc	gtattgaaat	aggagagttt	75720
ccttatcctt	ctcgcattgg	aagtgcagag	agtgtggctt	gcttctttgg	tgccccactg	75780
ctcaaatccc	taggggtgga	atgcagacag	tcagggtgtac	aggtcgtggg	agtgtttttg	75840
ggctccaacc	ccacagcagc	gtctagggtt	aagtgtttac	agctcctgaa	gccccaatgg	75900
gtgtgtgtta	cagtgtgatc	tttcagcttt	gctgtcttca	ggcggcttgc	attaatcagc	75960
tcagttagac	cctctgcatt	accacaaggg	cagcaggctt	tctgtattcc	aagttcttgc	76020
ccagtgtatc	ggaaaaattg	gatcacatgt	ggacatggag	gatgagtga	aggtttttatt	76080
gagtgggtgga	ggtggatctc	aatgagatgg	atggggagcc	agaaagggga	cggagtggga	76140
aattgggtctt	cccctggagt	cgggcagctc	atttgccgat	gatgctctga	ccacccccag	76200
acgaactccc	ctcgggtgtc	gcctcgttcc	accatcactg	gtctgctggc	atctgctggt	76260
gtctgctggt	gtcctcctct	gctcctgtca	acatccagcc	acttgtgtcc	atgccacta	76320
aggcctcggg	tttttttggg	cacaggatgg	ggcctgtggg	gggccagagt	ggtcttggaa	76380
aatgcaacat	ttgggtgcaa	aaacaggaga	gcctgttctc	acttaggtcc	ttgggcaaag	76440
gtctgtgggt	ggagccctca	ccagggaccc	cacccttctc	tacacatcac	ttcccaaccc	76500
tgctcctgta	tcaatattgg	attctgtata	ctatgtatct	gaggtccag	ttctaggttt	76560
tacaacttgt	aactttttcc	tatccttgac	ctactcctct	gctcgttctt	cctctatcat	76620
gcagaacctt	cccaacatac	tgacctagca	agcccagggt	ttccttattc	aagaggtggt	76680
caccttttat	tctgtcctga	cacagggttg	agacctactg	tggttttcct	tctttgtaca	76740
cacatcttag	ctgtagtctt	tttacctctc	tccacttatg	agcccttctt	ctctactgca	76800
attgtgtatt	cttggatccc	ataaaagcca	atgagcctct	cagtcaaaac	tgtttcagat	76860
ctcacaggca	gttattaagc	cacatgcaac	aaataagtta	ttctgcaaat	gaactcctct	76920
agtccaattt	cctactgtgt	ctttttmaat	ctgaaattcc	cacatcctga	tatattttct	76980
ctcatttttc	tttttgaac	cactgaaact	gtactctggg	gaaggccact	gatactcttg	77040
ataggaactt	gaaatgagta	acacttaacg	tgagaaagat	ttgaagtga	taagagtaaa	77100
gtgaaatata	tgtagttag	ggagcttagc	tggattttct	gcactttgca	ttaagtgtgt	77160
gtgtgtgtgt	gtttgtgtgt	gcacatacac	acacaaattt	cactcagtga	tagttttccaa	77220
agaaccatta	catctggtat	ccttgtattt	gctcgttatc	cttctgtaga	cccaggaatt	77280
ctgagacagg	tctcagttag	tttagaaagt	ttattttgcc	aagggtgagg	acacacctgt	77340
gacacagctt	ccagaggctc	tgaggacatg	tgttgaagg	ggtcatggta	cagcttgctt	77400
ttatacattt	tagagagaca	taatctatca	atcaatacat	gtaagattta	ccttgggttg	77460
gtgcagaaca	actcaaagtc	cagggtgggg	cagggtggcg	tgctgtttcc	aggctgtagg	77520
taaatttaaa	cattttctgg	ttgacaattg	gtttgtctaa	agacctgaga	tcaatagaaa	77580
agtctgtgtt	atgttaatgc	tggagaggaa	taatgaggca	tgtccgaccc	ccatttctct	77640
taaccgcctg	aactagtctt	tcaagttaaa	ttttacaagc	cctggctgag	gaggaagtcc	77700
ctttatttat	ttttggttta	cacttcttat	gatattcctt	ttagaagttt	tcttgcata	77760
gttgttgcca	taaactttac	tttttttttt	tttttggtag	aaccttattc	tgtcgccagg	77820
ctggagtaca	gtggctgac	tccgctcact	gcaacctctc	catcctgggc	ctagcaatt	77880
cttctgcctc	agcctccgaa	gtagctgaga	ttacaggcac	gtgccaccac	acctgactga	77940
tttttgtatt	tttagtagag	atgggggttt	tccgtgttgg	ccaggctggg	cctgaaactcc	78000
tgacctcagg	tgacctacct	gcctcagcct	cccaaagtgc	tcgaactaca	ggcatgagcc	78060
atcctgcctg	gccaaacatt	acttttttaa	tgaggtcttc	cttgactttc	ctttccccaa	78120
aactgtattt	cctttatttt	tctccacaac	agttatttga	atattattta	tttacttgaa	78180
ataatagctc	tctctgtcca	ctagaatggg	aaaacccaaa	aaagcagaaa	tttttgaaag	78240
gtttgttcgc	ttctgcatct	atagtgccca	atcacacaaa	atattgagta	tcagtaaata	78300
cttgtttcat	gaatatctat	tttgatgccc	aaaatgacat	gagaagagga	aagataaata	78360
ttattatttc	tattttacaca	tgggaaaaca	cagtgtattca	ttcagttgca	aagcttttaa	78420
attactgaag	taactctgta	atccagggtc	cctaaccagc	tcctaacatc	aagattatgtc	78480
atagcttcta	cttgatattt	cttagatata	tcacatacag	gtactcaagg	gcacaagtca	78540
gtcacatagt	agaacatgac	taagtgtga	gagaatgtgt	ctggcacaa	cctgtttatc	78600
atgggtgcact	atgtaagaat	gccatgacta	tctgtgtccc	cagaagttcc	ttatcatcat	78660
atatctcaag	gccttccagg	tctatacata	caattttatg	aaacagttta	gcttttagaaa	78720
ggtgatatgt	attgcagcag	cagctaataa	aggaagtttt	taaaatacat	aattttcagt	78780
tcttacctca	gattctcaga	ttgtatgcac	tagtagtgtg	acctcggttc	aattatttaa	78840
ccttttttga	cgttgtcttt	ctcaatagta	acagcaagac	agagttttga	ttataggcat	78900
tctaaaactt	acagtaaaat	aaatgagggtg	actcattttg	agatgagaca	agaattgaga	78960

agcctgtaat	aaaaatttca	agtatgaaag	aatggggcaaa	aattaaaaaac	ttctcgaag	79020
aaaggaaaaat	gtgaattagc	aaagatttctg	atgtgaagag	aggtaaaaaag	ccaaaaggat	79080
ttgtaataacc	tcttggttaga	tacaagttgt	gattaaaaaga	ttaaataaca	actctgaaaa	79140
tattaatttta	ttttcttttct	aaacacatta	agtcatttgc	ctaaacatcc	tcaagatact	79200
atatgaaaat	ttatttttatt	tcacagttct	ttgttctatt	atttggcata	tgttttattga	79260
gccatttctga	ctgtgcattt	tgagctatga	tcttgggaaca	cttgcattag	aatcctacag	79320
ataatcatta	gagatgaaga	ttccagttacc	ccacataaga	atttctgcaa	aaacctgtga	79380
tatgggctaa	taaacaagct	tcccaagaat	tgcttctaca	ctaagtttca	ataatcactt	79440
aattctctctg	agaacatgac	atcacgcaag	gctacatgga	gataaatctg	tgagtaaaaa	79500
ttgcaagctca	ttcatttctta	catgctctcc	tttttgcatt	ttaagaaaaat	ttagtataaa	79560
aatatgtggt	gagaagtata	attaaaaaat	gaacttcaact	ttgtccctgc	tctcaacacc	79620
attatgtgat	gagaaagtat	atactttata	atgatacaat	gggggctaaa	taataaatta	79680
gagaaatata	gaatactctg	gaaataaaga	agagagaatt	cagtgcacacg	tattaggaga	79740
aatggatgag	aatgcttca	caaagaagtg	gcctttaaag	tggtgcatgt	agcatgaata	79800
gaattaggtt	ttaaaaagaa	caggaagata	gaagagatgt	agctcagtca	tatagataga	79860
tagatagata	gatagataga	tagatagata	gatagataga	tagatgatgg	atagatagat	79920
acagggtgtag	gtatagatat	atctataggt	gtagagaaaag	aatatattag	taatgtaatg	79980
cctaggcaaa	tgatataatg	acattgtaga	cttacaaaat	tatagtaagt	ctaccataat	80040
tacaaaaaac	aaagtttatg	gtagtaccca	gaaatagata	actttcgaatg	atatatgaag	80100
atgtggagaa	aaactaattc	aaatgaacat	taacatggta	tggtgcatttg	tttatatttg	80160
ctttattttcc	atagcttgaa	gagcaaactg	tcaggaaaatg	tccaacacaa	atggcagtg	80220
aatcacagaa	ttcattttac	ttgggctcac	agattgccc	gaactccagt	ctctgctttt	80280
tggtgctgtt	ctgggtgtt	acctcgtcac	cctgctaggc	aacctgggca	tgataatgtt	80340
aatgagactg	gactctcgcc	ttcacacgcc	catgtacttc	ttcctcacta	acttagcctt	80400
tggtgatttg	tgctatacat	caaatgcaac	ccgcagatg	tcgactaata	tcgtatctga	80460
gaagaccatt	tcctttgtctg	gttgctttac	acagtgtctac	attttcattg	cccttctact	80520
cactgagttt	tacatgctgg	cagcaatggc	ctatgaccgc	tatgtggcca	tatatgacc	80580
tctgcgtct	agtgtgaaaa	cgtccaggag	agtttgcatt	tgcttggcca	catttcccta	80640
tgctatggc	ttctcagatg	gactcttcca	ggccatcctg	accttccgcc	tgaccttctg	80700
tagatccaat	gtcatcaacc	acttctactg	tgctgaccgc	ccgctcatta	agctttcttg	80760
ttctgatact	tatgtcaaag	agcatgccat	gttcatact	gctggcttca	acctctccag	80820
ctccctcacc	atcgtcttg	tgctctatgc	cttcattctt	gctgccatcc	tccggatcaa	80880
atcagcagag	ggaaggcaca	aggcattctc	cacctgtggt	tcccatatga	tggtgtgcac	80940
cctgttttat	gggactctct	tttgcattga	tataagacca	ccaacagata	agactgttga	81000
ggaatctaaa	ataatagctg	tcttttacac	ctttgtgagt	ccggtactta	atccattgat	81060
ctacagctg	aggaataaag	atgtgaagca	ggccttgaag	aatgtcctga	gatgaaatat	81120
tgcatgacc	atggtgatgc	ctttgtttcc	taataaacat	taaatcgaaa	tctttggctc	81180
acatgtccta	gcgttctgat	ggtgagtttt	aatattctct	gtgagtctat	gttgagtgtc	81240
tcagctaaaa	agctcatgct	gggtaaaaat	gagatttttc	taggctttgc	tcctccacat	81300
atattccatg	aatcagcagc	atgagctctt	ccttgagggt	tggttacacgt	acagaatcaa	81360
agtctgcacc	tcaggtgcac	tgtattttaa	tatgtgtttt	atccaaactc	ctagatgatt	81420
gataagcaca	ctgaattttg	aggagcactg	ctgtgggtga	aacgtggcat	gccctggaac	81480
actgttgtgc	tctttttgtt	tacaacggca	aacaaaataa	atgtgtctcc	agcccaattt	81540
cttgaatgta	ttctattctt	attctcgctc	gctgtctcag	cagagatgtc	tttaagaaac	81600
ccattcttct	gcactccaag	aaatccattc	ttctgtactc	cttctcgtac	ttgtctgtgt	81660
agaccagaaa	ctaggggcca	tggtgatggc	ttctgttttt	tataagtgtc	cttcatagat	81720
gaagagtggc	aatggaaaaa	gaggggaaga	gaatgattgt	acttttctta	aaacttgagtt	81780
tatggatcca	gctctctgag	ttacataaac	ccaccttccc	attctgagcc	tccagtgtat	81840
ggaggtcact	ttctgtttcg	cctgattttg	aaaaatttaa	gcaggctgat	ctgagaataa	81900
ggactaaaat	taaaatggga	aatgaaagaa	ccgagtaaac	aataggatcat	acgatagagt	81960
atccaccttg	ctttgaaatat	tccttctatt	tgtaatttaa	tttaggtaag	taatgttaat	82020
tttttgtttt	ccttagcact	ggcctgttta	tatgtgtcca	aggaagtaag	gatttcttcc	82080
acaggaagag	aagacattgc	tctggcatct	tcaagaaact	ttagaaagta	gaaagaattc	82140
ctcttttagac	attatgctaa	aaagaattat	ttaaaggaac	agtaaaaaat	atattttttt	82200
aagatagagt	ttcactctgt	tgcccagggt	ggagaacagt	ggcatgatca	tattaataac	82260
ttcctccaac	tcctaggctc	aagtgaccct	ccgcctgag	cctccctagt	agctgggacc	82320
acaggtgtgt	gctaccacac	tcggctaat	tttaaatttt	ttttagatgc	tgatatctgt	82380
ctatattgcc	caggcaggtc	ttaaactcct	gggtcgaagt	ggctctcctg	cctcagcctc	82440
ccaaagtgtc	gggattatag	gcataaatta	ctgtgcctgg	tcaagattct	tctactctcc	82500
aaactttcta	cttattgcct	caaaaatacta	aatattttct	aatatctttt	attggaaggc	82560
aaattctgcc	attacgccat	tagaaaataa	aaagataaaa	tattttgtgt	atatattaag	82620
ttgtacatta	agtaactgta	tttataaggc	ttctgcattt	tgttcctgtt	gttgtttggg	82680
ttgtgtgtta	gtttttacaag	gaaaaaagag	cccaaagcta	tctaagtcaa	caacggcaat	82740

ttatgacaaa	tatatgggta	tatttcacag	cttctaaaga	caagagtaca	gctgaatctc	82800
ggtaatcaac	caaaatgctg	aactctaagg	ccaagagaaa	ccgtatgtct	cattgtatat	82860
ttcatatcca	tttgttacta	ggatacataa	taattgagct	taattatgac	ccttgcatcc	82920
agcaaccctg	ctcatttgct	ttaattagag	tagaattttt	gtttgtttct	tctataaatt	82980
ctctaaaatt	tacttcattt	catctgcaaa	ttaacagatt	ttattccttt	ccaatattta	83040
tgagttttat	ttatttttcc	ttcatcattg	cagacttaga	ctgatattat	aatgtcaa	83100
agaggtagtg	aaaacaaata	tcaaggcctt	gttcttcatt	tcatttgtgt	tttgtttctt	83160
tgtttgtttt	gagacagagc	cttgctcctg	tcgcccaggt	tggagtgc	tggcacaatc	83220
ttggctcact	gcaacctctg	cctcccgggt	tcaagtgatt	ctccttcttc	agcctcctgg	83280
tagctgggga	ttacaggcac	ccaccaccat	gcctgactaa	tttttgtatt	tttaatagag	83340
atgggttttc	gccatggttg	tcaggctggt	ctcgaactcc	tgacctcatg	atccaccac	83400
ctcagcctcc	caaagtctct	ggattatagg	cgtgagccac	catacccagc	cctgtctcct	83460
attttagggg	gaacatattt	aatgtatcat	caggttgat	atcattagtt	tgattttttt	83520
tgtggcatta	ttaagattcc	atttaaaaa	ttgacatatt	tgttcacgca	tctgttggtt	83580
gaagtgggat	tgttttatta	agtatcaaat	tatcttaagt	ttcaggctta	atgacagtgt	83640
aatttcaggg	gcataaggaa	gattttccca	ctcatccaac	atagacttat	actgagagag	83700
atgtaattac	aattaacaac	catgtatttc	taatttcaca	tgtgctggat	gctttgttct	83760
ctttttctca	tctgatcaag	gcaccatggc	tccaacatcc	tcacttatgg	gatatcttgc	83820
tgacttttgt	aggtagaagt	aagcattttc	tgcatgtgt	ccataatcta	ctttttaatt	83880
agaaatttta	cttaatttca	cactatatct	atttctgttg	tcaaaaaaat	caaataaaat	83940
tgtgaattgg	gggtggtggc	gaaggatagt	aataatatgt	ttaggcaatt	tgggtaaatc	84000
atggagtatt	ttttctttta	tgaagaaata	tgctgttctg	cttcatccat	ttattgcaat	84060
tccaaaaagc	aaactaacta	tagtcagatt	atltggattt	tatgagaatt	tcataatatt	84120
ataattattg	caaaatttat	taattttaaa	aaatcacgtg	aaccaaaact	aaacacttgt	84180
ggatataatc	aagattcttg	ttttcaatat	atttactcaa	aaaacattta	tggataactt	84240
agcatgttcc	aggcagtgt	ctgagtgttg	tgtatacagt	gaatataaaa	tacagtttct	84300
tcttctcttg	gataacaggc	tggaggggaa	gatatactct	aaacaaacaa	aataaactgc	84360
acttaaaatt	aagattgtga	caagtgtcat	aaataagtag	aataaggcaa	caggagagag	84420
aacaattatg	atgggtgcaca	gattttactg	taggtagaag	atgtcttctc	ttaggggtga	84480
tatttaagct	ggcatcctag	agatgattag	ggaataacta	gaagaagtgt	gggagaaata	84540
gaattcaaag	cagtaattag	aactaagcac	cacatcgaaa	tgatagaaag	atctcaacaa	84600
cttaacataa	caactaaata	atataaggag	gctgctagct	agactaatat	gaagaaaaga	84660
gagatggccc	aaaaaacaaa	attataaatg	accaaggaga	tgttaccact	gaacccttag	84720
aaatacaaat	aaccatcaga	gactattatg	agcacctcta	tgacacacaa	cgacaaaatc	84780
tagaagggat	ggataaaatt	ctggacacat	acccttcaca	agactaagcc	aggaagaaat	84840
tgatttcttg	aacagaccaa	taatgagctc	caacattgaa	tcagttagta	gtagcctacc	84900
aacaaaaaga	aatcccagta	ccagatggat	tctctgccaa	attctaccag	atgtacaaag	84960
aagagatagt	accatttgta	ttgaacctat	gcaaaaaatt	taggaagaat	gattcttccc	85020
cagtcgttcc	ttaaggccag	catcattctg	atatcaaaac	ctggcaaaaa	cacaacaaaa	85080
aatgaaaatt	ttaggccaat	atccttgatg	aatattaatg	caaaaatctt	caacaaaata	85140
gttgcaaaact	taatccatga	gaacatcaaa	agcctaattct	atcacaatca	agtaggcttt	85200
atccctggga	tgtgaggttg	gttcaacata	cataaagtta	aatgtgattc	atcacacaga	85260
cagaactaga	ggcaaaaact	atgtgttatt	tcaacagata	cagaaaaggc	ttttattaaa	85320
attcaacatc	ccttcatggt	aaaaactctc	agttagctag	gtattgaagg	aacataacct	85380
aaaataataa	gagccatctg	tgacaaacc	acagccaaca	tcacacagaa	tggggaaaag	85440
ttggaagcat	tccccttaaa	aacctgcaca	aggcaaggat	gctgtctctc	accactcta	85500
tttaacatgg	tattggaagt	gttagccata	acaattaggc	aagagaaaga	aataaagggc	85560
atccaaatag	gaagagagga	attcaagcta	tgctgttttg	cagtcaatat	aattttatat	85620
ctagaaaacc	caaaaacttc	ttcagctgat	aaacaacttc	agcaaagtct	cagggtacag	85680
aatcaatgta	caaaaatcac	ttgctttcct	atacaccaat	aaactgtcagg	caaacagtca	85740
aatcaggaat	gcaatccaat	tcacaattgt	tagaagaaaa	ataaaatact	taggaatata	85800
actaactaga	aagatgaaag	agcactacaa	tgagaattac	aaaatctgct	caaaaaaatc	85860
agagatgaca	caaacaaaag	ggaaaacatt	ctgtgatggg	taataatgag	tgagtgtcaa	85920
cttgattgga	ttgaaggatg	caaagtattg	atccttgatg	tgtctgtgag	gggtgtgcct	85980
aaggagatta	acatttgagt	cagttaggtg	ggaaaggcag	acataaccct	aatctggatg	86040
ggcacaatct	aatcagctga	cagtgtgccc	agaatataaa	gtaggcagaa	aaacatgaaa	86100
aggttagact	ggcttagcct	cccaatctac	atctttctcc	cgtgctggat	gcttctctgc	86160
ctcaaacatt	gaactccatg	ttcttcagct	ttgagacttg	gactggcttc	cctgcccctc	86220
agcttgacga	tggcctattg	taggaccttg	ccttgatgat	atgtgagtta	ataatactta	86280
acaaactccc	atatatatat	atatacacac	acacacacac	atatatacat	atatatacat	86340
atatatatat	gtatatccta	ttagttctgt	ccctctagag	aaccctaata	cacattacat	86400
gctcatagat	aaggaaaaat	aatattatta	caatggccat	actacccaaa	gcaatttaca	86460
gattcaatgc	tattctctgc	aaactaccaa	tgacattctt	catagaatca	gaaaaaaagc	86520

tatttataaaa	tttatagggga	accttgaacc	caaataagcca	aagcaatcct	aagcaaaaaag	86580
aacaaacctg	gagcatcacg	ttacctgact	tcaaactata	ctataaggct	acaggaagca	86640
aaacagcatg	gtactggtgc	aaaaacagac	aaataaaaca	atgaaacaga	attgaaaggc	86700
cataaataag	accacacacc	tacaaccatc	tgatttttga	caaagctgac	aaaagaacag	86760
ggggaaagga	caccctattc	aataaatggt	gctaggctga	ctggctagcc	atatacagaa	86820
gattgaaacc	ggacctgttt	cttacaccat	acacaaaaat	caactaaaga	tgaattaaag	86880
acttaaatat	aaaaccttga	actgtcaaaa	ccctgaaaga	caacataggc	aacaccattc	86940
tggacatagg	aactggcaga	gatttccataa	tgaagacacc	aaaaacaatt	gcaataaaaag	87000
caaaaattga	caaattttttg	gatataaata	aacttaaaag	cttctgtgaa	agaaactttc	87060
aacagagtaa	acagacaacc	tacagaatgg	aataaaatat	ttgcaaacta	tccatctgac	87120
aaaggtgata	tccagcatct	ataagggaact	taaacgaatt	tacaagaaaa	aaatgatccc	87180
attaaaaagt	gagaaaaagga	catgaataga	tactttttcaa	aagaagacgt	aaatgggagc	87240
taaataatga	aaacacatgg	acacaaaggg	gagaacaaca	gacactgggg	cctacttgaa	87300
gatggaagat	gggagtaggg	aaaggatcag	aaaaaataac	tgtttggtac	taggcttagt	87360
atgtgggtga	tgaataaatc	tgtacaacaa	acccccatga	cgtgagttta	actgtatcaa	87420
aaaccttcac	atataccctt	gaacctaaaa	aaaaaaaaaa	aaaaaaaaagg	ttaaaaaacg	87480
gctctgtgaa	ggttctgagt	ttgaaaaggg	cttgacccaa	gaccagtatg	gctataccag	87540
ggaatgaggg	agacagtgac	agataatgct	gatttaggtg	tagactatag	taaaagtttt	87600
tttttttttt	tttttttttt	tttttttgag	cggagtcttcg	ctctgtcgcc	caggctggag	87660
tgcatgtggc	cgatctcgac	tcactgcaag	ctccgcctcc	cgggttttacg	ccattctcct	87720
gcctcagcct	cccgtgtagc	tgggactaca	ggcgcgcgcc	accatgcccg	gctaattttt	87780
gtatttttag	tagagacggg	gtttcaccgt	gttagccagg	atgggtctga	tctcctgacc	87840
tcgtgatccg	cccgcctcgg	cctcccaaag	tgctgggatt	acaggcgtga	gccaccgcgc	87900
ctggccctata	gtaaaagtgt	ttatttcggt	atatcattgg	aaaaatgtgc	ttccaatgaa	87960
gcattcatgt	atctcttttg	ccttcataat	tagggcaaat	acatgtacta	tttgatcaca	88020
tgtacaggtt	acatcttata	ttcatatgtc	ctagctaagt	gaggattgga	tacttggtaa	88080
aagggaaaaa	aaaggtaggc	aaaatatttt	gatctttatt	ctgtttgttt	tcataggttg	88140
gcaaataaat	aacatttttg	taagttacac	attcaccagg	ttttccataa	ataattactt	88200
cccaacacct	gagtttaaata	ccgtgaacta	actcaactac	aacaattttg	aggtccaaat	88260
tatttttacc	agtagatttt	acaatttaac	ttcttttatt	taaccatttt	gtgaaaggta	88320
gtgtccaaca	cacaattcag	gctgaaagag	aatcacagaa	acatcaacgc	ttatgaatta	88380
tgctattatt	tttttaccct	tattaatcat	tccattcatc	tgattggaat	aatgaaccat	88440
aatgcaaaac	cccatgtgaa	taaactcctg	atcccccagg	caatcatctc	gtagtgatta	88500
caaattgttg	caatcaagtt	gcttaagtcc	caagtttcta	ttgagcacat	gagtcctgtac	88560
caattactac	attttccctg	gagttgtgtt	ttttagtaac	attgcaattg	tttcttcaga	88620
gtgtattaaa	aaatacttta	gtgataagag	tcccaaatta	caagatgggt	ataacttatt	88680
cttggttaact	catttttttg	agcactagtg	tctgtgggag	tacctttctt	ggcatcaggt	88740
aggaataaaa	attctgactt	ctgcacttgt	actttctctt	cttgtctcaa	ttttggattt	88800
ttatcagtag	gagtcaagtg	acaataaaaag	tagcttcaaa	tgttagttaa	gattctcagc	88860
ctattaaaaat	gagtttgtat	acatttctta	tctagacggg	tgatgagaaa	gtattacact	88920
ttaattgaaa	ttattcacia	caactgtttc	actttacaaa	tatcattctc	accattcatt	88980
caaattattga	accacttga	ataactattg	gagtaaacat	taatatgaca	ataaattcaa	89040
gtgttgaaca	caccttgaat	aaccactgga	gtaaatatta	ataagacaat	caattcaagt	89100
gtttactaga	ataatatctg	ttgaaaagac	cccttataaa	ggaaacgctt	tatcaaaagt	89160
tcaaaagaga	tcttattttt	ttatggctga	atagtatttc	attgtatcat	agatggacac	89220
aatgaaatat	catagacatt	ttacattaag	taaaataagc	caggaaaaga	atattaaata	89280
ctctatgttc	tcactcgtac	gtggaaaacta	aaaaatgttt	atgtcagaga	agtaaaaagt	89340
agaaaagagg	atactagagg	cttccttagag	gctaggaagg	gtagagagaa	ggaaggatag	89400
gcagaaattt	gttaaaggat	acaaattata	gcaaggtaag	agggataagt	tctactgttc	89460
tatggtcctg	taggattact	gtagttcata	atatatagtt	tcaaatagct	agaaaaagga	89520
tagtgaatgt	tcccataata	aagaaatgat	aaatatttga	cataagggat	atgctaatta	89580
cccttatctg	atcactatac	atcatatgca	tcaaaacatc	actgtgtacc	cactaaagat	89640
gaacaagtat	tatatgtcat	ttaaaaataa	agtaaaaata	aggggaaaaa	tttgaaagag	89700
ggacagatca	attcattaga	aattgtactt	tttctagaaa	acataaaaaca	cttatagaac	89760
tttacatatc	tttcttttaa	ttatcagaga	aaatttggag	caaattttaat	attaactaag	89820
aagtgaatga	ctagtgatga	gtgtagaata	gaaaaatcta	tgaatgcaaa	atcagaatgt	89880
tagaaatgat	gggcacttta	gaaactattt	tgtcaaagtc	tgacattata	tagattagaa	89940
ttctaaagct	cataggaaaa	aatcaccata	tcgaggtaaa	gagactgctt	tctaaatgaa	90000
gacttaaatg	agttttttatt	gacatatcat	aggcaagaat	aaagccacaa	catataacat	90060
gccctagaac	ttaggttcat	gcactgtgct	tagataatgt	gccctgttat	tttatttgtg	90120
agacactaga	atggaaaaca	aagagaaaag	gatggtgctg	aagtccattg	tgactgtgta	90180
gacaaggaag	gtgctcctgg	ctgagaaaact	gatattcaca	ggagttgctt	ggctccacca	90240
actactagac	ttatctacct	ctgtttttaat	tgaagatcgt	aaaatatcat	tatttgccca	90300

gcagttcttg	cagacttata	tatgtcttat	tgctcagttg	aggctcgttc	tgggctcaat	90360
aactgaaaat	aagcttcagt	aatctttacc	tctgttttct	atggctcttt	ctttggcttc	90420
aattttctct	agtctccac	acaattcatt	ttataggatg	acataatggt	gacctgatgt	90480
atacagaatg	tttagtaact	atgaaagcag	ttccgtgcta	tcttattttg	ctatctcaaa	90540
tatttgattt	ctattttatt	tcattttatt	ttatgagaca	ggatctcact	gtgtcaccca	90600
ggctaaaagt	cagtgggtgca	atcatggcat	actgggccca	agggagcctc	tcacctcaac	90660
ctccccagta	gctgagacca	caggcatgca	ccaccacacc	tggagatggt	tttttttttt	90720
aatattttgt	ttttagagaga	tggagtctcc	ctatgttgcc	cagttttgtc	ttgaactctt	90780
aggctcaagc	ctcagcctac	caaagtgcata	ggagtaaagg	catgagccac	attgacctgac	90840
cttgcatttt	aactggagcc	tgaagaagcc	aaacttattc	ccaaatgaac	atttccacaa	90900
gtaactcaga	tatcagtaac	atttgtagaa	atttactttg	cacttttatt	gaatcaatgt	90960
aatttttttt	ttagtgtgga	ggatgggaaa	atcttggaac	tccgaatttc	acccaaatat	91020
ttaccatgtt	taccaattta	ccataaatga	cacctctagt	tttctgttca	acaatatatt	91080
caaacagsct	actaaatgac	aaataatgtt	acttgaaaaa	tatcttcatg	taataaarat	91140
aaacatatgg	atatagatat	cctgtgaatc	aaaattttacc	aacatgraaa	atatgtgttg	91200
actttgttat	ctagttttatc	tttagtaatt	ccaatacagt	gcgaagcaag	ttaacattat	91260
tgaagcagtg	aaacattttg	agtttttatt	tggttatatt	tcttgcaata	agaaacatag	91320
actttaaaaa	actcactgat	gtctacactg	attcctaatt	accagaaat	ttcagactga	91380
acaccaatgt	catggaaaaa	cccctttgca	gaaggacatc	tggtttaatc	catcattgag	91440
gcttaattat	ttttctgtgt	gttattttct	acacagagaa	caatgtatgt	atagctatta	91500
caaaactgat	tcagcactct	ttctaattgt	ttaatgtgaa	ttacttggca	atctatatgt	91560
gaataacaagt	tagaaaaata	gagtcataga	agataaattt	tgctactttt	tacacaaata	91620
ttaaataagt	gtgcactttt	tctaagcaca	gggcacactg	cgcatggtaa	acattaaata	91680
agttatcaaa	ggcaattcct	acaggcatta	aacatcacct	ttgatacatt	tcagcaaccc	91740
agtttaacca	ttggcaaata	aataacattt	tgctaagtta	cacattcacc	aggctttcca	91800
taaaatatta	cttcccagca	cctggattaa	ataccatgaa	ctaactctac	tacaagaatt	91860
ttgaggtcca	aattatttta	cccagtagaa	gtttaaataa	agaactagaa	atgatcttca	91920
gatgacgtgt	tattaaacat	ttcacaatca	ttcagctatt	tattttcagt	agactaaagg	91980
cttttagctct	gatgcagaaa	atttgaatat	atcatgggag	ttatcaaaat	tattttaaat	92040
ttaccaatag	tatttgtcat	atgcatgctt	ttagtaatct	cagttgagca	tatgcccccc	92100
caacatatat	atacacatac	atgaatatat	atagagggtc	ttgtatgtta	cactgaggcc	92160
ctctagaagt	gaaacttgaa	tgttttaata	tgactaagtt	cataatctcc	tgcccaggaa	92220
attataaaat	aaaaacattc	cagatctcaa	agagcttttc	tttactgaaa	tattgagaaa	92280
gacattttcc	aagtacttta	gccttttaaa	tatgattcat	gcaagcaact	aaattagaga	92340
gttcttggga	agagggctgt	ggataacaaa	agaaaagtga	gaagagaaga	aactaaggat	92400
gtgtgatcaa	agaacagggt	aacatgtaaa	aaattcaaaa	gaggaaaaaa	atgcttgcaa	92460
gttatatgag	agtattttta	atatttggac	gttgtctcat	ggattacatc	tttcttcta	92520
tctatctata	tctatctatc	tatctatcta	tctgtctatc	tatctctcca	tctatctatc	92580
atctatctgt	ctgtctatta	gtttgactta	tgctttacaa	ccaataaaca	cttaataagc	92640
aaccatgatt	atttgttaaa	tatgatatga	tgaataaaca	aatgctagta	tttaggattt	92700
cacaatacag	attgtttgag	agtagaatgg	attcacgtcc	acctgcaatt	gatacgcaga	92760
gctctgatat	cacattctgt	tttattttcc	tcagagttta	acattttttt	ctcctgtttc	92820
tattctctcc	ccattttatg	agtgcctctt	cagtgtctcag	tattttaccc	aagcattttt	92880
tttctataaa	tcaatgatag	ttctctacta	gtggcacggc	tgaatgaagc	tggtttccca	92940
aattgtggag	attatgtctt	acttcttgga	attttgttta	gtttttgagg	ttcagggatg	93000
acagcattcc	ctgtctgcca	gtgtgaaatt	agggatttta	gcctaaagag	aaaatttgat	93060
agtgtctctg	ggtctttgaa	taaggaaggt	tgggacatgc	tgaagcctt	tgcccacttt	93120
ctggagcttt	actttacaca	tgtccatata	gaaggatctg	tgatgttctg	caatagagca	93180
acctatttta	cctttcccca	cttaaaccca	gtattttcaa	actttttttt	ccccataggc	93240
ctattttgtt	gcttaatat	cagtggttct	tctgaacaaa	gttttgaaaa	ttctaacctt	93300
aaaactcaga	cgatagcaag	attaacatgt	ttacaacccc	ttttccttac	tcctaattggt	93360
acttgctcta	catcagttga	agggcttttc	taaaagtga	atgaaacaga	agcgggtgtga	93420
tttctttgta	gacctaaagt	gcctatgtca	atgggaggag	atactattat	ccaaatatga	93480
gttttctctt	taagctgtag	agggtagggt	gctgcatata	tttaaaggaa	agagcaggac	93540
atagaaaatt	aaatttatag	atctttttta	tcttcttttc	tttatttttg	tcatttatctt	93600
attatttggt	aagtataata	tgatgattaa	acagatgata	atatacaaga	tatattgcat	93660
aaatgtaaag	attagataaa	tatattttat	ccattaaaaac	ataagattta	tattttactaa	93720
ggtgaatatt	ttccaaaatg	atgcatcctt	ctggagagtg	aggaaagggc	actttttactc	93780
tttacataaa	tctttatttt	ctaattattg	catttttcctc	tcaaaggcca	aagttgtaga	93840
tttaagacaa	gaaatcattt	caattttccaa	gtaacagggg	acgtcagttc	taattcatca	93900
ccatcacttg	ggtgccatac	acacgcacag	gcacacacac	tcaaaaactg	cgtgtcaaaag	93960
acaaattcaa	agatgtgctt	ccttgttagat	ttcaggaggc	atgttcactc	ttcttgggtat	94020
gtgttgagaa	ctttaagttt	tgtttgacta	cttaccgctt	attaaatgtc	ttatttgcca	94080

caatagaaaa	gtcatccctg	catctatgtg	aaatatgttt	aattttctctt	gaaagttgcc	94140
taagacaatt	ttctgcatgt	actgttcata	ctagctaaaa	ctgctcccca	ctcttattcc	94200
tctaggaaat	tcctagttat	ttttcaagcc	ccagttagat	tattgtcctt	tgatgcttac	94260
cctgattcct	gaaacaatta	gttattttgt	ttgtattttt	attattgaac	taatcatatt	94320
taactttaat	tttcatgctc	cttaccatga	aaatcaacca	gctctttcaa	ggcaagcact	94380
gtgatcagtt	gtcttcaatt	ccccagcaaa	gcaacttgca	tgcatggagt	gttcagtgct	94440
gtttgtgcac	aaatgtaacc	atattacaat	ggttaaatca	tttagcatcc	tgaaagcatc	94500
acagagtcaa	agtagctaac	ttgtgtgaac	ccttaattca	atttccggga	agaggttaga	94560
cactgaagta	tgtagttgaa	gacactggtg	ttgcaaggaa	ttgtatccca	ctagctcaag	94620
cctacagact	tctgttttgt	gccctggatt	aagataaatt	taaaaatcga	atgaattgcc	94680
aacactatct	ttggtagatt	tcccataaaa	acaatgaatt	ctgatattta	aaatgtaaag	94740
ctcttaagac	cttacaacac	aaggctccctg	ctaacataaa	gcaaaattct	attggcctga	94800
gtgacttctg	agtctacact	gggaaccact	ctatgtttca	cttcagtgga	ctcttaaacc	94860
caaccctact	cactcattct	tattagctaa	agggctccca	tagacattta	agttttgatc	94920
tcttatctcc	tttagtggtt	tacttataaa	ataacacaag	gcaacattgg	gaattttataa	94980
taaaaaatta	ttgtatagaa	tcccagcacc	ataatttccc	attgtctcat	ttcattacaa	95040
ttgatattat	ctgaattaat	attatctgaa	agtataatct	gttcattata	atttgtattg	95100
tttgaactct	aggaataatt	ctatctctct	tgattacttt	tcatttttatt	attctggaga	95160
ttataatatt	ataaagaagt	ttgaactaat	gctgctagaa	acctgaaaca	aattttgtgtt	95220
ccactagcag	aacaaatttg	tcacattctg	ttatatgctg	taaacccctt	aaatgcattc	95280
aggattaaat	taaaacataa	atggaccagt	agataaaatc	tatgaaataa	catttggaac	95340
cttctcttgc	tttactccta	caaactcctt	cgactgaaaa	ttccttcatt	agtaattcat	95400
ataggccctt	gttattccaa	atttagaaac	cttatctttg	gtttattcac	aaagaaatga	95460
attgcttttg	attttggttg	tatagcagta	agaaaaaaaa	agtgaagaaa	aaaaaccag	95520
aatttccctc	aaacccctat	gattctggac	tctctaatac	agcacatagc	cagtgaattt	95580
ctcaaagggt	gagacactaa	agcaggggtc	ccctaacccc	caggccatga	actgggtatg	95640
tccatgtcct	gttgcaact	gggcccacaca	gcaggagaca	agccaccagc	aagtgcagcat	95700
tccgtcctga	gttccgcctc	ccgtcagatt	agtcttggca	ttagattctc	atgggagcac	95760
ccaccctatt	gtgaactgca	tgcgcatgcc	agctatctag	gttgtgtgct	ccttacgaga	95820
atctaattgt	tgattatccc	caacaacccc	accctccaac	ccccatccat	ggaaaaattg	95880
tcttccacaa	aactggctgt	tggtgctaaa	aagggtgggg	actgttggtt	taaaggaagc	95940
ccatgattgt	atagtcgaact	gaaaaaggca	gttagtggtc	taatccattt	ttcgacaaac	96000
tttaggacac	tattccctca	ttccaaaaaca	cgttggtaac	acagaaacca	ttcttttttag	96060
gaatcatctg	catatgatac	acccagttaa	ttggggcctt	tgctttttta	agaccaccag	96120
gccctatatt	cttgagtcct	gctgactggt	ctgtgtgagg	gagaacaaga	gagaaagaaa	96180
aagagagaga	gcaaataaga	gaaagagaaa	aaaggtaaca	tgtaatggac	ttctcattca	96240
ccttgatttt	ttttcatcca	tttaagtga	aaatgctggt	acctaagaaa	atgggttagag	96300
gaaattctac	tttgggtgacg	gaattttattc	tcttgggatt	aaaggatctt	ccagagcttc	96360
agcccatcct	ctttgtactg	ttcctgctaa	tctacctgat	cactgtcggg	gggaaccttg	96420
ggatgttggt	gttgatcagg	atagattcac	gcctccacac	ccccatgtat	ttctttcttg	96480
ctagtttgct	ctgcttggat	ttgtattact	ccactaatgt	gactcccaag	atggttggtga	96540
acttcttctc	agacaagaaa	gccatttccct	atgctgcttg	tttagtccag	tgctattttt	96600
tcattgctgt	ggtgattact	gaatattata	tgctagctgt	aatggcctat	gataggtatg	96660
tggccatctg	taaccctttg	ctttacagca	gcaagatgtc	caaagggtct	tgtattcgcc	96720
tgattgtctg	tccatatgtc	tatgggtttc	ttagtggact	gatggaaacc	atgtggacat	96780
accacttgac	cttctgtggc	tccaatatca	ttaatcactt	ctactgtgct	gacccacccc	96840
tcacccgact	ttcctgctct	gacactttca	ttaaggaaac	atccatgttt	gtggtagcat	96900
gatttaacct	ctccagctcc	ctcatcataa	tctcatctc	ctacatcttc	attctcattg	96960
ccatcctgag	gatgcgttct	gctgaaagta	ggcacaaaagc	gttctccacc	tgcggtgcc	97020
acctggtggc	agtgactgtg	ttttatggaa	ccctgttctg	catgtacgtt	agacctccca	97080
cggacagggt	agtggaacag	tccaaagtca	ttgctgtttt	ctacactttt	gtaagcccta	97140
tgttgaaacc	catcatctat	agtttgagga	acaaggatgt	gaaacaagct	ttttggaaac	97200
tgatcagaag	aaacgtgctt	ttgaagtaaa	atcagtgtat	ctttattagt	caaataaaaa	97260
aatctttcta	tttatgagaa	ctgtatttaa	ctttagttagc	tttacagtaa	agtcattttt	97320
agatccccaa	tgaaaaacta	taatactaaca	acaaaacata	gacatagata	gagaaaaattt	97380
atgggttttac	atgttacata	tgagtgaat	atgtgtgtgt	gaagggtagg	gaggtgtata	97440
tgcatgtatg	aggaataatt	attcttttat	tcataacatg	catacattta	catgtatgaa	97500
tttacatgtg	taacaattta	catgtaaatt	tacatgtaaa	ttacatttat	aacaacatat	97560
tttttacatt	ataaaaaatt	atacattggt	gtaataaaaac	attaggtctc	tatggaaagg	97620
taaaaagtaa	gagattaaaa	tattttattt	tctttcccac	accctgattt	tttattctca	97680
cttcctagag	ttacaacgat	taacagtttc	tttagttttt	tttttttaat	ttcttcgtat	97740
ctacaaacaa	atgtgtgggt	atatgtacac	acatatatac	acgattgtta	aaacacaagt	97800
tgactgtcat	ggttgctttt	tagtgggtta	caattctgta	gcaattacta	ccaagaaact	97860

tcagtctcat	ggtttagagg	aatgtcacaa	ctgctgggtga	gacttgctgt	ccctctaggg	97920
tgtttctcta	ggagagaaaa	cttacgataa	cacctctgtg	tccatgcctg	acaccactt	97980
atgtctctcc	acttgtgaga	gtcactttca	ataagacacc	tttctccttc	tgccacgaca	98040
ggacatgagg	ccagcccagc	agttattttt	caaataattaa	ctctggaagc	agacaaaagaa	98100
tggtctctat	aaggggtatat	gactgggtgc	aaataactgt	gacttctgca	gaacttatca	98160
attcaattct	acacttctgg	ggactagagt	ccttcatgct	ttctctcacc	tctgcttttt	98220
taatctattt	ttcaggatag	atcatatatt	tttattagta	gcacatttca	aattttactc	98280
acagtggtag	tttgtcacag	ttagttatta	tataccta	tttagaatga	catatgtcga	98340
cttgtttgta	agtatttttag	tgctaaagga	agcaaaggac	aagttgat	tttaaggatg	98400
tgacaaatct	ggtgactttg	cagttgataa	cataagcaaa	attgatgaat	gtgtgctgag	98460
tatctacaat	aagtcacact	tctcctaaca	ccaaggactt	ttcaaggagc	tcgacaatgg	98520
catagtttta	caggggtcat	gaaactgtaa	acagaaagat	caatacaatt	tgttaaatgc	98580
tgtaagacta	tggaggtgct	aacgaaagag	aggaaagaaa	aaattatctc	tgggcaaatt	98640
gaagctagcc	ctgtgattgt	ccaagactag	aacttgttta	tgctttatgc	accttctc	98700
gccctcccat	agctcctagt	atgacgta	gtcaggtggg	gtctgagcaa	aataattaag	98760
aaccaatttg	tgatcaaata	tgtagatgtt	agtttcaatg	aaaaagaaaa	aaccataaaa	98820
ctataacaag	tcacaactca	aaaagacatg	atatttttct	tcagttgtat	ttcaaagctt	98880
tctttgtacc	ttcaggttaa	tctctgctta	gtatttctac	agaaattttc	agactcattc	98940
attttatatt	attgcatata	attattttta	acctgtact	actacatgtt	cctattttaaa	99000
taccttgatt	ttgaaagtca	gattgcccac	aaattctgtt	aaaacacaca	tataaataaa	99060
aaagctattt	ttactaattt	tttacattta	attaacaatt	gttgaattcc	gcttagacac	99120
atacctagat	gtattcctgt	ttaaatacac	atatgttttt	agttatgtga	aaccagcttc	99180
ttaattatat	aaaattttct	gatctcaggg	cccatgcttc	tatctgtaca	gcctagcttg	99240
gcaccgaaga	aaggttcaat	gactgcagca	tgaaagagta	cacatcatac	acaattttat	99300
taaaagttaa	tgaatgtcca	ctttcaaagt	aaacaaagtg	cctcaatttt	agaattttata	99360
agaaaagtgt	ctttgaacag	accagcagat	gactctgagg	gaatatgtta	ttagtcataa	99420
gcccaattac	ttttcagaaa	tacaagtaac	cataatgtca	ttgatgttta	tgactgactt	99480
tagcaataca	aaaccaatag	ttacgccc	atacaca	gttcaagata	gaaaggaatt	99540
acaccaagtg	ctttcatgaa	ttgactggct	cgctggaatc	acgtctatca	gcctgttaag	99600
actatctaag	tccatatcat	attgtattag	acataaaata	aatatgtgct	gatgaaaatt	99660
tttggtatta	atatgttatt	ttagtagggc	ctggatttta	gctaaaaagt	aaagaataac	99720
tttcttattg	atgacattaa	aatcccatta	ttaaagtctg	tcataagaga	tttcaagaag	99780
agtctccaat	ttcatgtctc	ttttctttca	aagttaattc	tgctgaattc	tttatttgtt	99840
ggacaaattg	ggtaatacaa	tgaagaaata	atcagaaaaa	ataaagaata	tttactgtac	99900
ttttgaaaag	aacaataaat	atgatataat	attttctcct	cacctatcca	aaagatcatc	99960
actctgat	tctttcagg	aaaatttata	catgtgtata	aaataactaaa	tggtataggg	100020
agtagtgatg	ttatgagcct	aatgtcttta	ctcatataac	agatgttttt	gggaacaatg	100080
aataagtga	aaatatttag	acactcacac	tcacacatac	acacaaaaat	aagacagagt	100140
aatacttttt	attatagtct	aggtaatat	ttaatgtaag	ttgttttact	taatctgccc	100200
atcaacacta	tgcattcagt	actataatct	ccactttaaa	gaaaagacaa	cagattttaca	100260
agttgttaac	ctaaaagcac	ataggttagat	tagaagggga	gctcaaatat	gcctggcttt	100320
aaagtttatt	tgtttggttg	tgttactatt	atacttttgc	cactataactt	cattgaaggc	100380
aaaatcatac	aatgaaaaat	ataattattt	tctatcttcc	agaagtattg	ctgatcatgt	100440
atttgacagc	tgcattgcac	ctgaaggata	taatgcata	taaaaaattc	tttttataat	100500
gtatagataa	atttaacttg	ttccataaga	caaatttttg	cagtcagatc	ctaactccat	100560
cattttattag	ctaaatgagt	agttatgagc	atgaactctg	gaatctgatt	tactgagcaa	100620
gttatacaac	ctctctcggc	ctcagtgc	tcttctataa	agtgaagaca	tagtgatttt	100680
tcataaggat	gctgtcttca	cagaagatat	taattaacac	atgaaacaca	cttaggacag	100740
tactggatag	atagtattta	ctcaataaaa	ggtacctgtt	tttaattatta	actggaaagt	100800
tactttacct	atcttagact	taggttcctt	tcataacctt	ctatgttttc	ttttaataca	100860
tttattactc	tttgatata	attaatgtct	gtgttctcta	taatatgtga	agtgacatga	100920
ggtcagaaac	aatgatgttt	tgagagcaat	tattttctat	ttttcagcct	ggtatgtagt	100980
atgtgatccc	taaaaaatga	tagatagatg	attgatgggt	agatgacaga	tagatgatag	101040
atagatagat	agatagaaaa	aaagaagtaa	aaaaaataat	ggagattata	atattagt	101100
tgtaaggtaa	tgggattttc	ctgcaaaaca	aaacactgat	ggtaacttaa	atgtgtatat	101160
tttattcatg	tataatcagt	ctgcttttgt	ctccttcaac	agaattcatc	tggaatgtg	101220
cagaataaat	caaaccagag	agaagaaatt	tatcttctctg	agggtggcca	gttgcccggc	101280
gttgcatctt	gtcttctttc	tcttggttct	attaatttgt	atcttctctt	ttctggaaaa	101340
cttggcccta	aatctgcaca	tcacatcctc	acactgtctc	cttgccaatc	tctcaatcct	101400
acaaattctg	gttaactttt	tatttggtgaa	gttcaattcc	atagccaatt	tatatgaaca	101460
gcataacatg	gtcacattcc	cggttaaccca	gtgttttgtc	cctgcagcca	tctgtggcaa	101520
tcacatccac	atggtcatct	gccttccatg	tagtcacaat	attgggtcca	aagtgtctca	101580
cgtttatatg	gctgtccttc	tctatgtttg	catttcatgt	aaacttattt	aacatgggtg	101640

tatccccaga	gctgacgaca	tggaatagca	tcatatcctg	ccaccttggtg	gctactccga	101700
ccaaataaaa	ccaaatttca	ccacacgcca	tggtgctact	ccataatgtg	atggaagtgt	101760
atgagagttc	taactttata	ttttccaaac	aaatttgga	tctttctact	ctttgtaagc	101820
cagaaaaact	tctctgtttt	tgaatttcac	cttatgaata	tgtctagata	atgttacctc	101880
cttgaaggaa	tcaataacac	aaaacagtag	ctgccctata	tgtttgtgac	tctttttgaa	101940
caaccaaaata	aatagaata	gaaagaacgt	aacgtttgaa	aatagtagca	tgatgggttaa	102000
ttttatgtgt	caacttgact	ggcgacagag	gtgcacaaat	acttggtaaa	atgttatctc	102060
tgggtgtgtc	tgtgaatgtg	tgtctggaag	agattttacc	atttgaattg	gaagactgag	102120
taaaggagag	tgttctcacc	aatgtgggct	ggcatcatgc	aatctgctga	ggcctgaat	102180
agaatagaaa	ggcaaaagaa	gagcagattt	gttttctctg	ggtgagttgg	gacatcaatc	102240
ttcgctgtgt	cttggacaat	gttgggtgtc	ctggacctcg	gacctgcaga	ctctgaccag	102300
gacttaaact	atttgttccc	ctaccaggtc	ttcaaactta	gactgaatta	aaccaccagc	102360
tttctgtgtt	ttccagcctg	caggcggcaa	atcacaggac	tttttggcct	ttatagtgtc	102420
atgagccagt	ttccattgtg	tgtgtgctgt	tgtgtgtgtg	taatcatgta	atgttatata	102480
tatatatata	tatatatata	tatgtaaaat	cttcattcta	tatatagaat	gcttctcttt	102540
ctctggagaa	ccctgatgaa	tacagatttt	ggtattgaga	gtggttctag	agcaacataa	102600
ttttaaggat	atattttctt	atctgtttct	gaggtttctg	gaattggctc	tttaatttca	102660
ttagatttaa	agatgcta	gactatttag	agtatgcgaa	aaagcattga	tagtccatga	102720
cataaactgt	ttatacatat	atgcaaagta	tccacattgg	attatcctca	tcagacactt	102780
ataagatata	aggaactatg	tgactctcta	tatacttttg	tactttctta	gaaaactaag	102840
gattataacg	atattgattg	gttactctta	atgtcactgg	acaaagtgtc	gaaagataag	102900
gatgagcttg	gggattttta	tttccagctc	aaccttgaga	gcttctatgt	atgtctggaa	102960
ggagatcctt	gtctcctgta	gcttcaatta	gagaattgca	gaaagggatc	ctatatgttg	103020
cgttgggggt	ttgtgggaag	atcctgatga	agctggaaag	actgagcccc	taaattctga	103080
taagtgtat	ctgacagtga	aagaggtttc	cctactccta	tactcctagt	ggaattggcc	103140
tccccgttcc	cagtggatc	agcttttcca	cctatgtctt	gggtaattaa	ctccatattg	103200
ccagaataaa	tggtaaaagc	ttccccctgag	gcagtttcca	tacaagacaa	tacagattct	103260
ttttggggcc	cacctttacc	accttctctt	gcttctaacc	ttataactaa	acccaagtac	103320
caacagcccc	tgaagaaga	ggtaccaagc	aagaccatga	ggtgggtgcac	taaaaaagta	103380
gatgagtttt	ctaatttata	caaacagaaa	tccagggaac	atgtgtagga	atggatacta	103440
agcatatggt	aaaagagtag	aatgaagata	tagttggatc	aggtctaatt	tgtcaatatg	103500
agctcattaa	acagagattc	tccattttaat	gttgcaactt	ggggagttag	aaaaagctct	103560
aagtttggtt	gttttggtga	aacatgaatc	aaaagatggt	ccactgtgag	taaactggaa	103620
atgtttaact	tcccttggtt	taatgtagag	gaaggaattc	aaaggtctag	agaaattaaa	103680
attcaagagt	ggacttgcca	ttgaagacct	actcaccat	actggaagg	ttcagaagac	103740
aagcttttca	ccaatacatt	gataaataaa	cttgtgagg	gaaactgcaa	ccacacaatt	103800
ggaaaatcaa	aatgcagtaa	tagtaactag	atcatgggg	ggcagaggcc	aggtgggtggc	103860
tttcaatggc	ccaaggcaag	gtgggcatag	ttaccataat	gaacagcagg	ttaaagcatc	103920
aaatagaata	gtctgaccca	cacgtatcta	tgacattggc	tagcacaggc	tagttaatta	103980
tgggtgttccc	agttgtataa	gtaaatagaa	agcccactaa	attcttactt	gatctgaata	104040
tgcaaaaaca	ttttaggtca	agtgaacaaa	agtctattct	gaattataat	aactgatagt	104100
tacagtccct	caatcaattt	gtagacttga	ggcagtttac	agaccagaaa	ctccttaaat	104160
gaaggggaga	caaggtcttc	tcaaggaaga	tttccatata	ttgctaggtc	ccacagagag	104220
ggacctttta	tctgggtaac	tgcattggag	aaaaggagat	aatcagactt	ttgagtacta	104280
cttgacactg	gctctgaact	gacaatttca	ggctcacaac	atcattatag	ccccttcagt	104340
cagtgaaggg	ttatgatgat	tagattatca	gtgaattcca	tctcaaagtg	ggcccagtg	104400
gtccctgaac	tcagcctgtg	gttattttct	tggttctaaa	atgcataaat	agaatagaca	104460
tactggcaga	atccccatgt	tggtcctcct	acttgtggag	cttgggtaaa	agaaatagtt	104520
gaaataaatt	atttaaagtg	ttttgtgagc	acaaagaaag	aaaaaaatta	tcttgacaaa	104580
aagctttttg	ggtaattctc	ccagagaagg	taaccactga	gatgggtttt	gaaagttgag	104640
taggaatttc	aaagggtaga	ggatgaattg	caaagacttt	tcctaaagag	tgaaccaact	104700
gatcaagaag	aatagcttgg	ttgtgcttat	gacacaaata	atagatagga	aagtagtaaa	104760
taataaagtt	gaatagtaaa	ctagatcaga	taaggcaaga	atgaaatgct	tttttaacaa	104820
atttgacttt	aatggatctt	acatgatgtg	gtgatattgaa	cgtatcctca	aaaataatgt	104880
gttggaaagt	taatccccac	cgtaacagtg	ttaaaaagta	gggcctaattg	ggatgtgatt	104940
aggtcacaaa	agttacaacc	ttgtgggatt	gataaaaagg	ctaaataaag	gattactttt	105000
tttaaaaaag	caattataaa	tgggcttgag	gctgcaagtt	ctctaacttg	ctgtccccct	105060
ttcttgccct	ctgccttctc	ccatgggctg	acacagcatg	aaggccttta	gatagatgtc	105120
agcaccatgc	attttgactt	ctcggttacc	agaactataa	aacagggtaca	tttctattta	105180
ctataaatta	cttagtctgt	gttattctgt	tgtagcagca	taaaacagac	taagagaaat	105240
ttgggtactca	gaagtgtggc	tgttctatat	cagctgaaca	tgtgaaagtg	gccttagaac	105300
tgagtaatga	gtagaggcca	aaagaatttg	caggaaacagt	ctagaaaaag	cctagaatgc	105360
catgagtgga	ggtttaaggg	tgattatggt	gagggccagg	aaatgtaggg	aaagtctgga	105420

acttcttaaa	gactacatgt	gtggctatca	tcaaagtgt	ggtagaaata	ggggtagcaa	105480
aggccattct	gaaaagatct	caggtgaaac	tgagaaacaa	tgtactggaa	actagagtaa	105540
aggccatctt	ttttatacag	tggcaaataa	attggcagaa	ttgtgtccat	gtagcagggc	105600
tctgtggaat	acagaactta	agagtgggtga	gctagactat	ctggaagaag	aaatatctgc	105660
gaagcaaaaa	attaaagggtg	gtgcacagct	tattttgggt	gcttacagta	aaatgagaga	105720
agaaagaaaa	aaaagataga	atttgtaatg	aaaaggaagc	agcatgaagc	gatttagaaa	105780
actcttagcc	tggccatgta	aataataaaa	aagcatgttt	gggacagaat	actaaggaag	105840
tgttcatgta	ggatacagta	aattcctctt	caaagtttag	cctgttaact	tcaagaagga	105900
gaaaaattgt	taagtacaaa	gagttctgag	ttccacttca	aagaaccaat	caatatgtca	105960
gtatgtttag	cttccctggt	ctttgttctc	cattttaaag	tttaacctcc	tcgttcttta	106020
catctccttg	cccctagttt	cagtaaacia	ccccctcta	gcctctatca	cctgttctgt	106080
ccttagtcac	cctcagtcac	ctgctctgtc	cttagttatc	tagtcactca	cactgtaacc	106140
gtccttcccg	ccgaaactac	tcaccctgcc	actctggctc	ataccctgc	tctctttaaa	106200
atagccagtc	agaattagct	tagactgtgt	ggtccaaccc	cagccaatag	gggaaagaca	106260
gcagtaggga	ctagctgctt	taggataagc	acctcttccc	ctcccttgta	cgggtgtgctc	106320
tcgccatcgc	tccatccttg	agatgcaccc	ttctatagaa	gtaaattgcc	ttggtgagaa	106380
aacttttgcc	tgagtgttag	tttcaacttt	tagcaccgaa	catttacttc	caacaatcat	106440
ttgctacaga	gatgaacata	aatagaagga	atccaggttg	gatttatcaa	gacaatggga	106500
ggatgaccct	gaaagcattt	caaagatctt	gtggaaaagc	tgggattttt	agggcaagaa	106560
atccagagag	atacataaat	atatgtttag	tttttaactg	gaagtgaagt	gggatgtact	106620
gtatgtagta	caatcatata	ttttaacgat	gtggaaactg	aaataggggtg	actagcctaa	106680
aactaatgga	ctagcttggtg	aaaacaggat	ttctcgtctc	aaaaaaaaaa	aaaaaaaaaga	106740
aaacagggtt	tctcagtaga	actaaactgc	ctttccttgg	ttttatttct	agttaaatgt	106800
cgtaataaat	ttaccagata	ttgcttccgt	gtacctggaa	agcatagaca	ttttgattca	106860
ttgtaatcaa	tgtttaataca	tgaaattaga	tgaaataaca	gcaagtgaag	catgttagtg	106920
catgttagtg	gctagagaga	ggagattcat	agtcaaagct	gctttcttct	ctcagtgagc	106980
tcactcaaca	gctttttgaa	tttgagaaaa	ttgaattttc	tttctaaggc	tcagttcctt	107040
caatatataa	tgggtctaat	aatatttatt	tcataatttt	aatattttaca	taaaattata	107100
cataaaaaagt	tctgtacatt	gaattttata	aaacttttta	ttttaagtat	acttaattac	107160
cccaaatttt	aacatctgta	tgtggtacat	catggcctag	gaaaataaag	aataataaaa	107220
attatcctaa	tcatttgcac	tctagatttc	ttcaattata	ttcattttact	cttggaacttt	107280
tctacaaaca	aagcaacaca	aaataaacia	agaaaaagaa	ggggagcaaa	aataccctat	107340
gacttttttt	tttttttcaa	atgaatgtat	gctcaccgta	atgataccgt	gtggtagaac	107400
atgtttttgc	tgcatttagtg	gccaagtga	aagagtgaag	aagggtgttc	tttttgagtg	107460
cagttctttc	tgccaagtaa	tggaggagag	gaggtagaac	gatgccagct	gatacacgat	107520
aagcaataag	taaagtcatt	accaagagat	gtgaaaaaga	ggacacagaa	gagatgttaa	107580
gccattttta	aatccatggt	caacatcact	gagctgtctt	cagggaacat	ttaattggca	107640
gaaatgactg	cttctttgtg	atttcttttt	aatgcaacag	ggaaaaggag	tcaactttat	107700
aaacacaagc	aaacctttcc	ttattttatta	tctctgaagg	cccattgggt	ttcctgcttc	107760
tttataggta	gggctgtcta	tttgtgtgtg	tgtgttagga	actagacaaa	gtgttgctat	107820
ttatatattag	aagccaaata	cttattcagt	agaaatgatg	catgattaga	aatagttaaa	107880
taacttcata	ggagtatggg	tggttatata	ggtatcaatg	cacacaatct	gagaatttgt	107940
atttgttcta	actactgaac	aaatgggact	aagaaagtaa	aatttcttgc	aatggcctta	108000
tgtgcttcac	atgttgtcag	atctttacat	agattataac	ttttaatcct	caaaagatat	108060
tccttcaaca	acattttgaa	gtgagaaaaa	taaagctcaa	aaaagttatg	taagctgtct	108120
acaattgtag	agctaacatg	cagcatagtt	gtaatttttt	aagtcaaata	aggcaagtct	108180
caaaactttt	gagttgggtt	tgggagatga	ataccagtac	taaggatggt	ggaaacattt	108240
tagcacaaaa	taattttaat	gttttgga	gtacaaatgt	acatggcaga	ctatttctaa	108300
ggaaggtggg	atgtaagggt	aggacatgaa	tatatagaag	agtgcaagat	gatgttccag	108360
tgttctccag	aaaaaaagat	gaagaaaaga	ttgcaaagca	tctaactacc	caatcctcat	108420
gaaaacatat	gcatgcacac	tgaaataatt	aaaaactaca	tgtgtatgca	tgcattgcatg	108480
tacacatgtg	tgtatttatat	atgtctatgt	gtatacatat	aatatacata	gtcagggaga	108540
ctttatatata	atagtcaggg	gaagagagag	agaggttaaa	tcaccatcct	tctaagata	108600
atagttctca	ttacatgaac	agccttttag	ttcgtcaaag	caccttaatg	tgttcactag	108660
gcaaagtggg	agctagagta	gaatttgaga	ttaggagacc	ccaaaagggtg	aagaacttag	108720
aataaaaaata	tagagaaaaa	tacagttttt	gaggtcattt	tagaagagaa	ggaaggagag	108780
gtgagaaata	ggaggggag	agaattaaga	gaaaccagg	aggtatcatg	aattgggtta	108840
agtgtgtgaa	aataaccggt	gacaaatcct	ctatgattag	gcaacaggta	gaaaatttga	108900
gaaatataat	agattttaatg	ttttaatttt	aattttttatt	ctcttttgca	acaaatatct	108960
atcttctact	tgccttccac	agagttgcaa	tattatctgt	gtctgtgtgt	ttgcatactt	109020
gtaaacatta	cagattttcta	aatggcgtgg	aatagatagg	agttttaaga	tgattttgaa	109080
aggtctcaag	ttgctgacat	caggattatc	taagcattat	ccttacattt	tataagtcac	109140
accatagtcc	ttgaatataa	tctctcacag	attaatttaa	ttctaactaa	taacaatcac	109200

ttcatatggtt	ttcatcttat	atagcagtc	agttttacaat	aattcttatta	agcaccaacc	109260
ttaagagtat	ttatattagt	tagataacgg	attaaattcc	tatgagaaca	aaacaaaata	109320
acagttaaag	aaattagaag	tttattttctc	atttatgtaa	aattctgagc	tagtatgtca	109380
tatcagctct	gccaagggtt	taggagctcc	aactaattta	ctcttctttc	tctgctttct	109440
ataaagagtt	actctcatct	atatgattca	ggatgggtca	gcactatata	cacattacag	109500
ccagtggag	gcagaaaaga	agaagggaag	ggcaaacctg	ttttatcaat	ggatggataa	109560
aagtagctta	attttctttt	attacattct	cttgccaga	agctaccctt	ttgccatagc	109620
aaatctaatt	ttagaatttt	aaaaaaagga	aattctgggtc	atttttggtt	tgttttcttt	109680
ggctttggtt	tttaaaattt	atttaactta	tttattttta	agagctgtcc	cataattatc	109740
agttctggct	ctgaggagca	aatacttaac	ctgggttaagg	gaaagggtact	agcttctagt	109800
gcaggctcag	gctctgtcaa	atctgtctgt	tgtctggatg	tctggatgat	cacttagcca	109860
tctaatact	tcgctatgca	tgctcagtat	gcacaaatat	agacagacat	gttggaacaa	109920
gtcatttcca	tgctctaatt	caggctctgtc	gtccaaaaa	attacctact	ctgaagttaa	109980
tgaaattaac	tagaagcatg	ttagtagaca	ttttgaaaat	ttttctgtaa	aattttcaat	110040
tggtatcctc	ctcaaatatt	tatcttttat	tttcccccaa	aagtagcagc	tagtctaaat	110100
tagcatattc	tgtttgtcac	ataaagaatg	agctaaaatg	tatttttagt	tttttactac	110160
ctatccttat	aacaggaacc	taagggattt	tatctgacat	ggcatggaag	aattaactgt	110220
aatcagaaaa	agaatgtcag	gtaccagggt	ctcaacttac	agttaagtta	gataacttat	110280
agctaagtta	tctaacaat	taattttaca	aagtgtctgag	tattcatttg	tttattagca	110340
ctagtggcaa	aatctgagca	ataaagatgt	gagataaaaa	agcaaaatgt	aaaaaaaaat	110400
agacacagta	gaaatgaata	tgagtaagaa	attaagtgtac	ataaaccgaa	aagatttagac	110460
cctgtttcaa	ttaaatcact	atctctagt	tctcctgaca	caaaacaaat	ttagaaaaac	110520
tgacagagg	caatgcaaaa	caatgtttca	agaaaatata	aaaatgtttg	cccttttagaa	110580
aatatctact	aatccaacat	tctcatttcc	cactgaagga	aattatgaga	agaaactgta	110640
cattgggtgac	tgagttcatt	ctcctgggac	tgcccaatca	ccgggaatta	cagattttcc	110700
tcttcacgct	gtttctcacc	atttacattg	tcacggtggc	aggaaatctt	ggcatgattg	110760
ccctcatcca	ggccaacgcc	ccggctccac	acgcccactg	actttttcct	gagcaactta	110820
tcctttgtgg	atctgtgctt	ctcttccaat	gtgactccaa	ggatgctgga	gattttcctt	110880
tcagagaaga	aaagcatttc	ctatcctgcc	cgtcttgtgc	agtgttacct	ttttatcacc	110940
ttgggtccacg	ttgagctcta	catcctggct	gtgatggcct	ttgaccggta	catggccatc	111000
tgcaaccctc	tgctttatgg	cagcagaatg	tccaagagcg	tgtgctcttt	cctcatcaca	111060
gtgctttatg	tgtatggagc	actcactggc	ctgatggaga	ctatgtggac	ctacaaccta	111120
gccttctgtg	gccccagtga	aattaatcac	ttctactgtg	tggaaccacc	actgattaag	111180
ctggcttggt	ctgacaccta	caacaaggag	gtgtcaatgt	ttgttggtggc	tggtttcaac	111240
ttcacttatc	ctctccttat	catcctcatt	tcttatctct	acatatttcc	tgccacccta	111300
aggatctgct	ctacagaagg	caggcacaaa	ctgttttcta	cctgtggctc	ccatctgaca	111360
gccgttacta	ttttctattc	agctcttttc	ttcatgtatc	tcagacgtcc	atcagaagag	111420
tccatggagc	aggggaaaat	ggtagctgta	ttttatacca	ctgtaatccc	catgttgaat	111480
cccatgatct	acagtctgag	gaacaaagat	gtgaaagagg	cattatgcaa	agaactgttc	111540
aaaagaaaa	tgttttctaa	ataaacatta	ctactgattt	ttgttgtgtt	gtcattttat	111600
ttaccctatg	atttttcata	gagcatagtc	tgatacaaat	atatccaaaa	ttatatattt	111660
tcctagaagt	gttggggaat	ttttatgaag	tgtgaataca	agaaaaaatg	agtattttaca	111720
tcaattaaca	ggaattttga	attcaatata	gttttgctg	cccatacccc	aaagtaagaa	111780
gctctatagt	gaagaatcaa	tgtaaatttt	aaaaaatcta	atttatactt	tagagaaaaa	111840
aaatccctaa	aaccagacct	gggtttttct	tttgcaagga	gttaggcata	tagttttaga	111900
ctgcttctta	aacataatatt	aagctttttt	taaaaaaaac	aacaacaaca	acagcaacaa	111960
caaaaagaaa	acagcatctc	actccatcac	ccaggatgga	cctgagtgtca	gcgggtgtgat	112020
cacagcttac	tgcaatcttg	atctctgggtg	ctcaaatcat	cctcccacct	cagcccctca	112080
cctctgccat	agtagttggg	actacagggtg	tacaccatga	tacctgacta	atttttgtgt	112140
ttttttttgt	agagacggga	tttcaccatg	ctgcccagac	tggtcttgaa	ttgctgagct	112200
ccagtaatct	acctgcctgg	gcttcccaaa	atttaggaat	tacagggtgt	agccactctg	112260
cccagcctat	aataagcttt	aagaaaaata	gcagttctgc	taaactctac	taaatacttt	112320
tgtgtcttac	aaagaaagtc	aacattccac	tttaccatat	tcaacctaaa	atatgagcct	112380
catcccttgt	acactcagct	gtcatctcag	ctgttgctc	tgctgtacc	aacctcatct	112440
ccagccaaaa	acacaccaac	actttgggtcc	acagtgaggc	acacttatgt	ttccacagtc	112500
catacctgg	ttatttcttg	gcttttttaga	ggaaaaataa	atggctagta	gacttctaaa	112560
ttgaatgtta	cctaaaagtc	tgtctaagga	gatccaaggc	taacagacaa	tctgttcaat	112620
gcatgtctaa	aaccacatca	acccaaaagg	tgtaacatgt	ggttgtaatg	atactatcat	112680
cacagatttg	catgggatca	ctgtcttcca	gtcttgaaga	tgtgtgtttt	tggtgtgtgga	112740
ggcctatagt	tcccctagag	gtaacctaga	acttaagata	taatcacata	caaggaagcg	112800
agagactaat	gatgaggtgt	gtgcaagggtg	agaaattaga	acacagatgc	cctcatgaaa	112860
ttcggtatt	tgaagggtca	caacctctag	agtaggacag	agtcaacaac	agcaacaaca	112920
aggatgaaac	tagtccgttt	agacttggtt	tcatggagga	gttaaaaagt	cttatttaag	112980

aatttatgac	aataattaat	gctcatgtta	agtcagcatt	tatatattata	ctgcttttgat	113040
gggctatcaa	atctcaagct	aaataatgaa	gaacataaag	aggcccaggt	tagaagaagc	113100
ttcatgacac	tggaataagc	aaacataaac	ataagtcaga	gaatgggtta	tcaaccactg	113160
agacttcaaa	gatagccac	tgaaaaagtt	ctaattccaca	gaaattttcc	aggaaaaataa	113220
gaaataaaaa	gcacaaatga	atatcttttaa	tttattttcag	atattaggat	tacttgatgc	113280
aaattgtaaa	ataaagatat	ttaatcattg	aaaataaatg	tgaaaattta	aactctaaga	113340
ccatgtatat	atgtgtgtac	atatgtatgt	gtacatatat	atatgcaaag	actgattata	113400
gaaaccaata	attatatata	atatgtagag	ttccaagcat	atctgcaggc	tgaaggagag	113460
tctctgtgtt	ttataggcat	tgaagcattt	ttagagtggg	taggcaggta	tataaaatttt	113520
cacattgaaa	ggaagaggaa	gaaacagcta	agtccctctc	atgaggcttt	aagtggctctt	113580
ggagagtcag	cctttctctt	cttcttccct	agtaaatttc	atgcagacct	tggcagccta	113640
atcactacaa	tcctgcatca	gtgagtcctc	tgaactggca	ccatagttca	ctaggaaagg	113700
cactcatcca	ccaagttcag	agaggtggcc	atccgcattg	ctaaacagaa	taaaacaaaa	113760
attcactttg	tcactctgct	gacattggcc	ttgctataag	atagcctcat	aaactgcctg	113820
aaaggcctta	ttctttttcaa	aggattttgt	gctgtcttca	agtgatattt	ttctccatgt	113880
cagaaataaa	atatttcagg	attgacctgc	ctcaaatttt	agtttgtctt	ggttattggc	113940
cattgcatgt	ataagtctaa	ttgtgtgaca	gaagttttccg	atactctgct	tcattgaagta	114000
cccttttagga	ctatctctct	gtctcttcag	ttcttcaatc	aatttttccct	gaagttcttg	114060
tgtgaggctc	tgatacaaa	agtaggcagg	tgctggcatc	cagcccagag	ccaccctttc	114120
cagccctagc	acatccttaa	agcaccctctg	accagcaccc	tcaacctggc	caacagggtt	114180
ttcagcatct	acagggttaac	ctccatgggc	ttgagctgca	ccttcacaaa	tcacaagaga	114240
aaccacaaca	cagagtacag	ggaaaacagc	ttttcaaaat	tggttaagggt	agtagtggtg	114300
ttaagatatc	accctgtctt	cctattttgaa	taccctattt	tttttttgcc	tgattgccct	114360
ggccagatct	tccaatactg	tgtttaatag	gagtgggtgag	agagggcatc	cttgtcttgt	114420
gtcacttttc	aaagggaatg	tttccagctt	ttgcccattc	agtatgatat	tggctgtgag	114480
tttgtcataa	atagctctta	ttatttttag	atacatcca	tcaataccta	gtttatgtag	114540
agttttcagc	atgaaggggt	gttgaatttc	atagaacgcc	tttttttctt	catctattga	114600
gataatcagc	tggattttgt	cattcgttct	gtttatgtga	tggattatgt	ttattgactt	114660
gggtatgtta	agtttagcct	gcatcccagc	gataaagcca	acttgatcgt	ggtaggataag	114720
cttttttgatg	tgctgttgga	tttggtttgc	cagtatttta	ttgaggatat	ttgcatcgat	114780
gttcatcagg	gatactggcc	tgaaattttc	tttttttggt	gtgtctctgc	cagggttttg	114840
tatcaggatg	acgctggcct	cataaaatga	gttagggagg	agtcctctct	tttctgttat	114900
ttggaatagt	ttcagaagga	atggtaccag	ctcctgtttg	tacctctggt	agaattcggc	114960
tgtgattcca	tctggtcctg	ggtttttttt	gattggtagg	ctattaatta	ttgccacaa	115020
ttcagaactt	gttattgatc	tatccaggga	tttggtctct	tccttgtttt	ggagatgaca	115080
tgactgtata	tttagaaaac	cccattgtct	cagcccaaaa	tctccttaag	ctgatgaaca	115140
tcttcagcaa	agtcttagga	tacaaaatca	atgtgcaaaa	atcacaagca	ttcctataca	115200
ccaataacag	acaaacagag	agacaaatca	tgagtgaatt	cccattcaca	attgctacaa	115260
agagaataaa	atgcctagga	atccaaacta	caagggatgt	gaaggacctc	ttcaaggaga	115320
actacaaacc	accactcaag	gaaataagag	aggacacaaa	cagatggaaa	aacattccat	115380
gctcatggat	aggaagaatc	aatatcatga	aatgggtcaa	actgccccaa	gtaatttatt	115440
gattcaatgc	tatccctgtc	aagctaccat	tgactttctt	cacagaatta	gaaaaatctc	115500
ttgtaaattt	catatgaaac	tgaaaaagaa	cccatatagc	caagacaatc	ctaagcaaaa	115560
agaactaagc	tggaagcatc	atactacctg	acttcaaact	atactacaag	gctacagtaa	115620
caaaaacagc	atgatactgg	taccaaaaca	catatataga	ccaatggaac	agaacagagg	115680
cctcagaaat	gatgccacac	atctacaacc	atctgatctt	tgacaaaacct	ggcaaaaagca	115740
agcaatagga	taaaggattc	cctgtttaat	aatgatgtt	gggaaaactg	gctagccata	115800
tgcagaaaac	tgaagctgga	ccccttccct	atgccttaga	caaaaattaa	ctcaagaggg	115860
ataaaagact	taaacgtaag	acctaagacc	acaaaaacc	tagaagaaaa	cctaggcaat	115920
accattcagg	acataggaac	aggcaaagac	ttcatgacta	aaacatcaaa	agcaatggca	115980
acagaagcca	aaactggcaa	atgggatctc	actaaactaa	agagcttctg	cacagcaaag	116040
gaaactatca	tcagagtga	caggcaacct	acaaaattgg	agaaaatttt	tgcaatctat	116100
ccatccagaa	tctataagga	acttaaacaa	atttacagga	aataaacaaa	cgaccccatc	116160
aaaaagtggg	caaaagatat	gaacagacac	ttcacagaag	aagacattta	tgtgggcaat	116220
aaacatgtga	aaaaaacctc	atcatcactg	gtcattagag	aaatgcacat	caaaaaaaca	116280
caatgagata	ccatctcacg	ccagttagaa	tggcgatcat	gaaaaagtca	ggaaacaaca	116340
gatgctggag	aggacgtgga	gaaacaggaa	tgcttttaca	ttgttagtg	gagtataaat	116400
tagttcaacc	attgtggaag	acagtgtggt	gattcctcga	ggatctagaa	ccggaaatac	116460
catttgaccc	aacaatccca	ttactgggtt	acatacccaa	aagattataa	atattctact	116520
ataaagacac	atgcacatgt	atgttcattg	cagcactatt	cacaatagca	aagacttgaa	116580
accaacacaa	atgcccatca	accatagact	ggataaagaa	aatatggcac	atatacacca	116640
tggcacacta	tgcagacata	aaagaggatg	agttcatgtc	ctatgcaggg	aatggatga	116700
acctggaaac	catcattctc	agcaaactaa	cacaggaaca	gaaaacaaaa	cactgcatgt	116760

tggttctcact	tataagtggg	tgtgaacaat	gagaacacat	ggacacagga	aggggaatat	116820
cacacaccag	ggcttgtcag	gggttctggg	gctagggag	ggatagcact	aggagaaata	116880
cttaatgtag	attacagggt	gatgggtgca	gcaaacacc	atagcacata	tatacctatg	116940
taacaaacct	gcaggttctg	cacatgtatc	ccagaactta	aagtgttaata	aaacaaatgt	117000
atgtcacctt	gttaaaaaac	agatagtaga	aaaaccagca	aaatgagaac	tggtgctata	117060
taaaaatgta	ttcaaagaac	caagtaacat	atgactttgt	gctcaacttt	aataatcatt	117120
aggggaagtac	acattacaat	tacaagatat	ttgtgttttt	atatactctg	acctatatgt	117180
tgctaaatga	caaaaagaaa	aaaatgatat	tgctaagtac	tggtgggact	atggaacaat	117240
tgaatctctc	acataatggt	agtgagaata	caaattggata	caaccagttt	ggaaaactat	117300
taggcagcat	aaattttaagc	tggacatatt	tatactccat	aagccagcac	ttctactcat	117360
agttacagca	gtcagacatg	catgaatatg	ttcatgaaga	gatatgcaca	agactgaatt	117420
ttgtaatagc	cacatctgga	aataacctat	atataaagtt	tggtgtactt	attatacagc	117480
agtgacagatg	aaggaattat	ttacatatct	atcacactca	tcatcatgaa	taaaaatcac	117540
caacataata	tttagcacca	atgtagtggt	cattggagac	tagacctaac	aaaatatgca	117600
ctgtataatt	tctattacag	aaaattcaaa	accagacaca	attaatctac	agtggtaaaa	117660
gcaaagatat	agttaatttg	aggttactga	ctaggaaagg	gcatgaagac	agatgggtgga	117720
gtactggtaa	tcttctatct	gagaatttag	aagcaagtaa	tacaagtatg	ttcactttgt	117780
aaaaattcat	gaagcaggcc	gggcacgggt	gctcgtgcct	gtaatcccag	gactttggga	117840
ggccgaggca	ggtgaatcac	gaggtcagga	gggttgagacc	atcctggcca	gcacagtga	117900
accctgtctc	tactaaaaat	acaaaaaatt	agccaggcgt	ggtggcgggc	accgtagtc	117960
ccagctacta	gggaggctga	ggcaggagaa	tggtcatgaac	ccggaggcgg	agcttgacgt	118020
gagccgagat	cccaccactg	cactccagcc	tggtgcaacag	agcgacactc	tgactcaaaa	118080
aaaaaaaaaa	aatcataatt	catgaagctg	tacacttacg	ttttgtgctc	attatattgtg	118140
tgtaaattag	acttcaatat	aaagcttact	aaaaacgaat	aaaaatagta	ctagtcttca	118200
agcaagcaaa	gcttcattcc	aatatcaaag	cattctatct	acctatcagt	acacagaggg	118260
tattagtgtg	ctagggctgc	cacaaataag	taccatgaac	ttggtgactt	aaacatgcag	118320
atattattcc	tcacagttct	agaggctaga	agccaagat	caagggtgtg	gcaaaattgg	118380
tttcattctg	agttctcttt	ctggcttggt	gatgatcact	ttatcccagc	ctctttacac	118440
tttatttttc	tgtgtgtatc	tgtattctaa	tctcttctta	taaggatgca	agttatattg	118500
gattagggca	cagctcacc	attaggcttt	attttactaa	atgttctctt	tagatattgt	118560
gtctccaaca	gtcatgtctt	gtgggtgctt	gagttagaac	ttcagcatat	gaattttgga	118620
gagggaggga	aggggcacaa	tccagtcctt	aacacagatt	aagaaacgtg	aaaggcta	118680
agaagtttga	cacaaagttt	gtgacactag	tacgagagaa	actgtatcag	aaaagttgaa	118740
ttaagttgaa	agtaacatgg	taaacctaag	gcaatgtgag	aatccatggc	agacatgaat	118800
gttatcttat	ggattttcca	atgtaagaag	gaaataactg	agaatgaaac	ataaggcaga	118860
gaaggaccag	agagttgtga	gttcccattt	taaatttggt	ttgtgccaaa	tgtcatatct	118920
ctagagaaat	tattcagtga	gaaaaaaaat	ctgacagagt	aattgcttca	tttttgcata	118980
tctgtgaaat	cccttaggga	aataaagtca	tcatacaaat	attataaatt	attcctgtat	119040
ttgtcaccag	aaaagccatt	tgatattctt	tgtaaggata	gctcttccct	tattcataaa	119100
taagtttctg	catgtgtttg	taatcctgga	acacttggtg	tacaatcata	tgtattttca	119160
gagttagata	tatgattgtg	atgattaaat	gactaggtag	aaagaaaaat	gccaattacc	119220
agaaaaatgt	agacacttag	catttaaggt	acttttattt	gttaaagtct	tgaataatga	119280
ggatggaagt	taatggcata	aaaatataag	aggcatgctc	taggatcttt	cactcaatat	119340
aatgaaagc	taatatttat	taagggtttg	ccacacattg	ggcacagtgc	tatgcatact	119400
acatacccca	ttttgtgaaa	tccgaaaaag	agtgcttttg	tatttgctaa	tttcatctgt	119460
aatagaaaaa	aattatagtc	cagaattatt	aagaaacatg	acccagacta	ctcagatcag	119520
aagttctgac	atcagaatgt	gaactcaacc	agtcgactcc	caaacgtatg	tttctaccag	119580
tacagtatgc	tttatggttt	gtagtggaa	ttctttctgt	actaaccatg	agggaaatat	119640
gttattatcc	atatctatta	taggcaaaat	gtcatagaat	tggtttgagg	gttgaatgtg	119700
ttaaaactta	taaaatagat	tagtgtttgg	cttataagaa	acaccatgta	agtgctgggt	119760
aaattagtg	taaaactaaa	acacagaata	aggaacatgt	caaaagaaca	gagcagcatt	119820
tcagaaatat	ctaactccag	atcctgtgaa	ttgattttat	gctaaggcta	tcatattttt	119880
atcaaggcat	tcacttttgt	gtttgggtcta	gtccttaaaa	ttaagaatgt	caaccggatg	119940
tgtgcatttg	tcaaatacac	aaagtggggc	actttaaata	tatgaatttc	actgtatata	120000
aattattgca	taaacaacat	taaacattaa	acaaagaaac	aaagggtgaaa	tctgacagga	120060
gcttgatata	taaaaatgaa	tgaagggtatg	taggggaaaag	aaagagagat	cagactgtta	120120
ctgtgtctgt	gtagaaagga	aagacataag	agactccatt	ttgaaaaaga	cctgtacttt	120180
aaacaattgc	tttgctgaga	tggtgttaat	ttgtagcttt	gccccagcca	ctttgaccca	120240
accactttga	cccaacctgg	agctcacaaa	aacatgtgtt	gtatgaaatc	aagggtttaag	120300
tgatctaggg	ctgtgcagga	catgccttgt	taacaaaatg	tttacaagca	gtatacattg	120360
gtaaaagtca	tgcgccattct	ctagtcttga	taaaccagga	gcacaatgca	ctgtgggaaag	120420
ccgcaggggac	ctctgcctct	gaaagcggag	tattgtccaa	ggtttctccc	catgtgatag	120480
tctgaaatat	ggtctgaaac	caggggcaca	ttgcactgcy	gaaagccgta	gggacctctg	120540

cccttgaaag	cggggtattg	tccaaggttt	ctccccatgt	gatagtctga	aatatggcct	120600
tgtggcatga	gaaagacctg	accatcccc	agcccgacac	ccgtaaaggg	tctgtgatga	120660
ggaggattag	taaaagagga	aagcctcttg	cagttgagat	agaggaaggg	cactgtctcc	120720
tgectgcccc	tggggactga	atgtctcggt	ataaaacccg	atagtacatt	tgttcaattc	120780
tgagatcaga	taaaaactgc	cctatggtgg	gaggtgagac	acgtttgcag	caatgctgcc	120840
ttgttattct	ttactccact	gagatgtttg	ggtggagaga	aacataaatc	tggcttatgt	120900
gcatgtccag	tcatagtacc	ttcccttgaa	cttaattatg	acatagattc	tattgctcac	120960
atgtttgttg	ctgaccttct	tattatcacc	ctgccctcct	actacattcc	tttttgetga	121020
aataatgaag	ataataatta	ataaaaactg	agggaaactca	gaggctgggtg	caggctccttg	121080
atatgctgag	tgccgggtccc	ctggggcccat	tgttgtttct	ctgtactttg	tctctgtgtc	121140
ttatttcttt	tctcagtctt	tcacccccacc	caactagaaa	taccacacagg	tgtggagggg	121200
caggccaccc	cttcaaagggt	acatcactac	tatgattgaa	tagatgtaga	cacagctttt	121260
actcgatgtt	gtataaatca	caaataaaat	ctttgtttca	gatattcaaa	aataaccttc	121320
tataagatgt	tcttgtgaat	atagatgatt	tttatataga	aaaatagaag	gtacatttca	121380
ttaatatcag	tgtaaacagt	ttttgttggt	gttgtaagta	acagaacaca	gctctgggtta	121440
tgctaagcaa	aaccggaaca	ttctgaaagg	atgttagggc	tcctaaatca	atgtgccggt	121500
aaaagaccag	gcttagagaa	cagatagcag	cctaggcagg	tgtggagggt	gagcagatca	121560
aaccacacag	aatcagtggt	tctttgcaac	atcagcctga	tcttcaaacc	tcactgtaat	121620
gaattagatg	aaaaaaaaatt	ttgtcaaaact	tgagtcatta	actcactccc	ttaagacaag	121680
gagaggctag	catctgaccc	ctgcttaagc	ctttctaaac	agagaatctc	atctctcagt	121740
ggaaactaga	agtggaagat	caagaggaca	gaatttccat	gactctcaac	ttgacacatt	121800
ggaaaatttc	ctccaaaaaa	ttcaagtggg	gtgttaatgg	ctggaattta	atagctgtgc	121860
aaccctcgaa	acgcaaatat	gtagatattt	ttcaaaaata	ggggaacaaa	tcatgccctg	121920
cctggaaaat	ctctattgca	ttgagtcctg	aggaagaaga	aagcaacaag	tgagccccgc	121980
ttgtttgtct	aggcttctcc	aagaggggat	tgaactgggt	aaatctattc	agaaataaca	122040
agatcattca	gtcaatatgt	ttctttgata	tcttgttctt	tcctctctct	aaactcattc	122100
tctgccagaa	ttataatcag	gaataaagaa	attggttagt	tttaaatggt	atgttttggg	122160
gcaagtccac	ctataaagta	catttctcaa	atataaagag	gggcagaata	aggaaggag	122220
aaagaagaga	agaagaatag	agacagaagc	tgaattagaa	gggaatgaaa	agaaagacaa	122280
agggaacata	aacaagaaaa	ataaagggca	gtatcaaaaa	aggcagagag	ctgctttgaa	122340
tatccctact	ttagtttacc	tgaaacaaag	ttcattagaa	ataaaatgag	gaaaactgct	122400
gaaaagaggg	gaaaactttt	ggtaagaaga	ttattactct	actggtaata	atagtaataa	122460
tcagtgtgct	attgtattgc	aatcaatata	tatgtaaagt	tcctttctcc	cactgaagga	122520
aattatgaga	aggaacttca	cgttggtgac	tgagttcatt	ctcctgggac	tgacgaatca	122580
ccaggaatta	cagattctcc	tcttcatgct	gttctgtggc	atttacatgg	tcacagtggc	122640
agggaatctt	agcatgattg	ccctcatcca	ggccaatgcc	cggctccaca	cgcccatgta	122700
cttttctctg	agccacttat	ccttccctgga	tctgtgcttc	tcttccaatg	tgaccccaaa	122760
gatgctggag	attttctctt	cagagaagaa	aagcatttcc	tatcctgcct	gtcttgttca	122820
gtgttacctt	tatatcatct	tggtacacgt	tgagatctac	atcctggctg	tgatggcctt	122880
tgactagtac	atggccatct	gaaaccctct	gctttatggc	agcaaaatgt	ccaaaagtgt	122940
gtgttccttc	ctcatcacgg	tgcccttatgt	gtatggagcg	ctcactggcc	tgatggagac	123000
catgtggacc	tacaacctag	ccttctgtgg	ccccaacgaa	attaatcact	tctactgtgc	123060
agaccaccca	ctgattaagc	tggcttggtc	tgacacctac	aacaaggagt	tgtcaatgtt	123120
tgttgtggct	ggctggaatc	tttcgttttc	tctcttcac	atattttatt	cctactttta	123180
catttttctt	gctatcttaa	ggattcgctc	tacagagggc	aggcaaaaag	cttttctcat	123240
ctgtggctcc	catctgacag	ctgttactat	ttctatgca	actctgttct	tctatgtgtc	123300
cagacctcca	tcagaagagt	ccatggagca	aggacaaatg	gtagctgtac	tttataccac	123360
tgtgatcccc	atgttaatcc	catgatctac	agtctgagga	acaaggatgt	gaaaaaggct	123420
ttatccaaag	aactgttcaa	aagaaaattg	tttcctaaat	aaacatcagt	attgattttt	123480
gtcatgctgt	catttttatt	agcctataat	tttttcatag	agcttagtgc	aatacaaat	123540
tatccaaaat	tatacatatt	ccttgaaggg	ttagggaatt	tttatgaagt	gtgaataaaa	123600
gaaatatgag	tattttacatc	aattaacaga	tagtttgata	tcaatatagt	tttaactgcc	123660
cataccccaa	agtaaaaaat	tctatagtga	ggaatcaatg	taaataaaaa	aaaatcta	123720
ttgtatttta	gaaaaataaa	cccttaaaac	cagacctggg	ttttcttttt	ggaaggagtt	123780
aggcatatag	ttttaactg	cttcttaaac	atatattaag	ctattttttt	tttttgaaac	123840
agcatctcac	tccatccacc	aggatggact	ggagtgcagt	ggcatgatca	cagcttacag	123900
caaccttgat	ctcagggttt	caaaccatcc	tcccacttac	accctcacc	cctgccacag	123960
tagctgggac	tacagggtgtg	caccaccata	ccacactaat	ttttgtattt	ttttagagag	124020
cggggtttca	tcatgttgcc	cagactgggtc	ttgaactgct	gagtgcaggt	gatctatctg	124080
cctgggcctc	caaaagaggt	tgctaaactc	gggtgagcca	ctgtgccag	cctgtaataa	124140
ggtttaaaaa	agagcacttc	tgctaaactc	tactagatac	ttttgcctat	cttacagagg	124200
aagtcagcat	tccactttac	catgtccaac	ctaaaacgta	agcctcatcc	cttgacacact	124260
cagttgtcat	ctcagctggt	tcctctgcct	gtaccaacct	catctccagc	ctaaaacaca	124320

ccaatgcttt	ggtccacagt	gaggcacact	tatggtttcca	cagtccatat	ctgggtttatt	124380
tcttggtctt	ttagaggaaa	aataaatgac	cagtaggatt	ctaaattgaa	tgttacctaa	124440
aagtctgtct	aaggagaccc	aaggctaaca	gataatctgt	tcaatgcatg	tctaaaacca	124500
catcaaccca	aaaggtataa	catgtggttg	taatgatctt	gaagatgtgt	gtttttgggt	124560
gtggaggcct	atagttcccc	tagaggtaac	ctagaactta	agatataatc	acatacaagg	124620
aagacgagag	actaatgatg	aggtgtgtgc	aaggtgagaa	attagaacag	agatgccctc	124680
aggaaattcg	gattattgaa	gggctgcaac	ctctagagta	ggacagagtc	aacaacagca	124740
acaacaagga	tgaaactagt	ccgttttaggc	tttgtttcat	ggaggagtta	aaaagtctta	124800
tttaagaatt	tatgacaata	gattaacggt	catattaatt	cagcgtttat	atttacactg	124860
cctttagtgg	ctatcaaadc	tgaagctaaa	aaacatgaa	ataggcccgg	cgtgggtggc	124920
ccacctgaa	atcccagcac	tttgggaggc	ccaggcgggt	ggatcacgag	gtcaggagat	124980
tgagaccatc	tgccaaacac	ggtgaaaccc	cgtctctact	aagagtacaa	aaaatcagca	125040
gggctgtgtg	gcgggcgcgc	gtagtcttag	ctactcagga	gactgaggca	gaagaatggc	125100
ctgaacttgg	gaggcgcagc	ttgcagttag	tggagattga	gccactgcac	tccagcctgg	125160
gtgacagaag	gagactctgt	ctcaaaacaa	acataaacaa	aaacaaaaac	aagcaaacaa	125220
aaaacaaaaa	caagcaaacaa	aaaaacaaaa	cataaagagg	cccagggttag	aagaaacctc	125280
atgacactgg	aataagcaaa	tataaacata	agtcagagaa	tgaattatca	actactcaga	125340
cttcaaagat	atcccgcaga	taagtttcta	attgacagac	attttccagg	aaaataagaa	125400
ataaaaagca	caaatgaata	ccttcaactt	attacagata	ttaggattac	ttgatgcaaa	125460
ttataaaata	aagatatttta	atcattgaaa	taagtgtgaa	aattaaaaatt	cgaagaccat	125520
atataatgtg	gtatatatat	gtatgtgtac	atataatatgc	aaagactgat	tatataaagc	125580
aataattata	tataatatgt	agagttccga	gcataatctgc	aggccgaagg	agagactctg	125640
tgttttatag	gcattgaagc	attttacatt	tttttttatg	ttctcagcac	ctttattttat	125700
ttattttatt	tttttagtatt	tattgatcat	tcttggtgtg	ttctcgaaga	gggggatttg	125760
gcagggtcat	aggacaatag	tggagggaaag	gtcagcagat	aaacatgtga	acaagggtct	125820
ctgggtttcc	taggcagagg	accctgcggc	cttcgcagat	gtttgtgtcc	ctgggtactt	125880
gagattaggg	agtgggtgatg	actcttaacg	agcatgctgc	cttcaagcat	ctgtttaaca	125940
aagcacatct	tgaccgcgcc	ttaactccatt	taaccctgag	tggacacagc	acatgtttca	126000
gagagcacgg	ggttgggggg	aagggttatag	attaacagca	tcccaggga	gaagaatttt	126060
tcttagtaca	gaacaaaatg	gagtctccta	tgtctacttc	tttctacaca	gacacagtaa	126120
caatctgatt	tctcttttct	ttccccacat	ttccccctta	tctatttgac	aaaactgcca	126180
tcgtcatcat	ggcccattct	caatgagctg	ttgggtacac	ctcccagacg	gggtggcggc	126240
cgggcagagg	ggctcctcac	ttcccagacg	ggggggccgg	gcagaggcgc	ccccacctc	126300
ccgggcgggg	tggctgctgg	gcgggggctg	ccccccacct	ccctcccggg	tggggcggtc	126360
ggccgggtag	gggctgcccc	ccacctccct	ccgggacggg	gcagctggcc	ggggcggggg	126420
tgccccccac	ctccctcccg	gacggggcag	ctggccgggc	aggggctgac	ccccacctc	126480
tgagacgggc	ggctgctggg	tggagacacg	cctcacttcc	cggatggggc	ggctgcccag	126540
cggaggggct	cctcacttcc	cagacgtggc	ggctgccggg	cggaggggct	cctcacttct	126600
cagatgtggc	ggcggccatg	cggaggagct	cctgacttct	caggcagggc	agccgggcag	126660
agacggctct	cacctcccag	acggggtggc	ggctcgggcag	agacactcct	cagttcccag	126720
acggggtcgc	ggccaagcag	aggcgctcct	cacttcccag	actgggtggc	cgagcagagg	126780
ggctcctcac	atcccagacg	atgggcggcc	aggcagagac	gctcctcact	tcccagacag	126840
ggtggcggtc	gggcagaggc	tgcaatctgg	gcactttggg	aggccaaggc	aggcagctgg	126900
gaggtggagg	ttgtagcaag	ccgagatgac	gccactgcac	tccagcctgg	gtaacattga	126960
gcactgagtg	agtgagactc	cgtctgcaat	cccgccacct	cggggggctg	aggcgggcag	127020
atcactcgcg	gtcaggagct	ggagaccagc	ccggccaaca	cggcgaaaac	cacaaaaaaa	127080
tacaaaaaac	agtcagggtga	gcggggcatg	cctgcaatcc	ccggcactcg	gcaggctgag	127140
gcaggagaat	caggcaggga	ggttgcagtg	agccgagatg	gcggcagtag	agtccagcct	127200
cggctgggca	tcagagggat	accgtggaga	gagagggaga	gggagaggaa	gagggagacc	127260
gtggagggag	aggagagagg	agaccgtgga	aggagagggg	gagggagagc	attgaagcat	127320
tttagagtgg	ataggtagggt	atataaaattt	tcacattgaa	aggaagagga	agaaacagct	127380
aagtccctct	catgagactg	tcttgagagag	ggttacagca	gagaggctgc	ctttctctcc	127440
ttcctcctca	gtaaattttc	tacagacctt	ggcagcctaa	tctctacagt	cctgcagcag	127500
tgagtcctct	gaactggcac	catagttcac	tgggaaaggc	attcatccat	caagttcaga	127560
gaggtggcca	tccatgttgc	taaacagaat	aaaacaaaaa	ttcactttgt	catctgcctg	127620
acattggcct	tgctatgcaa	tagcatcata	aactgcctga	aaggctcttat	tattttcaaa	127680
ggattttgtg	ctgtctacaa	gtggtattttt	tctccacctc	agaaataaaa	tatttttagga	127740
ttgaccacc	tcaaattttc	gtttgtcttg	gttatcggcc	actgcttata	taagtctaata	127800
tgtgtgacag	aagttcccaa	tgctctgctt	catgaagtac	cctttaggac	tacctcttgt	127860
ctcttcagtt	cttcaatcaa	ctttttcctg	aagttctcgt	gtggggatct	gatataaaca	127920
gtaggcagct	gctggcatcc	agcccagagc	cacctcttcc	aggcccagga	catccttaaa	127980
gcacctctga	ccagcaacct	caatctggcc	aacacttttt	tcagcatata	caggtaaatac	128040
tccatgggct	tgatcagcac	cttcacaaat	cagaaaagaa	accacaaccc	agagtaaaga	128100

aaaaacaacc	tttcaaagtt	agtaaggcta	ttgggtggtgt	taaaaatatca	cccgggttaaa	128160
aaacaaaacaa	actgatagca	gaaaaaaatg	gcaaaaatatg	aactggtgct	atataaaaaac	128220
atattttaag	aaccaagtaa	cttatgactt	tgtgctcaac	ctgaataata	attaggggaag	128280
tgtacattac	aagatatctg	tatctttata	tatctgtacc	tatataatctg	tgtctgtatg	128340
ttgcagaatg	acagaaaaac	tgatattggt	aagcattgga	gagactgtgg	aacaactgac	128400
cctctcatat	aatgctagt	ggaatgcaaa	tggtatataaa	cagtatggaa	aactactagg	128460
cagcataaat	ttaagctgca	catatttata	ctccataaac	caacactact	gcccacaaagta	128520
ctaacaggca	gaaatacatg	aatatgttcg	tgaagagata	tgacacaagat	tgaattttgt	128580
aacagccaca	cctggaagta	tcttatatgt	gtatcaatag	taggaaggat	ttattaattt	128640
tggtgtactt	actatacagc	cgtggagatg	aaggaattat	ttacatatcc	atgacactcc	128700
tcatttttgaa	taaaaatcac	caacataata	tttagcacca	atgtagtgtt	cattggaagg	128760
ctagacctaa	cagaatatgc	actgtataat	ttctattatg	gaaaactcaa	aagcagacac	128820
aattaatgta	cagtgttaaa	agtgaagatg	tagttaattt	gaggttagt	actaggaaag	128880
ggcaagcaga	gagatagtgc	agtactgtta	atgttctact	tgaggattta	gaggcaagta	128940
atacaagtat	gttcactttg	taaaaattca	tgaagctgta	cgctacatt	ttgtgcacac	129000
tttctgtgtg	taaattagac	ttcaatataa	aggttactaa	aaacgaataa	aaatagtact	129060
agacttcaag	caagtaaagc	ttcattccaa	tatcaaagca	ttctattttac	ccatcagta	129120
acagagggtta	ttagtttgct	agggctgcca	caaataagta	ccatgaactt	gggtgacttaa	129180
acatgcagat	ttatttcctc	acagttctag	aggctagaag	tccaagatca	aggtgtgggc	129240
aaaactgggt	tcattctgag	ttctttttct	atcttgtgga	tgatcatctt	atcccgacct	129300
ctttacactt	tcctttttctg	tgtgtatctg	tatttctaate	tccttcttata	aggatgcaag	129360
tcattattgga	ttagggcaca	gctcaccgc	tagaccttat	cttacttaaa	tgttctcttt	129420
cgatatcgtg	tctccaacag	tcacgctctg	tggtggttgg	agctggaact	tcagcataag	129480
aattttggag	agtgagggaa	gaggcacaat	ccagtcacata	acacagatta	agaaatgtaa	129540
aatgctaata	gaattttgac	acaaagttt	tgacactggt	aggagagaaa	ctgtatcaga	129600
aaagtgaat	taagttgaaa	gtaacatggt	aaacctaagg	caatgtgaga	atccatggca	129660
gtcaggaatg	ttattgtatg	gattttctaa	tgtagaaggg	aaaatgctga	gactgaaaca	129720
taaggcagag	aaggaccaga	gagttgtgag	ttcccathtt	aaatttgtgt	tgtgccaat	129780
gtcatctctc	tagagaaatt	attcagtgag	aaaaaaaatc	taacagagta	attgtctcat	129840
ttttgcatat	ctgtgaaatc	ccttagggaa	ataaagtcac	catacaata	ttataaatta	129900
ttcctgtatt	tgtcaccaga	aaagccattg	atattctttg	taaggacagc	tcttccctta	129960
ttcataggta	agtttctgca	tgtgttttta	atcctggaac	tctacttgct	atacaatcgt	130020
atgtattttc	agagtttagat	atatgattgt	gatgattaaa	tgactaggta	gaaagaaaaa	130080
tgccaattac	cagaaaaatg	tagacagtta	gtattttaaga	tacttttatt	tgttaaagtt	130140
ttgattaatg	aggatggaag	ttaatggcat	aaaaataata	gaggcatgct	ctaggatcgt	130200
tcactcaata	taaatgaaag	ctaataatta	ttaaaggttt	accacacatt	gggcacagtg	130260
ctacgcata	tacatactcc	attttgtgaa	atcctaataa	tagcactttt	gtgtttgtta	130320
atttcatcag	taatagaaaa	aaactatagc	ccagagtatt	taagaaatat	gaccagact	130380
actcagatca	gaagttctga	catcacagtg	tgatctcaac	cagttgactc	caaagcacat	130440
gtttctacca	gtacagtatg	ctttatgggt	cgtagtggaa	tttccttctg	tactaaccat	130500
gagggaaata	tgctattatc	catacctatt	acaggcagag	tgtcatagaa	tcggtttgag	130560
ggttgaaatg	gttaaaactt	ataaaaataga	ttagcgtttg	gattataaga	aacaccatgt	130620
aagtgtggt	taaattagtt	gtaaaactaa	aacacagaat	aaggaacatg	tcaaaagaat	130680
agagcagcat	ttcagaaata	tctaactcca	gatcctgtga	actgatttta	tgctaagcct	130740
attgcatttt	tatcaaagca	ttcatctttt	tgtttgtttg	agtcctaata	cttaagaatg	130800
tcaaccagat	gtgtgcattt	gtcaaacaca	caaagtggg	cacttttaaat	atgtgaattt	130860
cactgtatat	aaattattgc	aaaaacaaca	ttaaacaaag	aaacaaaggt	gaaatctgac	130920
aggagcttga	tatataaaaa	tgaatgaggg	tacatcacta	ctatgattga	atagatgtag	130980
acacagcttt	tactcaatgt	tgtataaatc	acaaataaaa	tctttgtttc	agatattcaa	131040
aaataacctt	ctataagttg	ttcttgtgaa	tatagatgat	ttttatatag	aaaaatagaa	131100
ggtacatttc	attaatatca	gtgttaacag	tttttgttgt	tgttgtaagt	aacagaacac	131160
agctctgggt	atgctaagca	aaaccggaac	attctgaaag	gatgttaggg	ctcctaaatc	131220
aatgtgcggt	taaaagacca	ggctcagaga	acagatagca	gcctaggcag	gtgtggaggc	131280
tgagcagatc	aaaccacaca	gaatcagtg	ttctttgcaa	catcagcctg	atcttcaaac	131340
ttcactgtaa	tcaattagat	gaaaaaatat	tttgcaacct	tgagtcatga	acttacttaa	131400
gacaagcagg	gactaacatc	tgacccctgc	ctactccttt	atggtttttt	tttttttttt	131460
tttttttttt	tttttttttt	tttttttttt	agacagcatc	tggtctctgtc	gtccaggctg	131520
gagtgcagtg	gcaccgtctt	ggctcactgc	aagctccgcc	tcccggttc	acgccattct	131580
cctgcctcag	cctcctgagt	agctgggact	acaggcgctt	gccaccacac	ctgccctgac	131640
tactcctttc	taaacagaga	atctgggtctc	tcagtggaaa	ctagaagtgg	aagatcaaga	131700
ggagagaatt	tccatgagtc	ttaactccac	ataatggaaa	atttcctcca	aaaaattcaa	131760
agagagtgtt	actggctaga	gaatttaata	gctgtgcaac	cctcaaaagg	caaatatgca	131820
gacacttttc	aaaataaggg	gaaaaaaatc	atgccctgcc	tggagaatcc	ctattgcact	131880

gagcctggag	gaataagaaa	gcaacaaatg	agcccaacct	gtttgctcag	gcttctccag	131940
gaagggatcg	gattggtgaa	aactattcac	aaagaacaag	atcctcgggc	aaatattgct	132000
ttttgatact	tgctcttttc	tctctttacg	cgcattctct	gccagtgatt	ataatcgagg	132060
aaaaagaaat	tgcttagttc	tgaatgttat	gttttggggc	aagtccacct	ataaagtaca	132120
tttctcaaat	aaaaggagag	gcagaataag	gggaggagaa	acgagagaa	aagaatagaa	132180
aaacagaagc	tgaatttgaa	gggagtgaag	agaaagaaaa	tggaaagaaa	acaagaaaaa	132240
taaagggcag	tatcataaaa	ggtagagagc	tgctttgaat	atccctaatt	tagtttacct	132300
gaaacaaagt	tcagtagaaa	tagaatgagg	aaaactgcc	aaaagagggg	acgttttttg	132360
taaaagatca	tactgtaat	agtaataatc	atgttgctat	tgatttgtaa	tccaatatat	132420
atgtaaagtt	cctttcttc	accgaaggaa	attatgagaa	gaaactgcac	gttggtgact	132480
gagttcattc	tcctgggact	gaccagtcgc	cggaattac	aaattctcct	cttcacgctg	132540
tttctggcca	tttcatgggt	cacgggtggc	gggaaccttg	gcatgattgt	cctcatccag	132600
gccaacgcct	ggctccacat	gcccattgtac	tttttctcta	gccacttatc	cttcgtggat	132660
ctgtgcttct	cttccaatgt	gactccaaag	atgctggaga	ttttcctttc	agagaagaaa	132720
agcatttcct	atcctgcctg	tcttgtgcag	tgttaccttt	ttatcgctt	ggcccatgtt	132780
gagatctaca	tcctggctgt	gatggccttt	gaccgggtaca	tggccatctg	caaccctctg	132840
ctttatggca	gcagaatgtc	caagagtgtg	tgctccttcc	tcacacgggt	gccttatgtg	132900
tatggagcgc	tcactggcct	gatggagacc	atgtggacct	acaacctagc	cttctgtggc	132960
cccaatgaaa	ttaatcactt	ctactgtgcg	gaccaccac	tgattaagct	ggcttgttct	133020
gacacctaca	acaaggagtt	gtcaatgttt	attgtggctg	gctggaacct	ttctttttct	133080
ctcttcatca	tatgtatttc	ctacctttac	attttccctg	ctattttaaa	gattcgctct	133140
acagagggca	ggcaaaaagc	tttttctacc	tgtggctccc	atctgacagc	tgctactata	133200
ttctatgcaa	cccttttctt	catgtatctc	agacccccct	caaaggaatc	tggtgaacag	133260
ggtaaaatgg	tagctgtatt	ttataaccaca	gtaatcccta	tgctgaacct	tataatttat	133320
agccttagaa	ataaaaaatgt	aaaagaagca	ttaatcaaag	agctgtcaat	gaagatatac	133380
ttttcttaaa	aatcagttat	cttttggttt	ctaaagccct	tcctagactt	ttttcttttg	133440
ctgagaaata	tagtgcacat	atggagaaca	tgcagtttt	caaaacttta	tttattttta	133500
ctttattatt	atattttgag	atggagtttc	tctctgtctt	aggctggagt	gcagtgggtg	133560
gatctcggct	cactgcaacc	tttgctccc	gggttcaagc	aattctcctg	cctcagcctc	133620
ccgagtagct	gggaacacaa	gcgcacacca	ccatgcccga	ctcatttttt	gtatttttagt	133680
agagacaggg	tttcaccatg	ctggccaggc	tcggcctccc	aaagtgtctg	gattacacgc	133740
atgaaacacc	gcgcccagtc	taaaaacttt	attttctaaa	attcaaatac	gtacaatttt	133800
gttcacaaaa	gcttttatgt	tttaagttgt	cattcatctt	gttcagcagt	tattttaagt	133860
tctttgtctt	ccgtgcacag	aatggctttg	tacctccatg	cccttaggtt	taggtaagat	133920
catgtggcta	tttctggaag	atgagattaa	aattcacata	tgctacttct	tgcttgaata	133980
cttaattgat	tgttagarca	tttttgagtg	gatctgttgt	ttttattttt	ccatgggtga	134040
ccagcaagac	ttaatatagt	ggctgcccag	tcaggagaca	tggaaactg	ttctcatccg	134100
actcacaatg	gcaatacaaa	acggctgata	aataacgttt	tcataagcta	ctatgatatg	134160
tggagtttgc	ttgtttccct	agcacaaaat	agcctattct	gattgatgcc	atattaatta	134220
tacaaattca	cacaggctga	attatataat	atagaatgag	aacatcacaa	accttgaaga	134280
aatcacattt	gagattttgt	tttgtgttct	tgtagtcatt	tttaatgctt	ttacatacac	134340
atgtgtgttc	agttaaaatt	atttattata	attaccattt	gaacctactc	atgattaatg	134400
tatgtagttt	taaatgtcaa	ataatattac	aagccatata	taaactcctg	tctcacttct	134460
accttaccac	taactcccca	tagataatac	tttcttggtt	tttcttttgg	aaattaaccc	134520
attttaaatt	atatgcttgt	attcctctgt	actgattttt	caaatatgca	cataatttat	134580
tgacatctgt	ttattaaaga	taagggtgcca	tcattctttc	accaatcact	tcattcttac	134640
cctacaatga	tcacttcttt	ctcttcattg	tcacagtagg	atcacatttg	aatttttggc	134700
ttaatcagta	tctactgtta	aaattactat	gaatgtatca	ttaataatac	ctgaagtata	134760
ctataatact	ttgagcatca	ctaactactg	tattaattat	taataatatg	aataactacta	134820
tgattgtaat	tctcttcttg	cacagttact	ggattttcat	aaagttgaca	atggcctcca	134880
gttttgctct	tctttttgta	tagtagctac	ttttcccaa	actgtcacta	aactgtaaag	134940
cacctttata	gggtcaaaca	caatagatga	tctatagttt	ccatattttt	ttctcagacg	135000
ttctctgtcc	tcccattgga	ttctgctctg	tttgagagc	tgttatttga	agataattgat	135060
tccaatcatt	ggttttaaggc	atttcattca	ttcaacttga	ttacatgaca	atatgcaaca	135120
aactggagat	tcaacaaaaa	taagacagaa	aaaagtctta	aagagagttt	tatggaacag	135180
ttaatgaact	tttctgctgt	tatcatgagt	ggcacaaggt	cagagataac	taggtccatg	135240
catgtttgta	tttttctgca	atgtcagaat	tttcttgatg	ctatttcaat	cataaaatcc	135300
atgagctaca	tggggttccc	gaggaggcaa	ttctccttaa	aacttctctg	tcactcagta	135360
gtcagagcca	tgggcaaaca	ggctcaagtc	attcaacaag	tcagtcagta	ttgcagcca	135420
tgaattacag	tatatattaat	cagtctataa	atgtaataga	ttacacattg	tacagcaaac	135480
aaagtaacat	ttatcatcaa	gaataaagg	actggaaatg	ggttaaggaa	ccagtccact	135540
gagagtgaca	tgaacaaaaa	gaatagccta	ctcaggccct	ggtggtccat	caataacctt	135600
gtaaaagaaga	gttttcggtg	tgggcaaagc	cttcagtggc	aaatgcaaga	tgcttatctc	135660

aagtataaac	aagatggtgt	cttttaaggt	ggctgtttca	agctgctgaa	atcctgctct	135720
tttatggaca	cagagtcctc	tagtaagaac	tgatagtggg	agagtgactt	tggtatgtcc	135780
ttatctgggt	ggatgcagtc	tttcttgatt	aggcaaaaca	tctggccctt	gttggcatga	135840
tgcccttaaa	aatgtaagat	gaagtcattt	tctaagatgg	agtaacttat	atcaatgggg	135900
ctctatacta	cgattcagcc	ccaggttccc	ttctacactt	tcctttaccc	ttaccatttc	135960
agccttagct	gaagagctgg	gtgcagtgge	tcatgtttgt	aatcccagca	ctttgggagg	136020
ctgaggtggg	tgaatcacca	gaggtcagga	gttcgccact	agcctggcca	acatgggtaa	136080
accctgtttc	tactaaaaat	acaaaaatta	gctgagcatg	ctggtggaca	cctgtaatcc	136140
cagctatttg	ggaggctgag	gcaggagcat	tgcttgagcc	caggagacag	aggttgcaag	136200
gagccgagac	cgcactgttg	ccctccagcc	tgggcaacaa	gagtgaaatt	ctatctcaag	136260
aaaatagact	tagctgaaga	attatctctt	cctgcaaggt	ttctttaaca	cattcaggat	136320
gtgtagtgtc	aactgaggaa	tgatgagatt	cataaattta	gaaagggtga	ctttctcata	136380
aaggggtgta	gcctgtaggg	tgaccgttct	gacaggctgt	gaagcatatc	ctccagctag	136440
aagttggaaa	gagacacttc	gacagtatga	agagtaagac	agggatttat	gctgaatggg	136500
atgaccaaata	atattacaca	tatatgataa	tacatattca	acaggctata	gaaaaaacta	136560
tgaatattca	caaagaagag	gcacaggcat	gaatagtagg	ctaataataag	caacatgcat	136620
cccattgttc	ctttggagtg	gggacttaac	atttaaattgt	gtcatgatta	gactctatgc	136680
acccaaagg	gaatcagaag	acaccaagac	cctctgtgca	cagcctctgt	tgactggcaa	136740
gagccactag	gttattgggt	gtctcttatc	aagaagggaat	gctgggtcaat	tgctgtgttg	136800
aaaccgcaaa	aagagaagtc	cagtgtcagg	tggtttgcag	atatcagtg	tggtgcgagt	136860
ctcacaagg	cagggtttctg	tttaaccctt	attgtaggaa	gcctaattgg	gttttagcaag	136920
ggaggggaga	taacgaggca	tgtctgatct	cccatctgtc	atggcaggaa	ctcagatttt	136980
aaagtttttc	tgaggtttcc	ttgaccaaga	ggcagtcctg	tcaattgatt	caggggttag	137040
gattttatatt	gtattttctca	ttaggtacca	catgatgatt	cacccacaga	ttcacaatta	137100
tattattgca	ttcataacat	ggttctataa	ttatatgcat	gtaaatctgt	tccttccact	137160
attttagcaa	gttctcaaa	gaaaggacca	catctttttg	tttttatatt	tttaccacct	137220
taagatagt	ttctataaa	ggaggatgcc	catttttttt	ttgaaactgt	gagaacaatc	137280
cttccactt	tctaccttg	tctgtaatta	tgccaatta	cagattttctc	tcactgatac	137340
tcgcttctcc	catcctaaca	tatatccaag	gcagaacaat	agatcattta	gtttaagaaa	137400
accatgttca	agttctttat	cataaatggc	ccactgaaag	cccagcaacg	tgaatcataa	137460
ctgagcaaga	attggagaaa	gtaatttcat	tgccagcaga	caggaaagat	cacatactac	137520
atcctattct	tcatagcaga	gagacagata	acaataaatg	ctgaactaca	gtaaaagatg	137580
ttaagggaaa	tatttgtgag	gaataaatct	ttgtagcaat	gtattttcct	tgatatgcaa	137640
tcataattat	ccatagcatt	tgggaaacaa	ctgacaattt	ttatcacctt	tataaatgtt	137700
agttttgatc	tttatagcaa	ggttataatg	gaaaaatcaa	ccactgtgta	ataaaaattat	137760
tttaaaatga	acagaattac	actaggctgt	ctgggacaga	ggcaaggga	gggctgagtc	137820
atgatttaag	gtgcaggaaa	caaaagggac	ctcattgttg	ctcagacaga	aaagaggttt	137880
gggtgggaatc	agacaacagg	tatatattga	gacaacgaaa	tatccaatcc	ttgaaaaagt	137940
acattcttgt	gcatcacttt	ttcatagcca	accgtcctaa	gattttatgc	atgtgataag	138000
ctgatgataa	aacattctct	tcaagttgaa	acagaataca	gttgtggaaa	aatattttggc	138060
tttgtaatta	ttcagaactg	agcctgaatc	ctagttttat	tactattttg	ttagctgggt	138120
aaacttagag	aagttccctc	tccatattcag	tttattcaaa	tgcaaaaacc	catttcatgg	138180
agttattgtg	aatatcaaat	attattttta	atatacatat	tcctcaattg	catttttgagg	138240
caagtatgct	gagttccagt	gtggactcaa	tttcatgaaa	gttttttaac	atgggaaaca	138300
tgatcaaaa	aataagttaa	atatgttagt	tattcattta	tttaacatat	gattattgtc	138360
cctgtcagtc	actttcatca	ttggcagtc	ccagtcctct	ctacctgttt	cattgtttct	138420
tcacagtcct	cttcctgttg	tattgtttca	tctatctgtt	tctaaaacat	ttcatgtttt	138480
ttccagaaat	tatttgtacc	tagtattatt	tgtttacata	tcttaggcac	cccatcaaaa	138540
tgcaaatccc	tttggtgaag	aaatccttta	aaaatatttt	tattattcag	attaaatagt	138600
attgaagttt	gtacttagta	catattcttg	tgtgaacttg	ataaaggaca	aacaatggag	138660
gaaatatggt	agtgtctctg	agatgggaag	gacaattacc	tgaattcagg	tttcatgaga	138720
agttaagtgt	cctcagacta	ttttaaat	gtttttcagt	attgtataaa	gtgctaccct	138780
cgttggataa	cagggtgattg	ctttgagctc	tactgaagta	taaaatatag	atttttttct	138840
aacatcttga	ttcaagataa	aatagtacaa	ccaattagta	tttcccttga	gaatgttctc	138900
cactgtgatt	tcacttctaa	ttacctcttc	ttacacattt	ggggattctc	ctgagatata	138960
tgctgagccc	agtgatgtgg	gtatatatct	tccagcactg	gccagaattt	gacctttggt	139020
gtcatgaaaa	agacaccctt	attttccacag	gtaagaaagg	aaatgttttt	gcatattatt	139080
tttcagtatc	taataatgtc	tgtattcact	ttgttaaatt	gtgtacattt	tagacagcaa	139140
tgtgtttaaa	taggtagttt	tgaggcaaat	ttgcacagac	aatgcatttt	ccatgaaaga	139200
aaatctgtag	ggagcttact	tagcttcatc	tttcaacttt	ttgatattac	cagtgttatt	139260
gaaacatcct	ggtggaattt	catagtatgg	ctatttccagc	agatgttttc	actgttatta	139320
gtttcaagta	atattatttt	tgtgttttcc	atttgcctaa	tgtcttggtg	cctactgtca	139380
ccaatcgcca	caagaaaaag	gcaagttgaa	aataatttaa	gtctacatag	cttaattaat	139440

cacataaaat	ttttctgacg	tctaagtaaa	ataaatgctc	aaacaggctt	tttattgtga	139500
ccattaaaca	tgtgtgaaa	tggtccatta	gcttcagtat	gtggagctaa	cgaacttggg	139560
tgagtagatc	ttaagttctc	ttgggttctc	ttattttata	agatttctggg	ttcttttcca	139620
atgccctatt	tttgtctaga	gacctagttt	ttttacaagc	aatacttggtg	cctcagtgag	139680
actttagttt	tcagaatatt	attttacttt	tttcaacaaa	atacttgaaa	cataaatcag	139740
cctgattata	atcaaatcag	tctgattata	atcaaatcag	tctgatttcta	atcaaatcag	139800
taacttgtgt	caaggacctt	aaacagtaag	ttgatgaatg	aaatttctcat	acctattttt	139860
ctaggctgca	caagtagtca	cagaatcatt	ctcgggtcat	tatcaaattc	atcatcatca	139920
aagttattga	ctgcatttga	atgtttgttt	ttgagtgtttc	ttgcctctca	gcagcagttg	139980
acagatttct	catgggctct	atattgttat	attagctgtc	tctgattgct	attgtcccg	140040
aatgctagaa	ttaaaatatg	gttaaygata	atgggtctcca	ctaaaagtgc	atgtccagat	140100
gaccagtgaa	acctgagcaa	atttgcaaa	ctccttagag	actaagtcag	gactaaaacc	140160
aagacctggg	attgaagaag	ttgctcacca	ccagagagtt	aaaagaagcc	cttgtgcctt	140220
ccttcttgcc	aattaagtta	caattcatag	gcattattct	agatttcttg	cccagatttt	140280
tcatattctt	tacagtttctg	gcactgatac	ctcgggtggc	tgccttctct	cttctctatc	140340
catctcttat	ctttgttaga	gtgcttgctc	ctatcatctg	taactcaaag	acaactctaa	140400
ctcaaagtcc	tcattttattc	atatttgttt	cctgggacag	gataaggagg	caataatatt	140460
agataaattg	aattttaaca	ttttggaaac	aatttctgtc	attaccaac	cagtcaattg	140520
aaccaaagga	agagatagac	ctttctggga	aagtaaaata	ttacagaagg	agagcaccgt	140580
tctgagaatt	ataatatatg	atattgtctt	tgattcttct	gcttatgagt	tgtaagctgg	140640
gaccagaatg	tcaaattttc	tgagcctggg	tactcaccta	actaaattta	tttctactat	140700
attgtccact	gctctatttc	tagcatccag	caccatgtct	ggaacttgaa	aaatgctcaa	140760
taattatctg	ctataagcac	gcattgcatac	acaaatgcac	ggctgacaac	atattacaaa	140820
gtaaataggt	gttttttttaa	ctataaaatt	tcactttaat	aagagttag	caattgttgt	140880
aagatctcat	acaattttaat	agaaaatatg	tgtctgatat	tcttagatta	ggtgaaaaat	140940
aaagtgtac	tcgtattgac	ttcctgagac	tgctcagaag	agataagttt	tatcagcttc	141000
tgacaagttc	tccactaatg	acatttgctc	atgtctgaat	tgccccatgg	aaaaaaatta	141060
gatgtaaatt	tcattttacg	caattgttag	tactactgaa	ttgtttttta	ccaaaatttg	141120
gagacagatt	aacacatatg	atatttttaac	ttaatgtgat	attttatata	tttaarataa	141180
tttgtgataa	attcagtaaa	tgcataatgt	ctatataaat	tgtaagctac	aaaatataat	141240
gaatacacat	taaaccactc	cctagaatta	taagtaattt	ctgtgcattg	tttaaagtaa	141300
atgcacaatt	taataatttt	cccatttttaa	taatctataa	tccattaagc	caatagtaaa	141360
tactaaaata	gtccctcttt	ccaaccctga	tctgaaatgt	catctttgtt	atagccaca	141420
tcacctatat	acatgtagct	gttcctggac	tttctattct	ggaacattag	ttaaagtgt	141480
tatttttttt	caattttcatg	tcaataaac	actgtcctga	atactgggtt	tacagcaaat	141540
cttgatatct	aataagtaac	tctgcttatt	gcccctgag	atattgagtc	ttacgggtat	141600
tttactactc	cgtataaata	ttagaatcag	atactccaca	agaatttgtt	ttgaattttg	141660
attggaattt	atgtgactct	atgggtcact	taggaaagac	tgaccttttt	atgctattga	141720
atccttccct	tagtgaacaa	agaatctctc	tccattttta	gttctttctt	tctctctctt	141780
ttctttcctt	tcctttcctt	tcctttcctt	cctttccttt	cctttccttc	tttcttcttt	141840
ctttttcctt	ctttctttct	ttcttctctc	cttctctctc	tccttctctc	cttctctctc	141900
ttctttgttt	ctgagacgaa	ctctcgcctc	tcttttgccac	ccaggctgga	gtgcagtgga	141960
atgatctcag	tgactacaa	cctctgcctc	ctgtgttcaa	gtgattctcc	tgccctcagtc	142020
tcttgagtag	ctgggttac	aggtgcacac	ctccatacct	ggctgatttg	ttttattttt	142080
agtagagaca	gggtttcacc	atgttggtc	ggctggtctc	gaactcatga	ccagaagtga	142140
tcaaccctgc	ttggcctccc	aaaatgctgg	gattataggc	ataagccacc	acatccagcc	142200
cattttttaag	gctttttaat	gttgtgtggc	aatggcatca	aagtgatcac	ataattttat	142260
ctgggtatat	tagcagggag	taagtataga	ttgagaacct	gaaaacattt	ttttaatcat	142320
cttaggggtga	ttgagttaat	tccttttatc	ctaattggct	aactacacat	cagggttaac	142380
ataatggagg	aataggaaat	tctttgatat	aggacttctt	tatacagaga	tataaaaagag	142440
catgtgagcc	aagcagggga	ctataatgtt	ggttctatgc	agcatgaatg	ttgtaaaaata	142500
gcaagaaaat	aaaatatagg	aacaaattaa	aacatagatt	gataacctcaa	agataatata	142560
tatgaaaatt	catatagaat	tgagatattg	atgaaggagc	ataaaatacac	ttgtttaacc	142620
caacagacag	acaggctaaa	ttgggatgtg	caaattggaa	aaaatgctta	taaacacagt	142680
tatatcaatg	ttaagactca	aacgaaagcc	ttattttaca	taagttccca	aaaactaact	142740
tataaaca	gaaccaatat	acatatcaca	atgaaaagca	ctactactaa	aaacaacaaa	142800
atataaaaaat	acaccgagac	agtaagttga	actcgggtgag	atatatagta	tattagcaga	142860
tcaccgaatg	gggatgtatg	agataagcat	ctcagtgagg	ttagtcactt	catctctcta	142920
ggattcagtc	tctcagtcct	cagaatgaag	agctttgcct	gcattatcct	caaagtcctt	142980
tctacctctc	catgtagctt	tgtatgtata	tgtaagcatg	tcattagaag	ttctaagcat	143040
ttcaaaaatct	ctattacaat	ttaatcttta	acataataagt	tatctagatt	tttaaaagaa	143100
atttcccaca	gcataaggat	actttcgttt	ataattttgc	attaagcctc	caacttaatt	143160
gcacactgtg	attacaaatt	cagcctcagt	ggaaaccact	tgttgcaaat	gtttagactt	143220

46

```

gcttcataagt ataactgttc atcttcagtt acagaactgc tactgagata acataactaa 143280
agcctttttgg ctcttttttat acaaagcatg atattttaact aggggttttag tgatttttta 143340
aaagttttctc tttctcctta gatattcaga ccaatgcgtc tcatatgaga tgaagaaatg 143400
tccagaagaa actatactga actgacagaa tttgttctct tgggtctaac aagccgtcca 143460
gagctgcgag ttgttttctt ggcactgttc ctttttgtct acatagccac tgtggtagga 143520
aacttgggga tgattatttt aatcaaagtt gattctcgac ttcacactcc catgtaattt 143580
tttctctcca gtttgtccat tctagatctg tgtttctcca caaatttcac tcccaaaatg 143640
ctagaaaatt tcttatcaga gaagaagacc atttcctatg cagggtgttt gatgcagtgc 143700
tatgttgtca ttgctgtggt ccttgcagag cactgcatgt tggcagtcac ggcatatgac 143760
cgctatatgg ccattctgtaa tccattgctc tacagtagca aaatgtccca aggtgtttgt 143820
gtccacctgg tcatgttccc ttatgtctat ggctttcttc tcagtgtgat ggaaacctta 143880
aggacctaca acctctcctt ctgtggaaca aatgaaatca accatttcta ctgtgctgat 143940
cctcctctta tcaaactggc atgctctgac acgtacagca aggagctgtc catgtacata 144000
gtagccggct acagcaacgt ccagtctctt ctratcattc tcacatccta catgttcatc 144060
cttgctcgta tcctcagaag ccattctgca gaggaagga aaaaagcttt ttccacatgt 144120
ggttcccacc tgacagttgt cacaatcttc tatggaaccc tcttctgcat gcatttgaga 144180
cgtcccacag acgagtcctg ggagcagggg aaaatggtgg ctgtgtttta caccacagtg 144240
atactcatgc tgaactccat gatctatggc ctcaggaaca aggatgtgaa agaggcggtg 144300
aaaaaagcaa taggaaaaca aacattggga aaataaaaat gctaagctat cattaanaaa 144360
ttgtgaagta atgagatata atatcattgg gtttagatgc acattttagg ctacatttgc 144420
acaattcatt tctaattttc tgttaggtag ctgactgagt 144460

```

<210> 2

<211> 195

<212> DNA

<213> Homo sapiens

<400> 2

```

atg agc ttc tta ata aga agt gat tca aca cta cac act cca atg tgc 48
Met Ser Phe Leu Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Cys
1 5 10 15
ttg ttc ctg agt cat ctg tcc ttt gta gat ctg tat tat gcc acc aat 96
Leu Phe Leu Ser His Leu Ser Phe Val Asp Leu Tyr Tyr Ala Thr Asn
20 25 30
gcc act cct ccg atg ctg gtt aac ttt ttt ttt cca aga gaa aaa ccg 144
Ala Thr Pro Pro Met Leu Val Asn Phe Phe Phe Pro Arg Glu Lys Pro
35 40 45
ttt cct tta ttg gtt gct tta tcc aat ttc acc ttt tca ttg cac tgg 192
Phe Pro Leu Leu Val Ala Leu Ser Asn Phe Thr Phe Ser Leu His Trp
50 55 60
tga 195
*
65

```

<210> 3

<211> 948

<212> DNA

<213> Homo sapiens

<400> 3

```

atg ttc tcc cca aac cac acc ata gtg aca gaa ttc att ctg ttg gga 48
Met Phe Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
1 5 10 15
ctg aca gac gac cca gtg cta gag aag atc ctg ttt ggg gta ttc ctt 96
Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
20 25 30
gcg atc tac cta atc aca ctg gca ggc aac ctg tgc atg atc ctg ctg 144
Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
35 40 45
atc agg acc aat tcc cac ctg caa aca ccc atg tat ttc ttc ctt ggc 192
Ile Arg Thr Asn Ser His Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
50 55 60
cac ctg tcc ttt gta gac att tgc tat tct tcc aat gtt act cca aat 240

```

47

His	Leu	Ser	Phe	Val	Asp	Ile	Cys	Tyr	Ser	Ser	Asn	Val	Thr	Pro	Asn		
65					70					75					80		
atg	ctg	cac	aat	ttc	ctc	tca	gaa	cag	aag	acc	atc	tcc	tac	gct	gga	288	
Met	Leu	His	Asn	Phe	Leu	Ser	Glu	Gln	Lys	Thr	Ile	Ser	Tyr	Ala	Gly		
			85						90					95			
tgc	ttc	aca	cag	tgt	ctt	ctc	ttc	atc	gcc	cta	gtg	atc	act	gag	ttt	336	
Cys	Phe	Thr	Gln	Cys	Leu	Leu	Phe	Ile	Ala	Leu	Val	Ile	Thr	Glu	Phe		
			100						105					110			
tac	ttc	ctt	gct	tca	atg	gca	ttg	gat	cgc	tat	gta	gcc	att	tgc	agc	384	
Tyr	Phe	Leu	Ala	Ser	Met	Ala	Leu	Asp	Arg	Tyr	Val	Ala	Ile	Cys	Ser		
			115					120						125			
cct	tta	cat	tac	agt	tcc	agg	atg	tcc	aag	aac	att	tgc	atc	tct	ctg	432	
Pro	Leu	His	Tyr	Ser	Ser	Arg	Met	Ser	Lys	Asn	Ile	Cys	Ile	Ser	Leu		
			130				135							140			
gtc	act	gtg	cct	tac	atg	tat	ggc	ttc	ctt	aat	ggg	ctc	tct	cag	aca	480	
Val	Thr	Val	Pro	Tyr	Met	Tyr	Gly	Phe	Leu	Asn	Gly	Leu	Ser	Gln	Thr		
			145				150				155				160		
ctg	ctg	acc	ttt	cac	tta	tcc	ttc	tgt	ggc	tcc	ctt	gaa	atc	aat	cat	528	
Leu	Leu	Thr	Phe	His	Leu	Ser	Phe	Cys	Gly	Ser	Leu	Glu	Ile	Asn	His		
				165					170						175		
ttc	tac	tgc	gct	gat	cct	cct	ctt	atc	atg	ctg	gcc	tgc	tct	gac	acc	576	
Phe	Tyr	Cys	Ala	Asp	Pro	Pro	Leu	Ile	Met	Leu	Ala	Cys	Ser	Asp	Thr		
			180						185					190			
cgt	gtc	aaa	aag	atg	gca	atg	ttt	gta	gtt	gca	ggc	ttt	act	ctc	tca	624	
Arg	Val	Lys	Lys	Met	Ala	Met	Phe	Val	Val	Ala	Gly	Phe	Thr	Leu	Ser		
			195				200							205			
agc	tct	ctc	ttc	atc	att	ctt	ctg	tcc	tat	ctt	ttc	att	ttt	gca	gcg	672	
Ser	Ser	Leu	Phe	Ile	Ile	Leu	Leu	Ser	Tyr	Leu	Phe	Ile	Phe	Ala	Ala		
			210				215							220			
atc	ttc	agg	atc	cgt	tct	gct	gaa	ggc	agg	cac	aaa	gcc	ttt	tct	acg	720	
Ile	Phe	Arg	Ile	Arg	Ser	Ala	Glu	Gly	Arg	His	Lys	Ala	Phe	Ser	Thr		
						230					235				240		
tgt	gct	tcc	cac	ctg	aca	ata	gtc	act	ttg	ttt	tat	gga	acc	ctc	ttc	768	
Cys	Ala	Ser	His	Leu	Thr	Ile	Val	Thr	Leu	Phe	Tyr	Gly	Thr	Leu	Phe		
						245					250				255		
tgc	atg	tac	gta	agg	cct	cca	tca	gag	aag	tct	gta	gag	gag	tcc	aaa	816	
Cys	Met	Tyr	Val	Arg	Pro	Pro	Ser	Glu	Lys	Ser	Val	Glu	Glu	Ser	Lys		
			260						265						270		
ata	act	gca	gtc	ttt	tat	act	ttt	ttg	acc	cca	atg	ctg	aac	cca	ttg	864	
Ile	Thr	Ala	Val	Phe	Tyr	Thr	Phe	Leu	Thr	Pro	Met	Leu	Asn	Pro	Leu		
			275						280					285			
atc	tat	agc	cta	cgg	aac	aca	gat	gta	atc	ctt	gcc	atg	caa	caa	atg	912	
Ile	Tyr	Ser	Leu	Arg	Asn	Thr	Asp	Val	Ile	Leu	Ala	Met	Gln	Gln	Met		
			290				295							300			
att	agg	gga	aaa	tcc	ttt	cat	aaa	att	gca	gtt	tag					948	
Ile	Arg	Gly	Lys	Ser	Phe	His	Lys	Ile	Ala	Val	*						
					310					315							

<210> 4

<211> 519

<212> DNA

<213> Homo sapiens

<400> 4

atg	tta	aag	aaa	aac	cat	aca	gcc	gtg	act	gag	ttt	gtt	ctc	ctg	gga	48	
Met	Leu	Lys	Lys	Asn	His	Thr	Ala	Val	Thr	Glu	Phe	Val	Leu	Leu	Gly		
1			5						10					15			
ctg	aca	gat	cgg	gct	gag	ctg	cag	tcc	ctt	ctt	ttt	gtg	gta	ttt	cta	96	
Leu	Thr	Asp	Arg	Ala	Glu	Leu	Gln	Ser	Leu	Leu	Phe	Val	Val	Phe	Leu		
			20					25						30			
gtc	atc	tac	ctt	atc	aca	gta	atc	ggc	aat	gtg	agc	atg	atc	ttg	tta	144	
Val	Ile	Tyr	Leu	Ile	Thr	Val	Ile	Gly	Asn	Val	Ser	Met	Ile	Leu	Leu		
			35				40							45			

48

atc	aga	agt	gac	tcg	aca	cta	cac	act	cca	atg	tac	ttc	ttc	ctc	agt	192
Ile	Arg	Ser	Asp	Ser	Thr	Leu	His	Thr	Pro	Met	Tyr	Phe	Phe	Leu	Ser	
50						55					60					
cac	ctc	tcc	ttt	gta	gat	ctc	tgt	tat	acc	acc	aat	gtt	act	cct	cag	240
His	Leu	Ser	Phe	Val	Asp	Leu	Cys	Tyr	Thr	Thr	Asn	Val	Thr	Pro	Gln	
65					70				75					80		
atg	ctg	gtt	aac	ttt	tta	tcc	aag	aga	aaa	acc	att	tcc	ttc	atc	ggc	288
Met	Leu	Val	Asn	Phe	Leu	Ser	Lys	Arg	Lys	Thr	Ile	Ser	Phe	Ile	Gly	
			85						90					95		
tgc	ttt	atc	caa	ttt	cac	ttt	ttc	att	gca	ctg	gtg	att	aca	gat	tat	336
Cys	Phe	Ile	Gln	Phe	His	Phe	Phe	Ile	Ala	Leu	Val	Ile	Thr	Asp	Tyr	
			100					105					110			
tat	atg	ctc	aca	gtg	atg	gct	tat	gac	cgc	tac	atg	gcc	atc	tgc	aag	384
Tyr	Met	Leu	Thr	Val	Met	Ala	Tyr	Asp	Arg	Tyr	Met	Ala	Ile	Cys	Lys	
			115				120					125				
ccc	ttg	tta	tat	gga	agc	aaa	atg	acc	agg	tgt	gtc	tgc	ctc	tgt	ctg	432
Pro	Leu	Leu	Tyr	Gly	Ser	Lys	Met	Thr	Arg	Cys	Val	Cys	Leu	Cys	Leu	
	130					135				140						
gct	gct	gct	ccc	tat	att	tat	ggc	ttt	gca	aat	ggg	cta	agc	aca	gac	480
Ala	Ala	Ala	Pro	Tyr	Ile	Tyr	Gly	Phe	Ala	Asn	Gly	Leu	Ser	Thr	Asp	
145					150					155					160	
cac	cct	gat	gct	tcg	tct	gtc	ctt	ctg	tgg	acc	caa	tga				519
His	Pro	Asp	Ala	Ser	Ser	Val	Leu	Leu	Trp	Thr	Gln	*				
				165					170							

<210> 5

<211> 948

<212> DNA

<213> Homo sapiens

<400> 5

atg	ttg	tcc	cca	aac	cac	acc	ata	gtg	aca	gaa	ttc	att	ctc	tta	gga	48
Met	Leu	Ser	Pro	Asn	His	Thr	Ile	Val	Thr	Glu	Phe	Ile	Leu	Leu	Gly	
1				5					10					15		
ctg	aca	gac	gac	cca	gtg	cta	gag	aag	atc	ctg	ttt	ggg	gtg	ttc	ctg	96
Leu	Thr	Asp	Pro	Val	Leu	Glu	Lys	Ile	Leu	Phe	Gly	Val	Phe	Leu		
			20				25					30				
gcg	atc	tac	cta	atc	aca	ctg	gca	ggc	aac	ctg	tgc	atg	atc	ctg	ctg	144
Ala	Ile	Tyr	Leu	Ile	Thr	Leu	Ala	Gly	Asn	Leu	Cys	Met	Ile	Leu	Leu	
			35				40				45					
atc	agg	acc	aat	tcc	caa	ctg	caa	aca	ccc	atg	tat	ttc	ttc	ctt	ggg	192
Ile	Arg	Thr	Asn	Ser	Gln	Leu	Gln	Thr	Pro	Met	Tyr	Phe	Phe	Leu	Gly	
50					55					60						
cac	ctc	tcc	ttt	tta	gac	att	tgc	tat	tct	tcc	aat	gtt	act	cca	aat	240
His	Leu	Ser	Phe	Leu	Asp	Ile	Cys	Tyr	Ser	Ser	Asn	Val	Thr	Pro	Asn	
65					70				75					80		
atg	ctg	cac	aat	ttc	ctc	tca	gaa	cag	aag	acc	atc	tcc	tac	gct	gga	288
Met	Leu	His	Asn	Phe	Leu	Ser	Glu	Gln	Lys	Thr	Ile	Ser	Tyr	Ala	Gly	
			85						90					95		
tgc	ttc	aca	cag	tgt	ctt	ctc	ttc	atc	gcc	cta	gtg	atc	act	gag	ttt	336
Cys	Phe	Thr	Gln	Cys	Leu	Leu	Phe	Ile	Ala	Leu	Val	Ile	Thr	Glu	Phe	
			100					105					110			
tac	ttc	ctt	gct	tca	atg	gca	ttg	gat	cgc	tat	gta	gcc	att	tgc	agc	384
Tyr	Phe	Leu	Ala	Ser	Met	Ala	Leu	Asp	Arg	Tyr	Val	Ala	Ile	Cys	Ser	
			115				120					125				
cct	tta	cat	tac	agt	tcc	agg	atg	tcc	aag	aac	att	tgc	atc	tct	ctg	432
Pro	Leu	His	Tyr	Ser	Ser	Arg	Met	Ser	Lys	Asn	Ile	Cys	Ile	Ser	Leu	
	130					135				140						
gtc	act	gtg	cct	tac	atg	tat	ggc	ttc	ctt	aat	ggg	ctc	tct	cag	aca	480
Val	Thr	Val	Pro	Tyr	Met	Tyr	Gly	Phe	Leu	Asn	Gly	Leu	Ser	Gln	Thr	
145					150					155					160	
ctg	ctg	acc	ttt	cac	tta	tcc	ttc	tgt	ggc	tcc	ctt	gaa	atc	aat	cat	528
Leu	Leu	Thr	Phe	His	Leu	Ser	Phe	Cys	Gly	Ser	Leu	Glu	Ile	Asn	His	

49

				165					170				175				
ttc	tac	tgc	gct	gat	cct	cct	ctt	atc	atg	ctg	gcc	tgc	tct	gac	acc		576
Phe	Tyr	Cys	Ala	Asp	Pro	Pro	Leu	Ile	Met	Leu	Ala	Cys	Ser	Asp	Thr		
			180					185					190				
cgt	gtc	aaa	aag	atg	gca	atg	ttt	gta	gtt	gca	ggc	ttt	act	ctc	tca		624
Arg	Val	Lys	Lys	Met	Ala	Met	Phe	Val	Val	Ala	Gly	Phe	Thr	Leu	Ser		
		195					200					205					
agc	tct	ctc	ttc	atc	att	ctt	ctg	tcc	tat	ctt	ttc	att	ttt	gca	gcg		672
Ser	Ser	Leu	Phe	Ile	Ile	Leu	Leu	Ser	Tyr	Leu	Phe	Ile	Phe	Ala	Ala		
	210					215				220							
atc	ttc	agg	atc	cgt	tct	gct	gaa	ggc	agg	cac	aaa	gcc	ttt	tct	acg		720
Ile	Phe	Arg	Ile	Arg	Ser	Ala	Glu	Gly	Arg	His	Lys	Ala	Phe	Ser	Thr		
225					230				235					240			
tgt	gct	tcc	cac	ctg	aca	ata	gtc	act	ttg	ttt	tat	gga	acc	ctc	ttc		768
Cys	Ala	Ser	His	Leu	Thr	Ile	Val	Thr	Leu	Phe	Tyr	Gly	Thr	Leu	Phe		
			245					250					255				
tgc	atg	tac	gta	agg	cct	cca	tca	gag	aag	tct	gta	gag	gag	tcc	aaa		816
Cys	Met	Tyr	Val	Arg	Pro	Pro	Ser	Glu	Lys	Ser	Val	Glu	Glu	Ser	Lys		
		260					265					270					
ata	att	gca	gtc	ttt	tat	act	ttt	ttg	agc	cca	atg	ctg	aac	cca	ttg		864
Ile	Ile	Ala	Val	Phe	Tyr	Thr	Phe	Leu	Ser	Pro	Met	Leu	Asn	Pro	Leu		
	275					280					285						
atc	tat	agc	cta	cgg	aac	aga	gat	gta	atc	ctt	gcc	ata	caa	caa	atg		912
Ile	Tyr	Ser	Leu	Arg	Asn	Arg	Asp	Val	Ile	Leu	Ala	Ile	Gln	Gln	Met		
	290			295			300										
att	agg	gga	aaa	tcc	ttt	tgt	aaa	att	gca	gtt	tag						948
Ile	Arg	Gly	Lys	Ser	Phe	Cys	Lys	Ile	Ala	Val	*						
305				310			315										

<210> 6

<211> 918

<212> DNA

<213> Homo sapiens

<400> 6

atg	tcc	aac	aca	aat	ggc	agt	gca	atc	aca	gaa	ttc	att	tta	ctt	ggg		48
Met	Ser	Asn	Thr	Asn	Gly	Ser	Ala	Ile	Thr	Glu	Phe	Ile	Leu	Leu	Gly		
1				5			10						15				
ctc	aca	gat	tgc	ccg	gaa	ctc	cag	tct	ctg	ctt	ttt	gtg	ctg	ttt	ctg		96
Leu	Thr	Asp	Cys	Pro	Glu	Leu	Gln	Ser	Leu	Leu	Phe	Val	Leu	Phe	Leu		
		20					25					30					
gtt	gtt	tac	ctc	gtc	acc	ctg	cta	ggc	aac	ctg	ggc	atg	ata	atg	tta		144
Val	Val	Tyr	Leu	Val	Thr	Leu	Gly	Asn	Leu	Gly	Met	Ile	Met	Leu			
	35					40					45						
atg	aga	ctg	gac	tct	cgc	ctt	cac	acg	ccc	atg	tac	ttc	ttc	ctc	act		192
Met	Arg	Leu	Asp	Ser	Arg	Leu	His	Thr	Pro	Met	Tyr	Phe	Phe	Leu	Thr		
	50				55		60										
aac	tta	gcc	ttt	gtg	gat	ttg	tgc	tat	aca	tca	aat	gca	acc	ccg	cag		240
Asn	Leu	Ala	Phe	Val	Asp	Leu	Cys	Tyr	Thr	Ser	Asn	Ala	Thr	Pro	Gln		
65				70			75					80					
atg	tcg	act	aat	atc	gta	tct	gag	aag	acc	att	tcc	ttt	gct	ggg	tgc		288
Met	Ser	Thr	Asn	Ile	Val	Ser	Glu	Lys	Thr	Ile	Ser	Phe	Ala	Gly	Cys		
			85				90						95				
ttt	aca	cag	tgc	tac	att	ttc	att	gcc	ctt	cta	ctc	act	gag	ttt	tac		336
Phe	Thr	Gln	Cys	Tyr	Ile	Phe	Ile	Ala	Leu	Leu	Leu	Thr	Glu	Phe	Tyr		
	100					105						110					
atg	ctg	gca	gca	atg	gcc	tat	gac	cgc	tat	gtg	gcc	ata	tat	gac	cct		384
Met	Leu	Ala	Ala	Met	Ala	Tyr	Asp	Arg	Tyr	Val	Ala	Ile	Tyr	Asp	Pro		
	115				120		125										
ctg	cgc	tac	agt	gtg	aaa	acg	tcc	agg	aga	gtt	tgc	atc	tgc	ttg	gcc		432
Leu	Arg	Tyr	Ser	Val	Lys	Thr	Ser	Arg	Arg	Val	Cys	Ile	Cys	Leu	Ala		
	130				135		140										
aca	ttt	ccc	tat	gtc	tat	ggc	ttc	tca	gat	gga	ctc	ttc	cag	gcc	atc		480

50

Thr	Phe	Pro	Tyr	Val	Tyr	Gly	Phe	Ser	Asp	Gly	Leu	Phe	Gln	Ala	Ile		
145					150					155					160		
ctg	acc	ttc	cgc	ctg	acc	ttc	tgt	aga	tcc	aat	gtc	atc	aac	cac	ttc		528
Leu	Thr	Phe	Arg	Leu	Thr	Phe	Cys	Arg	Ser	Asn	Val	Ile	Asn	His	Phe		
				165					170					175			
tac	tgt	gct	gac	ccg	ccg	ctc	att	aag	ctt	tct	tgt	tct	gat	act	tat		576
Tyr	Cys	Ala	Asp	Pro	Pro	Leu	Ile	Lys	Leu	Ser	Cys	Ser	Asp	Thr	Tyr		
			180					185					190				
gtc	aaa	gag	cat	gcc	atg	ttc	ata	tct	gct	ggc	ttc	aac	ctc	tcc	agc		624
Val	Lys	Glu	His	Ala	Met	Phe	Ile	Ser	Ala	Gly	Phe	Asn	Leu	Ser	Ser		
		195					200					205					
tcc	ctc	acc	atc	gtc	ttg	gtg	tcc	tat	gcc	ttc	att	ctt	gct	gcc	atc		672
Ser	Leu	Thr	Ile	Val	Leu	Val	Ser	Tyr	Ala	Phe	Ile	Leu	Ala	Ala	Ile		
	210					215					220						
ctc	cgg	atc	aaa	tca	gca	gag	gga	agg	cac	aag	gca	ttc	tcc	acc	tgt		720
Leu	Arg	Ile	Lys	Ser	Ala	Glu	Gly	Arg	His	Lys	Ala	Phe	Ser	Thr	Cys		
225				230				235						240			
ggg	tcc	cat	atg	atg	gct	gtc	acc	ctg	ttt	tat	ggg	act	ctc	ttt	tgc		768
Gly	Ser	His	Met	Met	Ala	Val	Thr	Leu	Phe	Tyr	Gly	Thr	Leu	Phe	Cys		
			245					250						255			
atg	tat	ata	aga	cca	cca	aca	gat	aag	act	gtt	gag	gaa	tct	aaa	ata		816
Met	Tyr	Ile	Arg	Pro	Pro	Thr	Asp	Lys	Thr	Val	Glu	Glu	Ser	Lys	Ile		
			260				265						270				
ata	gct	gtc	ttt	tac	acc	ttt	gtg	agt	ccg	gta	ctt	aat	cca	ttg	atc		864
Ile	Ala	Val	Phe	Tyr	Thr	Phe	Val	Ser	Pro	Val	Leu	Asn	Pro	Leu	Ile		
	275					280						285					
tac	agt	ctg	agg	aat	aaa	gat	gtg	aag	cag	gcc	ttg	aag	aat	gtc	ctg		912
Tyr	Ser	Leu	Arg	Asn	Lys	Asp	Val	Lys	Gln	Ala	Leu	Lys	Asn	Val	Leu		
	290					295					300						
aga	tga																918
Arg	*																
305																	

<210> 7

<211> 612

<212> DNA

<213> Homo sapiens

<400> 7

atg	gtt	aga	gga	aat	tct	act	ttg	gtg	acg	gaa	ttt	att	ctc	ttg	gga		48
Met	Val	Arg	Gly	Asn	Ser	Thr	Leu	Val	Thr	Glu	Phe	Ile	Leu	Leu	Gly		
1			5					10					15				
tta	aag	gat	ctt	cca	gag	ctt	cag	ccc	atc	ctc	ttt	gta	ctg	ttc	ctg		96
Leu	Lys	Asp	Leu	Pro	Glu	Leu	Gln	Pro	Ile	Leu	Phe	Val	Leu	Phe	Leu		
			20					25				30					
cta	atc	tac	ctg	atc	act	gtc	ggg	ggg	aac	ctt	ggg	atg	ttg	gtg	ttg		144
Leu	Ile	Tyr	Leu	Ile	Thr	Val	Gly	Gly	Asn	Leu	Gly	Met	Leu	Val	Leu		
	35					40					45						
atc	agg	ata	gat	tca	cgc	ctc	cac	acc	ccc	atg	tat	ttc	ttt	ctt	gct		192
Ile	Arg	Ile	Asp	Ser	Arg	Leu	His	Thr	Pro	Met	Tyr	Phe	Phe	Leu	Ala		
	50					55					60						
agt	ttg	tcc	tgc	ttg	gat	ttg	tat	tac	tcc	act	aat	gtg	act	ccc	aag		240
Ser	Leu	Ser	Cys	Leu	Asp	Leu	Tyr	Tyr	Ser	Thr	Asn	Val	Thr	Pro	Lys		
65				70					75					80			
atg	ttg	gtg	aac	ttc	ttc	tca	gac	aag	aaa	gcc	att	tcc	tat	gct	gct		288
Met	Leu	Val	Asn	Phe	Phe	Ser	Asp	Lys	Lys	Ala	Ile	Ser	Tyr	Ala	Ala		
			85					90						95			
tgt	tta	gtc	cag	tgc	tat	ttt	ttc	att	gct	gtg	gtg	att	act	gaa	tat		336
Cys	Leu	Val	Gln	Cys	Tyr	Phe	Phe	Ile	Ala	Val	Val	Ile	Thr	Glu	Tyr		
			100					105					110				
tat	atg	cta	gct	gta	atg	gcc	tat	gat	agg	tat	gtg	gcc	atc	tgt	aac		384
Tyr	Met	Leu	Ala	Val	Met	Ala	Tyr	Asp	Arg	Tyr	Val	Ala	Ile	Cys	Asn		
		115					120					125					

51

cct	ttg	ctt	tac	agc	agc	aag	atg	tcc	aaa	ggg	ctc	tgt	att	cgc	ctg	432
Pro	Leu	Leu	Tyr	Ser	Ser	Lys	Met	Ser	Lys	Gly	Leu	Cys	Ile	Arg	Leu	
130						135					140					
att	gct	ggg	cca	tat	gtc	tat	ggg	ttt	ctt	agt	gga	ctg	atg	gaa	acc	480
Ile	Ala	Gly	Pro	Tyr	Val	Tyr	Gly	Phe	Leu	Ser	Gly	Leu	Met	Glu	Thr	
145					150					155					160	
atg	tgg	aca	tac	cac	ttg	acc	ttc	tgt	ggc	tcc	aat	atc	att	aat	cac	528
Met	Trp	Thr	Tyr	His	Leu	Thr	Phe	Cys	Gly	Ser	Asn	Ile	Ile	Asn	His	
				165					170						175	
ttc	tac	tgt	gct	gac	cca	ccc	ctc	atc	cga	ctt	tcc	tgc	tct	gac	act	576
Phe	Tyr	Cys	Ala	Asp	Pro	Pro	Leu	Ile	Arg	Leu	Ser	Cys	Ser	Asp	Thr	
			180					185						190		
ttc	att	aag	gaa	aca	tcc	atg	ttt	gtg	gta	gca	tga					612
Phe	Ile	Lys	Glu	Thr	Ser	Met	Phe	Val	Val	Ala	*					
		195					200									

<210> 8

<211> 807

<212> DNA

<213> Homo sapiens

<400> 8

ttg	ccc	tca	tcc	agg	cca	acg	ccc	cgg	ctc	cac	acg	ccc	atg	tac	ttt	48
Leu	Pro	Ser	Ser	Arg	Pro	Thr	Pro	Arg	Leu	His	Thr	Pro	Met	Tyr	Phe	
1				5				10						15		
ttc	ctg	agc	aac	tta	tcc	ttt	gtg	gat	ctg	tgc	ttc	tct	tcc	aat	gtg	96
Phe	Leu	Ser	Asn	Leu	Ser	Phe	Val	Asp	Leu	Cys	Phe	Ser	Ser	Asn	Val	
			20					25					30			
act	cca	agg	atg	ctg	gag	att	ttc	ctt	tca	gag	aag	aaa	agc	att	tcc	144
Thr	Pro	Arg	Met	Leu	Glu	Ile	Phe	Leu	Ser	Glu	Lys	Lys	Ser	Ile	Ser	
		35				40						45				
tat	cct	gcc	cgt	ctt	gtg	cag	tgt	tac	ctt	ttt	atc	acc	ttg	gtc	cac	192
Tyr	Pro	Ala	Arg	Leu	Val	Gln	Cys	Tyr	Leu	Phe	Ile	Thr	Leu	Val	His	
	50				55						60					
gtt	gag	ctc	tac	atc	ctg	gct	gtg	atg	gcc	ttt	gac	cgg	tac	atg	gcc	240
Val	Glu	Leu	Tyr	Ile	Leu	Ala	Val	Met	Ala	Phe	Asp	Arg	Tyr	Met	Ala	
65				70						75					80	
atc	tgc	aac	cct	ctg	ctt	tat	ggc	agc	aga	atg	tcc	aag	agc	gtg	tgc	288
Ile	Cys	Asn	Pro	Leu	Leu	Tyr	Gly	Ser	Arg	Met	Ser	Lys	Ser	Val	Cys	
			85					90						95		
tct	ttc	ctc	atc	aca	gtg	ctt	tat	gtg	tat	gga	gca	ctc	act	ggc	ctg	336
Ser	Phe	Leu	Ile	Thr	Val	Leu	Tyr	Val	Tyr	Gly	Ala	Leu	Thr	Gly	Leu	
			100				105						110			
atg	gag	act	atg	tgg	acc	tac	aac	cta	gcc	ttc	tgt	ggc	ccc	agt	gaa	384
Met	Glu	Thr	Met	Trp	Thr	Tyr	Asn	Leu	Ala	Phe	Cys	Gly	Pro	Ser	Glu	
		115					120						125			
att	aat	cac	ttc	tac	tgt	gtg	gac	cca	cca	ctg	att	aag	ctg	gct	tgt	432
Ile	Asn	His	Phe	Tyr	Cys	Val	Asp	Pro	Pro	Leu	Ile	Lys	Leu	Ala	Cys	
	130					135						140				
tct	gac	acc	tac	aac	aag	gag	gtg	tca	atg	ttt	gtt	gtg	gct	ggg	ttc	480
Ser	Asp	Thr	Tyr	Asn	Lys	Glu	Val	Ser	Met	Phe	Val	Val	Ala	Gly	Phe	
145				150						155					160	
aac	ttc	act	tat	cct	ctc	ctt	atc	atc	ctc	att	tcc	tat	ctc	tac	ata	528
Asn	Phe	Thr	Tyr	Pro	Leu	Leu	Ile	Ile	Leu	Ile	Ser	Tyr	Leu	Tyr	Ile	
				165					170					175		
ttt	cct	gcc	acc	cta	agg	atc	tgc	tct	aca	gaa	ggc	agg	cac	aaa	gct	576
Phe	Pro	Ala	Thr	Leu	Arg	Ile	Cys	Ser	Thr	Glu	Gly	Arg	His	Lys	Ala	
			180				185						190			
ttt	tct	acc	tgt	ggc	tcc	cat	ctg	aca	gcc	gtt	act	att	ttc	tat	tca	624
Phe	Ser	Thr	Cys	Gly	Ser	His	Leu	Thr	Ala	Val	Thr	Ile	Phe	Tyr	Ser	
		195					200					205				
gct	ctt	ttc	ttc	atg	tat	ctc	aga	cgt	cca	tca	gaa	gag	tcc	atg	gag	672
Ala	Leu	Phe	Phe	Met	Tyr	Leu	Arg	Arg	Pro	Ser	Glu	Glu	Ser	Met	Glu	

52

210	215	220	
cag ggg aaa atg gta gct gta ttt tat acc act gta atc ccc atg ttg			720
Gln Gly Lys Met Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu			
225	230	235	240
aat ccc atg atc tac agt ctg agg aac aaa gat gtg aaa gag gca tta			768
Asn Pro Met Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Glu Ala Leu			
	245	250	255
tgc aaa gaa ctg ttc aaa aga aaa ttg ttt tct aaa taa			807
Cys Lys Glu Leu Phe Lys Arg Lys Leu Phe Ser Lys *			
	260	265	

<210> 9
 <211> 363
 <212> DNA
 <213> Homo sapiens

<400> 9	
atg aga agg aac ttc acg ttg gtg act gag ttc att ctc ctg gga ctg	48
Met Arg Arg Asn Phe Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu	
1	5
acg aat cac cag gaa tta cag att ctc ctc ttc atg ctg ttt ctg gcc	96
Thr Asn His Gln Glu Leu Gln Ile Leu Leu Phe Met Leu Phe Leu Ala	
	20
att tac atg gtc aca gtg gca ggg aat ctt agc atg att gcc ctc atc	144
Ile Tyr Met Val Thr Val Ala Gly Asn Leu Ser Met Ile Ala Leu Ile	
	35
cag gcc aat gcc cgg ctc cac acg ccc atg tac ttt ttc ctg agc cac	192
Gln Ala Asn Ala Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ser His	
	50
tta tcc ttc ctg gat ctg tgc ttc tct tcc aat gtg acc cca aag atg	240
Leu Ser Phe Leu Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met	
	65
ctg gag att ttc ctt tca gag aag aaa agc att tcc tat cct gcc tgt	288
Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys	
	85
ctt gtt cag tgt tac ctt tat atc atc ttg gta cac gtt gag atc tac	336
Leu Val Gln Cys Tyr Leu Tyr Ile Ile Leu Val His Val Glu Ile Tyr	
	100
atc ctg gct gtg atg gcc ttt gac tag	363
Ile Leu Ala Val Met Ala Phe Asp *	
	115
	120

<210> 10
 <211> 936
 <212> DNA
 <213> Homo sapiens

<400> 10	
atg aga aga aac tgc acg ttg gtg act gag ttc att ctc ctg gga ctg	48
Met Arg Arg Asn Cys Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu	
1	5
acc agt cgc cgg gaa tta caa att ctc ctc ttc acg ctg ttt ctg gcc	96
Thr Ser Arg Arg Glu Leu Gln Ile Leu Leu Phe Thr Leu Phe Leu Ala	
	20
att tac atg gtc acg gtg gca ggg aac ctt ggc atg att gtc ctc atc	144
Ile Tyr Met Val Thr Val Ala Gly Asn Leu Gly Met Ile Val Leu Ile	
	35
cag gcc aac gcc tgg ctc cac atg ccc atg tac ttt ttc ctg agc cac	192
Gln Ala Asn Ala Trp Leu His Met Pro Met Tyr Phe Phe Leu Ser His	
	50
tta tcc ttc gtg gat ctg tgc ttc tct tcc aat gtg act cca aag atg	240
Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met	
	65
	70
	75
	80

53

ctg gag att ttc ctt tca gag aag aaa agc att tcc tat cct gcc tgt	288
Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys	
85 90 95	
ctt gtg cag tgt tac ctt ttt atc gcc ttg gtc cat gtt gag atc tac	336
Leu Val Gln Cys Tyr Leu Phe Ile Ala Leu Val His Val Glu Ile Tyr	
100 105 110	
atc ctg gct gtg atg gcc ttt gac cgg tac atg gcc atc tgc aac cct	384
Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala Ile Cys Asn Pro	
115 120 125	
ctg ctt tat ggc agc aga atg tcc aag agt gtg tgc tcc ttc ctc atc	432
Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys Ser Phe Leu Ile	
130 135 140	
acg gtg cct tat gtg tat gga gcg ctc act ggc ctg atg gag acc atg	480
Thr Val Pro Tyr Val Tyr Gly Ala Leu Thr Gly Leu Met Glu Thr Met	
145 150 155 160	
tgg acc tac aac cta gcc ttc tgt ggc ccc aat gaa att aat cac ttc	528
Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Asn Glu Ile Asn His Phe	
165 170 175	
tac tgt gcg gac cca ctg att aag ctg gct tgt tct gac acc tac	576
Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ala Cys Ser Asp Thr Tyr	
180 185 190	
aac aag gag ttg tca atg ttt att gtg gct ggc tgg aac ctt tct ttt	624
Asn Lys Glu Leu Ser Met Phe Ile Val Ala Gly Trp Asn Leu Ser Phe	
195 200 205	
tct ctc ttc atc ata tgt att tcc tac ctt tac att ttc cct gct att	672
Ser Leu Phe Ile Ile Cys Ile Ser Tyr Leu Tyr Ile Phe Pro Ala Ile	
210 215 220	
tta aag att cgc tct aca gag ggc agg caa aaa gct ttt tct acc tgt	720
Leu Lys Ile Arg Ser Thr Glu Gly Arg Gln Lys Ala Phe Ser Thr Cys	
225 230 235 240	
ggc tcc cat ctg aca gct gtc act ata ttc tat gca acc ctt ttc ttc	768
Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ala Thr Leu Phe Phe	
245 250 255	
atg tat ctc aga ccc ccc tca aag gaa tct gtt gaa cag ggt aaa atg	816
Met Tyr Leu Arg Pro Pro Ser Lys Glu Ser Val Glu Gln Gly Lys Met	
260 265 270	
gta gct gta ttt tat acc aca gta atc cct atg ctg aac ctt ata att	864
Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu Asn Leu Ile Ile	
275 280 285	
tat agc ctt aga aat aaa aat gta aaa gaa gca tta atc aaa gag ctg	912
Tyr Ser Leu Arg Asn Lys Asn Val Lys Glu Ala Leu Ile Lys Glu Leu	
290 295 300	
tca atg aag ata tac ttt tct taa	936
Ser Met Lys Ile Tyr Phe Ser *	
305 310	

<210> 11

<211> 180

<212> DNA

<213> Homo sapiens

<400> 11

atg tcc aga aga aac tat act gaa ctg aca gaa ttt gtt ctc ttg ggt	48
Met Ser Arg Arg Asn Tyr Thr Glu Leu Thr Glu Phe Val Leu Leu Gly	
1 5 10 15	
cta aca agc cgt cca gag ctg cga gtt gct ttc ttg gca ctg ttc ctt	96
Leu Thr Ser Arg Pro Glu Leu Arg Val Ala Phe Leu Ala Leu Phe Leu	
20 25 30	
ttt gtc tac ata gcc act gtg gta gga aac ttg ggg atg att att tta	144
Phe Val Tyr Ile Ala Thr Val Val Gly Asn Leu Gly Met Ile Ile Leu	
35 40 45	
atc aaa gtt gat tct cga ctt cac act ccc atg taa	180
Ile Lys Val Asp Ser Arg Leu His Thr Pro Met *	

50 55 60

<210> 12
 <211> 64
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Ser Phe Leu Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Cys
 1 5 10 15
 Leu Phe Leu Ser His Leu Ser Phe Val Asp Leu Tyr Tyr Ala Thr Asn
 20 25 30
 Ala Thr Pro Pro Met Leu Val Asn Phe Phe Phe Pro Arg Glu Lys Pro
 35 40 45
 Phe Pro Leu Leu Val Ala Leu Ser Asn Phe Thr Phe Ser Leu His Trp
 50 55 60

<210> 13
 <211> 315
 <212> PRT
 <213> Homo sapiens

<400> 13
 Met Phe Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
 1 5 10 15
 Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
 20 25 30
 Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
 35 40 45
 Ile Arg Thr Asn Ser His Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
 50 55 60
 His Leu Ser Phe Val Asp Ile Cys Tyr Ser Ser Asn Val Thr Pro Asn
 65 70 75 80
 Met Leu His Asn Phe Leu Ser Glu Gln Lys Thr Ile Ser Tyr Ala Gly
 85 90 95
 Cys Phe Thr Gln Cys Leu Leu Phe Ile Ala Leu Val Ile Thr Glu Phe
 100 105 110
 Tyr Phe Leu Ala Ser Met Ala Leu Asp Arg Tyr Val Ala Ile Cys Ser
 115 120 125
 Pro Leu His Tyr Ser Ser Arg Met Ser Lys Asn Ile Cys Ile Ser Leu
 130 135 140
 Val Thr Val Pro Tyr Met Tyr Gly Phe Leu Asn Gly Leu Ser Gln Thr
 145 150 155 160
 Leu Leu Thr Phe His Leu Ser Phe Cys Gly Ser Leu Glu Ile Asn His
 165 170 175
 Phe Tyr Cys Ala Asp Pro Pro Leu Ile Met Leu Ala Cys Ser Asp Thr
 180 185 190
 Arg Val Lys Lys Met Ala Met Phe Val Val Ala Gly Phe Thr Leu Ser
 195 200 205
 Ser Ser Leu Phe Ile Ile Leu Leu Ser Tyr Leu Phe Ile Phe Ala Ala
 210 215 220
 Ile Phe Arg Ile Arg Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr
 225 230 235 240
 Cys Ala Ser His Leu Thr Ile Val Thr Leu Phe Tyr Gly Thr Leu Phe
 245 250 255
 Cys Met Tyr Val Arg Pro Pro Ser Glu Lys Ser Val Glu Glu Ser Lys
 260 265 270
 Ile Thr Ala Val Phe Tyr Thr Phe Leu Thr Pro Met Leu Asn Pro Leu
 275 280 285
 Ile Tyr Ser Leu Arg Asn Thr Asp Val Ile Leu Ala Met Gln Gln Met
 290 295 300
 Ile Arg Gly Lys Ser Phe His Lys Ile Ala Val
 305 310 315

<210> 14
 <211> 172
 <212> PRT
 <213> Homo sapiens

<400> 14
 Met Leu Lys Lys Asn His Thr Ala Val Thr Glu Phe Val Leu Leu Gly
 1 5 10 15
 Leu Thr Asp Arg Ala Glu Leu Gln Ser Leu Leu Phe Val Val Phe Leu
 20 25 30
 Val Ile Tyr Leu Ile Thr Val Ile Gly Asn Val Ser Met Ile Leu Leu
 35 40 45
 Ile Arg Ser Asp Ser Thr Leu His Thr Pro Met Tyr Phe Phe Leu Ser
 50 55 60
 His Leu Ser Phe Val Asp Leu Cys Tyr Thr Thr Asn Val Thr Pro Gln
 65 70 75 80
 Met Leu Val Asn Phe Leu Ser Lys Arg Lys Thr Ile Ser Phe Ile Gly
 85 90 95
 Cys Phe Ile Gln Phe His Phe Phe Ile Ala Leu Val Ile Thr Asp Tyr
 100 105 110
 Tyr Met Leu Thr Val Met Ala Tyr Asp Arg Tyr Met Ala Ile Cys Lys
 115 120 125
 Pro Leu Leu Tyr Gly Ser Lys Met Thr Arg Cys Val Cys Leu Cys Leu
 130 135 140
 Ala Ala Ala Pro Tyr Ile Tyr Gly Phe Ala Asn Gly Leu Ser Thr Asp
 145 150 155 160
 His Pro Asp Ala Ser Ser Val Leu Leu Trp Thr Gln
 165 170

<210> 15
 <211> 315
 <212> PRT
 <213> Homo sapiens

<400> 15
 Met Leu Ser Pro Asn His Thr Ile Val Thr Glu Phe Ile Leu Leu Gly
 1 5 10 15
 Leu Thr Asp Asp Pro Val Leu Glu Lys Ile Leu Phe Gly Val Phe Leu
 20 25 30
 Ala Ile Tyr Leu Ile Thr Leu Ala Gly Asn Leu Cys Met Ile Leu Leu
 35 40 45
 Ile Arg Thr Asn Ser Gln Leu Gln Thr Pro Met Tyr Phe Phe Leu Gly
 50 55 60
 His Leu Ser Phe Leu Asp Ile Cys Tyr Ser Ser Asn Val Thr Pro Asn
 65 70 75 80
 Met Leu His Asn Phe Leu Ser Glu Gln Lys Thr Ile Ser Tyr Ala Gly
 85 90 95
 Cys Phe Thr Gln Cys Leu Leu Phe Ile Ala Leu Val Ile Thr Glu Phe
 100 105 110
 Tyr Phe Leu Ala Ser Met Ala Leu Asp Arg Tyr Val Ala Ile Cys Ser
 115 120 125
 Pro Leu His Tyr Ser Ser Arg Met Ser Lys Asn Ile Cys Ile Ser Leu
 130 135 140
 Val Thr Val Pro Tyr Met Tyr Gly Phe Leu Asn Gly Leu Ser Gln Thr
 145 150 155 160
 Leu Leu Thr Phe His Leu Ser Phe Cys Gly Ser Leu Glu Ile Asn His
 165 170 175
 Phe Tyr Cys Ala Asp Pro Pro Leu Ile Met Leu Ala Cys Ser Asp Thr
 180 185 190
 Arg Val Lys Lys Met Ala Met Phe Val Val Ala Gly Phe Thr Leu Ser
 195 200 205
 Ser Ser Leu Phe Ile Ile Leu Leu Ser Tyr Leu Phe Ile Phe Ala Ala

56

210	215	220
Ile Phe Arg Ile Arg Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr		
225	230	235
Cys Ala Ser His Leu Thr Ile Val Thr Leu Phe Tyr Gly Thr Leu Phe		240
	245	250
Cys Met Tyr Val Arg Pro Pro Ser Glu Lys Ser Val Glu Glu Ser Lys		255
	260	265
Ile Ile Ala Val Phe Tyr Thr Phe Leu Ser Pro Met Leu Asn Pro Leu		270
	275	280
Ile Tyr Ser Leu Arg Asn Arg Asp Val Ile Leu Ala Ile Gln Gln Met		285
	290	295
Ile Arg Gly Lys Ser Phe Cys Lys Ile Ala Val		300
305	310	315

<210> 16
 <211> 305
 <212> PRT
 <213> Homo sapiens

<400> 16

Met Ser Asn Thr Asn Gly Ser Ala Ile Thr Glu Phe Ile Leu Leu Gly		
1	5	10
Leu Thr Asp Cys Pro Glu Leu Gln Ser Leu Leu Phe Val Leu Phe Leu		15
	20	25
Val Val Tyr Leu Val Thr Leu Leu Gly Asn Leu Gly Met Ile Met Leu		30
	35	40
Met Arg Leu Asp Ser Arg Leu His Thr Pro Met Tyr Phe Phe Leu Thr		45
	50	55
Asn Leu Ala Phe Val Asp Leu Cys Tyr Thr Ser Asn Ala Thr Pro Gln		60
65	70	75
Met Ser Thr Asn Ile Val Ser Glu Lys Thr Ile Ser Phe Ala Gly Cys		80
	85	90
Phe Thr Gln Cys Tyr Ile Phe Ile Ala Leu Leu Leu Thr Glu Phe Tyr		95
	100	105
Met Leu Ala Ala Met Ala Tyr Asp Arg Tyr Val Ala Ile Tyr Asp Pro		110
	115	120
Leu Arg Tyr Ser Val Lys Thr Ser Arg Arg Val Cys Ile Cys Leu Ala		125
	130	135
Thr Phe Pro Tyr Val Tyr Gly Phe Ser Asp Gly Leu Phe Gln Ala Ile		140
145	150	155
Leu Thr Phe Arg Leu Thr Phe Cys Arg Ser Asn Val Ile Asn His Phe		160
	165	170
Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ser Cys Ser Asp Thr Tyr		175
	180	185
Val Lys Glu His Ala Met Phe Ile Ser Ala Gly Phe Asn Leu Ser Ser		190
	195	200
Ser Leu Thr Ile Val Leu Val Ser Tyr Ala Phe Ile Leu Ala Ala Ile		205
	210	215
Leu Arg Ile Lys Ser Ala Glu Gly Arg His Lys Ala Phe Ser Thr Cys		220
225	230	235
Gly Ser His Met Met Ala Val Thr Leu Phe Tyr Gly Thr Leu Phe Cys		240
	245	250
Met Tyr Ile Arg Pro Pro Thr Asp Lys Thr Val Glu Glu Ser Lys Ile		255
	260	265
Ile Ala Val Phe Tyr Thr Phe Val Ser Pro Val Leu Asn Pro Leu Ile		270
	275	280
Tyr Ser Leu Arg Asn Lys Asp Val Lys Gln Ala Leu Lys Asn Val Leu		285
	290	295
Arg		300
305		

<210> 17
 <211> 203

<212> PRT

<213> Homo sapiens

<400> 17

```

Met Val Arg Gly Asn Ser Thr Leu Val Thr Glu Phe Ile Leu Leu Gly
1          5          10          15
Leu Lys Asp Leu Pro Glu Leu Gln Pro Ile Leu Phe Val Leu Phe Leu
20          25          30
Leu Ile Tyr Leu Ile Thr Val Gly Asn Leu Gly Met Leu Val Leu
35          40          45
Ile Arg Ile Asp Ser Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ala
50          55          60
Ser Leu Ser Cys Leu Asp Leu Tyr Tyr Ser Thr Asn Val Thr Pro Lys
65          70          75          80
Met Leu Val Asn Phe Phe Ser Asp Lys Lys Ala Ile Ser Tyr Ala Ala
85          90          95
Cys Leu Val Gln Cys Tyr Phe Phe Ile Ala Val Val Ile Thr Glu Tyr
100         105         110
Tyr Met Leu Ala Val Met Ala Tyr Asp Arg Tyr Val Ala Ile Cys Asn
115         120         125
Pro Leu Leu Tyr Ser Ser Lys Met Ser Lys Gly Leu Cys Ile Arg Leu
130         135         140
Ile Ala Gly Pro Tyr Val Tyr Gly Phe Leu Ser Gly Leu Met Glu Thr
145         150         155         160
Met Trp Thr Tyr His Leu Thr Phe Cys Gly Ser Asn Ile Ile Asn His
165         170         175
Phe Tyr Cys Ala Asp Pro Pro Leu Ile Arg Leu Ser Cys Ser Asp Thr
180         185         190
Phe Ile Lys Glu Thr Ser Met Phe Val Val Ala
195         200

```

<210> 18

<211> 268

<212> PRT

<213> Homo sapiens

<400> 18

```

Leu Pro Ser Ser Arg Pro Thr Pro Arg Leu His Thr Pro Met Tyr Phe
1          5          10          15
Phe Leu Ser Asn Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val
20          25          30
Thr Pro Arg Met Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser
35          40          45
Tyr Pro Ala Arg Leu Val Gln Cys Tyr Leu Phe Ile Thr Leu Val His
50          55          60
Val Glu Leu Tyr Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala
65          70          75          80
Ile Cys Asn Pro Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys
85          90          95
Ser Phe Leu Ile Thr Val Leu Tyr Val Tyr Gly Ala Leu Thr Gly Leu
100         105         110
Met Glu Thr Met Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Ser Glu
115         120         125
Ile Asn His Phe Tyr Cys Val Asp Pro Pro Leu Ile Lys Leu Ala Cys
130         135         140
Ser Asp Thr Tyr Asn Lys Glu Val Ser Met Phe Val Val Ala Gly Phe
145         150         155         160
Asn Phe Thr Tyr Pro Leu Leu Ile Ile Leu Ile Ser Tyr Leu Tyr Ile
165         170         175
Phe Pro Ala Thr Leu Arg Ile Cys Ser Thr Glu Gly Arg His Lys Ala
180         185         190
Phe Ser Thr Cys Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ser
195         200         205

```

58

Ala Leu Phe Phe Met Tyr Leu Arg Arg Pro Ser Glu Glu Ser Met Glu
 210 215 220
 Gln Gly Lys Met Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu
 225 230 235 240
 Asn Pro Met Ile Tyr Ser Leu Arg Asn Lys Asp Val Lys Glu Ala Leu
 245 250 255
 Cys Lys Glu Leu Phe Lys Arg Lys Leu Phe Ser Lys
 260 265

<210> 19
 <211> 120
 <212> PRT
 <213> Homo sapiens

<400> 19
 Met Arg Arg Asn Phe Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu
 1 5 10 15
 Thr Asn His Gln Glu Leu Gln Ile Leu Phe Met Leu Phe Leu Ala
 20 25 30
 Ile Tyr Met Val Thr Val Ala Gly Asn Leu Ser Met Ile Ala Leu Ile
 35 40 45
 Gln Ala Asn Ala Arg Leu His Thr Pro Met Tyr Phe Phe Leu Ser His
 50 55 60
 Leu Ser Phe Leu Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met
 65 70 75 80
 Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys
 85 90 95
 Leu Val Gln Cys Tyr Leu Tyr Ile Ile Leu Val His Val Glu Ile Tyr
 100 105 110
 Ile Leu Ala Val Met Ala Phe Asp
 115 120

<210> 20
 <211> 311
 <212> PRT
 <213> Homo sapiens

<400> 20
 Met Arg Arg Asn Cys Thr Leu Val Thr Glu Phe Ile Leu Leu Gly Leu
 1 5 10 15
 Thr Ser Arg Arg Glu Leu Gln Ile Leu Leu Phe Thr Leu Phe Leu Ala
 20 25 30
 Ile Tyr Met Val Thr Val Ala Gly Asn Leu Gly Met Ile Val Leu Ile
 35 40 45
 Gln Ala Asn Ala Trp Leu His Met Pro Met Tyr Phe Phe Leu Ser His
 50 55 60
 Leu Ser Phe Val Asp Leu Cys Phe Ser Ser Asn Val Thr Pro Lys Met
 65 70 75 80
 Leu Glu Ile Phe Leu Ser Glu Lys Lys Ser Ile Ser Tyr Pro Ala Cys
 85 90 95
 Leu Val Gln Cys Tyr Leu Phe Ile Ala Leu Val His Val Glu Ile Tyr
 100 105 110
 Ile Leu Ala Val Met Ala Phe Asp Arg Tyr Met Ala Ile Cys Asn Pro
 115 120 125
 Leu Leu Tyr Gly Ser Arg Met Ser Lys Ser Val Cys Ser Phe Leu Ile
 130 135 140
 Thr Val Pro Tyr Val Tyr Gly Ala Leu Thr Gly Leu Met Glu Thr Met
 145 150 155 160
 Trp Thr Tyr Asn Leu Ala Phe Cys Gly Pro Asn Glu Ile Asn His Phe
 165 170 175
 Tyr Cys Ala Asp Pro Pro Leu Ile Lys Leu Ala Cys Ser Asp Thr Tyr
 180 185 190
 Asn Lys Glu Leu Ser Met Phe Ile Val Ala Gly Trp Asn Leu Ser Phe

59

```

      195                200                205
Ser Leu Phe Ile Ile Cys Ile Ser Tyr Leu Tyr Ile Phe Pro Ala Ile
      210                215                220
Leu Lys Ile Arg Ser Thr Glu Gly Arg Gln Lys Ala Phe Ser Thr Cys
225                230                235                240
Gly Ser His Leu Thr Ala Val Thr Ile Phe Tyr Ala Thr Leu Phe Phe
      245                250                255
Met Tyr Leu Arg Pro Pro Ser Lys Glu Ser Val Glu Gln Gly Lys Met
      260                265                270
Val Ala Val Phe Tyr Thr Thr Val Ile Pro Met Leu Asn Leu Ile Ile
      275                280                285
Tyr Ser Leu Arg Asn Lys Asn Val Lys Glu Ala Leu Ile Lys Glu Leu
      290                295                300
Ser Met Lys Ile Tyr Phe Ser
305                310

```

<210> 21
 <211> 59
 <212> PRT
 <213> Homo sapiens

```

<400> 21
Met Ser Arg Arg Asn Tyr Thr Glu Leu Thr Glu Phe Val Leu Leu Gly
1                5                10                15
Leu Thr Ser Arg Pro Glu Leu Arg Val Ala Phe Leu Ala Leu Phe Leu
      20                25                30
Phe Val Tyr Ile Ala Thr Val Val Gly Asn Leu Gly Met Ile Ile Leu
      35                40                45
Ile Lys Val Asp Ser Arg Leu His Thr Pro Met
      50                55

```

<210> 22
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<400> 22
 cctggagggt ttcaaaggct gatacttttag 30

<210> 23
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<400> 23
 ctccagcctg agcaacagag caatac 26

<210> 24
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<400> 24
 ctcacattca ttgttcttca cagacccagc 30

<210> 25
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<400> 25
 ccctgctggg atctggatca agac 24

<210> 26
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> sequencing oligonucleotide PrimerPU

<400> 26
tgtaaaacga cggccagt 18

<210> 27
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> sequencing oligonucleotide PrimerRP

<400> 27
caggaaacag ctatgacc 18